<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for basal cell carcinoma of the skin - Thomson, J - 2020 | Cochrane Library</title> <meta content="Interventions for basal cell carcinoma of the skin - Thomson, J - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003412.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for basal cell carcinoma of the skin - Thomson, J - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003412.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003412.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for basal cell carcinoma of the skin" name="citation_title"/> <meta content="Jason Thomson" name="citation_author"/> <meta content="Royal London Hospital, Barts Health NHS Trust" name="citation_author_institution"/> <meta content="jason.thomson@nhs.net" name="citation_author_email"/> <meta content="Sarah Hogan" name="citation_author"/> <meta content="Royal London Hospital, Barts Health NHS Trust" name="citation_author_institution"/> <meta content="Jo Leonardi-Bee" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Hywel C Williams" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Fiona J Bath-Hextall" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD003412.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/11/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003412.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003412.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003412.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Aminolevulinic Acid [analogs &amp; derivatives, therapeutic use]; Antineoplastic Agents [therapeutic use]; Carcinoma, Basal Cell [surgery, *therapy]; Cryotherapy; Imiquimod [therapeutic use]; Immunocompetence; Laser Therapy [methods]; Mohs Surgery; Neoplasm Recurrence, Local; Photochemotherapy; Photosensitizing Agents [therapeutic use]; Radiotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms [surgery, *therapy]; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003412.pub3&amp;doi=10.1002/14651858.CD003412.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="dLyXbLct";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003412\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003412\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003412\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003412\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003412.pub3",title:"Interventions for basal cell carcinoma of the skin",firstPublishedDate:"Nov 17, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=dLyXbLct&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003412.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003412.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003412.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003412.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003412.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003412.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003412.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003412.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003412.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003412.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7288 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003412.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-sec-0310"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-sec-0023"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-sec-0024"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-sec-0054"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-sec-0298"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/appendices#CD003412-sec-0315"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/supinfo/CD003412StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/supinfo/CD003412StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for basal cell carcinoma of the skin</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/information#CD003412-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Jason Thomson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/information#CD003412-cr-0005">Sarah Hogan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/information#CD003412-cr-0006">Jo Leonardi-Bee</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/information#CD003412-cr-0007">Hywel C Williams</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003412.pub3/information#CD003412-cr-0008">Fiona J Bath-Hextall</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/information/en#CD003412-sec-0326">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 November 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003412.pub3">https://doi.org/10.1002/14651858.CD003412.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003412-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003412-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003412-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003412-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003412-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003412-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003412-abs-0001" lang="en"> <section id="CD003412-sec-0001"> <h3 class="title" id="CD003412-sec-0001">Background</h3> <p>Basal cell carcinoma (BCC) is the commonest cancer affecting white‐skinned individuals, and worldwide incidence is increasing. Although rarely fatal, BCC is associated with significant morbidity and costs. First‐line treatment is usually surgical excision, but alternatives are available. New published studies and the development of non‐surgical treatments meant an update of our Cochrane Review (first published in 2003, and previously updated in 2007) was timely. </p> </section> <section id="CD003412-sec-0002"> <h3 class="title" id="CD003412-sec-0002">Objectives</h3> <p>To assess the effects of interventions for BCC in immunocompetent adults.</p> </section> <section id="CD003412-sec-0003"> <h3 class="title" id="CD003412-sec-0003">Search methods</h3> <p>We updated our searches of the following databases to November 2019: Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL, and LILACS. </p> </section> <section id="CD003412-sec-0004"> <h3 class="title" id="CD003412-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of interventions for BCC in immunocompetent adults with histologically‐proven, primary BCC. Eligible comparators were placebo, active treatment, other treatments, or no treatment. </p> </section> <section id="CD003412-sec-0005"> <h3 class="title" id="CD003412-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. Primary outcome measures were recurrence at three years and five years (measured clinically) (we included recurrence data outside of these time points if there was no measurement at three or five years) and participant‐ and observer‐rated good/excellent cosmetic outcome. Secondary outcomes included pain during and after treatment, early treatment failure within six months, and adverse effects (AEs). We used GRADE to assess evidence certainty for each outcome. </p> </section> <section id="CD003412-sec-0006"> <h3 class="title" id="CD003412-sec-0006">Main results</h3> <p>We included 52 RCTs (26 new) involving 6690 participants (median 89) in this update. All studies recruited from secondary care outpatient clinics. More males than females were included. Study duration ranged from six weeks to 10 years (average 13 months). Most studies (48/52) included only low‐risk BCC (superficial (sBCC) and nodular (nBCC) histological subtypes). The majority of studies were at low or unclear risk of bias for most domains. Twenty‐two studies were industry‐funded: commercial sponsors conducted most of the studies assessing imiquimod, and just under half of the photodynamic therapy (PDT) studies. </p> <p>Overall, surgical interventions have the lowest recurrence rates. For high‐risk facial BCC (high‐risk histological subtype or located in the facial 'H‐zone' or both), there may be slightly fewer recurrences with Mohs micrographic surgery (MMS) compared to surgical excision (SE) at three years (1.9% versus 2.9%, respectively) (risk ratio (RR) 0.64, 95% confidence interval (CI) 0.16 to 2.64; 1 study, 331 participants; low‐certainty evidence) and at five years (3.2% versus 5.2%, respectively) (RR 0.61, 95% CI 0.18 to 2.04; 1 study, 259 participants; low‐certainty evidence). However, the 95% CI also includes the possibility of increased risk of recurrence and no difference between treatments. There may be little to no difference regarding improvement of cosmetic outcomes between MMS and SE, judged by participants and observers 18 months post‐operatively (one study; low‐certainty evidence); however, no raw data were available for this outcome. </p> <p>When comparing imiquimod and SE for nBCC or sBCC at low‐risk sites, imiquimod probably results in more recurrences than SE at three years (16.4% versus 1.6%, respectively) (RR 10.30, 95% CI 3.22 to 32.94; 1 study, 401 participants; moderate‐certainty evidence) and five years (17.5% versus 2.3%, respectively) (RR 7.73, 95% CI 2.81 to 21.3; 1 study, 383 participants; moderate‐certainty evidence). There may be little to no difference in the number of participant‐rated good/excellent cosmetic outcomes (RR 1.00, 95% CI 0.94 to 1.06; 1 study, 326 participants; low‐certainty evidence). However, imiquimod may result in greater numbers of good/excellent cosmetic outcomes compared to SE when observer‐rated (60.6% versus 35.6%, respectively) (RR 1.70, 95% CI 1.35 to 2.15; 1 study, 344 participants; low‐certainty evidence). Both cosmetic outcomes were measured at three years. </p> <p>Based on one study of 347 participants with high‐ and low‐risk primary BCC of the face, radiotherapy may result in more recurrences compared to SE under frozen section margin control at three years (5.2% versus 0%, respectively) (RR 19.11, 95% CI 1.12 to 325.78; low‐certainty evidence) and at four years (6.4% versus 0.6%, respectively) (RR 11.06, 95% CI 1.44 to 84.77; low‐certainty evidence). Radiotherapy probably results in a smaller number of participant‐ (RR 0.76, 95% CI 0.63 to 0.91; 50.3% versus 66.1%, respectively) or observer‐rated (RR 0.48, 95% CI 0.37 to 0.62; 28.9% versus 60.3%, respectively) good/excellent cosmetic outcomes compared to SE, when measured at four years, where dyspigmentation and telangiectasia can occur (both moderate‐certainty evidence). </p> <p>Methyl‐aminolevulinate (MAL)‐PDT may result in more recurrences compared to SE at three years (36.4% versus 0%, respectively) (RR 26.47, 95% CI 1.63 to 429.92; 1 study; 68 participants with low‐risk nBCC in the head and neck area; low‐certainty evidence). There were no useable data for measurement at five years. MAL‐PDT probably results in greater numbers of participant‐ (RR 1.18, 95% CI 1.09 to 1.27; 97.3% versus 82.5%) or observer‐rated (RR 1.87, 95% CI 1.54 to 2.26; 87.1% versus 46.6%) good/excellent cosmetic outcomes at one year compared to SE (2 studies, 309 participants with low‐risk nBCC and sBCC; moderate‐certainty evidence). </p> <p>Based on moderate‐certainty evidence (single low‐risk sBCC), imiquimod probably results in fewer recurrences at three years compared to MAL‐PDT (22.8% versus 51.6%, respectively) (RR 0.44, 95% CI 0.32 to 0.62; 277 participants) and five years (28.6% versus 68.6%, respectively) (RR 0.42, 95% CI 0.31 to 0.57; 228 participants). There is probably little to no difference in numbers of observer‐rated good/excellent cosmetic outcomes at one year (RR 0.98, 95% CI 0.84 to 1.16; 370 participants). Participant‐rated cosmetic outcomes were not measured for this comparison. </p> <p>AEs with surgical interventions include wound infections, graft necrosis and post‐operative bleeding. Local AEs such as itching, weeping, pain and redness occur frequently with non‐surgical interventions. Treatment‐related AEs resulting in study modification or withdrawal occurred with imiquimod and MAL‐PDT. </p> </section> <section id="CD003412-sec-0007"> <h3 class="title" id="CD003412-sec-0007">Authors' conclusions</h3> <p>Surgical interventions have the lowest recurrence rates, and there may be slightly fewer recurrences with MMS over SE for high‐risk facial primary BCC (low‐certainty evidence). Non‐surgical treatments, when used for low‐risk BCC, are less effective than surgical treatments, but recurrence rates are acceptable and cosmetic outcomes are probably superior. Of the non‐surgical treatments, imiquimod has the best evidence to support its efficacy. </p> <p>Overall, evidence certainty was low to moderate. Priorities for future research include core outcome measures and studies with longer‐term follow‐up. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003412-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003412-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003412-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003412-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003412-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003412-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003412-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003412-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003412-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003412-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003412-abs-0002" lang="en"> <h3>Interventions for basal cell carcinoma of the skin</h3> <p><b>Why is this question important?</b> </p> <p>Basal cell carcinoma (BCC) is the most common form of skin cancer among people with white skin. </p> <p>BCC is not usually life‐threatening but if left untreated, it can cause important disfigurement, especially on the face. </p> <p>Surgical removal of the affected area and surrounding skin is usually the first option for treating BCC. Several different surgical approaches exist as well as non‐surgical treatments, such as radiotherapy (high doses of radiation that kill cancer cells), and anti‐cancer creams, gels and ointments. </p> <p>We reviewed the evidence from research studies, to find out which treatments work best for BCC. </p> <p><b>How did we identify and evaluate the evidence?</b> </p> <p>We searched for randomised controlled studies (studies where people are randomly put into one of two or more treatment groups), because these provide the most robust evidence about the effects of a treatment. We compared and summarised the evidence from all the studies. Finally, we rated our confidence in the evidence, based on factors such as study methods and sizes, and the consistency of findings across studies. </p> <p><b>What did we find?</b> </p> <p>We found 52 studies that involved a total of 6690 adults with BCC. Most studies (48 out of 52) included hospital outpatients with small, superficial or nodular BCC. Studies lasted for between six weeks and 10 years (average duration: 13 months). Twenty‐two studies were funded by pharmaceutical companies. </p> <p>Our confidence in the evidence presented here is low to moderate, mainly because many studies were small. </p> <p><i>Comparison between different surgical treatments</i> </p> <p>‐ Mohs micrographic surgery (a specialised surgical approach that removes less skin) may slightly decrease recurrence rates at three and five years compared to surgical excision (one of the most common surgical treatments for BCC). </p> <p>‐There may be little to no difference in how well scars heal between these two surgical treatments according to patients and observers (one study). </p> <p><i>Surgery versus non‐surgical treatments</i> </p> <p>Compared against surgical excision:</p> <p>‐ Imiquimod (an anti‐cancer cream) probably increases BCC recurrence rates at three and five years. There may be little to no difference in scar healing according to patients, although imiquimod may increase chances of scars healing well when healing is rated by an observer (one study).<br/>‐ Radiotherapy may increase BCC recurrence rates at three and four years, and probably decreases chances of scars healing well (one study).<br/>‐ MAL‐PDT, a type of photodynamic therapy (that uses a light source and light‐sensitive medicine to kill cancer cells), may increase BCC recurrence rates at three years. MAL‐PDT probably increases chances of scars healing well (two studies). </p> <p><i>Comparison of different non‐surgical treatments</i> </p> <p>Compared against imiquimod:</p> <p>‐ MAL‐PDT probably increases BCC recurrence rates at three and five years. There is probably little to no difference in scar healing (one study); </p> <p><b>What does this mean?</b> </p> <p>Overall, the evidence suggests that:</p> <p>‐ surgery could reduce chances of BCC recurrence;<br/>‐ non‐surgical treatments such as anti‐cancer creams or photodynamic therapy carry an increased chance of BCC recurrence, but could increase chances of scars healing well compared with surgery. </p> <p>Complications with surgical treatments include wound infections, skin graft failure and bleeding after the procedure. Non‐surgical treatments frequently lead to localised itching, weeping, pain and redness. Treatment‐related side effects that caused modifications to the study or the withdrawal of participants occurred with imiquimod and MAL‐PDT. </p> <p><b>How‐up‐to date is this review?</b> </p> <p>The evidence in this Cochrane Review is current to November 2019.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003412-sec-0310" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003412-sec-0310"></div> <h3 class="title" id="CD003412-sec-0311">Implications for practice</h3> <section id="CD003412-sec-0311"> <p>The overall quality of research on interventions for basal cell carcinoma (BCC) has improved since our 2007 review with the publication of several randomised controlled trials (RCTs) with long‐term follow‐up, but many of the included studies have provided low‐ or moderate‐certainty evidence that should be interpreted with caution. </p> <p>The majority of studies have been performed on low‐risk histological BCCs, located on low‐risk sites, the results of which are probably not applicable to high‐risk tumours. Only four studies have looked at high‐risk histological subtypes, and three studies looked at BCCs at high‐risk facial sites. More studies or subgroup analyses are required for morphoeic tumours. </p> <p>Surgery remains the most effective treatment modality for BCC in terms of reducing recurrences, and there may be a slightly reduced recurrence rate with Mohs micrographic surgery (MMS) compared to surgical excision (SE); however, the 95% CI also includes the possibility of both increased risk and no difference between treatments (low‐certainty evidence). With regard to improvement of participant‐ and observer‐rated cosmetic outcomes, there may be little to no difference between MMS and SE (low‐certainty evidence); however, no raw data were available for this outcome. Radiotherapy is effective but probably worse than surgery (under frozen section margin control) in terms of the number of good cosmetic outcomes (moderate‐certainty evidence) and is therefore best reserved for tumours not amenable to surgery. Radiotherapy may also lead to increased recurrence compared to SE (low‐certainty evidence). </p> <p>Non‐surgical treatments are less effective, but the evidence suggests that recurrence rates are acceptable and they are important options to offer patients. Imiquimod probably results in more recurrences than SE (moderate‐certainty evidence) and there is probably little to no difference between groups in the number of participant‐rated good/excellent cosmetic outcomes (low‐certainty evidence). However, imiquimod may increase the number of observer‐rated good/excellent cosmetic outcomes compared to SE (low‐certainty evidence). Overall, imiquimod has the best evidence to support its efficacy out of the non‐surgical treatments. </p> <p>Moderate‐certainty evidence indicates that imiquimod probably leads to fewer recurrences than MAL‐PDT and there is probably little to no difference between these treatments in terms of observer‐rated good/excellent cosmetic outcomes (participant‐rated cosmetic outcomes were not measured in this comparison). MAL‐PDT may result in more recurrences at three years than SE (low‐certainty evidence; no useable data for measurement at five years), but probably increases the number of good/excellent cosmetic results (moderate‐certainty evidence). </p> <p>Adverse effects with surgical interventions include wound infections, graft necrosis and post‐operative bleeding. Local adverse effects such as itching, weeping, pain and redness occur frequently with non‐surgical interventions. Treatment‐related adverse effects resulting in study modification or withdrawal occurred with imiquimod and MAL‐PDT. </p> <p>The six studies in <a href="./references#CD003412-bbs1-0003" title="">Studies awaiting classification</a> may alter the conclusions of the review once assessed. </p> </section> <h3 class="title" id="CD003412-sec-0312">Implications for research</h3> <section id="CD003412-sec-0312"> <p>Currently, there is only low‐certainty evidence informing us on the efficacy of MMS against SE, with only one study assessing MMS against SE that met our inclusion criteria. Given this is the main comparison of our review, further studies assessing these treatments against each other are needed. Future studies exclusively assessing interventions for high‐risk BCC (high‐risk histological subtypes and high‐risk locations) are needed. As a minimum, future studies should present data on high‐risk tumours in subgroup analyses. </p> <p>Cost:benefit ratios have an important impact on clinical practice and guidelines and so future systematic reviews on interventions for BCC should also include cost‐analyses as an outcome measure. This will allow us to answer important questions such as whether the higher operative costs and procedure times of MMS offset the potential higher number of recurrences seen with SE over time. It will also be important for imiquimod and 5‐FU cream as there is a big cost difference between these treatments, which may offset the differences in efficacy so defining this further will be important in future research to impact clinical practice. </p> <p>Given that the radiotherapy studies included were all conducted over 20 years ago, and based on the fact that radiotherapy techniques and protocols have changed a lot since then, up‐to‐date studies assessing the efficacy of radiotherapy using current methods are needed, as these older studies may not be reflective of modern radiotherapy outcomes. </p> <p>One of the key problems with RCTs on interventions for BCC is the lack of an agreed set of core outcome measures and also the lack of longer‐term outcomes for many of the studies which are now standard for most other cancer studies (for example, clinical recurrence at five years). An international group, in collaboration with the Core Outcome Measures in Effectiveness Trials (COMET) initiative and Cochrane Skin Group‐ Core Outcome Set Initiative (CSG‐COUSIN) have begun the task of developing broad consensus for a core outcome set for BCC intervention trials, which will be essential to improve the evidence we have for BCC in the future (<a href="./references#CD003412-bbs2-0131" title="SchlessingerDI , IyengarS , YanesAF , LazaroffJM , Godinez-PuigV , ChenBR , et al. Development of a core outcome set for clinical trials in basal cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials2017;18(1):490.">Schlessinger 2017</a>). For example, core outcome sets would determine whose opinion should be sought for assessing cosmetic outcomes (dermatologist, participant, or both), and when or how best to report it. BCC research should benefit greatly from this initiative, but future studies must also ensure that all outcomes are pre‐specified and registered prospectively to mitigate against the risk of selective outcome reporting bias. </p> <p>Only a fifth of included RCTs followed participants up for at least three years and given that the majority of BCCs are likely to recur during the first three years after treatment, future studies should have follow‐up periods of at least three years. Further research is needed into what the optimal length of follow‐up should be as there is conflicting evidence documenting recurrences beyond five years. If at least 20% of recurrences occur beyond five years, then studies should follow up participants for up to 10 years. This will also impact the time points used for our primary outcome measures in future reviews. </p> <p>Moreover, inadequate reporting of study methodology leads to biased estimates of treatment effects (<a href="./references#CD003412-bbs2-0132" title="SchulzKF , ChalmersI , HayesRJ . Empirical evidence of bias. JAMA1995;273:408-12.">Schulz 1995</a>). Future studies on interventions for BCC must be well‐designed RCTs and should include a power calculation to ensure that sufficient numbers of participants are recruited to avoid problems with imprecision. Studies must also be rigorously reported and conform to the Consolidated Standards of Reporting Trials (CONSORT) statement (<a href="./references#CD003412-bbs2-0133" title="SchulzKF , AltmanDG , MoherD . CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Medicine2010;8(1):18.">Schulz 2010</a>). This will ensure a fair interpretation of the results and allow accurate appraisal and judgements to be made about the risk of bias and the overall certainty of evidence. </p> <p>Given that curettage and cautery is commonly used in the treatment of low‐risk BCC, more evidence is needed to assess its efficacy as currently we only have one small study with only two years follow‐up that compared curettage and cautery with SE. Further RCTs with long‐term follow‐up are needed to assess its efficacy against other interventions including non‐surgical interventions. Further RCTs with long‐term follow‐up are needed for solasodine glycosides, ingenol mebutate, topical valproic acid, tazarotene, diclofenac, calcitriol and sinecatechin. These non‐surgical interventions should be compared against other non‐surgical interventions with established efficacy in treating BCC, such as imiquimod. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003412-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003412-sec-0008"></div> <div class="table" id="CD003412-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mohs micrographic surgery compared to surgical excision for basal cell carcinoma of the skin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mohs micrographic surgery compared to surgical excision for high‐risk BCC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from hospitals in the Netherlands<br/><b>Intervention:</b> Mohs micrographic surgery<br/><b>Comparison:</b> surgical excision </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Surgical excision</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Mohs micrographic surgery</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.64<br/>(0.16 to 2.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>331<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Study measured outcome at 30 months.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000<br/>(5 to 77) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.61<br/>(0.18 to 2.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>259<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/>(9 to 107) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cosmetic outcome</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Although a reported outcome, raw data were not available. The authors of <a href="./references#CD003412-bbs2-0045" title="EssersBA , DirksenCD , NiemanFH , SmeetsNW , KrekelsGA , PrinsMH , et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Archives of Dermatology2006;142(2):187-94. [CENTRAL: CN-00555278] MosterdK , KrekelsGA , NiemanFH , OstertagJU , EssersBA , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncology2008;9(12):1149-56. [CENTRAL: CN-00665334] SmeetsNW , KrekelsGA , OstertagJU , EssersBA , DirksenCD , NiemanFH , et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet2004;364(9447):1766-72. [CENTRAL: CN-00492695] Van LooE , MosterdK , KrekelsGA , RoozeboomMH , OstertagJU , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European Journal of Cancer2014;50(17):3011-20. [CENTRAL: CN-01043314] ">Smeets 2004</a> state that overall, cosmetic outcomes did not significantly differ between groups. </p> <p>The cosmetic outcomes were judged by participants 18 months post‐operatively, and photographs of a selected group of tumours (first 139 primary) were judged retrospectively by a panel of six individuals. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early treatment failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm. </p> <p><sup>2</sup> Downgraded two levels for very serious indirectness as although the authors did compare the cosmetic outcomes between the two groups, they did not present the data for analysis. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003412-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Imiquimod compared to surgical excision for basal cell carcinoma of the skin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Imiquimod compared to surgical excision for low‐risk BCC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from hospitals in the UK<br/><b>Intervention:</b> 5% imiquimod cream<br/><b>Comparison:</b> surgical excision </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with surgical excision</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Imiquimod</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 10.30<br/>(3.22 to 32.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>401<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1000<br/>(51 to 526) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 7.73<br/>(2.81 to 21.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>383<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>175 per 1000<br/>(64 to 481) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.70<br/>(1.35 to 2.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>344<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Observer‐rated at 3 years on a 6‐point scale.<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>356 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>606 per 1000<br/>(481 to 766) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.00<br/>(0.94 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>326<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participant‐rated at 3 years on a 6‐point scale.<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>922 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>922 per 1000<br/>(866 to 977) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain (moderate/severe)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.36<br/>(0.98 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>443<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain measured during treatment.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>219 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>298 per 1000<br/>(215 to 412) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain (moderate/severe)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.47<br/>(0.29 to 0.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>439<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain measured during follow‐up.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>199 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000<br/>(58 to 153) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early treatment failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI. </p> <p><sup>2</sup> Downgraded one level for serious imprecision as only a single study with a small sample size and one level for serious risk of bias as unable to truly blind due to the nature of interventions (i.e. presence or absence of scar will unblind to treatment allocation). </p> <p><sup>3</sup> Downgraded one level for serious imprecision as only a single study with a small sample size and one level for serious risk of attrition bias as fewer pain data were available for the surgical excision group. </p> <p><sup>4</sup> 6‐point scale: unable to see lesion, very poor, poor, fair, good, excellent. </p> <p><sup>5</sup> Measured on a scale from: no pain, mild pain, mild‐to‐moderate pain, moderate pain, moderate‐to‐severe pain and severe pain. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003412-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Radiotherapy compared to surgical excision (with or without frozen section margin control) for basal cell carcinoma of the skin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Radiotherapy compared to surgical excision for high‐ and low‐risk BCC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from a single hospital in France<br/><b>Intervention:</b> radiotherapy<br/><b>Comparison:</b> surgical excision (with or without frozen section margin control) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with surgical excision</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with radiotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 19.11<br/>(1.12 to 325.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>347<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000<br/>(6 to 1883) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 4 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 11.06</p> <p>(1.44 to 84.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>347<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 1000<br/>(8 to 487) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.76 (0.63 to 0.91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>347<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participant‐rated at 4 years on a 3‐point scale.<sup>4</sup> ITT analysis performed. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>661 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>502 per 1000<br/>(416 to 601) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.48<br/>(0.37 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>347<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Observer‐rated at 4 years on a 3‐point scale.<sup>4</sup> ITT analysis performed. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>603 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 per 1000<br/>(223 to 374) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early treatment failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>ITT:</b> intention‐to‐treat; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for very serious imprecision due to very wide 95% CI (although excludes 1, there is a greater than 100‐fold difference). </p> <p><sup>2</sup> Downgraded one level for serious indirectness (outcome outside our pre‐specified time‐points) and downgraded one level for serious imprecision as only a single study with a small sample size. </p> <p><sup>3</sup> Downgraded one level for serious risk of bias as unable to truly blind due to the nature of interventions. </p> <p><sup>4</sup> 3‐point scale: bad, fair, good. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003412-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">MAL‐PDT compared to surgical excision for basal cell carcinoma of the skin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>MAL‐PDT compared to surgical excision for low‐risk BCC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from hospitals in Brazil, the UK, Germany, Switzerland and Australia<br/><b>Intervention:</b> MAL‐PDT<br/><b>Comparison:</b> surgical excision </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with surgical excision</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with MAL‐PDT</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 26.47<br/>(1.63 to 429.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>68<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>364 per 1000<br/>(49 to 13027) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (excellent/good)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/>(1.09 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>309<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participant‐rated at 1 year on a 4‐point scale.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>825 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>973 per 1000<br/>(899 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (excellent/good)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.87<br/>(1.54 to 2.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>256<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Observer‐rated at 1 year on a 4‐point scale.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>466 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>871 per 1000<br/>(717 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.20</p> <p>(0.60 to 8.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>101</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Study reported frequency of "pain in skin" and "burning sensation of skin" as part of AEs. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000</p> <p>(37 to 492)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Early treatment failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 6.66<br/>(1.22 to 36.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>173<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000<br/>(14 to 419) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>AEs:</b> adverse effects; <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for very serious imprecision due to very wide 95% CI (although excludes 1, there is a greater than 100‐fold difference). </p> <p><sup>2</sup> Downgraded one level for serious risk of bias as unable to truly blind due to the nature of interventions. </p> <p><sup>3</sup> Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm. </p> <p><sup>4</sup> Downgraded one level for serious imprecision due to small sample size and wide 95% CI. </p> <p><sup>5</sup> 4‐point scale: poor (extensive occurrence of scarring, atrophy, or induration), fair (slight to moderate occurrence of scarring, atrophy or induration), good (no scarring, atrophy or induration and moderate redness or increase in pigmentation compared with adjacent skin), excellent (no scarring, atrophy, or induration and slight or no redness or change in pigmentation compared with adjacent skin). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003412-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Imiquimod cream compared to MAL‐PDT for basal cell carcinoma of the skin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Imiquimod cream compared to MAL‐PDT for low‐risk BCC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from seven hospitals in the Netherlands<br/><b>Intervention:</b> 5% imiquimod cream<br/><b>Comparison:</b> MAL‐PDT </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PDT</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Imiquimod cream</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.44<br/>(0.32 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>277<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>516 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>227 per 1000<br/>(165 to 320) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.42<br/>(0.31 to 0.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>228<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>686 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>288 per 1000<br/>(213 to 391) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (excellent/good)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.84 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>370<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blinded observer‐rated at 1 year on 4‐point scale.<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>624 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>611 per 1000<br/>(524 to 723) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain (moderate/severe)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.60<br/>(0.41 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>371<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>During treatment: week of treatment with highest frequency of reported moderate/severe pain (week 6 for imiquimod, treatment cycle 2 for PDT). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>305 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1000<br/>(125 to 266) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Early treatment failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.64<br/>(0.37 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>385<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/>(59 to 172) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for serious imprecision as only a single study with a small sample size. </p> <p><sup>2</sup> Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI. </p> <p><sup>3</sup> 4‐point scale: poor, fair, good, excellent. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003412-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003412-sec-0009"></div> <section id="CD003412-sec-0010"> <h3 class="title" id="CD003412-sec-0010">Description of the condition</h3> <section id="CD003412-sec-0011"> <h4 class="title">Disease definition and burden</h4> <p>Basal cell carcinoma (BCC) is the most common skin cancer and the most common cancer found in white‐skinned individuals (<a href="./references#CD003412-bbs2-0096" title="DessiniotiC , AntoniouC , KatsambasA , StratigosAJ . Basal cell carcinoma: what’s new under the sun. Photochemistry and Photobiology2010;86(3):481-91.">Dessinioti 2010</a>; <a href="./references#CD003412-bbs2-0114" title="LomasA , Leonardi-BeeJ , Bath-HextallF . A systematic review of worldwide incidence of nonmelanoma skin cancer. British Journal of Dermatology2012;166(5):1069-80.">Lomas 2012</a>; <a href="./references#CD003412-bbs2-0115" title="MadanV , LearJT . Basal cell carcinoma. In: Rook's Textbook of Dermatology, Ninth Edition. John Wiley &amp; Sons, Ltd, 2016.">Madan 2016</a>; <a href="./references#CD003412-bbs2-0145" title="VerkouterenJA , RamdasKH , WakkeeM , NijstenT . Epidemiology of basal cell carcinoma: scholarly review. British Journal of Dermatology2017;177(2):359–72.">Verkouteren 2017</a>). BCCs are slow‐growing, locally invasive, malignant (but not life threatening), epidermal skin tumours (<a href="./references#CD003412-bbs2-0128" title="Roewert-HuberJ , Lange-AsschenfeldtB , StockflethE , KerlH . Epidemiology and aetiology of basal cell carcinoma. British Journal of Dermatology2007;157(s2):47-51.">Roewert‐Huber 2007</a>; <a href="./references#CD003412-bbs2-0148" title="WongCS , StrangeRC , LearJT . Basal cell carcinoma. BMJ2003;327(7418):794-8.">Wong 2003</a>). Patients with BCC place a considerable burden on healthcare systems worldwide due to their high, increasing incidence and associated morbidity. Furthermore, people with BCC are at high risk of developing further BCCs and other ultraviolet radiation (UVR)‐related skin cancers. As a result, the disability adjusted life years and healthcare costs of BCCs have risen significantly in recent decades (<a href="./references#CD003412-bbs2-0145" title="VerkouterenJA , RamdasKH , WakkeeM , NijstenT . Epidemiology of basal cell carcinoma: scholarly review. British Journal of Dermatology2017;177(2):359–72.">Verkouteren 2017</a>). </p> </section> <section id="CD003412-sec-0012"> <h4 class="title">Clinical features</h4> <p>Clinical appearances and morphology of BCC can be diverse (more than 26 subtypes have been described), with no universally accepted classification system. The main clinical subtypes are: nodular, superficial, ulcerated (rodent ulcer), morphoeic (sclerodermiform), fibroepithelial (fibroepithelioma of Pinkus) and advanced BCC (resulting from prolonged neglect) (<a href="./references#CD003412-bbs2-0115" title="MadanV , LearJT . Basal cell carcinoma. In: Rook's Textbook of Dermatology, Ninth Edition. John Wiley &amp; Sons, Ltd, 2016.">Madan 2016</a>). Histopathological patterns are also diverse and include: nodular, superficial, morphoeic, micronodular, infiltrative, pigmented and basosquamous or metatypical subtypes (<a href="./references#CD003412-bbs2-0095" title="CrowsonAN . Basal cell carcinoma: biology, morphology and clinical implications. Modern Pathology2006;19(S2):S127.">Crowson 2006</a>). Early BCCs may appear as a small red patch or a scab that fails to heal. Symptoms such as pain are rare. Nodular BCC (nBCC) is the most common subtype in the UK, making up to 60% of all BCCs (<a href="./references#CD003412-bbs2-0135" title="ScrivenerY , GrosshansE , CribierB . Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. British Journal of Dermatology2002;147(1):41-7.">Scrivener 2002</a>). However, in other countries such as Australia, superficial BCC (sBCC) is the most common subtype (<a href="./references#CD003412-bbs2-0125" title="RaaschBA , BuettnerPG . Multiple nonmelanoma skin cancer in an exposed Australian population. International Journal of Dermatology2002;41(10):652-8.">Raasch 2002</a>). BCCs affect the head and neck region in the majority of cases (<a href="./references#CD003412-bbs2-0135" title="ScrivenerY , GrosshansE , CribierB . Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. British Journal of Dermatology2002;147(1):41-7.">Scrivener 2002</a>). A recent UK study of first registered BCCs in the population identified BCCs affected the head and neck region around 70% of the time and the trunk and extremities around 30% of the time (<a href="./references#CD003412-bbs2-0144" title="VenablesZC , NijstenTA , WongKF , AutierP , BroggioJ , DeasA , et al. Epidemiology of basal and cutaneous squamous cell carcinoma in the United Kingdom 2013-2015: a cohort study. British Journal of Dermatology 2019 Mar 12 [Epub ahead of print]. [DOI: 10.1111/bjd.17873]">Venables 2019</a>). </p> <p>Clinicopathological features of the tumours can be used to differentiate them into high‐risk and low‐risk subtypes, which has implications on the management approach. High‐risk BCCs include: morphoeic, infiltrative, micronodular histological subtypes; presence of perineural or perivascular invasion; size &gt; 5 cm; recurrent lesion; centrofacial location, including periocular and ears and host immunosuppression (<a href="./references#CD003412-bbs2-0115" title="MadanV , LearJT . Basal cell carcinoma. In: Rook's Textbook of Dermatology, Ninth Edition. John Wiley &amp; Sons, Ltd, 2016.">Madan 2016</a>). Low‐risk BCCs include: superficial and nodular histological subtypes when they are located on a low‐risk site (e.g. not centrofacial location). </p> </section> <section id="CD003412-sec-0013"> <h4 class="title">Natural history</h4> <p>BCCs are usually slow‐growing tumours that only very rarely metastasize (spread) to other distant parts of the body (0.0028% to 0.55% of advanced BCCs metastasize) (<a href="./references#CD003412-bbs2-0140" title="TingPT , KasperR , ArletteJP . Metastatic basal cell carcinoma: report of two cases and literature review. Journal of Cutaneous Medicine and Surgery2005;9(1):10-5.">Ting 2005</a>). In people with a competent immune system, growth of a BCC is usually localised to the area of origin. BCCs tend to infiltrate surrounding tissues in a three‐dimensional fashion through the irregular growth of finger‐like projections which may not be apparent clinically (<a href="./references#CD003412-bbs2-0091" title="BreuningerH , DietzK . Prediction of subclinical tumor infiltration in basal cell carcinoma. Journal of Dermatologic Surgery and Oncology1991;17(7):574-8.">Breuninger 1991</a>; <a href="./references#CD003412-bbs2-0117" title="MillerSJ . Biology of basal cell carcinoma (part 1). Journal of the American Academy of Dermatology1991;24(1):1-13.">Miller 1991</a>). If left untreated, or inadequately treated, the BCC can cause extensive tissue destruction, particularly on the face. Neglected cases may even infiltrate bone and deeper structures, like the brain. The clinical course of BCC is unpredictable; it may remain small for years with little tendency to grow, it may grow rapidly, or it may proceed by successive spurts of extension of tumour and partial regression (<a href="./references#CD003412-bbs2-0100" title="FranchimontC , PierardGE , CauwenbergeD , AndcMD , LapiereH . Episodic progression and regression of basal cell carcinomas. British Journal of Dermatology1982;106(3):305-10.">Franchimont 1982</a>). </p> </section> <section id="CD003412-sec-0014"> <h4 class="title">Epidemiology and causes</h4> <p>Considerable variation exists in the literature for incidence rates of BCC. Latitude, sun exposure and skin type of a country's inhabitants contribute to much of this variation. Additionally, despite being common tumours, numbers of BCCs recorded in cancer registries are frequently underestimated due to their high volume and low perceived risk and often they are treated without a confirmatory biopsy. Depending on the registry, it is estimated that between 30% to 50% of BCCs are unreported (<a href="./references#CD003412-bbs2-0122" title="National Cancer Intelligence Network (NCIN). Data Briefing. The importance of skin cancer registration; September 2010. Available at www.ncin.org.uk/publications/data_briefings/skin_cancer_registration.">NCIN 2010</a>). However, since 2013 the UK has vastly improved registry data collection and now records all cases of BCC and squamous cell carcinoma (SCC). This has greatly improved the accuracy of epidemiological analysis of keratinocyte cancers and the UK now has the largest population‐based keratinocyte cancer registry in the world (<a href="./references#CD003412-bbs2-0144" title="VenablesZC , NijstenTA , WongKF , AutierP , BroggioJ , DeasA , et al. Epidemiology of basal and cutaneous squamous cell carcinoma in the United Kingdom 2013-2015: a cohort study. British Journal of Dermatology 2019 Mar 12 [Epub ahead of print]. [DOI: 10.1111/bjd.17873]">Venables 2019</a>). From 2013 to 2015, the European age standardised incidence rate of BCC in the UK was 285 per 100,000 people annually. The highest BCC rate was observed in Southwest England with 362 per 100,000 people annually. </p> <p>Direct comparison of incidence rates between countries is limited by the fact that studies often use different standardisation methods and because each country will have their own registry with different registration criteria. The highest incidence of BCC is found in Australia where in Queensland from 1997 to 2006, the rate was 1813 per 100,000 males annually and 1269 per 100,000 females annually (<a href="./references#CD003412-bbs2-0145" title="VerkouterenJA , RamdasKH , WakkeeM , NijstenT . Epidemiology of basal cell carcinoma: scholarly review. British Journal of Dermatology2017;177(2):359–72.">Verkouteren 2017</a>). Parts of Africa have the lowest reported incidence rates with less than 1 per 100,000 people annually (<a href="./references#CD003412-bbs2-0114" title="LomasA , Leonardi-BeeJ , Bath-HextallF . A systematic review of worldwide incidence of nonmelanoma skin cancer. British Journal of Dermatology2012;166(5):1069-80.">Lomas 2012</a>). In mainland Europe, there is large variation dependent on country and sex with the highest rate of 164.7 per 100,000 males annually found in the Netherlands and the lowest rate of 24.5 per 100,000 females annually observed in Croatia (<a href="./references#CD003412-bbs2-0145" title="VerkouterenJA , RamdasKH , WakkeeM , NijstenT . Epidemiology of basal cell carcinoma: scholarly review. British Journal of Dermatology2017;177(2):359–72.">Verkouteren 2017</a>). In the USA, California had the highest incidence rate of 1069 per 100,000 males annually. Data from the USA provides compelling evidence for the role of decreasing geographical latitude on increasing BCC incidence with a rate in New Hampshire (43 degrees) of 309.9 per 100,000 males annually (<a href="./references#CD003412-bbs2-0110" title="KaragasMR , GreenbergER , SpencerSK , StukelTA , MottLA . Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. International Journal of Cancer1999;81(4):555–9.">Karagas 1999</a>) whereas in Arizona (35 degrees) the rate is 935.9 per 100,000 males annually (<a href="./references#CD003412-bbs2-0104" title="HarrisRB , GriffithK , MoonTE . Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona. Journal of the American Academy of Dermatology2001;45(4):528–36.">Harris 2001</a>). The studies reporting these incidence rates both used the same standardisation method. </p> <p>The incidence of BCC is increasing globally. A systematic review identified that incidence is increasing in Europe by 5.5% annually (<a href="./references#CD003412-bbs2-0114" title="LomasA , Leonardi-BeeJ , Bath-HextallF . A systematic review of worldwide incidence of nonmelanoma skin cancer. British Journal of Dermatology2012;166(5):1069-80.">Lomas 2012</a>), and the study by <a href="./references#CD003412-bbs2-0144" title="VenablesZC , NijstenTA , WongKF , AutierP , BroggioJ , DeasA , et al. Epidemiology of basal and cutaneous squamous cell carcinoma in the United Kingdom 2013-2015: a cohort study. British Journal of Dermatology 2019 Mar 12 [Epub ahead of print]. [DOI: 10.1111/bjd.17873]">Venables 2019</a> calculated a mean annual percentage increase of 5% between 2013 to 2015 for both BCC and SCC across the UK. In the USA, the incidence is increasing by around 2% annually (<a href="./references#CD003412-bbs2-0145" title="VerkouterenJA , RamdasKH , WakkeeM , NijstenT . Epidemiology of basal cell carcinoma: scholarly review. British Journal of Dermatology2017;177(2):359–72.">Verkouteren 2017</a>). The Australian national surveys have shown that the incidence rate has been increasing since 1985, but that it may now be reaching a plateau (<a href="./references#CD003412-bbs2-0114" title="LomasA , Leonardi-BeeJ , Bath-HextallF . A systematic review of worldwide incidence of nonmelanoma skin cancer. British Journal of Dermatology2012;166(5):1069-80.">Lomas 2012</a>). There has been a very large increase in BCC incidence in young females in Europe and the USA that has led to a reversal of the male:female ratio, such that the ratio observed now is female &gt; male in the younger population (<a href="./references#CD003412-bbs2-0145" title="VerkouterenJA , RamdasKH , WakkeeM , NijstenT . Epidemiology of basal cell carcinoma: scholarly review. British Journal of Dermatology2017;177(2):359–72.">Verkouteren 2017</a>). Higher frequency of tanning bed use and higher likelihood of seeking medical attention in females are reasons postulated to contribute to this observed trend. </p> <p>Risk factors for BCC include: advanced age, male sex, fair skin, low ability to tan, intense intermittent UVR exposure during childhood, signs of actinic damage (skin changes due to excessive sun exposure), personal/family history of skin cancer, excessive sun bed use, phototherapy, radiotherapy, systemic immunosuppression and a genetic predisposition (<a href="./references#CD003412-bbs2-0145" title="VerkouterenJA , RamdasKH , WakkeeM , NijstenT . Epidemiology of basal cell carcinoma: scholarly review. British Journal of Dermatology2017;177(2):359–72.">Verkouteren 2017</a>). </p> <p>Germ‐line mutations can also have a large effect on the risk of developing BCC such as those seen in Gorlin syndrome (naevoid BCC syndrome). This is an autosomal (non‐sex determining chromosome) dominantly inherited condition characterised by developmental abnormalities and the occurrence of multiple BCCs. Mutations in people with Gorlin syndrome have been found on the <i>PTCH1</i> gene located on chromosome nine, which appears to be crucial for proper embryonic development and for tumour suppression (<a href="./references#CD003412-bbs2-0108" title="JohnsonRL , RothmanAL , XieJ , GoodrichLV , BareJW , BonifasJM , et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science1996;272(5268):1668-71.">Johnson 1996</a>). </p> </section> </section> <section id="CD003412-sec-0015"> <h3 class="title" id="CD003412-sec-0015">Description of the intervention</h3> <p>The primary aim of treatment is complete removal or destruction of the BCC lesion to result in cure and minimise the risk of recurrence. This should also be balanced against the patient's requirement for a good/acceptable cosmetic result (<a href="./references#CD003412-bbs2-0115" title="MadanV , LearJT . Basal cell carcinoma. In: Rook's Textbook of Dermatology, Ninth Edition. John Wiley &amp; Sons, Ltd, 2016.">Madan 2016</a>). There are numerous interventions currently available for BCC and the choice of intervention is determined by tumour factors such as the histological/clinical subtype of BCC, site, size, whether primary or recurrent tumour, as well as patient factors (e.g. co‐morbidities, importance of cosmesis) and other factors such as available resources, costs and local health economics. The different interventions are usually split into surgical and non‐surgical interventions. Generally, surgical interventions are used as first‐line treatments for both high‐risk and low‐risk BCC subtypes and non‐surgical interventions are usually reserved for low‐risk BCC subtypes where histological margins are less important (<a href="./references#CD003412-bbs2-0115" title="MadanV , LearJT . Basal cell carcinoma. In: Rook's Textbook of Dermatology, Ninth Edition. John Wiley &amp; Sons, Ltd, 2016.">Madan 2016</a>). Radiotherapy and electrochemotherapy are the exceptions as they tend to be used for high‐risk BCCs not amenable to surgical intervention. </p> <section id="CD003412-sec-0016"> <h4 class="title">Surgical (physical) interventions</h4> <p> <ul id="CD003412-list-0001"> <li> <p>Surgical excision (with predetermined margins)</p> </li> <li> <p>Surgical excision (with frozen section margin control)</p> </li> <li> <p>Mohs micrographic surgery (MMS ‐ technique that takes serial horizontal frozen sections intraoperatively to examine histologically the entire surgical margin to confirm complete tumour clearance) </p> </li> <li> <p>Curettage and cautery (synonymous for electrodesiccation)</p> </li> <li> <p>Cryosurgery (synonymous for cryotherapy, delivered by a variety of methods)</p> </li> <li> <p>Laser therapy (ablative lasers, pulsed dye laser)</p> </li> </ul> </p> </section> <section id="CD003412-sec-0017"> <h4 class="title">Non‐surgical (medical) interventions</h4> <p> <ul id="CD003412-list-0002"> <li> <p>Radiotherapy</p> </li> <li> <p>Topical imiquimod</p> </li> <li> <p>Topical 5‐fluorouracil</p> </li> <li> <p>Photodynamic therapy</p> </li> <li> <p>Ingenol mebutate</p> </li> <li> <p>Intralesional interferon, fluorouracil</p> </li> <li> <p>Electrochemotherapy</p> </li> <li> <p>Others (solasodine glycosides, sinecatechins, diclofenac, calcitriol)</p> </li> </ul> </p> </section> </section> <section id="CD003412-sec-0018"> <h3 class="title" id="CD003412-sec-0018">How the intervention might work</h3> <section id="CD003412-sec-0019"> <h4 class="title">Surgical (physical) interventions</h4> <p>Surgical excision (SE) with predetermined margins is one of the most common treatments for BCC and is often regarded as the gold‐standard. SE involves excising the tumour under local anaesthetic with a variable margin of clinically normal surrounding tissue. A key advantage of SE over non‐surgical techniques is that it allows the histological examination of the excised specimen and therefore an accurate assessment of the surgical margins. A peripheral margin of 4 mm to 5mm is usually suggested for well‐defined, small BCC (<a href="./references#CD003412-bbs2-0147" title="WolfDJ , ZitelliJA . Surgical margins for basal cell carcinoma. Archives of Dermatology1987;123(3):340-4.">Wolf 1987</a>, <a href="./references#CD003412-bbs2-0112" title="Kimyai-AsadiA , AlamM , GoldbergLH , PetersonSR , SilapuntS , JihMH . Efficacy of narrow-margin excision of well-demarcated primary facial basal cell carcinomas. Journal of the American Academy of Dermatology2005;53(3):464-8.">Kimyai‐Asadi 2005</a>) and the use of curettage prior to excision to delineate the margins of the BCC is often performed (<a href="./references#CD003412-bbs2-0093" title="ChillerK , PassaroD , McCalmontT , Vin-ChristianK . Efficacy of curettage before excision in clearing surgical margins of nonmelanoma skin cancer. Archives of Dermatology2000;136(11):1327-32.">Chiller 2000</a>). Excision through subcutaneous fat is generally advisable for the deep surgical margin, however there is a lack of evidence informing this. Factors such as the local anatomy, size and histological subtype of the BCC will influence this decision (<a href="./references#CD003412-bbs2-0139" title="TelferNR , ColverGB , MortonCA . Guidelines for the management of basal cell carcinoma. British Journal of Dermatology 2008, 2008;159(1):35-48.">Telfer 2008</a>). </p> <p>Mohs micrographic surgery (MMS) was pioneered in the 1930s by Frederic Mohs and is a specialised surgical procedure in which serial horizontal frozen sections allow the microscopic examination of the entire surgical margin during surgery (in contrast to the 1% to 2% of the margin asseessed by "bread‐loafing" of vertical sections examined with standard excision), so that the extent of excision can be defined precisely (<a href="./references#CD003412-bbs2-0115" title="MadanV , LearJT . Basal cell carcinoma. In: Rook's Textbook of Dermatology, Ninth Edition. John Wiley &amp; Sons, Ltd, 2016.">Madan 2016</a>). The technique produces very high cure rates and is often used as the gold‐standard for high‐risk facial BCC. Another important benefit is that it allows for tissue sparing as smaller margins than SE can be taken. </p> <p>Similar to MMS is the technique of surgical excision with frozen section margin control, which employs a similar serial frozen section technique but often with standard excision margins. Frozen section margin control also differs from MMS in that excision of the tumour and an accompanying annular strip of surrounding tissue is performed with vertical margins (<a href="./references#CD003412-bbs2-0123" title="NizamogluM , DouglasH , McArdleC , MathewB , VizeC , MatteucciP . Using frozen section margin control technique to manage non-melanomatous skin lesions in high-risk sites. Journal of Plastic, Reconstructive &amp; Aesthetic Surgery2016;69(5):657-62.">Nizamoglu 2016</a>; <a href="./references#CD003412-bbs2-0006" title="AvrilMF , AuperinA , MargulisA , GerbauletA , DuvillardP , BenhamouE , et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. British Journal of Cancer1997;76(1):100-6. [CENTRAL: CN-00141470] PetitJY , AvrilMF , MargulisA , ChassagneD , GerbauletA , DuvillardP , et al. Evaluation of cosmetic results of a randomised trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plastic and Reconstructive Surgery2000;105(7):2544-51. [CENTRAL: CN-00278207] ">Avril 1997</a>). </p> <p>Curettage and cautery (C&amp;C) and curettage alone are traditional surgical BCC treatment methods that are sometimes used for small, low‐risk BCCs. There is wide variation in the protocols and techniques used, including type of curette used (e.g. Volkmann spoon curette, disposable loop curette) and the number of treatment cycles. The procedure normally destroys epidermis and upper dermis and therefore scarring tends to be mild (<a href="./references#CD003412-bbs2-0115" title="MadanV , LearJT . Basal cell carcinoma. In: Rook's Textbook of Dermatology, Ninth Edition. John Wiley &amp; Sons, Ltd, 2016.">Madan 2016</a>). Curetted tissue is usually histologically examined but assessment of surgical margins is usually not possible. </p> <p>Cryosurgery involves the direct application of liquid nitrogen to freeze a BCC lesion to between ‐50 °C and ‐60 °C resulting in destruction of both the tumour and a margin of surrounding normal tissue (<a href="./references#CD003412-bbs2-0139" title="TelferNR , ColverGB , MortonCA . Guidelines for the management of basal cell carcinoma. British Journal of Dermatology 2008, 2008;159(1):35-48.">Telfer 2008</a>). Techniques and liquid nitrogen delivery methods are variable and protocols differ including number of freeze‐thaw cycles. <a href="./references#CD003412-bbs2-0116" title="MallonE , DawberR . Cryosurgery in the treatment of basal cell carcinoma: assessment of one and two freeze‐thaw cycle schedules. Dermatologic Surgery1996;22(10):854-8.">Mallon 1996</a> showed that a double 30‐second freeze‐thaw cycle achieved higher cure rates than a single freeze‐thaw cycle for facial BCC, and that a single freeze‐thaw cycle achieves high cure rates for truncal BCC. </p> <p>Ablative lasers (e.g. carbon dioxide laser) utilise their tissue‐heating properties to destroy BCC with high accuracy but this technique does not allow any histological examination and consequently it is not suitable for high‐risk lesions. It is therefore not widely used in the treatment of BCC. There are some data suggesting that, following ablative laser treatment, recurrent BCC can develop into a more aggressive histological subtype (<a href="./references#CD003412-bbs2-0109" title="JungDS , ChoHH , KoHC , BaeYC , OhCK , KimMB , et al. Recurrent basal cell carcinoma following ablative laser procedures. Journal of the American Academy of Dermatology2011;64(4):723-9.">Jung 2011</a>). Pulsed dye laser is generally used to treat vascular skin lesions and is also used as a treatment for thin, low‐risk BCCs based on the observation that they are often highly vascular with clinically evident telangiectasias (dilated blood vessels) (<a href="./references#CD003412-bbs2-0136" title="ShahSM , KonnikovN , DuncanLM , TannousZS . The effect of 595 nm pulsed dye laser on superficial and nodular basal cell carcinomas. Lasers in Surgery and Medicine2009;41(6):417-22.">Shah 2009</a>). </p> </section> <section id="CD003412-sec-0020"> <h4 class="title">Non‐surgical (medical) interventions</h4> <p>Radiotherapy involves directing ionising radiation to destroy tumour tissue and a margin of surrounding normal tissue. Several different techniques and methods are currently used including conventional X‐ray therapy, interstitial brachytherapy and superficial contact therapy with the choice of technique dependent on factors such as size and location of the lesion and performance status of the patient (<a href="./references#CD003412-bbs2-0139" title="TelferNR , ColverGB , MortonCA . Guidelines for the management of basal cell carcinoma. British Journal of Dermatology 2008, 2008;159(1):35-48.">Telfer 2008</a>). Radiotherapy can be used for high‐risk (including recurrent tumours) and low‐risk BCCs and is often the first‐line for high‐risk BCCs in patients who do not want surgical intervention. Radiotherapy is usually only available at specialist hospital centres due to the high costs of the equipment and need for a clinical oncologist to decide on the treatment regimen. Usually the treatment is given in a fractionated regimen which requires multiple hospital visits over several days to weeks. Importantly, radiotherapy should not be used in the treatment of previously radiotherapy‐treated recurrent BCCs and is contraindicated in patients with Gorlin syndrome as they have a increased radiosensitivity and can develop multiple BCCs within a field of radiation (<a href="./references#CD003412-bbs2-0113" title="KleinermanRA . Radiation-sensitive genetically susceptible pediatric sub-populations. Pediatric Radiology2009;39(1):27-31.">Kleinerman 2009</a>). </p> <p>Imiquimod is an immunomodulator topical treatment that works by stimulating toll‐like receptors‐7 and ‐8, present on immune cells, inducing interferon‐α which promotes a Th1 innate and adaptive cell‐mediated immune response. This results in the recognition and subsequent destruction of tumour cells by the immune system (<a href="./references#CD003412-bbs2-0098" title="DummerR , UrosevicM , KempfW , HoekK , HafnerJ , BurgG . Imiquimod in basal cell carcinoma: how does it work?British Journal of Dermatology2003;149:57-8.">Dummer 2003</a>). Imiquimod is licensed in the treatment of low‐risk BCCs up to 2 cm diameter in immunocompetent patients and the treatment regimen is five times per week for six weeks (sBCC) or 12 weeks (nBCC). It is fairly common for patients to experience influenza‐like symptoms (due to the interferon release) and local application‐site reactions are common. </p> <p>5‐fluorouracil (5‐FU) is a pyrimidine analogue that disrupts DNA and RNA synthesis by inhibiting the enzyme thymidylate synthetase, thereby preventing purine and pyrimidine (DNA/RNA building blocks) from becoming incorporated into DNA during the cell‐cycle (<a href="./references#CD003412-bbs2-0138" title="SloanKB , SherertzEF , McTiernanRG . The effect of 5-fluorouracil on inhibition of epidermal DNA synthesis in vivo: a comparison of the effect of formulations and a prodrug of 5-FU. Archives of Dermatological Research1990;282(7):484-6.">Sloan 1990</a>). 5‐FU cream is commonly used in the treatment of pre‐malignant actinic keratosis (AK) and Bowen disease and is less commonly used in the treatment of small, low‐risk BCC. Application site reactions are common. 5‐FU can also be administered intralesionally to treat low‐risk BCC. </p> <p>Photodynamic therapy (PDT) is a procedure that involves the application of a photosensitiser to BCC lesions and surrounding normal skin. It relies on the principle that the sensitiser accumulates in higher concentration within rapidly proliferating malignant cells compared to cells in adjacent normal tissues. The photosensitiser is activated by visible light of certain wavelengths which produces cytotoxic oxygen species and free radicals that selectively destroy the tumour cells (<a href="./references#CD003412-bbs2-0101" title="FritschC , GoerzG , RuzickaT . Photodynamic therapy in dermatology. Archives of Dermatology1998;134(2):207-14.">Fritsch 1998</a>). Systemic PDT is utilised for some solid organ tumours, however in dermatology the mainstay of PDT is topical using the photosensitisers 5‐aminolevulinic acid (ALA; Levulan® Kerastick®, Ameluz® and Alacare®), the methyl ester of ALA, methyl aminolevulinate (MAL; Metvix®/Metvixia®) and more recently hexylaminolevulinate (HAL, Hexvix®) has been used. These photosensitisers utilise the principles of the haem biosynthesis pathway, acting as pro‐drugs that enter and accumulate in cells and are metabolised to form protoporphyrin IX which accumulates in the target tissue (<a href="./references#CD003412-bbs2-0107" title="IbbotsonS , McKennaK . Principles of photodynamic therapy. In: Rook's Textbook of Dermatology, Ninth Edition. John Wiley &amp; Sons, Ltd, 2016.">Ibbotson 2016</a>). Protoporphyrin IX is a potent and efficient photosensitiser when it is present in high concentration and can be activated by light of the appropriate wavelengths (<a href="./references#CD003412-bbs2-0107" title="IbbotsonS , McKennaK . Principles of photodynamic therapy. In: Rook's Textbook of Dermatology, Ninth Edition. John Wiley &amp; Sons, Ltd, 2016.">Ibbotson 2016</a>). </p> <p>Ingenol mebutate is a topical treatment derived from the plant <i>Euphorbia peplus</i> and is licensed in the treatment of AK. It has a dual mechanism of action whereby it destroys epidermal cells within hours and induces production of antibodies that result in neutrophils targeted to kill any residual dysplastic epidermal cells (<a href="./references#CD003412-bbs2-0129" title="RosenRH , GuptaAK , TyringSK . Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. Journal of the American Academy of Dermatology2012;66(3):486-93.">Rosen 2012</a>). </p> <p>Intralesional interferon utilises the principles of the naturally occurring interferon family of proteins. These proteins are secreted by cells in response to viral infections and function by binding to promote Th1 innate and adaptive cell‐mediated immune responses than can be harboured to destroy tumour cells (<a href="./references#CD003412-bbs2-0141" title="TuckerSB , PolasekJW , PerriAJ , GoldsmithEA . Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. Journal of the American Academy of Dermatology2006;54(6):1033-8.">Tucker 2006</a>). The treatment usually needs to be delivered over multiple sessions and is expensive which limits its widespread use. Systemic side‐effects are common (<a href="./references#CD003412-bbs2-0115" title="MadanV , LearJT . Basal cell carcinoma. In: Rook's Textbook of Dermatology, Ninth Edition. John Wiley &amp; Sons, Ltd, 2016.">Madan 2016</a>). </p> <p>Electrochemotherapy (ECT) involves permeating cytotoxic agents (classically bleomycin) into the tumour using short electric pulses (a process known as electroporation), resulting in a direct cytotoxic effect (<a href="./references#CD003412-bbs2-0092" title="CampanaLG , MarconatoR , ValpioneS , GaluppoS , AlaibacM , RossiCR , et al. Basal cell carcinoma: 10-year experience with electrochemotherapy. Journal of Translational Medicine2017;15(1):122.">Campana 2017</a>). </p> <p>Zycure cream is a mixture of 0.005% solasodine glycosides (mainly solasonine and solamargine) found in solanaceous plants of the nightshade family, such as aubergine (<a href="./references#CD003412-bbs2-0035" title="PunjabiS , CookLJ , KerseyP , MarksR , CerioR . Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicentre study. International Journal of Dermatology2008;47(1):78-82. [CENTRAL: CN-00629144] PunjabiS , CookLJ , KerseyP , MarksR , FinlayA , SharpG , et al. A double-blind, multicentre parallel group study of BEC-5 cream in basal cell carcinoma. European Academy of Dermatology &amp; Venereology2000;14(Suppl 1):49. [CENTRAL: CN-01616931] ">Punjabi 2008</a>). The mechanism of action of these compounds is thought to involve direct cell lysis and induction of apoptosis with selectivity towards tumour cells (<a href="./references#CD003412-bbs2-0143" title="van derMostRG , HimbeckR , AaronsS , CarterSJ , LarmaI , RobinsonC , et al. Antitumor efficacy of the novel chemotherapeutic agent coramsine is potentiated by cotreatment with CpG-containing oligodeoxynucleotides. Journal of Immunotherapy2006;29(2):134-42.">van der Most 2006</a>). </p> <p>Sinecatechin ointment contains epigallocatechin‐3‐gallate (EGCG) which is an active constituent of green tea. It is licensed in the treatment of genital warts and has been shown to have cytotoxic effects on tumours cells through inhibition of cell growth, induction of apoptosis and possible inactivation of β‐catenin signalling through the Wingless (Wnt) pathway (<a href="./references#CD003412-bbs2-0137" title="SinghT , KatiyarSK . Green tea polyphenol,(−)-epigallocatechin-3-gallate, induces toxicity in human skin cancer cells by targeting β-catenin signaling. Toxicology and Applied Pharmacology2013;273(2):418-24.">Singh 2013</a>). </p> <p>Sonic hedgehog pathway inhibitors target the approximate 90% of BCC that have mutations in genes causing unregulated activation of the sonic hedgehog pathway. Oral hedgehog pathway inhibitors (vismodegib and sonidegib) are licensed for the treatment of metastatic BCC and locally advanced BCC not appropriate for surgery or radiotherapy (<a href="./references#CD003412-bbs2-0115" title="MadanV , LearJT . Basal cell carcinoma. In: Rook's Textbook of Dermatology, Ninth Edition. John Wiley &amp; Sons, Ltd, 2016.">Madan 2016</a>). Trials are under way assessing the safety and efficacy of topical hedgehog inhibitors for BCCs in Gorlin syndrome patients, but none of these studies met our inclusion criteria. </p> </section> <section id="CD003412-sec-0021"> <h4 class="title">Intervention outcomes</h4> <p>The ideal outcome of any intervention to treat a BCC would be to achieve complete clearance with no recurrence at follow‐up, and to fulfil satisfactory cosmetic results with minimal risk of discomfort or adverse effects before or after the intervention. All interventions have the potential to fall short of these expectations to varying degrees. The more complete the removal or destruction of the lesion, the lower the risk of recurrence, but both modes of tumour eradication unfortunately cause localised tissue damage. The resultant inflammation can lead to adverse effects such as pain, erythema, bleeding, crusting, vesicles, oedema, and paraesthesia. Pain of varying degrees is one of the more common adverse effects, and therefore has the potential to influence the patient’s treatment choice and/or adherence. After the initial inflammatory phase lasting a week or so, a healing wound undergoes a three‐week proliferation stage during which collagen is deposited and a scar begins to form. This is followed by a remodelling stage lasting a year, during which collagen cross‐linking occurs and the scar matures (<a href="./references#CD003412-bbs2-0120" title="MulhollandMW , LillemoeKD , DohertyGM , MaierRV , SimeoneDM , UpchurchGR . Greenfield's surgery: Scientific principles &amp; practice. Lippincott Williams &amp; Wilkins, 2012.">Mulholland 2012</a>). Other undesired post‐inflammatory cosmetic outcomes include hypo‐ and hyper‐pigmentation. </p> </section> </section> <section id="CD003412-sec-0022"> <h3 class="title" id="CD003412-sec-0022">Why it is important to do this review</h3> <p>BCC is common, continuously rising in incidence and is associated with significant morbidity and costs to healthcare systems. Although there are a wide variety of treatment modalities used in the management of BCCs, and the vast majority of the tumours are successfully treated, little research is available which accurately compares these different treatment modalities. </p> <p>It is essential for both healthcare providers and patients to have the best available evidence so that they can weigh up the risks and benefits of the available treatments; to allow and promote shared decision making. </p> <p>Since the publication of the previous version of this review (<a href="./references#CD003412-bbs2-0150" title="Bath‐HextallFJ , PerkinsW , BongJ , WilliamsHC . Interventions for basal cell carcinoma of the skin. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD003412. [DOI: 10.1002/14651858.CD003412.pub2]">Bath‐Hextall 2007</a>), the results of several long‐term studies on interventions for BCC have become available and several novel, non‐surgical treatments have been developed and entered into clinical trials making this update timely and necessary. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003412-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003412-sec-0023"></div> <p>To assess the effects of interventions for basal cell carcinoma (BCC) in immunocompetent adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003412-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003412-sec-0024"></div> <section id="CD003412-sec-0025"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003412-sec-0026"> <h4 class="title">Types of studies</h4> <p>We included published and unpublished randomised controlled trials (RCTs) of interventions for basal cell carcinoma (BCC). We aimed to identify all relevant RCTs regardless of language or publication status (published, unpublished, in press, or in progress). </p> </section> <section id="CD003412-sec-0027"> <h4 class="title">Types of participants</h4> <p>All immunocompetent adults who have one or more histologically‐proven, primary BCC, who were eligible for randomisation to either active treatment, placebo, other treatment or no treatment were included. Persistent (where a number of treatments have been tried with no success) or recurrent tumours have been excluded. Studies including participants with Gorlin syndrome (basal cell naevus syndrome), organoid naevi or other genetic syndromes have been excluded. Excluding such patients from trials is commonplace as the aetiology of the BCCs are different and treatments are known to work differently (for example radiotherapy can increase risk of developing further BCCs in Gorlin syndrome) and with large numbers of lesions, confounding of results can occur. </p> </section> <section id="CD003412-sec-0028"> <h4 class="title">Types of interventions</h4> <p>Treatments for BCC including the following.</p> <section id="CD003412-sec-0029"> <h5 class="title">1. Surgical (physical)</h5> <p> <ul id="CD003412-list-0003"> <li> <p>Surgical excision</p> </li> <li> <p>Mohs micrographic surgery</p> </li> <li> <p>Curettage and cautery</p> </li> <li> <p>Cryosurgery</p> </li> <li> <p>Laser therapy (ablative lasers, pulsed dye laser)</p> </li> </ul> </p> </section> <section id="CD003412-sec-0030"> <h5 class="title">2. Non‐surgical (medical)</h5> <p> <ul id="CD003412-list-0004"> <li> <p>Radiotherapy</p> </li> <li> <p>Topical imiquimod</p> </li> <li> <p>Topical 5‐fluorouracil</p> </li> <li> <p>Photodynamic therapy (using any photosensitiser or light source)</p> </li> <li> <p>Ingenol mebutate</p> </li> <li> <p>Intralesional interferon</p> </li> <li> <p>Electrochemotherapy</p> </li> <li> <p>Others (solasodine glycosides, tazarotene, valproic acid, sinecatechins, diclofenac, calcitriol) </p> </li> </ul> </p> </section> </section> <section id="CD003412-sec-0031"> <h4 class="title">Types of outcome measures</h4> <section id="CD003412-sec-0032"> <h5 class="title">Primary outcomes</h5> <p>1. Recurrence at three years and five years, measured clinically (to reflect what actually happens in clinical practice). Rather than exclude potentially clinically useful data, we included recurrence data that fell outside our primary outcome time points if data were not available for three and five years. </p> <p>2. Cosmetic outcome (participant‐ and observer‐rated). We have included any validated method for assessing cosmetic outcome including the four‐point scale, the Vancouver scar scale and the Patient and Observer Scar Assessment Scale (POSAS) (<a href="./references#CD003412-bbs2-0119" title="MosterdK , AritsAH , NelemansPJ , Kelleners-SmeetsNW . Aesthetic evaluation after non-invasive treatment for superficial basal cell carcinoma. Journal of the European Academy of Dermatology and Venereology : JEADV2013;27(5):647-50. [DOI: 10.1111/j.1468-3083.2011.04347.x]">Mosterd 2013</a>). We did not pre‐specify a time point for our cosmetic outcome but aimed to include outcomes measured after at least one year (minimum time taken for a scar to mature). If multiple time points were reported, we reported the closest time point to one year (but not less than one year). </p> </section> <section id="CD003412-sec-0033"> <h5 class="title">Secondary outcomes</h5> <p>1. Pain during treatment and thereafter. We included any pain reported, but prioritised outcomes that included a measure of severity e.g. 'moderate/severe pain' reported by participants as well as pain measured by visual analogue scale (VAS). We did not specify how long after treatment to measure the pain outcome but included any pain measurement if it was recorded in the follow‐up period. Due to the varied nature of pain and manner in which it is recorded, we also collated pain data into <a href="#CD003412-tbl-0006">Table 1</a>. </p> <div class="table" id="CD003412-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Pain table</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study (comparator)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Analgesia</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assessment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Severe pain</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Other notable outcomes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0003" title="Abd El-NabyNM , El-FarNN , Al-Shenawy HA , ElshwadfySE , KouraAA . Pulsed dye laser in the treatment of basal cell carcinoma: a single session versus two sessions–a randomized controlled trial. Indian Journal of Dermatology, Venereology, and Leprology2019;85(5):475. ">Abd El‐Naby 2019</a> (one PDL session / two PDL sessions) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 2 patients experienced pain and ulceration in the single‐session group. There was no significant difference between the two groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0004" title="AlpsoyE , YikmazE , BasaranE , YazarS . Comparison of the effects of intralesional interferon alfa-1a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. Journal of Dermatology1996;23(6):394-6. [CENTRAL: CN-00127615] ">Alpsoy 1996</a> (Interferon alpha 2a / 2b / 2a&amp;b) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transient local discomfort at injection site (requiring no treatment) experienced in all patients during injection. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a> (MAL PDT / Imiquimod / 5‐FU) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weekly post‐treatment patient‐reported maximum score for pain and burning sensation on a visual analogue scale (0–10) for six weeks, and maximum score during the first and second photodynamic therapy sessions. Categorised as 0‐3 = mild, 4‐6 moderate, 7‐10 = severe. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Highest overall percentage experienced pain during second PDT treatment (10%). Highest severe pain rating in imiquimod group found at week 6 (7%) and in Fluorouracil group at week 4 (4%). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maximum duration of pain and burning sensation: Imiquimod group = 6 weeks, Fluorouracil group = 4 weeks, PDT group = 2 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0007" title="Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Methyl aminolaevulinate photodynamic therapy vs. cryotherapy in primary superficial basal cell carcinoma: results of a 36-month follow-up. British Journal of Dermatology2005;153(1):29. Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Topical methyl aminolevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. European Journal of Dermatolology2008;18(5):547-53. [CENTRAL: CN-00668120] ">Basset‐Seguin 2008</a> (MAL‐PDT / cryosurgery) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs at each follow‐up visit up to three months post‐treatment according to three‐point severity scale (mild/moderate/severe). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1% in cryosurgery group and 5% in MAL‐ PDT group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Local pain in 33% in cryosurgery group compared to 37% in MAL‐PDT group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0008" title="Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , MillerPS , et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncology2014;15(1):96-105. [CENTRAL: CN-00959373] WilliamsHC , Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. Journal of Investigative Dermatology2017;137(3):614-9. [CENTRAL: CN-01340067] [EMBASE: 614596349]">Bath‐Hextall 2014</a> (Imiquimod / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Routine analgesia after surgery. 1 week break and restart at lower frequency of application if unable to tolerate Imiquimod. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During treatment and at 16 weeks using six‐point scale. Number of days of moderate to severe pain. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30% of patients in the imiquimod group and 22% patients in the SE group had moderate or severe pain at some time during treatment. </p> <p>9% of patients treated with imiquimod had moderate or severe pain in the 16 weeks after treatment compared with 20% of patients who underwent SE. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>More patients reported pain during treatment in imiquimod group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0010" title="BrinkhuizenT , FrenckenKJ , NelemansPJ , HoffML , Kelleners-SmeetsNW , Zur HausenA , et al. The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): a phase II, randomized controlled trial. Journal of the American Academy of Dermatology2016;75(1):126-34. [CENTRAL: CN-01342883] [DOI: 10.1016/j.jaad.2016.01.050]">Brinkhuizen 2016</a> (diclofenac / diclofenac and calcitriol / calcitriol and no treatment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weekly patient‐reported pain score on a VAS (0–10).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain at application site most likely to occur in the combination therapy group (40.6%) as compared to the diclofenac group (25.8%) and the calcitriol group (12.5%). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0011" title="ChoiSH , KimKH , SongKH . Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial. Journal of the European Academy of Dermatology and Venereology2015;30(5):783-8. [CENTRAL: CN-01158122] [DOI: 10.1111/jdv.13453]">Choi 2016</a> (Er:YAG AFL‐PDT / MAL‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaesthetic cream prior to procedure.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS scores (11‐point scale) during illumination.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All patients experienced mild to moderate pain during PDT illumination. After illumination had ceased, the pain intensity immediately lessened, resolving over the next few hours. VAS scores (11‐point scale) during illumination were similar with Er:YAG AFL‐PDT (4.632 +/‐1.257) and MAL‐PDT (4.222 +/‐ 1.865; P = 0.437). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0017" title="EzughahFI , DaweRS , IbbotsonSH , FlemingCJ . A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment2008;19(2):111-7. [CENTRAL: CN-00706567] ">Ezughah 2008</a> (Imiquimod 8 weeks / 5 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients with intolerable reactions were allowed a rest period.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weekly visual analogue scale scores (10‐point scale).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One patient in 8‐week arm failed to complete course due to severe pain.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Composite weekly median VAS scores for tolerability are low, suggesting little discomfort in both study arms; there was no overall difference between the two groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0018" title="FoleyP , FreemanM , MenterA , SillerG , El-AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] FoleyP , FreemanM , SillerG , GebauerK , MurrellD , BarnetsonR , et al. A phase III randomized study comparing photodynamic therapy (PDT) using methyl aminolevulinate or placebo cream in nodular basal cell carcinoma (NBCC). Journal of the European Academy of Dermatology and Venereology2003;17(Suppl 3):231. [CENTRAL: CN-00478536] ">Foley 2009a</a>/<a href="./references#CD003412-bbs2-0019" title="FoleyP , FreemanM , MenterA , SillerG , El‐AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] TopeWD , MenterA , El AzharyR , SotoP . A comparison of topical MAL-PDT versus placebo-PDT in nodular basal cell carcinoma: results of a North American study. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology; 2005 Sep 28-Oct 03; Kuala Lumpur, Malaysia. 2005:376. [CENTRAL: CN-00602617] ">Foley 2009b</a> (MAL‐PDT / placebo) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects noted at each follow‐up visit and rated as mild/moderate/severe.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Burning more common than stinging or other skin pain. 29% in treatment arm compared to 12% in placebo group. Pain = 18% and 5%, respectively, stinging = 15% and 8%, respectively. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0020" title="Garcia-MartinE , Gil-ArribasLM , IdoipeM , AlfaroJ , PueyoV , PabloLE , et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. British Journal of Ophthalmology2011;95(10):1393-6. [CENTRAL: CN-00801928] ">Garcia‐Martin 2011</a> (Imiquimod / radiotherapy) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tobramycin and dexamethasone drops supplied if pain reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects noted at each follow‐up visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intense conjunctival irritation reported in 2 patents in the Imiquimod group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50% of the patients in the radiotherapy group compared to 60% in the imiquimod group reported symptoms of discomfort with blinking during treatment. One patient complained of slight pain in the lower eyelid during radiotherapy treatment. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0021" title="GeisseJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating superficial BCC. In: The 8th World Congress on Cancer of the Skin; 2001 July 18-21; Zurich, Switzerland. 2001:P58. [CENTRAL: CN-00520431] GeisseJK , RichP , PandyaA , GrossK , AndresK , GinkelA , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a randomized, vehicle-controlled study. Journal of the American Academy of Dermatology2002;47(3):390-8. [CENTRAL: CN-00390933] ">Geisse 2002</a> (Imiquimod BD / OD / 5xpw / 3xpw / vehicle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rest period of up to 14 days allowed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient‐reported adverse effects at each visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain and tenderness at the target site were reported less frequently than itching.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0022" title="GeisseJ , CaroI , LindholmJ , GolitzL , StamponeP , OwensM . Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology2004;50(5):722-33. [CENTRAL: CN-00469536] ">Geisse 2004</a> (Imiquimod 5xpw / 7xpw / vehicle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rest period allowed during which light dressing / emollient could be used.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient‐reported adverse effects at each visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient‐reported adverse effects at each visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0023" title="HaakCS , Togsverd-BoK , Thaysen-PetersenD , WulfHC , PaaschU , AndersonRR , et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas - a randomized clinical trial. British Journal of Dermatology2015;172(1):215-22. [CENTRAL: CN-01039978] ">Haak 2015</a> (AFXL‐PDT / MAL‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mepivacaine 10mg/mL injected prior to procedure.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain scores during LED illumination, scored from 0‐10.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>“AFXL pre‐treatment did not influence median pain scores during LED illumination and pain intensities were similar at first and second illumination: first treatment AFXL‐PDT median 3 (IQR 2–55) vs MAL‐PDT 35 (25–5), second treatment AFXL‐PDT 35 (3–65) vs MAL‐PDT 3 (3–45), (P&gt;0519). The presumed enhanced uptake of MAL did not affect the pain level during illumination. Pain scores were similar during AFXL‐PDT and MAL‐PDT and rated as mild to moderate.” </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0025" title="KarsaiS , FriedlH , BuhckH , JüngerM , PoddaM . The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: Outcome of a double-blind randomized placebo-controlled trial. British Journal of Dermatology2015;172(3):677-83. [CENTRAL: CN-01068975] ">Karsai 2015</a> (PDL / sham) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain intensity using a VAS (0 cm = ‘no pain’ to 10 cm = ‘maximal pain’) at every visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>“The following median values were indicated on the pain intensity scale (ordinal scale 0–10) among patients at the four treatment sessions surveyed (minimum–maximum): Laser treatment: 2 (0–6), 3 (0–6), 3 (0–8) and 4 (0–9); Sham treatment: 0 (0–1), 0 (0–1), 0 (0–1) and 0 (0–2).” </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0026" title="KesselsJ , VoetenL , NelemansP , CleutjensJ , HillenLM , MosterdK , et al. Topical sinecatechins, 10%, ointment for superficial basal cell carcinoma: A randomized clinical trial. JAMA Dermatology2017;153(10):1061-3. [CENTRAL: CN-01420948] ">Kessels 2017</a> (Sinecatechins / placebo) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral paracetamol for local skin reactions (if severe, treatment could be stopped for 1 week) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective symptoms including pain were recorded in personal diary kept by patients once a week during treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A burning sensation was reported in the treatment group in 5% of patients, at week four compared to 1% in the treatment group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0027" title="KesselsJP , KreukelsH , NelemansPJ , RoozeboomMH , vanPeltH , MosterdK , et al. Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5‐aminolaevulinic acid 20% vs. two‐stage topical methyl aminolaevulinate: results of a randomized controlled trial. British Journal of Dermatology2018;178(5):1056-63. [CENTRAL: CN-01991773] ">Kessels 2018</a> (MAL‐PDT / two‐fold fractionated ALA‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain and burning sensation</p> <p>were scored using a numerical rating scale (score 0–10),</p> <p>directly after both illuminations and 1 week later. The maximum</p> <p>pain scores for both illuminations were assessed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>“After the second illumination, mean pain scores were significantly higher in the two‐fold ALA‐PDT group compared with patients treated with MAL‐PDT, with mean pain scores of 3.36 +‐ 2.57 and 2.48 +‐ 2.57 respectively (P=0.039). None of the patients discontinued treatment because of pain. 16.4% in the ALA‐PDT group vs 5.8% in the MAL‐PDT group reported the use of pain medication post‐treatment.” </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0028" title="KuijpersDI , ThissenMR , ThissenCA , NeumannMH . Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. Journal of Drugs in Dermatology2006;5(7):642-5. [CENTRAL: CN-00566805] ">Kuijpers 2006</a> (ALA‐PDT / MAL‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient description of pain and rating on 10‐point visual analogue scale.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Majority of pain was reported as burning or stinging (59 and 41% respectively); also described as throbbing, lingering or tingling. Intensity and character was the same between groups. Generally pain was experienced during illumination and sporadically after, with the second cycle reported as the worst. No radiation reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0031" title="MarksR , GebauerK , ShumackS , AmiesM , BrydenJ , FoxTL , et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicentre 6-week dose-response trial. Journal of the American Academy of Dermatology2001;44(5):807-13. [CENTRAL: CN-00326531] ">Marks 2001</a> (Imiquimod BD / OD / BD for 3 days / OD for 2 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Three‐point rating scale applied by assessor based on descriptive terms used by patient.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain more frequent in the BD group (100%) &gt; OD group (24.2%) &gt; BD for three days (13.3%) &gt; OD for 2 days (3%). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0032" title="MillerBH , ShavinJS , CognettaA , TaylorRJ , SalascheS , KoreyA , et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. Journal of the American Academy of Dermatology1997;36(1):72-7. [CENTRAL: CN-00135753] ">Miller 1997</a> (Intralesional sustained‐release 6‐fluorouracil / epinephrine injectable gel, variable frequencies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reduced dose if</p> <p>tenderness or pain at the injection site or erosion/</p> <p>ulceration. Local anaesthetic not permitted.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At each treatment visit, patients were asked to report injection site</p> <p>pain, including burning or stinging, and tenderness.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All patients experienced transient moderate to severe stinging, burning or pain at the time of injection lasting less than 15 </p> <p>to 20 minutes after drug administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0033" title="MortonCA , DominicusR , RadnyP , DirschkaT , HauschildA , ReinholdU , et al. A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). British Journal of Dermatology2018;179(2):309-19. [CENTRAL: CN-02000788] [PMID: 29432644]">Morton 2018</a> (BF 200 ALA‐PDT / MAL‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain management:</p> <p>physical cooling measures, reduction of light intensity</p> <p>at the expense of longer exposure times, or “slight analgesia”.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Local pain experienced during PDT was assessed for each PDT session (on a numerical rating pain scale). </p> <p>Ranking of the subjective sensations</p> <p>pain, burning and itching was done by the patient. Pain during</p> <p>PDT assessed with a numerical rating pain scale ranging</p> <p>from 0 (no pain at all) to 10 (worst possible pain).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain was one of the most frequently reported reactions, experienced by 100% patients undergoing MAL‐PDT and 97.1% patients undergoing BF 200 ALA‐PDT. Local pain experienced during each session showed little variation between both treatments and was most commonly experienced during the first two sessions. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a> (MAL‐PDT / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None in MAL‐PDT group, local anaesthetic in SE group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Local skin reactions during and after treatment at each clinic visit were documented, and rated as mild, moderate or severe. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One patient in MAL‐PDT group discontinued treatment because of severe burning sensation which resolved without medical intervention. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14% in the MAL‐PDT group experienced pain, compared to 6% in the SE group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0042" title="ShumackS , MarksR , AmiesM , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks treating nodular BCC. 8th World Congress on Cancers of the Skin, Zurich, Switzerland2001;-:p55. [CENTRAL: CN-00849091] ShumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , SchroeterA , et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002a</a> (Imiquimod, several regimes for 6 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maximum of two 7‐day periods of rest allowed if local skin reaction occurred.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects documented at every study visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain was one of the three most frequent symptomatic adverse effects and two patients discontinued treatment due to pain. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0043" title="RobinsonJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating nodular BCC. 8th World Congress on Cancer of the Skin, Zurich, Switzerland2001;-(-):p57. [CENTRAL: CN-00849091] SchumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , Schroeter, A et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002b</a> (Imiquimod, several regimes for 12 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maximum of two 7‐day periods of rest allowed if local skin reaction occurred.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects documented at every study visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two patients from the imiquimod twice daily 7‐day dosing group reported severe application site reactions, one with pain at the target site and one with tenderness, stinging and pain at the target site. One patient from the once‐daily, 7 day group reported severe tenderness at the target site. One patient discontinued due to pain, tenderness and drainage at the target site. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0044" title="SillerG , RosenR , FreemanM , WelburnP , KatsamasJ , OgbourneSM . PEP005 (Ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomised phase IIa trial. Australasian Journal of Dermatology2010;51(2):99-105. [CENTRAL: CN-00771587] ">Siller 2010</a> (ingenol mebutate gel 0.0025 % / ingenol mebutate gel 0.01% / ingenol mebutate gel 0.05% / vehicle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment was withheld if there was a severe local reaction occurred after the first dose. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects documented at every study visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain at the application site was most common in ingenol mebutate gel group 0.05% (n=2, treatment arm B), and 1 patient experienced pharyngolaryngeal pain in ingenol mebutate gel group 0.0025% (treatment arm A). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0046" title="SolerAM , Angell-PetersenE , WarloeT , TausjoJ , SteenHB , MoanJ , et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: A comparison of two light sources. Photochemistry and Photobiology2000;71(6):724-9. [CENTRAL: CN-00297518] ">Soler 2000</a> (Laser light / broadband light) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain reported during treatment and in follow‐up period (patient questionnaires).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83% of patients in the laser group and 76% in the broadband group reported some discomfort during and after illumination. Types of pain included stinging and burning sensation. There was no significant difference between the groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0048" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. In: 8th World Congress on cancers of the skin, Zurich, Switzerland. 2001:61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] [PMID: 12452875]">Sterry 2002a</a>/<a href="./references#CD003412-bbs2-0049" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. 8th World Congress on cancers of the skin, Zurich, Switzerland2001;-(-):p61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] ">Sterry 2002b</a> (Imiquimod with / without occlusion) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prescribed rest periods from treatment</p> <p>if local skin reactions or treatment site adverse effects.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects documented at every study visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One patient reported continuous stinging and pain at the application site; one reported irritation and another reported irritation and pruritus. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a> (MAL‐PDT / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cooling of irradiation sites with fan‐cooler during treatment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects documented at every study visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Post procedural pain was reported in 3 of the surgical participants and none of the MAL‐PDT group. Pain was reported in 2 and 1 of the participants in the MAL‐PDT and surgical groups respectively. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0052" title="WangI , BendsoeN , KlintebergCA , EnejderAM , Andersson‐EngelsS , SvanbergS , et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. British Journal of Dermatology2000;144(4):832-40. [CENTRAL: CN-00326537] ">Wang 2001</a> (ALA‐PDT / cryosurgery) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In the</p> <p>PDT group, low fluence rate to minimise thermal effects and lesions sprayed with water.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain recorded in first week after treatment using 115‐mm visual analogue scale (VAS) for pain indication and analgesia diary. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall VAS scores low for both treatment modalities, and insignificantly higher in PDT group (43 +/‐ 31mm SD in PDT group, 32 +/‐ 27mm SD in cryosurgery group). Most pain reported during treatment. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0001" title="2005-001474-27. A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001474-27/results (first accessed 12 August 2016). ">2005‐001474‐27</a> (placebo gel + tazarotene gel / valproic acid gel + tazarotene gel) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 patients in the placebo group experienced pain in comparison to 6 in the treatment group. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>MAL:</b> methyl aminolevulinate; <b>PDL:</b> pulsed dye laser; <b>PDT:</b> photodynamic therapy; <b>SE:</b> surgical excision; <b>VAS:</b> visual analogue scale; <b>xpw:</b> times per week. </p> </div> </div> <p>2. Early treatment failure within six months, measured histologically.</p> <p>3. Adverse effects (AEs). We did not perform numerical analyses on AEs but provided a narrative synthesis in the results and expanded on this in <a href="#CD003412-tbl-0007">Table 2</a>. </p> <div class="table" id="CD003412-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse effects table</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study (comparator)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>AEs associated with treatment leading to discontinuation of treatment / participation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Common AEs (number/onset/duration)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Other notable outcomes (number/onset/duration)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0003" title="Abd El-NabyNM , El-FarNN , Al-Shenawy HA , ElshwadfySE , KouraAA . Pulsed dye laser in the treatment of basal cell carcinoma: a single session versus two sessions–a randomized controlled trial. Indian Journal of Dermatology, Venereology, and Leprology2019;85(5):475. ">Abd El‐Naby 2019</a> (one PDL session / two PDL sessions) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the group who received two sessions of treatment, 4 patients experienced dyspigmentation (2 hyper‐ and 2 hypo‐pigmentation). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a> (MAL‐PDT / Imiquimod / 5‐FU) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local skin redness reported as moderate or severe in all treatment groups.</p> <p>Patients treated with imiquimod or 5‐FU more often reported moderate to severe local swelling, erosion, crust formation and itching of the skin than patients treated with MAL‐PDT. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unexpected serious adverse effects in 1) Imiquimod group include wound infection (n = 1) and influenza‐like symptoms (n = 8) and 2) in 5‐FU group include two local wound infections, erysipelas of the lower extremity (n = 1), leg ulcer (n = 1). </p> <p>The erysipelas and ulcer were treated with ambulant compression therapy and antibiotics. None of these patients needed hospitalisation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse reactions more common in last treatment weeks.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0006" title="AvrilMF , AuperinA , MargulisA , GerbauletA , DuvillardP , BenhamouE , et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. British Journal of Cancer1997;76(1):100-6. [CENTRAL: CN-00141470] PetitJY , AvrilMF , MargulisA , ChassagneD , GerbauletA , DuvillardP , et al. Evaluation of cosmetic results of a randomised trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plastic and Reconstructive Surgery2000;105(7):2544-51. [CENTRAL: CN-00278207] ">Avril 1997</a> (SE / radiotherapy) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Main adverse characteristics of surgical scars were "deformations" and "constrictions", affecting 25% and 5% of patients respectively by year 4. Radiodystrophy and necrosis affected 41% and 5% of the radiotherapy group at 4 years respectively. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three ophthalmic complications were observed: 1 ectropion, 1 cataract ‐ after surgery. One lacrimal duct stenosis after radiotherapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0007" title="Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Methyl aminolaevulinate photodynamic therapy vs. cryotherapy in primary superficial basal cell carcinoma: results of a 36-month follow-up. British Journal of Dermatology2005;153(1):29. Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Topical methyl aminolevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. European Journal of Dermatolology2008;18(5):547-53. [CENTRAL: CN-00668120] ">Basset‐Seguin 2008</a> (MAL‐PDT / cryosurgery) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crusting: MAL PDT = 35%, cryosurgery = 47%.</p> <p>Erythema: MAL PDT = 30%, cryosurgery 21%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blisters: cryosurgery only = 21%.</p> <p>Suppuration: cryosurgery group only.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most were transient, resolving in 5 days.</p> <p>More likely to experience severe AE in MAL‐PDT group and moderate AE in cryosurgery group, although most were mild (73% and 80%, respectively). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0008" title="Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , MillerPS , et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncology2014;15(1):96-105. [CENTRAL: CN-00959373] WilliamsHC , Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. Journal of Investigative Dermatology2017;137(3):614-9. [CENTRAL: CN-01340067] [EMBASE: 614596349]">Bath‐Hextall 2014</a> (Imiquimod / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (5%) participants in the imiquimod group withdrew because of adverse effects (five [42%] of these events were treatment related). </p> <p>Four (2%) of 229 participants withdrew because of adverse effects in the surgery group (all non‐related events). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itching: Imiquimod =211, SE = 129.</p> <p>Weeping: Imiquimod = 160, SE = 81.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher frequency adverse effects more common in imiquimod group include 1) Mild/moderate events: occurrence of new tumours, redness and swelling at tumour site, cold/influenza‐like symptoms, headache, scab at tumour site, spots close to trial tumour, discomfort and bleeding, 2) Severe events: cold/flu, inflammatory reactions. </p> <p>Other high‐frequency adverse effects, more common in SE group include 1) Mild/moderate events: Pain and swelling at tumour site and 2) Severe events: Heat attack / heart failure and pneumonia. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the imiquimod group, 38 (15%) participants needed a dose reduction.</p> <p>No deaths or serious adverse effects were regarded as related to treatment.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0010" title="BrinkhuizenT , FrenckenKJ , NelemansPJ , HoffML , Kelleners-SmeetsNW , Zur HausenA , et al. The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): a phase II, randomized controlled trial. Journal of the American Academy of Dermatology2016;75(1):126-34. [CENTRAL: CN-01342883] [DOI: 10.1016/j.jaad.2016.01.050]">Brinkhuizen 2016</a> (diclofenac / diclofenac and calcitriol / calcitriol and no treatment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 16 cases the severity of the application‐site reactions led to discontinuation of the therapy and prescription (diclofenac = 6, calcitriol = 2, combination = 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema: diclofenac = 21, calcitriol = 20, combined treatment = 22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other commonly reported AEs in all groups include swelling, erosions, pruritus.</p> <p>Other less frequent AEs include crust formation, vesicles, scaling, and paraesthesia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects were mostly mild to moderate.</p> <p>No serious adverse effects were considered to be related to the study medication.</p> <p>Three patients had serious adverse effects requiring hospitalisation.</p> <p>No adverse effects were reported in the control group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0011" title="ChoiSH , KimKH , SongKH . Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial. Journal of the European Academy of Dermatology and Venereology2015;30(5):783-8. [CENTRAL: CN-01158122] [DOI: 10.1111/jdv.13453]">Choi 2016</a> (Er:YAG AFL MAL‐PDT / MAL‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crusting: Er‐YAG AFL‐PDT = 17, MAL‐PDT = 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema, burning sensation at application site, hyperpigmentation and itching more frequent in Er:YAG AFL‐PDT group. </p> <p>Other reactions include scale, bullae, oozing and bleeding.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All patients in both groups experienced some AEs.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0015" title="EigentlerTK , KaminA , WeideBM , BreuningerH , CaroliUM , MöhrleM , et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. Journal of the American Academy of Dermatology2007;57(4):616-21. [CENTRAL: CN-00610509] ">Eigentler 2007</a> (Imiquimod 8 weeks / 12 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema and oedema occurred in 92% of participants. Reporting of vesicles, erosions, ulcerations, desquamation and drainage during treatment was infrequent (12‐53%). Post‐treatment hypopigmentation was reported in 9% of participants. Most AEs were judged by physicians as moderate severity and by patients as moderate (17%) to severe (54%). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Authors reported "no differences between treatment arms in adverse events".</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for AEs were not presented separately for treatment groups.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0016" title="EimpunthS , OganesyanG , HammanMS , LeeRA , JiangSI , KimSS . Effectiveness of a 595-nm pulsed dye laser for the treatment of basal cell carcinoma using 1 stacked-pulse session. Journal of the American Academy of Dermatology2014;70(5 (S1)):AB134. [CENTRAL: CN-01057471] ">Eimpunth 2014</a> (Double‐stacked PDL / control) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Purpura immediately after laser treatment: 100% PDL group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Late AEs in PDL group: blister (21.4%), dyspigmentation (21.4%) and hypertrophic scar (7.14%). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0017" title="EzughahFI , DaweRS , IbbotsonSH , FlemingCJ . A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment2008;19(2):111-7. [CENTRAL: CN-00706567] ">Ezughah 2008</a> (Imiquimod 8 weeks / 5 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient in 5 week group withdrew from the study due to application site reactions.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild erythema (at week 1): 8‐week group = 69%, 5 week group = 69%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other reactions include pain, swelling, weeping, broken skin and scabbing.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema decreased in both groups at week 5.</p> <p>One patient on 8 week course developed severe erythema and soreness and was unable to apply 7<sup>th</sup> treatment. </p> <p>The severity of local site reactions was greatest in the first half of the treatment phase in the 8‐week group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0018" title="FoleyP , FreemanM , MenterA , SillerG , El-AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] FoleyP , FreemanM , SillerG , GebauerK , MurrellD , BarnetsonR , et al. A phase III randomized study comparing photodynamic therapy (PDT) using methyl aminolevulinate or placebo cream in nodular basal cell carcinoma (NBCC). Journal of the European Academy of Dermatology and Venereology2003;17(Suppl 3):231. [CENTRAL: CN-00478536] ">Foley 2009a</a>/<a href="./references#CD003412-bbs2-0019" title="FoleyP , FreemanM , MenterA , SillerG , El‐AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] TopeWD , MenterA , El AzharyR , SotoP . A comparison of topical MAL-PDT versus placebo-PDT in nodular basal cell carcinoma: results of a North American study. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology; 2005 Sep 28-Oct 03; Kuala Lumpur, Malaysia. 2005:376. [CENTRAL: CN-00602617] ">Foley 2009b</a> (MAL‐PDT / placebo) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 patient in MAL‐PDT group received only one treatment due to local adverse event.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Burning: MAL‐PDT = 19, placebo = 8.</p> <p>Erythema: MAL‐PDT = 14, placebo = 4.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other reactions include stinging of skin, crusting and bleeding (more frequent in treatment group). </p> <p>Severe events: cholangiocarcinoma, cholelithiasis, carotid stenosis, pulmonary oedema and acute MI, melanoma, femoral artery surgery. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One serious AE deemed not treatment‐related.</p> <p>All were mild‐to‐moderate intensity and most lasted &lt;1 day.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0020" title="Garcia-MartinE , Gil-ArribasLM , IdoipeM , AlfaroJ , PueyoV , PabloLE , et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. British Journal of Ophthalmology2011;95(10):1393-6. [CENTRAL: CN-00801928] ">Garcia‐Martin 2011</a> (Imiquimod / radiotherapy) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blink discomfort (during treatment): Imiquimod = 60%, radiotherapy = 50%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intense conjunctival irritation 13.3% imiquimod group, discomfort 8.3% radiotherapy group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After treatment, radiotherapy group reported ectropion, dry eye and loss of eyelashes. imiquimod group reported no post‐treatment AEs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0021" title="GeisseJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating superficial BCC. In: The 8th World Congress on Cancer of the Skin; 2001 July 18-21; Zurich, Switzerland. 2001:P58. [CENTRAL: CN-00520431] GeisseJK , RichP , PandyaA , GrossK , AndresK , GinkelA , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a randomized, vehicle-controlled study. Journal of the American Academy of Dermatology2002;47(3):390-8. [CENTRAL: CN-00390933] ">Geisse 2002</a> (Imiquimod BD / OD / 5xpw / 3xpw / vehicle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thirteen patients discontinued due to local skin reactions, six of which were severe and four of which were due to adverse effects (BD = 1, OD = 2, 5xpw = 1). </p> <p>Four discontinued dosing (3 because of pain, 1 of which was severe, and one because of bleeding). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itching: 5xpw = 62%, OD = 61%, 3xpw = 38%, BD = 30%, vehicle = 13%.</p> <p>Pain: BD = 30%, OD = 16%, 3xpw = 10%, 5xpw = 8%, vehicle = 0.</p> <p>Tenderness: BD = 20%, OD = 16%, 5xpw = 8%, 3xpw = 7%, vehicle = 6%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other reactions include erythema, scabbing, erosion, excoriation/flaking, ulceration, vesicles, induration and oedema. </p> <p>Severe erythema and scabbing occurred more commonly in the twice‐daily treatment groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs occurred in all treatment groups, as did local skin reactions (all of those deemed related to study drug were in the OD group). </p> <p>Six serious AEs, all unrelated to treatment, five of which resulted in hospitalisation.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0022" title="GeisseJ , CaroI , LindholmJ , GolitzL , StamponeP , OwensM . Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology2004;50(5):722-33. [CENTRAL: CN-00469536] ">Geisse 2004</a> (Imiquimod 5xpw / 7xpw / vehicle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4% of the imiquimod 5xpw group and 2% of the 7xpw group discontinued treatment due to AE or local site reaction. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema: most frequently observed and most intense LSR: 5xpw = 87, 7xpw = 92, vehicle = 48. </p> <p>Itching: 5xpw = 16%, 7xpw = 26%.</p> <p>Burning: 5xpw = 6%, 7xpw = 9%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other reactions include oedema, induration, vesicle, erosion, ulceration, scabbing and flaking. </p> <p>The incidence of headache was statistically higher in the Imiquimod 5xpw group compared to the corresponding vehicle group (P = 0.027), although this difference was not seen in the 7xpw group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local site reactions reached maximum intensity at week 3, and most were mild.</p> <p>Local site reactions were experienced in all groups but more likely in imiquimod groups, and these were statistically more likely to be severe (P = 0.001). </p> <p>AEs occurred more frequently during treatment than after and were more likely to occur in the imiquimod 7xpw group than the 5xpw group or the vehicle groups (64% compared to 58% and 36% (combined vehicle groups). </p> <p>Local site reactions were experienced more commonly in 7xpw Imiquimod group compared to the 5xpw group (P = 0.002). </p> <p>AEs considered possibly or probably related to treatment include local site reactions and lymphadenopathy in the 7xpw Imiquimod group. </p> <p>All local site reactions were significantly more likely to be intense than 7xpw group than 5xpw group (P &lt; 0.5). </p> <p>Overall the severe AEs experience by participants were in the 7xpw Imiquimod group.</p> <p>A decrease in WCC and neutrophils was noted in the treatment groups.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0023" title="HaakCS , Togsverd-BoK , Thaysen-PetersenD , WulfHC , PaaschU , AndersonRR , et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas - a randomized clinical trial. British Journal of Dermatology2015;172(1):215-22. [CENTRAL: CN-01039978] ">Haak 2015</a> (AFXL‐PDT / MAL‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immediate skin reactions (white micro‐spots at the surrounding skin surface and minor pinpoint bleeding) seen in all AFXL group. </p> <p>Pigmentary changes and scarring similar in both groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minor bleeding and bruising in debulked areas.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scarring was the most frequently observed reaction at 3 months.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0025" title="KarsaiS , FriedlH , BuhckH , JüngerM , PoddaM . The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: Outcome of a double-blind randomized placebo-controlled trial. British Journal of Dermatology2015;172(3):677-83. [CENTRAL: CN-01068975] ">Karsai 2015</a> (PDL / sham) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crusting (lasted an average of 10 days): intervention group only.</p> <p>Hyperpigmentation: intervention group only (21 of 56 cases, 37%).</p> <p>Hypopigmentation: intervention group only (did not manifest until after the third session; its rate increased with the number of sessions) seen in 52 of 56 cases (93%). </p> <p>Purpura in 100% of the laser group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Purpura was considered a desired concomitant effect and was seen for an average of 6 days. </p> <p>Hyper‐ and hypopigmentation persisted until the end of the final follow‐up at 6 months.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0026" title="KesselsJ , VoetenL , NelemansP , CleutjensJ , HillenLM , MosterdK , et al. Topical sinecatechins, 10%, ointment for superficial basal cell carcinoma: A randomized clinical trial. JAMA Dermatology2017;153(10):1061-3. [CENTRAL: CN-01420948] ">Kessels 2017</a> (Sinecatechins / placebo) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema: sinecatechins 9‐12%, placebo 2‐6%.</p> <p>Oedema: sinecatechins 2‐6%, placebo 0%.</p> <p>Erosions: sinecatechins 4‐7%, placebo 1%.</p> <p>Crusts: sinecatechins 3‐10%, placebo 2%.</p> <p>Itching: sinecatechins 10‐13 %, placebo 1‐3%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other reactions include oedema, erosions, bullae and squamae.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference for all common AEs.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0027" title="KesselsJP , KreukelsH , NelemansPJ , RoozeboomMH , vanPeltH , MosterdK , et al. Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5‐aminolaevulinic acid 20% vs. two‐stage topical methyl aminolaevulinate: results of a randomized controlled trial. British Journal of Dermatology2018;178(5):1056-63. [CENTRAL: CN-01991773] ">Kessels 2018</a> (MAL‐PDT / two‐fold fractionated ALA‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema: MAL‐PDT = 65, ALA‐PDT = 73.</p> <p>Wounds/erosions: MAL‐PDT = 64, ALA‐PDT = 72.</p> <p>Vesicles: MAL‐PDT = 66, ALA‐PDT = 72.</p> <p>All significantly higher after ALA‐PDT compared with MAL‐PDT.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other reactions include swelling, crusts, scaling and pruritus.</p> <p>Four serious AEs unrelated to study treatment (three hospitalizations owing to transient ischaemic attack, chemotherapy for lung carcinoma and dizziness, and one patient died owing to cancer). </p> <p>No serious unexpected adverse reactions were reported in either group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE incidence higher during treatment period than after treatment.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0029" title="KuijpersDI , ThissenMR , BerrettyPJ , IdelerFH , NelemansPJ , NeumannMH . Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatologic Surgery2007;33(5):579-87. [CENTRAL: CN-00588176] ThissenMR , NiemanFH , IdelerAH , BerrettyPJ , NeumannHA . Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatologic Surgery2000;26(8):759-64. [CENTRAL: CN-00298974] ">Kuijpers 2007</a> (SE / curettage and cryosurgery) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary wound infection requiring systemic antibiotics: curettage and cryosurgery group = 3 patients, SE group = 4 patients. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0031" title="MarksR , GebauerK , ShumackS , AmiesM , BrydenJ , FoxTL , et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicentre 6-week dose-response trial. Journal of the American Academy of Dermatology2001;44(5):807-13. [CENTRAL: CN-00326531] ">Marks 2001</a> (Imiquimod BD / OD / BD for 3 days / OD for 2 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient discontinued because of a self‐reported application site symptom of pruritus.</p> <p>No patient withdrew from the study because of signs of a local skin reaction assessed by the investigators. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema: BD = 66.7%, OD = 27.3%, BDx3pw, = 13.3 %, OD x3pw = 9.1%.</p> <p>Itching: BD =33.3%, OD = 66.7%, BDx3pw, = 36.7%, OD x3pw = 45.5%.</p> <p>Weeping: decreased as the dosing frequency decreased BD = 66.7% OD = 12.1% BDx3pw, = 3.3%, OD x3pw = 0%. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other reactions include scabbing, flaking, erosion, ulceration, oedema and induration.</p> <p>One patient died as the result of a coincidental cerebrovascular accident.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local skin reactions occurred in all 4 dose regimens; dose‐dependent application site reactions being reported most often. </p> <p>In the twice‐every‐day group, all the local skin reactions were assessed as severe by both the patient and the investigator in two thirds of the patients. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0032" title="MillerBH , ShavinJS , CognettaA , TaylorRJ , SalascheS , KoreyA , et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. Journal of the American Academy of Dermatology1997;36(1):72-7. [CENTRAL: CN-00135753] ">Miller 1997</a> (Intralesional sustained‐release 6‐ fluorouracil / epinephrine injectable gel, variable frequencies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local tissue reactions were confined to the treatment site and included erythema, swelling, desquamation, erosions and eschar in most patients. </p> <p>Hyperpigmentation was observed in 83% of treated patients but typically cleared during the FU period. </p> <p>Ulcerations at the treatment site occurred in 47% of patients; only one patent had a residual scar. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no clinically significant serious or unexpected adverse effects or changes in any lab values or physical examination findings as judged by the investigator to be related to the administration of 5‐FU/epi gel. The number of events per regimen ranged from 17 to 28. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0033" title="MortonCA , DominicusR , RadnyP , DirschkaT , HauschildA , ReinholdU , et al. A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). British Journal of Dermatology2018;179(2):309-19. [CENTRAL: CN-02000788] [PMID: 29432644]">Morton 2018</a> (BF 200 ALA‐PDT / MAL‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient withdrew due to treatment‐related AEs in the BF 200 ALA group and 2 in the MAL group. </p> <p>Two other patients withdrew due to related treatment emergent adverse effects (one in each group). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most frequently reported reactions included pain, erythema, pruritus and oedema; most frequently at mild to moderate intensity. </p> <p>Frequencies were comparable between the groups and revealed no statistically significant differences. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were ten serious AEs, none of which were related to the study medication.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0034" title="MosterdK , ThissenMR , NelemansP , Kelleners‐SmeetsNW , JanssenRL , BroekhofKG , et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. British Journal of Dermatology2008;159(4):864-70. [CENTRAL: CN-00667266] RoozeboomMH , AardoomMA , NelemansPJ , ThissenMR , Kelleners-SmeetsNW , KuijpersDI , et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. Journal of the American Academy of Dermatology August 2013;69(2):280-7. [CENTRAL: CN-00876800] [DOI: 10.1016/j.jid.2016.03.043]">Mosterd 2008</a> (ALA‐PDT / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary wound infection was observed once after ALA‐PDT treatment. No serious complications such as wound dehiscence or necrosis were observed in either ALA‐PDT or SE group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0035" title="PunjabiS , CookLJ , KerseyP , MarksR , CerioR . Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicentre study. International Journal of Dermatology2008;47(1):78-82. [CENTRAL: CN-00629144] PunjabiS , CookLJ , KerseyP , MarksR , FinlayA , SharpG , et al. A double-blind, multicentre parallel group study of BEC-5 cream in basal cell carcinoma. European Academy of Dermatology &amp; Venereology2000;14(Suppl 1):49. [CENTRAL: CN-01616931] ">Punjabi 2008</a> (Solasodine glycoside cream / vehicle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 patients withdrew due to severity of local irritation in the treatment group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were four serious adverse effects in treatment group (3 unrelated, 1 unlikely to be related to treatment), and 2 in the vehicle group (one unrelated and one unlikely related to treatment). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No SAEs were considered likely or related to the treatment and there was no significant difference between the two groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a> (MAL‐PDT / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One discontinuation due to adverse vent in MAL‐PDT group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema: MAL‐PDT = 7, SE = 1.</p> <p>Skin infection: MAL‐PDT = 0, SE = 3.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three patients had skin infections after SE (none in PDT group).</p> <p>Other local adverse effects included crusting and itching.</p> <p>There were three deaths, all unrelated to treatment, and one patient was diagnosed with breast cancer during treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>More patients with MAL‐PDT than SE experienced adverse effects (52% compared to 29%).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0038" title="RomagosaR , SaapL , GivensM , SalvarreyA , HeJL , HsiaSL , et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatologic Surgery2000;26(4):338-40. [CENTRAL: CN-00296475] ">Romagosa 2000</a> (5‐FU in PC vehicle / 5‐FU in petrolatum base) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local irritation, erythema, ulceration, tenderness were common but well‐tolerated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimal itching in both treatment arms.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0041" title="SchulzeHJ , CribierB , RequenaL , ReifenbergerJ , FerrandizC , DiezG , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. British Journal of Dermatology2005;152(5):939-47. [CENTRAL: CN-00513173] ">Schulze 2005</a> (Imiquimod / vehicle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two in imiquimod group discontinued due to treatment‐related AEs (one in vehicle group discontinued due to myeloma). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema, oedema, induration, vesicles, erosion, ulceration, scaling/flaking and scabbing/crusting were all significantly more likely to occur in the treatment group (P &lt; 0.001). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Imiquimod‐treated patients also experienced statistically significant changes in skin quality assessment scores for hypo‐ or irregular pigmentation, and skin surface texture. </p> <p>Severe AE more common in treatment group but none due to treatment. No deaths.</p> <p>Central and peripheral nervous system disorders e.g. headache, gastrointestinal disorders and respiratory system disorders were also reported. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local skin reactions were more intense in the imiquimod group (statistically significant).</p> <p>Local skin reactions increased at week 2 and plateaued until week 6.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0042" title="ShumackS , MarksR , AmiesM , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks treating nodular BCC. 8th World Congress on Cancers of the Skin, Zurich, Switzerland2001;-:p55. [CENTRAL: CN-00849091] ShumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , SchroeterA , et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002a</a> (imiquimod, several regimes for 6 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient discontinued due to treatment related side effects (OD 7 day dosing group), one discontinued due to cerebral vascular accident. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema and scabbing commonly reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Influenza‐like symptoms, probably related to drug noted in 10 patients.</p> <p>Fatigue in the OD 7 day group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs occurred in all dosing groups (42% possibly / probably due to study treatment).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0043" title="RobinsonJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating nodular BCC. 8th World Congress on Cancer of the Skin, Zurich, Switzerland2001;-(-):p57. [CENTRAL: CN-00849091] SchumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , Schroeter, A et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002b</a> (imiquimod, several regimes for 12 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 patients discontinued treatment owing to local skin reaction (2 in OD 5 day group, 4 in OD 7 day group, 2 in BD 7 day group). </p> <p>2 discontinued due to AEs (1 = pain and drainage at target site and 1 = spider bite adjacent to target site). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema and scabbing commonly reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two patients in the BD 7 day group and one in the OD 7 day group reported severe local skin reactions. </p> <p>Influenza‐like symptoms, probably related to drug, were noted in 5 patients.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local skin reactions occurred in all study groups, and were the most commonly reported AE (most mild/moderate intensity). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0044" title="SillerG , RosenR , FreemanM , WelburnP , KatsamasJ , OgbourneSM . PEP005 (Ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomised phase IIa trial. Australasian Journal of Dermatology2010;51(2):99-105. [CENTRAL: CN-00771587] ">Siller 2010</a> (ingenol mebutate gel 0.0025 % / ingenol mebutate gel 0.01% / ingenol mebutate gel 0.05% / vehicle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two discontinued due to AE (one in 0.01% group and one in 0.05% group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The most common reactions were erythema and flaking/scaling/dryness, which occurred in a minimum of 75 and 50% respectively, of all patients in all groups (including vehicle group). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyper‐ and hypopigmentation, erosion/ulceration, oedema, scabbing/crusting, vesicles all more common in ingenol mebutate gel 0.05% group. Most were mild to moderate reactions, although 2 were severe (ingenol mebutate gel 0.01 and 0.05% respectively). </p> <p>Other skin reactions include itch, weeping/exudate, scarring.</p> <p>Other adverse effects include liver function derangement, diarrhoea, erythema, flaking, headache, oedema, pustules at application site, pustular rash, scabbing and telangiectasia. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE.</p> <p>Severe AE included mild/mod erythema extending beyond treatment site and headache.</p> <p>10 severe local skin reactions seen in Arm A in ingenol mebutate gel 0.01% / ingenol mebutate gel 0.05% groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0045" title="EssersBA , DirksenCD , NiemanFH , SmeetsNW , KrekelsGA , PrinsMH , et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Archives of Dermatology2006;142(2):187-94. [CENTRAL: CN-00555278] MosterdK , KrekelsGA , NiemanFH , OstertagJU , EssersBA , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncology2008;9(12):1149-56. [CENTRAL: CN-00665334] SmeetsNW , KrekelsGA , OstertagJU , EssersBA , DirksenCD , NiemanFH , et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet2004;364(9447):1766-72. [CENTRAL: CN-00492695] Van LooE , MosterdK , KrekelsGA , RoozeboomMH , OstertagJU , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European Journal of Cancer2014;50(17):3011-20. [CENTRAL: CN-01043314] ">Smeets 2004</a> (MMS / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs in SE group include wound infection, necrosis of grafts or flaps or post‐operative bleeding. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 patients died due to conditions not related to the treatment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12% complications in MMS group and 14% in SE group (P = 0.981).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0046" title="SolerAM , Angell-PetersenE , WarloeT , TausjoJ , SteenHB , MoanJ , et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: A comparison of two light sources. Photochemistry and Photobiology2000;71(6):724-9. [CENTRAL: CN-00297518] ">Soler 2000</a> (laser light / broadband light) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During the 1st week after treatment, 68% patients in the laser group and 74% of those in the broadband group also reported some degree of discomfort (stinging, itching, pain, suppuration headache, sensation of warmth or blushing). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AEs reported in the 6‐month follow‐up period.</p> <p>There was no statistically significant difference between the groups.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0047" title="RosenR , FreemanM , ZibertJR , KatsamasJ , KnudsenKM , SpelmanL . Ingenol mebutate 0.05% gel under occlusion is efficacious in treating superficial basal cell carcinoma. British Journal of Dermatology2014;171(Suppl 4):50. [CENTRAL: CN-01057057] ">Spelman 2014</a> (Ingenol mebutate under different occlusion types: full ODr, Semi‐ODr or no‐ODr) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.5% tolerated only one treatment in full‐ODr group, compared to 20.8% in semi‐ODr group and 4.2% in non‐ODr group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local skin reactions in 11.3 full ODr group, 7,5 in semi‐ODr group and 8.9 in no‐ODr group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The majority of AEs were not considered treatment related. The percentage of AEs was similar across all treatment groups, the most common being application site pain. The majority of treatment‐related AEs were in the ALU group, and in this group the majority only tolerated one treatment due to the severity of the local skin reaction. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0048" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. In: 8th World Congress on cancers of the skin, Zurich, Switzerland. 2001:61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] [PMID: 12452875]">Sterry 2002a</a>, sBCC study (Imiquimod with / without occlusion, both 2 or 3 days per week) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two patients discontinued from the study, one due to an adverse event (neurological dysregulation; not treatment‐related) and one due to a local skin reaction. One patient in without‐occlusion group required interrupted dosing and two required rest periods (3xpw with occlusion and 2xpw without occlusion). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itching, burning and hypopigmentation most frequently reported AEs.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two severe application site reactions were considered due to the medication (in 2xpw without occlusion group and in 3xpw with occlusion group). </p> <p>Fever and influenza‐like symptoms were infrequently reported.</p> <p>Four patients experienced serious adverse effects unrelated to the medication.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs occurred in all treatment groups with 59% reporting at least one.</p> <p>32% reported application site reactions, which occurred more often in groups treated three times per week. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0049" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. 8th World Congress on cancers of the skin, Zurich, Switzerland2001;-(-):p61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] ">Sterry 2002b</a>, nBCC study (Imiquimod with / without occlusion, both 2 or 3 days per week) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two discontinued due to local skin reactions (severe erythema, oedema and crust) and three discontinued due to application site reactions. Rest periods were taken by three patients. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding, itching and irritation most frequently reported AEs.</p> <p>Erythema was the most frequently reported local skin reaction and was most common in the 3xpw group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Five experienced severe application site reactions considered probably related to the study drug. In groups receiving 3xpw treatment, severe local skin reactions were most common. </p> <p>Four experienced severe AEs unrelated to study drug.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70% reported adverse effects. 42% reported application site reactions; local skin reactions occurred in all treatment groups, most frequently in the 3xpw occlusion group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a> (MAL‐PDT / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 patients in MAL‐PDT group and one in SE group (none treatment related).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Photosensitivity reactions: MAL‐PDT = 37%, SE = 0%.</p> <p>Wound infection: MAL‐PDT = 0%, SE = 5.2%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other reported AEs included erythema, post‐procedural pain, milia and wound dehiscence.</p> <p>21 serious AEs were reported; none were considered related and any permanent discontinuations were unrelated to treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment‐related AEs were higher in MAL‐PDT group than in SE group (37% versus 14.6%).</p> <p>All AEs were mild to moderate severity except one severe wound infection in SE group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0051" title="TranHT , LeeRA , OganesyanG , JiangSB . Single treatment of non-melanoma skin cancers using a pulsed-dye laser with stacked pulses. Lasers in Surgery and Medicine2012;44(6):459-67. [CENTRAL: CN-00969795] ">Tran 2012</a> (PDL 7mm spot single pulses / PDL 10mm stacked pulses) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both treatment group participants developed eschars at 2 weeks, followed by mild erythema at 1 month and hypopigmentation at 5 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0029" title="KuijpersDI , ThissenMR , BerrettyPJ , IdelerFH , NelemansPJ , NeumannMH . Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatologic Surgery2007;33(5):579-87. [CENTRAL: CN-00588176] ThissenMR , NiemanFH , IdelerAH , BerrettyPJ , NeumannHA . Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatologic Surgery2000;26(8):759-64. [CENTRAL: CN-00298974] ">Kuijpers 2007</a> (cryosurgery / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infections: SE = 2, cryosurgery = 3.</p> <p>In the cryosurgery group, 90% complained about moderate to severe swelling of the treatment area, followed by leaking from the defect. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One death (unrelated to study tumour).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0052" title="WangI , BendsoeN , KlintebergCA , EnejderAM , Andersson‐EngelsS , SvanbergS , et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. British Journal of Dermatology2000;144(4):832-40. [CENTRAL: CN-00326537] ">Wang 2001</a> (ALA‐PDT / cryosurgery) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were two patient deaths, and both were unrelated to the BCC or the treatment.</p> <p>One patient reported pain radiating from treatment site (PDT group) and one developed bacterial infection cryosurgery group). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0001" title="2005-001474-27. A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001474-27/results (first accessed 12 August 2016). ">2005‐001474‐27</a> (placebo gel + Tazarotene gel / Baceca® + Tazarotene gel) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema (17/25 and 20/25 in the two treatment groups).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itch (18 versus 15 patients), ulceration (11 versus 16 patients) and local pain (8 versus 6 patients). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant differences between the two groups. Extension phase outcomes not reported.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>MAL:</b> methyl aminolevulinate; <b>PDL:</b> pulsed dye laser; <b>PDT:</b> photodynamic therapy; <b>SE:</b> surgical excision; <b>xpw:</b> times per week. </p> </div> </div> <p>Due to the large number of studies included in this review update and to improve the overall readability of the review, we have excluded studies that did not measure any of our outcomes of interest. </p> </section> </section> </section> <section id="CD003412-sec-0034"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant RCTs regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD003412-sec-0035"> <h4 class="title">Electronic searches</h4> <p>For this update, we revised our search strategies in line with current Cochrane Skin practices, and expanded our list of disease terms. Details of the previous search strategies are available in <a href="./references#CD003412-bbs2-0150" title="Bath‐HextallFJ , PerkinsW , BongJ , WilliamsHC . Interventions for basal cell carcinoma of the skin. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD003412. [DOI: 10.1002/14651858.CD003412.pub2]">Bath‐Hextall 2007</a>. </p> <p>The Cochrane Skin Information Specialist searched the following databases up to 19 November 2019: </p> <p> <ul id="CD003412-list-0005"> <li> <p>the Cochrane Skin Group Specialised Register using the search strategy in <a href="./appendices#CD003412-sec-0316">Appendix 1</a>; </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library <i>(</i>2019, Issue 11) using the strategy in <a href="./appendices#CD003412-sec-0317">Appendix 2</a>; </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="./appendices#CD003412-sec-0318">Appendix 3</a>; </p> </li> <li> <p>Embase via Ovid (from 1974) using the strategy in <a href="./appendices#CD003412-sec-0319">Appendix 4</a>; </p> </li> <li> <p>CINAHL via EBSCO (from 1981) using the strategy in <a href="./appendices#CD003412-sec-0320">Appendix 5</a>; and </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database from 1982) using the strategy in <a href="./appendices#CD003412-sec-0321">Appendix 6</a>. </p> </li> </ul> </p> </section> <section id="CD003412-sec-0036"> <h4 class="title">Searching other resources</h4> <section id="CD003412-sec-0037"> <h5 class="title">Trials registers</h5> <p>Two review authors (SH and JT) searched the following trials registers up to 3 March 2019 using the term "basal cell carcinoma": </p> <p> <ul id="CD003412-list-0006"> <li> <p>the ISRCTN registry (<a href="http://www.controlled-trials.com" target="_blank">www.controlled-trials.com</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>the Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>); </p> </li> <li> <p>the World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>); and </p> </li> <li> <p>the EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">www.clinicaltrialsregister.eu/</a>). </p> </li> </ul> </p> </section> <section id="CD003412-sec-0038"> <h5 class="title">Published and unpublished trials</h5> <p>We checked the reference lists of included studies for further references to eligible trials.<br/>We contacted corresponding authors of study publications to request information on ongoing, unpublished or published trials where we needed additional information. </p> </section> <section id="CD003412-sec-0039"> <h5 class="title">Adverse effects</h5> <p>We did not perform a separate search for adverse effects of interventions for BCC. However, we did examine data on adverse effects from the included studies we identified, and we extracted these data into a table (see <a href="#CD003412-tbl-0007">Table 2</a>). </p> </section> </section> </section> <section id="CD003412-sec-0040"> <h3 class="title" id="CD003412-sec-0040">Data collection and analysis</h3> <section id="CD003412-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Three review authors (FB, JT, SH) checked the titles and abstracts identified from the searches and independently assessed the full text of all RCTs of possible relevance. The review authors decided which trials fitted the inclusion criteria and recorded their methodological quality. Any disagreements were resolved by discussion between the review authors. Where there were missing data from the trial reports attempts were made to obtain that data by contacting the trial author. </p> </section> <section id="CD003412-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (FB, JT, SH) independently performed data extraction, using a pre‐derived data extraction form for consistency. Discrepancies were resolved by a fourth review author (HW). Missing data were obtained from the trial authors where possible. Three review authors (FB, JT, SH) checked and entered the data. Data recorded included: demographics, sites, clinical types, histological diagnosis, inclusion criteria, treatment modalities and regimens, rates of recurrence, cosmetic outcomes, pain outcomes, early treatment failure rates, adverse effects data, setting and funding sources. </p> </section> <section id="CD003412-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The Cochrane 'Risk of bias' assessment framework (<a href="./references#CD003412-bbs2-0105" title="HigginsJP , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org.">Higgins 2011</a>) was used to evaluate the internal validity of studies, covering the main sources of bias across the following components: </p> <p>a) the method of generation of the randomisation sequence (selection bias)</p> <p>b) the method of allocation concealment ‐ we considered it 'adequate' if the assignment could not have been foreseen (selection bias) </p> <p>c) who was blinded or not blinded (participants, clinicians, outcome assessors) (performance bias and detection bias) </p> <p>d) how many participants were lost to follow‐up in each arm (attrition bias)</p> <p>e) if there was selective outcome reporting (reporting bias)</p> <p>Two authors (JT, SH) independently assessed risk of bias in included studies. Any disagreements were resolved through discussion between the authors including a third author (HW). The overall 'Risk of bias' assessment for each study's bias sources (presented in the <a href="./references#CD003412-sec-0332" title="">Characteristics of included studies</a> table) was performed in relation to our recurrence rate primary outcomes. </p> </section> <section id="CD003412-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed the results as risk ratio (RR) with 95% confidence intervals (CIs) for dichotomous outcomes, and difference in means (MD) with 95% CIs for continuous outcomes. </p> </section> <section id="CD003412-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis in the included studies was based on either participants or lesions. Where possible, data at participant level were used in preference. Where there were multiple intervention groups within a trial, we made pair‐wise comparisons of similar active interventions versus placebo, or another active intervention. We analysed internally‐controlled trials using appropriate techniques for paired designs (for example, for continuous outcomes using Wilcoxon Signed Ranks test or paired t‐test; or for dichotomous data using McNemars test), where available, and we did not pool them with studies of other designs. Where dichotomous data permitted, we estimated paired odds ratios (OR) with 95% CIs. Where paired data could not be extracted from the papers, we presented the data narratively. </p> </section> <section id="CD003412-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>If participant dropout led to missing data we conducted an intention‐to‐treat analysis, as reported in the publications of the trials. We contacted trial authors to provide missing statistics, such as standard deviations (SDs), where appropriate. </p> </section> <section id="CD003412-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity using the I² statistic.</p> </section> <section id="CD003412-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>Study registrations and protocols were identified where available and any differences between registered and reported outcomes were flagged as potential reporting bias. We did not test publication bias as none of the comparisons in our review had the minimum number of 10 studies required in a meta‐analysis to apply tests for funnel plot asymmetry (<a href="./references#CD003412-bbs2-0124" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Page 2019</a>). </p> </section> <section id="CD003412-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We calculated a weighted treatment effect (using random effects) across trials since the treatment effects for interventions are likely to vary by participant and methodological variations between studies, as per the standard methods used within Cochrane Skin. The results were expressed as RR and 95% CI for dichotomous outcomes. All analyses were conducted using <a href="./references#CD003412-bbs2-0127" title="Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration, May 2020. available at https://training.cochrane.org/.">RevMan 5.4</a>. </p> <p>Wherever possible, a meta‐analysis was conducted to assess the overall intervention effect of different primary research studies that considered the effectiveness of the same intervention. This approach has the benefits of improving the accuracy of the results and addressing disputes between studies (<a href="./references#CD003412-bbs2-0105" title="HigginsJP , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org.">Higgins 2011</a>). </p> <p>Where we performed a meta‐analysis, we calculated a weighted treatment effect across trials, using a random‐effects model. Where it was not possible to perform a meta‐analysis, we summarised the data for each trial and have only presented forest plots. If raw data could not be extracted, we extracted the results from appropriate statistical analyses presented in the paper and reported these in the review. We considered a P value &lt; 0.05 as statistically significant. </p> </section> <section id="CD003412-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Due to insufficient studies being included across the comparisons, we were unable able to perform any subgroup analyses. </p> </section> <section id="CD003412-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses to examine the effects of excluding studies with a moderate or high risk of bias (<a href="./references#CD003412-bbs2-0105" title="HigginsJP , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org.">Higgins 2011</a>), but insufficient numbers of studies were included in meta‐analyses. </p> </section> <section id="CD003412-sec-0052"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>'Summary of findings' tables were produced for the outcomes that we determined to be the most clinically relevant. This was based on the experiences of study authors and an electronic survey sent to clinicians in our centre, on what were felt to be the most important outcomes and comparisons to patients and clinicians. </p> <p>For 'Summary of findings' tables we included the following comparisons.</p> <p> <ul id="CD003412-list-0007"> <li> <p>MMS (Mohs micrographic surgery) versus SE (surgical excision)</p> </li> <li> <p>Imiquimod cream versus SE</p> </li> <li> <p>Radiotherapy versus SE (with or without frozen section margin control)</p> </li> <li> <p>MAL‐PDT versus SE</p> </li> <li> <p>Imiquimod cream versus MAL‐PDT</p> </li> </ul> </p> <p>MMS versus SE was our main comparison based on our authors' own clinical experiences and the fact that this issue has been debated for years between dermatologists and plastics surgeons. Additionally, the experience of our centre also suggested this was the most important comparison which we established through our electronic survey. </p> <p>All of our pre‐defined outcomes were reported in each 'Summary of findings' table except adverse effects data which were not included. Instead these were presented as a narrative synthesis within the results and discussion sections and collated into <a href="#CD003412-tbl-0007">Table 2</a>. </p> <p>'Summary of findings' tables are based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) principles (<a href="./references#CD003412-bbs2-0134" title="SchünemannH , BrozekJ , Oxman A editors. GRADE handbook. The GRADE Working Group, 2013.">Schünemann 2013</a>), and we used <a href="./references#CD003412-bbs2-0102" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime, Inc.), accessed 2018. Available at gradepro.org.">GRADEpro</a> to assess the certainty of evidence for each review outcome. Evidence from the included RCTs was downgraded from 'high certainty' by one level for each serious study limitation found in the domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias. Where confidence intervals included important benefit and serious harm (i.e. &gt; 1.25 and &lt; 0.75), we rated down two levels for very serious imprecision as described in the GRADE handbook (<a href="./references#CD003412-bbs2-0134" title="SchünemannH , BrozekJ , Oxman A editors. GRADE handbook. The GRADE Working Group, 2013.">Schünemann 2013</a>). We also rated down two levels for imprecision if there was a very wide confidence interval (more than 100‐fold difference) even if it excluded no effect (RR of 1.0). We rated down three levels when confidence intervals were so wide that we cannot have any certainty in the results and defined this as a confidence interval that includes no effect with a more than 100‐fold difference. </p> <section id="CD003412-sec-0053"> <h5 class="title">Other</h5> <p>A consumer (an experienced patient representative) was consulted throughout, particularly for readability and understanding of the plain language summary. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003412-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003412-sec-0054"></div> <section id="CD003412-sec-0055"> <h3 class="title">Description of studies</h3> <p>For a full description of the studies please see the <a href="./references#CD003412-sec-0332" title="">Characteristics of included studies</a> tables. </p> <section id="CD003412-sec-0056"> <h4 class="title">Results of the search</h4> <p>The database searches (see <a href="#CD003412-sec-0035">Electronic searches</a>) for this update retrieved a total of 4566 records. We did not identify any records of trials from our scanning of reference lists or correspondence with pharmaceutical companies (see <a href="#CD003412-sec-0036">Searching other resources</a>). After removing 179 duplicates, we had 4387 records. We screened these and excluded 4309 records based on titles and abstracts. </p> <p>We obtained the full text of the remaining 78 records. Twenty‐eight studies did not meet our inclusion criteria and were excluded (see <a href="./references#CD003412-sec-0333" title="">Characteristics of excluded studies</a>). One study included from the previous review (<a href="./references#CD003412-bbs2-0068" title="LuiH , HobbsL , TopeWD , LeePK , ElmetsC , ProvostN , et al. Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes. Archives of Dermatology2004;140(1):26-32. [CENTRAL: CN-00460095] ">Lui 2004</a>) was also excluded as we identified that not all lesions included were histologically proven and it included a large number of Gorlin syndrome patients. </p> <p>Six studies were not classified as we did not have enough information to decide if they met our eligibility criteria despite attempts to contact the authors to obtain the full study details for review (<a href="./references#CD003412-bbs2-0082" title="BunkerC . 5 Fluoracil/Adrenaline injectable gel in basal cell carcinoma. National Research Register. ">Bunker 2000</a>; <a href="./references#CD003412-bbs2-0083" title="IRCT2017030732933N1. A comparison between efficacy and safety of 585-nanometer pulsed dye laser alone and with cryotherapy in treating superficial basal cell carcinoma. en.irct.ir/trial/25544 (first received 21 May 2017). ">IRCT 2017 030732933N1</a>; <a href="./references#CD003412-bbs2-0084" title="ISRCTN 92678315. Effect of penetration enhancers in topical photodynamic therapy [Comparison of 20% Aminolaevulinic acid (ALA) versus 20% ALA 2% dimethyl sulphoxide (DMSO) 2% ethylene diamine tetraacetic acid (EDTA) in topical photodynamic therapy]. doi.org/10.1186/ISRCTN92678315 (first received 8 April 2002). ">ISRCTN 92678315</a>; <a href="./references#CD003412-bbs2-0085" title="KangK , HanM , CongM , ChenS , ZhangX , ZhangJ . The effects of Ella light power combined with imiquimod cream on basal cell carcinoma. Anti-Tumor Pharmacy2018;8(2):258-62. [en.cnki.com.cn/Article_en/CJFDTotal-LIYX201802033.htm]">Kang 2018</a>; <a href="./references#CD003412-bbs2-0086" title="MaX , LiL , MaX , YangJ , HeY . Effect of adriamycin combined with cisplatin on basal cell carcinoma and the level of vascular endothelial growth factor in patients. Anti-tumor Pharmacy2018;6:951-4. ">Ma 2018</a>; <a href="./references#CD003412-bbs2-0087" title="RPCEC00000147. Efficacy study, randomized, controlled, with CIGB-128-A injected perilesional in basal cell carcinoma in different treatment schedules (InCarbacel-V study). registroclinico.sld.cu/en/trials/RPCEC00000147-En (first received 1 February 2013). ">RPCEC00000147</a>; see <a href="./references#CD003412-bbs1-0003" title="">Studies awaiting classification</a>). Three studies are ongoing with no results available yet (<a href="./references#CD003412-bbs2-0088" title="EudraCT 2016-002255-25. Electrochemotherapy compared with radiotherapy for the treatment of basal cell carcinoma. www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002255-25 (first received 12 September 2016). [2016-002255-25]">EudraCT 2016‐002255‐25</a>; <a href="./references#CD003412-bbs2-0089" title="NCT02242929. Surgery versus combined treatment with curettage and imiquimod for nodular basal cell carcinoma (SCIN). clinicaltrials.gov/ct2/show/NCT02242929 (first received 17 September 2014). ">NCT02242929</a>; <a href="./references#CD003412-bbs2-0090" title="NCT03573401. A randomized, double blind, vehicle-controlled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT). clinicaltrials.gov/ct2/show/NCT03573401 (first received 29 June 2018). ">NCT03573401</a>). </p> <p>This left us with 41 records. Nine of these were related to studies included in the previous version of this review. The remaining 32 records reported 26 new studies which we included. We combined them with 26 included studies (reported in 43 references) from the previous version of the review. We then had a total of 52 included studies reported in 75 references (see <a href="./references#CD003412-sec-0332" title="">Characteristics of included studies</a>). We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD003412-bbs2-0118" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine2009;6(7):e1000097. [PMID: 19621072]">Moher 2009</a>) (<a href="#CD003412-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD003412-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram." data-id="CD003412-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> </div> <p>We contacted 21 corresponding authors to obtain further information. The authors of <a href="./references#CD003412-bbs2-0012" title="CloverAJ , SalwaS , McKiernanJ , BuckleyC , BourkeM , KellyEJ , et al. Prospective randomised control trial comparing electrochemotherapy and surgery for the primary treatment of basal cell carcinoma. Melanoma Research2016;26:e76. [CENTRAL: CN-01212975] [DOI: 10.1097/CMR.0000000000000285] [EMBASE: 612248066]CloverAJ , SalwaSP , BourkeMG , McKiernanJ , FordePF , O'SullivanST , et al. Electrochemotherapy for the treatment of primary basal cell carcinoma; a randomised control trial comparing electrochemotherapy and surgery with five year follow up. European Journal of Surgical Oncology2020;46(5):847-54. [CENTRAL: CN-02049463] [PMID: 31862134]">Clover 2016</a> and <a href="./references#CD003412-bbs2-0029" title="KuijpersDI , ThissenMR , BerrettyPJ , IdelerFH , NelemansPJ , NeumannMH . Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatologic Surgery2007;33(5):579-87. [CENTRAL: CN-00588176] ThissenMR , NiemanFH , IdelerAH , BerrettyPJ , NeumannHA . Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatologic Surgery2000;26(8):759-64. [CENTRAL: CN-00298974] ">Kuijpers 2007</a> kindly responded and provided further information. </p> </section> <section id="CD003412-sec-0057"> <h4 class="title">Included studies</h4> <p>Nine papers were identified from our search that had follow‐up data from earlier studies: <a href="./references#CD003412-bbs2-0007" title="Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Methyl aminolaevulinate photodynamic therapy vs. cryotherapy in primary superficial basal cell carcinoma: results of a 36-month follow-up. British Journal of Dermatology2005;153(1):29. Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Topical methyl aminolevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. European Journal of Dermatolology2008;18(5):547-53. [CENTRAL: CN-00668120] ">Basset‐Seguin 2008</a>; <a href="./references#CD003412-bbs2-0035" title="PunjabiS , CookLJ , KerseyP , MarksR , CerioR . Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicentre study. International Journal of Dermatology2008;47(1):78-82. [CENTRAL: CN-00629144] PunjabiS , CookLJ , KerseyP , MarksR , FinlayA , SharpG , et al. A double-blind, multicentre parallel group study of BEC-5 cream in basal cell carcinoma. European Academy of Dermatology &amp; Venereology2000;14(Suppl 1):49. [CENTRAL: CN-01616931] ">Punjabi 2008</a>; <a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a>; <a href="./references#CD003412-bbs2-0045" title="EssersBA , DirksenCD , NiemanFH , SmeetsNW , KrekelsGA , PrinsMH , et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Archives of Dermatology2006;142(2):187-94. [CENTRAL: CN-00555278] MosterdK , KrekelsGA , NiemanFH , OstertagJU , EssersBA , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncology2008;9(12):1149-56. [CENTRAL: CN-00665334] SmeetsNW , KrekelsGA , OstertagJU , EssersBA , DirksenCD , NiemanFH , et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet2004;364(9447):1766-72. [CENTRAL: CN-00492695] Van LooE , MosterdK , KrekelsGA , RoozeboomMH , OstertagJU , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European Journal of Cancer2014;50(17):3011-20. [CENTRAL: CN-01043314] ">Smeets 2004</a> (four references), <a href="./references#CD003412-bbs2-0029" title="KuijpersDI , ThissenMR , BerrettyPJ , IdelerFH , NelemansPJ , NeumannMH . Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatologic Surgery2007;33(5):579-87. [CENTRAL: CN-00588176] ThissenMR , NiemanFH , IdelerAH , BerrettyPJ , NeumannHA . Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatologic Surgery2000;26(8):759-64. [CENTRAL: CN-00298974] ">Kuijpers 2007</a> (was Thissen 2000); <a href="./references#CD003412-bbs2-0018" title="FoleyP , FreemanM , MenterA , SillerG , El-AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] FoleyP , FreemanM , SillerG , GebauerK , MurrellD , BarnetsonR , et al. A phase III randomized study comparing photodynamic therapy (PDT) using methyl aminolevulinate or placebo cream in nodular basal cell carcinoma (NBCC). Journal of the European Academy of Dermatology and Venereology2003;17(Suppl 3):231. [CENTRAL: CN-00478536] ">Foley 2009a</a>; <a href="./references#CD003412-bbs2-0019" title="FoleyP , FreemanM , MenterA , SillerG , El‐AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] TopeWD , MenterA , El AzharyR , SotoP . A comparison of topical MAL-PDT versus placebo-PDT in nodular basal cell carcinoma: results of a North American study. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology; 2005 Sep 28-Oct 03; Kuala Lumpur, Malaysia. 2005:376. [CENTRAL: CN-00602617] ">Foley 2009b</a> (was Tope 2005). </p> <section id="CD003412-sec-0058"> <h5 class="title">Design</h5> <p>All studies were prospective, RCTs with a parallel‐group design. Eight RCTs were reported as pilot studies (<a href="./references#CD003412-bbs2-0003" title="Abd El-NabyNM , El-FarNN , Al-Shenawy HA , ElshwadfySE , KouraAA . Pulsed dye laser in the treatment of basal cell carcinoma: a single session versus two sessions–a randomized controlled trial. Indian Journal of Dermatology, Venereology, and Leprology2019;85(5):475. ">Abd El‐Naby 2019</a>; <a href="./references#CD003412-bbs2-0009" title="BeutnerKR , GeisseJK , HelmanD , FoxTL , GinkelA , OwensMA . Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. Journal of the American Academy of Dermatology1999;41(6):1002-7. [CENTRAL: CN-00264417] ">Beutner 1999</a>; <a href="./references#CD003412-bbs2-0011" title="ChoiSH , KimKH , SongKH . Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial. Journal of the European Academy of Dermatology and Venereology2015;30(5):783-8. [CENTRAL: CN-01158122] [DOI: 10.1111/jdv.13453]">Choi 2016</a>; <a href="./references#CD003412-bbs2-0016" title="EimpunthS , OganesyanG , HammanMS , LeeRA , JiangSI , KimSS . Effectiveness of a 595-nm pulsed dye laser for the treatment of basal cell carcinoma using 1 stacked-pulse session. Journal of the American Academy of Dermatology2014;70(5 (S1)):AB134. [CENTRAL: CN-01057471] ">Eimpunth 2014</a>; <a href="./references#CD003412-bbs2-0023" title="HaakCS , Togsverd-BoK , Thaysen-PetersenD , WulfHC , PaaschU , AndersonRR , et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas - a randomized clinical trial. British Journal of Dermatology2015;172(1):215-22. [CENTRAL: CN-01039978] ">Haak 2015</a>; <a href="./references#CD003412-bbs2-0028" title="KuijpersDI , ThissenMR , ThissenCA , NeumannMH . Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. Journal of Drugs in Dermatology2006;5(7):642-5. [CENTRAL: CN-00566805] ">Kuijpers 2006</a>; <a href="./references#CD003412-bbs2-0038" title="RomagosaR , SaapL , GivensM , SalvarreyA , HeJL , HsiaSL , et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatologic Surgery2000;26(4):338-40. [CENTRAL: CN-00296475] ">Romagosa 2000</a>; <a href="./references#CD003412-bbs2-0051" title="TranHT , LeeRA , OganesyanG , JiangSB . Single treatment of non-melanoma skin cancers using a pulsed-dye laser with stacked pulses. Lasers in Surgery and Medicine2012;44(6):459-67. [CENTRAL: CN-00969795] ">Tran 2012</a>). The most common comparators were non‐surgical treatments, with 20 RCTs comparing a non‐surgical treatment against another non‐surgical treatment. Fourteen RCTs compared a non‐surgical treatment against placebo. Eighteen RCTs had a surgical treatment comparator, with 10 RCTs comparing a surgical treatment against a non‐surgical treatment, five RCTs comparing a surgical treatment against a surgical treatment, and three RCTs comparing a surgical treatment against placebo. </p> <p>Twenty‐six of our included studies compared an intervention against at least one active treatment (head‐to‐head studies), 13 compared different regimens of the same active treatment, and 13 compared against placebo/vehicle/sham/no treatment. Seventeen studies had multiple intervention arms (three or four arms). </p> <p>All intervention groups were deemed to be relevant in these multi‐arm studies, but due to the large number of comparisons in the review, we only presented the active treatment‐arm comparisons. </p> <p>The duration of the included studies ranged from six weeks to 10 years, with an average of 13 months. Just under half of the studies were multi‐centre (24/52), with 26/52 single‐centre studies. We were unable to ascertain the number of study centres for two studies. </p> </section> <section id="CD003412-sec-0059"> <h5 class="title">Setting</h5> <p>All of the studies included in this review recruited participants from secondary care clinics, with the vast majority being dermatology outpatient clinics. The studies were conducted in many parts of the world. Thirty‐two studies were conducted in Europe, 11 in North America, five in Australasia, three in Asia/middle East and one in South America. </p> </section> <section id="CD003412-sec-0060"> <h5 class="title">Participants</h5> <p>A total of 6690 participants were randomised across the 52 RCTs included in this review. Studies recruited participants ranging in age from 20 to 95 years old with a median age of 64.9 years. Twelve studies did not provide data on the age of participants. Ten studies did not provide data on the gender of participants. Based on the studies that did provide data on gender, there were more male participants than females (ratio 1.48 males:1 female). </p> <p>The vast majority (48/52) of studies exclusively included basal cell carcinomas (BCC) of low‐risk histological subtypes (nodular, superficial). Only four studies included high‐risk histological subtypes (<a href="./references#CD003412-bbs2-0004" title="AlpsoyE , YikmazE , BasaranE , YazarS . Comparison of the effects of intralesional interferon alfa-1a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. Journal of Dermatology1996;23(6):394-6. [CENTRAL: CN-00127615] ">Alpsoy 1996</a>; <a href="./references#CD003412-bbs2-0006" title="AvrilMF , AuperinA , MargulisA , GerbauletA , DuvillardP , BenhamouE , et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. British Journal of Cancer1997;76(1):100-6. [CENTRAL: CN-00141470] PetitJY , AvrilMF , MargulisA , ChassagneD , GerbauletA , DuvillardP , et al. Evaluation of cosmetic results of a randomised trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plastic and Reconstructive Surgery2000;105(7):2544-51. [CENTRAL: CN-00278207] ">Avril 1997</a>; <a href="./references#CD003412-bbs2-0012" title="CloverAJ , SalwaS , McKiernanJ , BuckleyC , BourkeM , KellyEJ , et al. Prospective randomised control trial comparing electrochemotherapy and surgery for the primary treatment of basal cell carcinoma. Melanoma Research2016;26:e76. [CENTRAL: CN-01212975] [DOI: 10.1097/CMR.0000000000000285] [EMBASE: 612248066]CloverAJ , SalwaSP , BourkeMG , McKiernanJ , FordePF , O'SullivanST , et al. Electrochemotherapy for the treatment of primary basal cell carcinoma; a randomised control trial comparing electrochemotherapy and surgery with five year follow up. European Journal of Surgical Oncology2020;46(5):847-54. [CENTRAL: CN-02049463] [PMID: 31862134]">Clover 2016</a>; <a href="./references#CD003412-bbs2-0045" title="EssersBA , DirksenCD , NiemanFH , SmeetsNW , KrekelsGA , PrinsMH , et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Archives of Dermatology2006;142(2):187-94. [CENTRAL: CN-00555278] MosterdK , KrekelsGA , NiemanFH , OstertagJU , EssersBA , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncology2008;9(12):1149-56. [CENTRAL: CN-00665334] SmeetsNW , KrekelsGA , OstertagJU , EssersBA , DirksenCD , NiemanFH , et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet2004;364(9447):1766-72. [CENTRAL: CN-00492695] Van LooE , MosterdK , KrekelsGA , RoozeboomMH , OstertagJU , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European Journal of Cancer2014;50(17):3011-20. [CENTRAL: CN-01043314] ">Smeets 2004</a>), but none of these exclusively included high‐risk histological subtypes and the majority of BCCs in these studies were low‐risk histological subtypes. </p> <p>Most studies (27/52) included BCCs located on the head, neck and body regions. Six studies excluded BCCs located on the head and neck region (<a href="./references#CD003412-bbs2-0025" title="KarsaiS , FriedlH , BuhckH , JüngerM , PoddaM . The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: Outcome of a double-blind randomized placebo-controlled trial. British Journal of Dermatology2015;172(3):677-83. [CENTRAL: CN-01068975] ">Karsai 2015</a>; <a href="./references#CD003412-bbs2-0026" title="KesselsJ , VoetenL , NelemansP , CleutjensJ , HillenLM , MosterdK , et al. Topical sinecatechins, 10%, ointment for superficial basal cell carcinoma: A randomized clinical trial. JAMA Dermatology2017;153(10):1061-3. [CENTRAL: CN-01420948] ">Kessels 2017</a>; <a href="./references#CD003412-bbs2-0038" title="RomagosaR , SaapL , GivensM , SalvarreyA , HeJL , HsiaSL , et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatologic Surgery2000;26(4):338-40. [CENTRAL: CN-00296475] ">Romagosa 2000</a>; <a href="./references#CD003412-bbs2-0040" title="SalmivuoriMK , GrönroosM , TaniT , PölönenI , RäsänenJ , AnnalaL , et al. Hexylaminolevulinate and aminolevulinic acid nanoemulsion have similar tolerability, initial efficacy and cosmetic outcome as methylaminolevulinate in photodynamic therapy of basal cell carcinoma in a prospective randomized double-blinded trial. Journal of Investigative Dermatology2019;139(9):S234. [CENTRAL: CN-01978390] [DOI: 10.1016/j.jid.2019.07.119]">Salmivuori 2019</a>; <a href="./references#CD003412-bbs2-0047" title="RosenR , FreemanM , ZibertJR , KatsamasJ , KnudsenKM , SpelmanL . Ingenol mebutate 0.05% gel under occlusion is efficacious in treating superficial basal cell carcinoma. British Journal of Dermatology2014;171(Suppl 4):50. [CENTRAL: CN-01057057] ">Spelman 2014</a>; <a href="./references#CD003412-bbs2-0051" title="TranHT , LeeRA , OganesyanG , JiangSB . Single treatment of non-melanoma skin cancers using a pulsed-dye laser with stacked pulses. Lasers in Surgery and Medicine2012;44(6):459-67. [CENTRAL: CN-00969795] ">Tran 2012</a>). Nine studies included BCCs only located on the head and neck region (<a href="./references#CD003412-bbs2-0002" title="AbbadeL , GigeT , AmaralV , AquinoS , MiotH . Higher recurrence rates of head and neck nodular basal cell carcinoma treated with topical photodynamic therapy (MAL-PDT) compared to surgical excision: a randomized controlled study. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB185. [CENTRAL: CN-01076055] ">Abbade 2015</a>; <a href="./references#CD003412-bbs2-0003" title="Abd El-NabyNM , El-FarNN , Al-Shenawy HA , ElshwadfySE , KouraAA . Pulsed dye laser in the treatment of basal cell carcinoma: a single session versus two sessions–a randomized controlled trial. Indian Journal of Dermatology, Venereology, and Leprology2019;85(5):475. ">Abd El‐Naby 2019</a>; <a href="./references#CD003412-bbs2-0006" title="AvrilMF , AuperinA , MargulisA , GerbauletA , DuvillardP , BenhamouE , et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. British Journal of Cancer1997;76(1):100-6. [CENTRAL: CN-00141470] PetitJY , AvrilMF , MargulisA , ChassagneD , GerbauletA , DuvillardP , et al. Evaluation of cosmetic results of a randomised trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plastic and Reconstructive Surgery2000;105(7):2544-51. [CENTRAL: CN-00278207] ">Avril 1997</a>; <a href="./references#CD003412-bbs2-0020" title="Garcia-MartinE , Gil-ArribasLM , IdoipeM , AlfaroJ , PueyoV , PabloLE , et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. British Journal of Ophthalmology2011;95(10):1393-6. [CENTRAL: CN-00801928] ">Garcia‐Martin 2011</a>; <a href="./references#CD003412-bbs2-0023" title="HaakCS , Togsverd-BoK , Thaysen-PetersenD , WulfHC , PaaschU , AndersonRR , et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas - a randomized clinical trial. British Journal of Dermatology2015;172(1):215-22. [CENTRAL: CN-01039978] ">Haak 2015</a>; <a href="./references#CD003412-bbs2-0029" title="KuijpersDI , ThissenMR , BerrettyPJ , IdelerFH , NelemansPJ , NeumannMH . Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatologic Surgery2007;33(5):579-87. [CENTRAL: CN-00588176] ThissenMR , NiemanFH , IdelerAH , BerrettyPJ , NeumannHA . Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatologic Surgery2000;26(8):759-64. [CENTRAL: CN-00298974] ">Kuijpers 2007</a>; <a href="./references#CD003412-bbs2-0030" title="LandthalerM , Braun-FalcoO . Use of the TDF factor in soft roentgen radiotherapy [Anwendung des TDF-Faktors in der Röntgenweichstrahlentherapie]. Hautarzt1989;40(12):774-7. [CENTRAL: CN-00194309] [PMID: 2695500]">Landthaler 1989</a>; <a href="./references#CD003412-bbs2-0039" title="SalmanpoorR , MotevalliD , SakiN , SakiM . Efficacy of excisional surgery, curettage and combined curettage and electrodessication in treatment of basal cell carcinoma. Iranian Journal of Dermatology2012;15(2):66-7. [CENTRAL: CN-00908884] ">Salmanpoor 2012</a>; <a href="./references#CD003412-bbs2-0045" title="EssersBA , DirksenCD , NiemanFH , SmeetsNW , KrekelsGA , PrinsMH , et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Archives of Dermatology2006;142(2):187-94. [CENTRAL: CN-00555278] MosterdK , KrekelsGA , NiemanFH , OstertagJU , EssersBA , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncology2008;9(12):1149-56. [CENTRAL: CN-00665334] SmeetsNW , KrekelsGA , OstertagJU , EssersBA , DirksenCD , NiemanFH , et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet2004;364(9447):1766-72. [CENTRAL: CN-00492695] Van LooE , MosterdK , KrekelsGA , RoozeboomMH , OstertagJU , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European Journal of Cancer2014;50(17):3011-20. [CENTRAL: CN-01043314] ">Smeets 2004</a>). Three studies included BCCs exclusively on high‐risk facial sites (H‐zone of the face) (<a href="./references#CD003412-bbs2-0045" title="EssersBA , DirksenCD , NiemanFH , SmeetsNW , KrekelsGA , PrinsMH , et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Archives of Dermatology2006;142(2):187-94. [CENTRAL: CN-00555278] MosterdK , KrekelsGA , NiemanFH , OstertagJU , EssersBA , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncology2008;9(12):1149-56. [CENTRAL: CN-00665334] SmeetsNW , KrekelsGA , OstertagJU , EssersBA , DirksenCD , NiemanFH , et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet2004;364(9447):1766-72. [CENTRAL: CN-00492695] Van LooE , MosterdK , KrekelsGA , RoozeboomMH , OstertagJU , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European Journal of Cancer2014;50(17):3011-20. [CENTRAL: CN-01043314] ">Smeets 2004</a>; <a href="./references#CD003412-bbs2-0023" title="HaakCS , Togsverd-BoK , Thaysen-PetersenD , WulfHC , PaaschU , AndersonRR , et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas - a randomized clinical trial. British Journal of Dermatology2015;172(1):215-22. [CENTRAL: CN-01039978] ">Haak 2015</a>; <a href="./references#CD003412-bbs2-0020" title="Garcia-MartinE , Gil-ArribasLM , IdoipeM , AlfaroJ , PueyoV , PabloLE , et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. British Journal of Ophthalmology2011;95(10):1393-6. [CENTRAL: CN-00801928] ">Garcia‐Martin 2011</a>). Ten studies did not report the location of BCCs (<a href="./references#CD003412-bbs2-0011" title="ChoiSH , KimKH , SongKH . Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial. Journal of the European Academy of Dermatology and Venereology2015;30(5):783-8. [CENTRAL: CN-01158122] [DOI: 10.1111/jdv.13453]">Choi 2016</a>; <a href="./references#CD003412-bbs2-0012" title="CloverAJ , SalwaS , McKiernanJ , BuckleyC , BourkeM , KellyEJ , et al. Prospective randomised control trial comparing electrochemotherapy and surgery for the primary treatment of basal cell carcinoma. Melanoma Research2016;26:e76. [CENTRAL: CN-01212975] [DOI: 10.1097/CMR.0000000000000285] [EMBASE: 612248066]CloverAJ , SalwaSP , BourkeMG , McKiernanJ , FordePF , O'SullivanST , et al. Electrochemotherapy for the treatment of primary basal cell carcinoma; a randomised control trial comparing electrochemotherapy and surgery with five year follow up. European Journal of Surgical Oncology2020;46(5):847-54. [CENTRAL: CN-02049463] [PMID: 31862134]">Clover 2016</a>; <a href="./references#CD003412-bbs2-0014" title="EdwardsL , TuckerSB , PeredniaD , SmilesKA , TaylorEL , TannerDJ , et al. The effects of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinoma. Archives of Dermatology1990;126(8):1029-32. [CENTRAL: CN-00069443] ">Edwards 1990</a>; <a href="./references#CD003412-bbs2-0016" title="EimpunthS , OganesyanG , HammanMS , LeeRA , JiangSI , KimSS . Effectiveness of a 595-nm pulsed dye laser for the treatment of basal cell carcinoma using 1 stacked-pulse session. Journal of the American Academy of Dermatology2014;70(5 (S1)):AB134. [CENTRAL: CN-01057471] ">Eimpunth 2014</a>; <a href="./references#CD003412-bbs2-0031" title="MarksR , GebauerK , ShumackS , AmiesM , BrydenJ , FoxTL , et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicentre 6-week dose-response trial. Journal of the American Academy of Dermatology2001;44(5):807-13. [CENTRAL: CN-00326531] ">Marks 2001</a>; <a href="./references#CD003412-bbs2-0035" title="PunjabiS , CookLJ , KerseyP , MarksR , CerioR . Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicentre study. International Journal of Dermatology2008;47(1):78-82. [CENTRAL: CN-00629144] PunjabiS , CookLJ , KerseyP , MarksR , FinlayA , SharpG , et al. A double-blind, multicentre parallel group study of BEC-5 cream in basal cell carcinoma. European Academy of Dermatology &amp; Venereology2000;14(Suppl 1):49. [CENTRAL: CN-01616931] ">Punjabi 2008</a>; <a href="./references#CD003412-bbs2-0037" title="RogozinskiTT , JablonskaS , BrzoskaIM , WohrC , GausW . Intralesional treatment with recombinant interferon beta is an effective alternative for the treatment of basal cell carcinoma. Double-blind, placebo-controlled study. [Doogniskowe podawanie rekombinantowego interferonu beta. Skuteczna alternatywa w leczeniu basalimoma (wyniki podwojnie slepej proby)]. Przeglad Dermatologiczny1997;84(3):259-63. [CENTRAL: CN-00193051] ">Rogozinski 1997</a>; <a href="./references#CD003412-bbs2-0044" title="SillerG , RosenR , FreemanM , WelburnP , KatsamasJ , OgbourneSM . PEP005 (Ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomised phase IIa trial. Australasian Journal of Dermatology2010;51(2):99-105. [CENTRAL: CN-00771587] ">Siller 2010</a>; <a href="./references#CD003412-bbs2-0046" title="SolerAM , Angell-PetersenE , WarloeT , TausjoJ , SteenHB , MoanJ , et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: A comparison of two light sources. Photochemistry and Photobiology2000;71(6):724-9. [CENTRAL: CN-00297518] ">Soler 2000</a>; <a href="./references#CD003412-bbs2-0001" title="2005-001474-27. A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001474-27/results (first accessed 12 August 2016). ">2005‐001474‐27</a>). </p> </section> <section id="CD003412-sec-0061"> <h5 class="title">Sample sizes</h5> <p>The number of participants randomised in each study ranged from 13 (<a href="./references#CD003412-bbs2-0038" title="RomagosaR , SaapL , GivensM , SalvarreyA , HeJL , HsiaSL , et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatologic Surgery2000;26(4):338-40. [CENTRAL: CN-00296475] ">Romagosa 2000</a>) to 724 (<a href="./references#CD003412-bbs2-0022" title="GeisseJ , CaroI , LindholmJ , GolitzL , StamponeP , OwensM . Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology2004;50(5):722-33. [CENTRAL: CN-00469536] ">Geisse 2004</a>) with a median of 89 participants. We did not re‐count the participants in the follow‐up studies, and therefore there were a total of 6690 participants randomised in the 52 primary RCTs included in this review. Thirty‐eight RCTs used participants as the unit of analysis, and 14 RCTs used lesions as the unit of analysis. A total of 7241 lesions were included in this review. </p> </section> <section id="CD003412-sec-0062"> <h5 class="title">Funding</h5> <p>Overall, 22 studies were industry funded, with studies of imiquimod and photodynamic therapy being over‐represented in this group. Seventy‐nine per cent of studies (11/14) assessing imiquimod were funded by the same company (3M), and seven out of 16 PDT studies were industry‐funded (five by PhotoCure/Galderma). </p> </section> <section id="CD003412-sec-0063"> <h5 class="title">Interventions</h5> <p>The trials fell into 15 broad therapeutic categories. For a full description of the studies, please see the <a href="./references#CD003412-sec-0332" title="">Characteristics of included studies</a> table. *Denotes study new to this update. </p> <section id="CD003412-sec-0064"> <h6 class="title">1. Surgical excision (SE)</h6> <p>Ten RCTs.</p> <p> <ul id="CD003412-list-0008"> <li> <p>Mohs micrographic surgery versus SE (<a href="./references#CD003412-bbs2-0045" title="EssersBA , DirksenCD , NiemanFH , SmeetsNW , KrekelsGA , PrinsMH , et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Archives of Dermatology2006;142(2):187-94. [CENTRAL: CN-00555278] MosterdK , KrekelsGA , NiemanFH , OstertagJU , EssersBA , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncology2008;9(12):1149-56. [CENTRAL: CN-00665334] SmeetsNW , KrekelsGA , OstertagJU , EssersBA , DirksenCD , NiemanFH , et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet2004;364(9447):1766-72. [CENTRAL: CN-00492695] Van LooE , MosterdK , KrekelsGA , RoozeboomMH , OstertagJU , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European Journal of Cancer2014;50(17):3011-20. [CENTRAL: CN-01043314] ">Smeets 2004</a>) </p> </li> <li> <p>Imiquimod versus SE (<a href="./references#CD003412-bbs2-0008" title="Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , MillerPS , et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncology2014;15(1):96-105. [CENTRAL: CN-00959373] WilliamsHC , Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. Journal of Investigative Dermatology2017;137(3):614-9. [CENTRAL: CN-01340067] [EMBASE: 614596349]">Bath‐Hextall 2014</a>*) </p> </li> <li> <p>Radiotherapy versus SE (with option for frozen section margin control) (<a href="./references#CD003412-bbs2-0006" title="AvrilMF , AuperinA , MargulisA , GerbauletA , DuvillardP , BenhamouE , et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. British Journal of Cancer1997;76(1):100-6. [CENTRAL: CN-00141470] PetitJY , AvrilMF , MargulisA , ChassagneD , GerbauletA , DuvillardP , et al. Evaluation of cosmetic results of a randomised trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plastic and Reconstructive Surgery2000;105(7):2544-51. [CENTRAL: CN-00278207] ">Avril 1997</a>) </p> </li> <li> <p>Curettage versus curettage and cautery versus SE (<a href="./references#CD003412-bbs2-0039" title="SalmanpoorR , MotevalliD , SakiN , SakiM . Efficacy of excisional surgery, curettage and combined curettage and electrodessication in treatment of basal cell carcinoma. Iranian Journal of Dermatology2012;15(2):66-7. [CENTRAL: CN-00908884] ">Salmanpoor 2012</a>*) </p> </li> <li> <p>Curettage and cryosurgery versus SE (<a href="./references#CD003412-bbs2-0029" title="KuijpersDI , ThissenMR , BerrettyPJ , IdelerFH , NelemansPJ , NeumannMH . Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatologic Surgery2007;33(5):579-87. [CENTRAL: CN-00588176] ThissenMR , NiemanFH , IdelerAH , BerrettyPJ , NeumannHA . Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatologic Surgery2000;26(8):759-64. [CENTRAL: CN-00298974] ">Kuijpers 2007</a>*) </p> </li> <li> <p>MAL‐PDT versus SE (<a href="./references#CD003412-bbs2-0002" title="AbbadeL , GigeT , AmaralV , AquinoS , MiotH . Higher recurrence rates of head and neck nodular basal cell carcinoma treated with topical photodynamic therapy (MAL-PDT) compared to surgical excision: a randomized controlled study. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB185. [CENTRAL: CN-01076055] ">Abbade 2015</a>*; <a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a>; <a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a>) </p> </li> <li> <p>ALA‐PDT versus SE (<a href="./references#CD003412-bbs2-0034" title="MosterdK , ThissenMR , NelemansP , Kelleners‐SmeetsNW , JanssenRL , BroekhofKG , et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. British Journal of Dermatology2008;159(4):864-70. [CENTRAL: CN-00667266] RoozeboomMH , AardoomMA , NelemansPJ , ThissenMR , Kelleners-SmeetsNW , KuijpersDI , et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. Journal of the American Academy of Dermatology August 2013;69(2):280-7. [CENTRAL: CN-00876800] [DOI: 10.1016/j.jid.2016.03.043]">Mosterd 2008</a>*) </p> </li> <li> <p>Electrochemotherapy versus SE (<a href="./references#CD003412-bbs2-0012" title="CloverAJ , SalwaS , McKiernanJ , BuckleyC , BourkeM , KellyEJ , et al. Prospective randomised control trial comparing electrochemotherapy and surgery for the primary treatment of basal cell carcinoma. Melanoma Research2016;26:e76. [CENTRAL: CN-01212975] [DOI: 10.1097/CMR.0000000000000285] [EMBASE: 612248066]CloverAJ , SalwaSP , BourkeMG , McKiernanJ , FordePF , O'SullivanST , et al. Electrochemotherapy for the treatment of primary basal cell carcinoma; a randomised control trial comparing electrochemotherapy and surgery with five year follow up. European Journal of Surgical Oncology2020;46(5):847-54. [CENTRAL: CN-02049463] [PMID: 31862134]">Clover 2016</a>*) </p> </li> </ul> </p> </section> <section id="CD003412-sec-0065"> <h6 class="title">2. Radiotherapy</h6> <p>Four RCTs.</p> <p> <ul id="CD003412-list-0009"> <li> <p>Radiotherapy versus SE (<a href="./references#CD003412-bbs2-0006" title="AvrilMF , AuperinA , MargulisA , GerbauletA , DuvillardP , BenhamouE , et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. British Journal of Cancer1997;76(1):100-6. [CENTRAL: CN-00141470] PetitJY , AvrilMF , MargulisA , ChassagneD , GerbauletA , DuvillardP , et al. Evaluation of cosmetic results of a randomised trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plastic and Reconstructive Surgery2000;105(7):2544-51. [CENTRAL: CN-00278207] ">Avril 1997</a>) </p> </li> <li> <p>Imiquimod versus radiotherapy (<a href="./references#CD003412-bbs2-0020" title="Garcia-MartinE , Gil-ArribasLM , IdoipeM , AlfaroJ , PueyoV , PabloLE , et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. British Journal of Ophthalmology2011;95(10):1393-6. [CENTRAL: CN-00801928] ">Garcia‐Martin 2011</a>*) </p> </li> <li> <p>Low dose versus high‐dose radiotherapy (<a href="./references#CD003412-bbs2-0030" title="LandthalerM , Braun-FalcoO . Use of the TDF factor in soft roentgen radiotherapy [Anwendung des TDF-Faktors in der Röntgenweichstrahlentherapie]. Hautarzt1989;40(12):774-7. [CENTRAL: CN-00194309] [PMID: 2695500]">Landthaler 1989</a>*) </p> </li> <li> <p>Radiotherapy versus cryosurgery (<a href="./references#CD003412-bbs2-0024" title="HallVL , LeppardBJ , McGillJ , KesselerME , WhiteJE , GoodwinP . Treatment of basal cell carcinoma: comparison of radiotherapy and cryotherapy. Clinical Radiology1986;37(1):33-4. [CENTRAL: CN-00478536] ">Hall 1986</a>) </p> </li> </ul> </p> </section> <section id="CD003412-sec-0066"> <h6 class="title">3. Cryosurgery</h6> <p>Four RCTs.</p> <p> <ul id="CD003412-list-0010"> <li> <p>Radiotherapy versus cryosurgery (<a href="./references#CD003412-bbs2-0024" title="HallVL , LeppardBJ , McGillJ , KesselerME , WhiteJE , GoodwinP . Treatment of basal cell carcinoma: comparison of radiotherapy and cryotherapy. Clinical Radiology1986;37(1):33-4. [CENTRAL: CN-00478536] ">Hall 1986</a>) </p> </li> <li> <p>Curettage and cryosurgery versus SE (<a href="./references#CD003412-bbs2-0029" title="KuijpersDI , ThissenMR , BerrettyPJ , IdelerFH , NelemansPJ , NeumannMH . Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatologic Surgery2007;33(5):579-87. [CENTRAL: CN-00588176] ThissenMR , NiemanFH , IdelerAH , BerrettyPJ , NeumannHA . Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatologic Surgery2000;26(8):759-64. [CENTRAL: CN-00298974] ">Kuijpers 2007</a>) </p> </li> <li> <p>PDT versus cryosurgery (<a href="./references#CD003412-bbs2-0052" title="WangI , BendsoeN , KlintebergCA , EnejderAM , Andersson‐EngelsS , SvanbergS , et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. British Journal of Dermatology2000;144(4):832-40. [CENTRAL: CN-00326537] ">Wang 2001</a>; <a href="./references#CD003412-bbs2-0007" title="Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Methyl aminolaevulinate photodynamic therapy vs. cryotherapy in primary superficial basal cell carcinoma: results of a 36-month follow-up. British Journal of Dermatology2005;153(1):29. Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Topical methyl aminolevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. European Journal of Dermatolology2008;18(5):547-53. [CENTRAL: CN-00668120] ">Basset‐Seguin 2008</a>*) </p> </li> </ul> </p> </section> <section id="CD003412-sec-0067"> <h6 class="title">4. Curettage and cautery (C&amp;C)</h6> <p>One RCT.</p> <p> <ul id="CD003412-list-0011"> <li> <p>Curettage versus curettage and cautery versus SE (<a href="./references#CD003412-bbs2-0039" title="SalmanpoorR , MotevalliD , SakiN , SakiM . Efficacy of excisional surgery, curettage and combined curettage and electrodessication in treatment of basal cell carcinoma. Iranian Journal of Dermatology2012;15(2):66-7. [CENTRAL: CN-00908884] ">Salmanpoor 2012</a>*) </p> </li> </ul> </p> </section> <section id="CD003412-sec-0068"> <h6 class="title">5. Photodynamic therapy (PDT)</h6> <p>Sixteen RCTs.</p> <p> <ul id="CD003412-list-0012"> <li> <p>MAL‐PDT versus SE (<a href="./references#CD003412-bbs2-0002" title="AbbadeL , GigeT , AmaralV , AquinoS , MiotH . Higher recurrence rates of head and neck nodular basal cell carcinoma treated with topical photodynamic therapy (MAL-PDT) compared to surgical excision: a randomized controlled study. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB185. [CENTRAL: CN-01076055] ">Abbade 2015</a>*; <a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a>; <a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a>) </p> </li> <li> <p>ALA‐PDT versus SE (<a href="./references#CD003412-bbs2-0034" title="MosterdK , ThissenMR , NelemansP , Kelleners‐SmeetsNW , JanssenRL , BroekhofKG , et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. British Journal of Dermatology2008;159(4):864-70. [CENTRAL: CN-00667266] RoozeboomMH , AardoomMA , NelemansPJ , ThissenMR , Kelleners-SmeetsNW , KuijpersDI , et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. Journal of the American Academy of Dermatology August 2013;69(2):280-7. [CENTRAL: CN-00876800] [DOI: 10.1016/j.jid.2016.03.043]">Mosterd 2008</a>*) </p> </li> <li> <p>ALA‐PDT versus MAL‐PDT (<a href="./references#CD003412-bbs2-0028" title="KuijpersDI , ThissenMR , ThissenCA , NeumannMH . Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. Journal of Drugs in Dermatology2006;5(7):642-5. [CENTRAL: CN-00566805] ">Kuijpers 2006</a>*) </p> </li> <li> <p>MAL‐PDT versus HAL‐PDT versus BF200‐ALA‐PDT (<a href="./references#CD003412-bbs2-0040" title="SalmivuoriMK , GrönroosM , TaniT , PölönenI , RäsänenJ , AnnalaL , et al. Hexylaminolevulinate and aminolevulinic acid nanoemulsion have similar tolerability, initial efficacy and cosmetic outcome as methylaminolevulinate in photodynamic therapy of basal cell carcinoma in a prospective randomized double-blinded trial. Journal of Investigative Dermatology2019;139(9):S234. [CENTRAL: CN-01978390] [DOI: 10.1016/j.jid.2019.07.119]">Salmivuori 2019</a>*) </p> </li> <li> <p>BF‐200 ALA‐PDT versus MAL‐PDT (<a href="./references#CD003412-bbs2-0033" title="MortonCA , DominicusR , RadnyP , DirschkaT , HauschildA , ReinholdU , et al. A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). British Journal of Dermatology2018;179(2):309-19. [CENTRAL: CN-02000788] [PMID: 29432644]">Morton 2018</a>*) </p> </li> <li> <p>Two‐fold ALA‐PDT versus conventional MAL‐PDT (<a href="./references#CD003412-bbs2-0027" title="KesselsJP , KreukelsH , NelemansPJ , RoozeboomMH , vanPeltH , MosterdK , et al. Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5‐aminolaevulinic acid 20% vs. two‐stage topical methyl aminolaevulinate: results of a randomized controlled trial. British Journal of Dermatology2018;178(5):1056-63. [CENTRAL: CN-01991773] ">Kessels 2018</a>*) </p> </li> <li> <p>PDT versus cryosurgery (<a href="./references#CD003412-bbs2-0052" title="WangI , BendsoeN , KlintebergCA , EnejderAM , Andersson‐EngelsS , SvanbergS , et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. British Journal of Dermatology2000;144(4):832-40. [CENTRAL: CN-00326537] ">Wang 2001</a>; <a href="./references#CD003412-bbs2-0007" title="Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Methyl aminolaevulinate photodynamic therapy vs. cryotherapy in primary superficial basal cell carcinoma: results of a 36-month follow-up. British Journal of Dermatology2005;153(1):29. Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Topical methyl aminolevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. European Journal of Dermatolology2008;18(5):547-53. [CENTRAL: CN-00668120] ">Basset‐Seguin 2008</a>) </p> </li> <li> <p>Imiquimod cream versus MAL‐PDT (<a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a>*) </p> </li> <li> <p>5‐FU cream versus MAL‐PDT(<a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a>*) </p> </li> <li> <p>Laser ALA‐PDT versus broadband halogen light ALA‐PDT (<a href="./references#CD003412-bbs2-0046" title="SolerAM , Angell-PetersenE , WarloeT , TausjoJ , SteenHB , MoanJ , et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: A comparison of two light sources. Photochemistry and Photobiology2000;71(6):724-9. [CENTRAL: CN-00297518] ">Soler 2000</a>) </p> </li> <li> <p>Ablative fractional laser‐assisted MAL‐PDT versus MAL‐PDT (<a href="./references#CD003412-bbs2-0011" title="ChoiSH , KimKH , SongKH . Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial. Journal of the European Academy of Dermatology and Venereology2015;30(5):783-8. [CENTRAL: CN-01158122] [DOI: 10.1111/jdv.13453]">Choi 2016</a>*; <a href="./references#CD003412-bbs2-0023" title="HaakCS , Togsverd-BoK , Thaysen-PetersenD , WulfHC , PaaschU , AndersonRR , et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas - a randomized clinical trial. British Journal of Dermatology2015;172(1):215-22. [CENTRAL: CN-01039978] ">Haak 2015</a>*) </p> </li> <li> <p>MAL‐PDT versus placebo (<a href="./references#CD003412-bbs2-0018" title="FoleyP , FreemanM , MenterA , SillerG , El-AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] FoleyP , FreemanM , SillerG , GebauerK , MurrellD , BarnetsonR , et al. A phase III randomized study comparing photodynamic therapy (PDT) using methyl aminolevulinate or placebo cream in nodular basal cell carcinoma (NBCC). Journal of the European Academy of Dermatology and Venereology2003;17(Suppl 3):231. [CENTRAL: CN-00478536] ">Foley 2009a</a>; <a href="./references#CD003412-bbs2-0019" title="FoleyP , FreemanM , MenterA , SillerG , El‐AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] TopeWD , MenterA , El AzharyR , SotoP . A comparison of topical MAL-PDT versus placebo-PDT in nodular basal cell carcinoma: results of a North American study. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology; 2005 Sep 28-Oct 03; Kuala Lumpur, Malaysia. 2005:376. [CENTRAL: CN-00602617] ">Foley 2009b</a>) </p> </li> </ul> </p> </section> <section id="CD003412-sec-0069"> <h6 class="title">6. Imiquimod (5% cream unless otherwise stated)</h6> <p>Fourteen RCTs.</p> <p> <ul id="CD003412-list-0013"> <li> <p>Imiquimod versus MAL‐PDT (<a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a>*) </p> </li> <li> <p>Imiquimod versus 5‐FU cream (<a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a>*) </p> </li> <li> <p>Imiquimod versus SE (<a href="./references#CD003412-bbs2-0008" title="Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , MillerPS , et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncology2014;15(1):96-105. [CENTRAL: CN-00959373] WilliamsHC , Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. Journal of Investigative Dermatology2017;137(3):614-9. [CENTRAL: CN-01340067] [EMBASE: 614596349]">Bath‐Hextall 2014</a>*) </p> </li> <li> <p>Imiquimod versus radiotherapy (<a href="./references#CD003412-bbs2-0020" title="Garcia-MartinE , Gil-ArribasLM , IdoipeM , AlfaroJ , PueyoV , PabloLE , et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. British Journal of Ophthalmology2011;95(10):1393-6. [CENTRAL: CN-00801928] ">Garcia‐Martin 2011</a>*) </p> </li> <li> <p>Dose response trial of imiquimod with and without occlusion for BCC ‐ one trial for sBCC and one trial for nBCC (<a href="./references#CD003412-bbs2-0048" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. In: 8th World Congress on cancers of the skin, Zurich, Switzerland. 2001:61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] [PMID: 12452875]">Sterry 2002a</a>; <a href="./references#CD003412-bbs2-0049" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. 8th World Congress on cancers of the skin, Zurich, Switzerland2001;-(-):p61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] ">Sterry 2002b</a>) </p> </li> <li> <p>Five different doses of imiquimod for sBCC and nBCC versus vehicle (<a href="./references#CD003412-bbs2-0009" title="BeutnerKR , GeisseJK , HelmanD , FoxTL , GinkelA , OwensMA . Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. Journal of the American Academy of Dermatology1999;41(6):1002-7. [CENTRAL: CN-00264417] ">Beutner 1999</a>) </p> </li> <li> <p>Open‐label dose response trial of imiquimod for primary superficial BCC (<a href="./references#CD003412-bbs2-0031" title="MarksR , GebauerK , ShumackS , AmiesM , BrydenJ , FoxTL , et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicentre 6-week dose-response trial. Journal of the American Academy of Dermatology2001;44(5):807-13. [CENTRAL: CN-00326531] ">Marks 2001</a>) </p> </li> <li> <p>Open‐label dose response trial of imiquimod for nBCC (<a href="./references#CD003412-bbs2-0042" title="ShumackS , MarksR , AmiesM , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks treating nodular BCC. 8th World Congress on Cancers of the Skin, Zurich, Switzerland2001;-:p55. [CENTRAL: CN-00849091] ShumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , SchroeterA , et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002a</a>) </p> </li> <li> <p>Dose response trial of imiquimod versus vehicle for sBCC (<a href="./references#CD003412-bbs2-0021" title="GeisseJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating superficial BCC. In: The 8th World Congress on Cancer of the Skin; 2001 July 18-21; Zurich, Switzerland. 2001:P58. [CENTRAL: CN-00520431] GeisseJK , RichP , PandyaA , GrossK , AndresK , GinkelA , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a randomized, vehicle-controlled study. Journal of the American Academy of Dermatology2002;47(3):390-8. [CENTRAL: CN-00390933] ">Geisse 2002</a>; <a href="./references#CD003412-bbs2-0022" title="GeisseJ , CaroI , LindholmJ , GolitzL , StamponeP , OwensM . Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology2004;50(5):722-33. [CENTRAL: CN-00469536] ">Geisse 2004</a>; <a href="./references#CD003412-bbs2-0041" title="SchulzeHJ , CribierB , RequenaL , ReifenbergerJ , FerrandizC , DiezG , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. British Journal of Dermatology2005;152(5):939-47. [CENTRAL: CN-00513173] ">Schulze 2005</a>; <a href="./references#CD003412-bbs2-0043" title="RobinsonJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating nodular BCC. 8th World Congress on Cancer of the Skin, Zurich, Switzerland2001;-(-):p57. [CENTRAL: CN-00849091] SchumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , Schroeter, A et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002b</a>) </p> </li> <li> <p>Two different doses of imiquimod (<a href="./references#CD003412-bbs2-0017" title="EzughahFI , DaweRS , IbbotsonSH , FlemingCJ . A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment2008;19(2):111-7. [CENTRAL: CN-00706567] ">Ezughah 2008</a>*; <a href="./references#CD003412-bbs2-0015" title="EigentlerTK , KaminA , WeideBM , BreuningerH , CaroliUM , MöhrleM , et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. Journal of the American Academy of Dermatology2007;57(4):616-21. [CENTRAL: CN-00610509] ">Eigentler 2007</a>*) </p> </li> </ul> </p> </section> <section id="CD003412-sec-0070"> <h6 class="title">7. Fluorouracil (5‐FU)</h6> <p>Three RCTs.</p> <p> <ul id="CD003412-list-0014"> <li> <p>5‐FU cream versus MAL‐PDT (<a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a>*) </p> </li> <li> <p>Imiquimod cream versus 5‐FU cream (<a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a>*) </p> </li> <li> <p>5‐FU cream in phosphatidyl choline versus 5‐FU cream in petrolatum (<a href="./references#CD003412-bbs2-0038" title="RomagosaR , SaapL , GivensM , SalvarreyA , HeJL , HsiaSL , et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatologic Surgery2000;26(4):338-40. [CENTRAL: CN-00296475] ">Romagosa 2000</a>) </p> </li> <li> <p>Varying treatment regimens of 5‐FU/epinephrine injectable gel (<a href="./references#CD003412-bbs2-0032" title="MillerBH , ShavinJS , CognettaA , TaylorRJ , SalascheS , KoreyA , et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. Journal of the American Academy of Dermatology1997;36(1):72-7. [CENTRAL: CN-00135753] ">Miller 1997</a>) </p> </li> </ul> </p> </section> <section id="CD003412-sec-0071"> <h6 class="title">8. Electrochemotherapy (ECT)</h6> <p>One RCT.</p> <p> <ul id="CD003412-list-0015"> <li> <p>Electrochemotherapy versus SE (<a href="./references#CD003412-bbs2-0012" title="CloverAJ , SalwaS , McKiernanJ , BuckleyC , BourkeM , KellyEJ , et al. Prospective randomised control trial comparing electrochemotherapy and surgery for the primary treatment of basal cell carcinoma. Melanoma Research2016;26:e76. [CENTRAL: CN-01212975] [DOI: 10.1097/CMR.0000000000000285] [EMBASE: 612248066]CloverAJ , SalwaSP , BourkeMG , McKiernanJ , FordePF , O'SullivanST , et al. Electrochemotherapy for the treatment of primary basal cell carcinoma; a randomised control trial comparing electrochemotherapy and surgery with five year follow up. European Journal of Surgical Oncology2020;46(5):847-54. [CENTRAL: CN-02049463] [PMID: 31862134]">Clover 2016</a>*) </p> </li> </ul> </p> </section> <section id="CD003412-sec-0072"> <h6 class="title">9. Ingenol mebutate</h6> <p>Two RCTs.</p> <p> <ul id="CD003412-list-0016"> <li> <p>Ingenol mebutate gel 0.0025% versus ingenol mebutate gel 0.01% versus ingenol mebutate gel 0.05% versus vehicle gel (<a href="./references#CD003412-bbs2-0044" title="SillerG , RosenR , FreemanM , WelburnP , KatsamasJ , OgbourneSM . PEP005 (Ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomised phase IIa trial. Australasian Journal of Dermatology2010;51(2):99-105. [CENTRAL: CN-00771587] ">Siller 2010</a>*) </p> </li> <li> <p>Ingenol mebutate gel + full occlusive aluminium disk versus ingenol mebutate gel and semi‐occlusive dressing with Opsite or Ingenol mebutate gel with no occlusion (<a href="./references#CD003412-bbs2-0047" title="RosenR , FreemanM , ZibertJR , KatsamasJ , KnudsenKM , SpelmanL . Ingenol mebutate 0.05% gel under occlusion is efficacious in treating superficial basal cell carcinoma. British Journal of Dermatology2014;171(Suppl 4):50. [CENTRAL: CN-01057057] ">Spelman 2014</a>*) </p> </li> </ul> </p> </section> <section id="CD003412-sec-0073"> <h6 class="title">10. Solasodine glycosides</h6> <p>One RCT.</p> <p> <ul id="CD003412-list-0017"> <li> <p>Solasodine glycoside (Zycure) cream versus matching vehicle (<a href="./references#CD003412-bbs2-0035" title="PunjabiS , CookLJ , KerseyP , MarksR , CerioR . Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicentre study. International Journal of Dermatology2008;47(1):78-82. [CENTRAL: CN-00629144] PunjabiS , CookLJ , KerseyP , MarksR , FinlayA , SharpG , et al. A double-blind, multicentre parallel group study of BEC-5 cream in basal cell carcinoma. European Academy of Dermatology &amp; Venereology2000;14(Suppl 1):49. [CENTRAL: CN-01616931] ">Punjabi 2008</a>) </p> </li> </ul> </p> </section> <section id="CD003412-sec-0074"> <h6 class="title">11. Topical valproic acid gel and tazarotene gel</h6> <p>One RCT.</p> <p> <ul id="CD003412-list-0018"> <li> <p>Valproic acid (Baceca®) gel followed by Tazarotene gel versus placebo gel followed by Tazarotene gel (placebo cross‐over after eight weeks) (<a href="./references#CD003412-bbs2-0001" title="2005-001474-27. A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001474-27/results (first accessed 12 August 2016). ">2005‐001474‐27</a>*) </p> </li> </ul> </p> </section> <section id="CD003412-sec-0075"> <h6 class="title">12. Topical diclofenac and vitamin D</h6> <p>One RCT.</p> <p> <ul id="CD003412-list-0019"> <li> <p>Diclofenac‐3% gel versus calcitriol 3ug/g ointment versus diclofenac‐3% gel plus calcitriol 3ug/g ointment versus no topical treatment (<a href="./references#CD003412-bbs2-0010" title="BrinkhuizenT , FrenckenKJ , NelemansPJ , HoffML , Kelleners-SmeetsNW , Zur HausenA , et al. The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): a phase II, randomized controlled trial. Journal of the American Academy of Dermatology2016;75(1):126-34. [CENTRAL: CN-01342883] [DOI: 10.1016/j.jaad.2016.01.050]">Brinkhuizen 2016</a>*) </p> </li> </ul> </p> </section> <section id="CD003412-sec-0076"> <h6 class="title">13. Pulsed dye laser (PDL)</h6> <p>Four RCTs.</p> <p> <ul id="CD003412-list-0020"> <li> <p>PDL versus sham (<a href="./references#CD003412-bbs2-0025" title="KarsaiS , FriedlH , BuhckH , JüngerM , PoddaM . The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: Outcome of a double-blind randomized placebo-controlled trial. British Journal of Dermatology2015;172(3):677-83. [CENTRAL: CN-01068975] ">Karsai 2015</a>*) </p> </li> <li> <p>PDL single session versus PDL two sessions (<a href="./references#CD003412-bbs2-0003" title="Abd El-NabyNM , El-FarNN , Al-Shenawy HA , ElshwadfySE , KouraAA . Pulsed dye laser in the treatment of basal cell carcinoma: a single session versus two sessions–a randomized controlled trial. Indian Journal of Dermatology, Venereology, and Leprology2019;85(5):475. ">Abd El‐Naby 2019</a>*) </p> </li> <li> <p>PDL 7mm spot‐size, single pulses versus PDL 10mm spot‐size, stacked pulses (<a href="./references#CD003412-bbs2-0051" title="TranHT , LeeRA , OganesyanG , JiangSB . Single treatment of non-melanoma skin cancers using a pulsed-dye laser with stacked pulses. Lasers in Surgery and Medicine2012;44(6):459-67. [CENTRAL: CN-00969795] ">Tran 2012</a>*) </p> </li> <li> <p>PDL 10mm spot‐size, one stacked pulse session versus no treatment (<a href="./references#CD003412-bbs2-0016" title="EimpunthS , OganesyanG , HammanMS , LeeRA , JiangSI , KimSS . Effectiveness of a 595-nm pulsed dye laser for the treatment of basal cell carcinoma using 1 stacked-pulse session. Journal of the American Academy of Dermatology2014;70(5 (S1)):AB134. [CENTRAL: CN-01057471] ">Eimpunth 2014</a>*) </p> </li> </ul> </p> </section> <section id="CD003412-sec-0077"> <h6 class="title">14. Intralesional interferon (IFN) therapy</h6> <p>Four RCTs.</p> <p> <ul id="CD003412-list-0021"> <li> <p>IFN alpha‐2a, 2b or alpha‐2a and 2b (<a href="./references#CD003412-bbs2-0004" title="AlpsoyE , YikmazE , BasaranE , YazarS . Comparison of the effects of intralesional interferon alfa-1a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. Journal of Dermatology1996;23(6):394-6. [CENTRAL: CN-00127615] ">Alpsoy 1996</a>) </p> </li> <li> <p>IFN alpha 2b versus vehicle (<a href="./references#CD003412-bbs2-0013" title="CornellRC , GreenwayHT , TuckerSB , EdwardsL , AshworthS , VanceJC , et al. Intralesional interferon therapy for basal cell carcinoma. Journal of the American Academy of Dermatology1990;23(4 Pt 1):694-700. [CENTRAL: CN-00071018] ">Cornell 1990</a>) </p> </li> <li> <p>Number of dosages of IFN alpha 2b (<a href="./references#CD003412-bbs2-0014" title="EdwardsL , TuckerSB , PeredniaD , SmilesKA , TaylorEL , TannerDJ , et al. The effects of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinoma. Archives of Dermatology1990;126(8):1029-32. [CENTRAL: CN-00069443] ">Edwards 1990</a>) </p> </li> <li> <p>IFN beta versus placebo (<a href="./references#CD003412-bbs2-0037" title="RogozinskiTT , JablonskaS , BrzoskaIM , WohrC , GausW . Intralesional treatment with recombinant interferon beta is an effective alternative for the treatment of basal cell carcinoma. Double-blind, placebo-controlled study. [Doogniskowe podawanie rekombinantowego interferonu beta. Skuteczna alternatywa w leczeniu basalimoma (wyniki podwojnie slepej proby)]. Przeglad Dermatologiczny1997;84(3):259-63. [CENTRAL: CN-00193051] ">Rogozinski 1997</a>) </p> </li> </ul> </p> </section> <section id="CD003412-sec-0078"> <h6 class="title">15. Topical sinecatechins</h6> <p>One RCT.</p> <p> <ul id="CD003412-list-0022"> <li> <p>Sinecatechin 10% ointment versus vehicle (<a href="./references#CD003412-bbs2-0026" title="KesselsJ , VoetenL , NelemansP , CleutjensJ , HillenLM , MosterdK , et al. Topical sinecatechins, 10%, ointment for superficial basal cell carcinoma: A randomized clinical trial. JAMA Dermatology2017;153(10):1061-3. [CENTRAL: CN-01420948] ">Kessels 2017</a>*) </p> </li> </ul> </p> </section> </section> <section id="CD003412-sec-0079"> <h5 class="title">Outcomes</h5> <p>Out of the 52 comparisons, only 21% (11/52) reported our 3‐year recurrence primary outcome and only 17% (9/52) reported our 5‐year recurrence primary outcome. Cosmetic outcome data were reported for 37% (19/52) of the comparisons (14/52 had data available for analysis). Early treatment failure was reported in 75% (39/52) of comparisons. Pain data were reported in 46% (24/52) of the comparisons (10/52 had data available for analysis). Adverse effects data were reported for most comparisons (81%, 42/52), but due to their heterogeneity we did not perform any analyses and instead summarised these data in <a href="#CD003412-tbl-0007">Table 2</a>. </p> </section> </section> <section id="CD003412-sec-0080"> <h4 class="title">Excluded studies</h4> <p>We excluded 29 studies due to the following reasons: no outcomes of interest measured (8); not all lesions histologically proven (7); not an RCT (8); not all lesions primary, untreated BCC (3); inclusion of Gorlin syndrome participants (3) and a study on adjuvant treatment (1). Please see the <a href="./references#CD003412-sec-0333" title="">Characteristics of excluded studies</a> tables for further details. </p> <section id="CD003412-sec-0081"> <h5 class="title">Studies awaiting classification</h5> <p>We were unable to make a final decision on whether to include or exclude six studies despite attempts to contact the study investigators. See the <a href="./references#CD003412-bbs1-0003" title="">Studies awaiting classification</a> tables for further details. </p> </section> <section id="CD003412-sec-0082"> <h5 class="title">Ongoing studies</h5> <p>Three studies were identified that are currently ongoing and had no data available for us to include in this review. See the <a href="./references#CD003412-bbs1-0004" title="">Ongoing studies</a> tables for further details. </p> </section> </section> </section> <section id="CD003412-sec-0083"> <h3 class="title">Risk of bias in included studies</h3> <p>In order to objectively assess risk of bias, we used Cochrane 'Risk of bias' methods (<a href="./references#CD003412-bbs2-0105" title="HigginsJP , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org.">Higgins 2011</a>). Occasionally, our ability to assess risk was hampered by limited reporting of data. Where there was inadequate information to make a judgement, for example abstract‐only studies, attempts to contact the authors were made in order to get access to the data needed. Please see the <a href="./references#CD003412-sec-0332" title="">Characteristics of included studies</a> tables for full details. <a href="#CD003412-fig-0002">Figure 2</a> and <a href="#CD003412-fig-0003">Figure 3</a> summarise the overall data. </p> <div class="figure" id="CD003412-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003412-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003412-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003412-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003412-sec-0084"> <h4 class="title">Allocation</h4> <section id="CD003412-sec-0085"> <h5 class="title">Random sequence generation and concealment of allocation</h5> <p>The randomisation process in general and concealment of allocation are the most important and sensitive indicators that bias has been minimised in a clinical trial (<a href="./references#CD003412-bbs2-0132" title="SchulzKF , ChalmersI , HayesRJ . Empirical evidence of bias. JAMA1995;273:408-12.">Schulz 1995</a>). </p> <p>Twenty‐nine studies had a low risk of bias for random sequence generation and 22 studies had an unclear risk of bias. Twenty‐three studies had a low risk of bias for allocation of concealment whereas 28 studies had an unclear risk of bias. Only one study (<a href="./references#CD003412-bbs2-0020" title="Garcia-MartinE , Gil-ArribasLM , IdoipeM , AlfaroJ , PueyoV , PabloLE , et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. British Journal of Ophthalmology2011;95(10):1393-6. [CENTRAL: CN-00801928] ">Garcia‐Martin 2011</a>) had a high risk of bias for random sequence generation and allocation of concealment. </p> </section> </section> <section id="CD003412-sec-0086"> <h4 class="title">Blinding</h4> <p>Only 14 studies were rated as having a low risk of bias for blinding of participants/personnel with the remaining 38 studies being assessed as having an unclear risk of performance bias. Unclear risk of bias was chosen in three situations: 1) if the blinding method was not clearly stated by the study authors 2) the study was unblinded 3) the study was blinded but due to the nature of the interventions it is likely that participants/personnel would be aware of the treatment allocation. The reason we decided to rate all these situations as "unclear" is that it is unclear how lack of blinding would impact our outcomes of interest. </p> <p>Only 19 studies were assessed as low risk of bias for blinding of the outcome assessor. Thirty‐three studies were assessed as having unclear risk of detection bias. We rated the bias as unclear for the same situations as detailed above for performance bias. Even if studies reported that outcome assessors were blinded, for all the studies comparing a surgical intervention against a non‐surgical intervention, we felt that it was not possible to truly blind due to the nature of the interventions and again we were unclear whether being unblinded would bias the assessing of clinical response with regards to recurrence rates. However we decided that being unblinded would bias the rating of cosmetic outcomes and in this situation we consider the risk of bias to be high. As recurrence rate is our primary outcome the risk of bias rating displayed in the <a href="./references#CD003412-sec-0332" title="">Characteristics of included studies</a> table relates to this. </p> </section> <section id="CD003412-sec-0087"> <h4 class="title">Incomplete outcome data</h4> <p>Analysis should be performed according to intention‐to‐treat principle to minimise risk of attrition bias (<a href="./references#CD003412-bbs2-0099" title="FergussonD , AaronSD , GuyattG , HébertP . Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ2002;325(7365):652-4.">Fergusson 2002</a>). However, in many of the trials analysis of outcome was carried out only in those participants who completed the trial. Thirty‐two studies had a low risk of bias for incomplete outcome data. Nineteen studies had an unclear risk and one study (<a href="./references#CD003412-bbs2-0035" title="PunjabiS , CookLJ , KerseyP , MarksR , CerioR . Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicentre study. International Journal of Dermatology2008;47(1):78-82. [CENTRAL: CN-00629144] PunjabiS , CookLJ , KerseyP , MarksR , FinlayA , SharpG , et al. A double-blind, multicentre parallel group study of BEC-5 cream in basal cell carcinoma. European Academy of Dermatology &amp; Venereology2000;14(Suppl 1):49. [CENTRAL: CN-01616931] ">Punjabi 2008</a>) had a high risk of attrition bias as there was a large difference in the number of participants that withdrew from the study between groups and the authors used the "last observation carried forward" method to deal with missing data which is an imputation method that fails to acknowledge uncertainty in the imputed values (<a href="./references#CD003412-bbs2-0105" title="HigginsJP , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org.">Higgins 2011</a>). </p> </section> <section id="CD003412-sec-0088"> <h4 class="title">Selective reporting</h4> <p>To minimise the risk of selective outcome reporting bias, outcomes for studies should all be specified prior to recruitment in a time‐stamped, publicly available trial registry. This has been a prerequisite for publication since 2005 for publication in International Committee of Medical Journal Editors (ICMJE) member journals. Only 11 studies prospectively registered their primary outcomes and of these only six were rated as low risk of selective reporting bias which is a concerningly low number. Forty‐four studies were rated as unclear risk of bias and two studies were reported as having a high risk of reporting bias: <a href="./references#CD003412-bbs2-0001" title="2005-001474-27. A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001474-27/results (first accessed 12 August 2016). ">2005‐001474‐27</a> and <a href="./references#CD003412-bbs2-0007" title="Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Methyl aminolaevulinate photodynamic therapy vs. cryotherapy in primary superficial basal cell carcinoma: results of a 36-month follow-up. British Journal of Dermatology2005;153(1):29. Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Topical methyl aminolevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. European Journal of Dermatolology2008;18(5):547-53. [CENTRAL: CN-00668120] ">Basset‐Seguin 2008</a>. </p> </section> </section> <section id="CD003412-sec-0089"> <h3 class="title" id="CD003412-sec-0089">Effects of interventions</h3> <p>See: <a href="./full#CD003412-tbl-0001"><b>Summary of findings 1</b> Mohs micrographic surgery compared to surgical excision for basal cell carcinoma of the skin</a>; <a href="./full#CD003412-tbl-0002"><b>Summary of findings 2</b> Imiquimod compared to surgical excision for basal cell carcinoma of the skin</a>; <a href="./full#CD003412-tbl-0003"><b>Summary of findings 3</b> Radiotherapy compared to surgical excision (with or without frozen section margin control) for basal cell carcinoma of the skin</a>; <a href="./full#CD003412-tbl-0004"><b>Summary of findings 4</b> MAL‐PDT compared to surgical excision for basal cell carcinoma of the skin</a>; <a href="./full#CD003412-tbl-0005"><b>Summary of findings 5</b> Imiquimod cream compared to MAL‐PDT for basal cell carcinoma of the skin</a> </p> <p>Not all of the comparisons measured or reported all primary and secondary outcomes. If an outcome has not been reported under a comparison, this means it was not measured by any study. </p> <section id="CD003412-sec-0090"> <h4 class="title">1. Surgical excision</h4> <section id="CD003412-sec-0091"> <h5 class="title">Mohs micrographic surgery (MMS) versus surgical excision (SE)</h5> <p>One study (<a href="./references#CD003412-bbs2-0045" title="EssersBA , DirksenCD , NiemanFH , SmeetsNW , KrekelsGA , PrinsMH , et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Archives of Dermatology2006;142(2):187-94. [CENTRAL: CN-00555278] MosterdK , KrekelsGA , NiemanFH , OstertagJU , EssersBA , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncology2008;9(12):1149-56. [CENTRAL: CN-00665334] SmeetsNW , KrekelsGA , OstertagJU , EssersBA , DirksenCD , NiemanFH , et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet2004;364(9447):1766-72. [CENTRAL: CN-00492695] Van LooE , MosterdK , KrekelsGA , RoozeboomMH , OstertagJU , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European Journal of Cancer2014;50(17):3011-20. [CENTRAL: CN-01043314] ">Smeets 2004</a>) compared SE against MMS in 374 participants (408 lesions) with high‐risk facial primary basal cell carcinomas (BCCs) (high‐risk histological subtype or located in the ‘H‐zone’ of the face or both). The study also randomised 204 recurrent facial BCCs but we have not included these data as we are only interested in primary BCC. The study used 3 mm margins for both treatments to standardise the two modalities (smaller margins are usually used for MMS). If the defect margins were found to be positive after SE, a re‐excision with a 3 mm margin was done. If the margins remained positive after a second excision then MMS was undertaken. The primary outcome was recurrence at 30 months (which we have considered to be approximately three years). Recurrence at five years and 10 years were published in two further papers. See <a href="./full#CD003412-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD003412-sec-0092"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0093"> <p><b>Recurrence</b></p> <p>There may be slightly fewer recurrences with MMS and SE at three years (1.9%, 3/160 versus 2.9%, 5/171, respectively) (risk ratio (RR) 0.64, 95% confidence interval (CI) 0.16 to 2.64; <a href="./references#CD003412-fig-0004" title="">Analysis 1.1</a>), and at five years (3.2%, 4/125 versus 5.2%, 7/134, respectively) (RR 0.61, 95% CI 0.18 to 2.04; <a href="./references#CD003412-fig-0005" title="">Analysis 1.2</a>). We rated the certainty of evidence as low for both these outcomes, rating down two levels for very serious imprecision due to the very wide 95% CIs. This CI indicates that the true MMS recurrence rate may represent an important improvement or worsening of recurrence rates when compared to SE. </p> </section> <section id="CD003412-sec-0094"> <p><b>Cosmetic outcome (participant‐ and observer‐rated).</b></p> <p>The authors state that overall, participant‐ and observer‐rated cosmetic outcomes did not significantly differ between MMS and SE when measured at 18 months. We rated the certainty of evidence as low, rating down two levels for very serious indirectness as although the authors did compare the cosmetic outcomes between the two groups, they did not present the data for analysis. </p> </section> </section> <section id="CD003412-sec-0095"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0096"> <p><b>Adverse effects</b></p> <p>The study reported in their text that there was quote: "no difference in post‐operative complications between SE and MMS"; however raw data were not presented for this outcome to verify this. See <a href="#CD003412-tbl-0007">Table 2</a> for further adverse effect (AE) data from this study. </p> </section> </section> </section> <section id="CD003412-sec-0097"> <h5 class="title">Imiquimod cream versus surgical excision (SE)</h5> <p>One study (<a href="./references#CD003412-bbs2-0008" title="Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , MillerPS , et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncology2014;15(1):96-105. [CENTRAL: CN-00959373] WilliamsHC , Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. Journal of Investigative Dermatology2017;137(3):614-9. [CENTRAL: CN-01340067] [EMBASE: 614596349]">Bath‐Hextall 2014</a>) compared imiquimod to SE in 501 participants with nodular BCC (nBCC) or superficial BCC (sBCC) at low‐risk sites in a non‐inferiority trial design with five‐year follow‐up. Participants randomised to imiquimod treatment applied the cream daily for six weeks (sBCC) or 12 weeks (nBCC). The licensed imiquimod regimen for sBCC is five days a week for six weeks and for nBCC is five days a week for 12 weeks. SE margins were 4 mm. See <a href="./full#CD003412-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD003412-sec-0098"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0099"> <p><b>Recurrence</b></p> <p>Imiquimod probably results in more recurrences (16.4%, 35/213) than SE (1.6%, 3/188) at three years corresponding to a 10‐fold increased risk of recurrence with imiquimod (RR 10.30, 95% CI 3.22 to 32.94; <a href="./references#CD003412-fig-0006" title="">Analysis 2.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision due to the wide 95% CI and because this was only a single study. </p> <p>By five years, imiquimod may result in more recurrences (17.5%, 36/206) compared with SE (2.3%, 4/177) with a nearly 8 fold increased risk of recurrence (RR 7.73, 95% CI 2.81 to 21.30; <a href="./references#CD003412-fig-0007" title="">Analysis 2.2</a>). We rated the certainty of evidence as moderate, rating down for imprecision (wide 95% CI, single study). </p> </section> <section id="CD003412-sec-0100"> <p><b>Cosmetic outcome (participant‐ and observer‐rated)</b></p> <p>Cosmetic outcome was assessed at six months and three years by participants and two independent dermatologists using a six‐point scale (unable to see lesion, very poor, poor, fair, good, excellent). Our analyses focused on using data from three‐year follow‐up due to the reasons outlined in the methods section. </p> <p>When participant‐rated, there may be little to no difference between imiquimod (91.9%, 147/160) and SE (92.2%, 153/166) on the rate of good/excellent cosmetic outcomes (RR 1.00, 95% CI 0.94 to 1.06; <a href="./references#CD003412-fig-0008" title="">Analysis 2.3</a>). When dermatologist‐rated, imiquimod may improve rate of good/excellent cosmetic outcomes (60.6%, 103/170) compared to SE (35.6%, 62/174), corresponding to a 70% increase rate for imiquimod (RR 1.70, 95% CI 1.35 to 2.15; <a href="./references#CD003412-fig-0008" title="">Analysis 2.3</a>). We rated the certainty of evidence as low for both these comparisons, rating down for serious risk of bias (unable to truly blind due to nature of interventions) and serious risk of imprecision (only one study). </p> </section> </section> <section id="CD003412-sec-0101"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0102"> <p><b>Pain during and after treatment</b></p> <p>Patient diaries were used to record information about the level of pain felt before and after the lesion was treated. During treatment, imiquimod probably worsens the risk of moderate/severe pain compared to SE (30%, 72/242 versus 22%, 44/201, respectively) corresponding to a 36% increased risk with imiquimod (RR 1.36, 95% CI 0.98 to 1.88; <a href="./references#CD003412-fig-0009" title="">Analysis 2.4</a>). We rated the certainty of evidence as low, rating down for serious imprecision (wide 95% CI, including the null effect which indicates there may be no difference between the two treatments) and serious risk of attrition bias.<br/><br/>However, during the 16‐week follow‐up period imiquimod probably reduces the risk of moderate/severe pain compared to SE (9%, 22/233 versus 20%, 41/206) corresponding to a 53% decreased risk with imiquimod (RR 0.47, 95% CI 0.29 to 0.77; <a href="./references#CD003412-fig-0009" title="">Analysis 2.4</a>). We rated the certainty of evidence as low, rating down for serious risk of imprecision (only one study) and serious risk of attrition bias. See <a href="#CD003412-tbl-0006">Table 1</a> for further pain data from this study. </p> </section> <section id="CD003412-sec-0103"> <p><b>Adverse effects</b></p> <p>There were slightly more mild/moderate AEs reported during the first six months of treatment in the imiquimod group compared to the SE group (94% of participants versus 88%, respectively). Itching at the tumour site was frequently reported (85%, 211/249 imiquimod versus 56%, 129/229 SE), but weeping at the tumour site was also common (64%, 160/249 for imiquimod versus 35%, 81/229 for SE). Five participants treated with imiquimod withdrew from the study because of AEs related to the treatment whereas no participants withdrew because of AEs related to SE. Thirty‐eight (15%) of participants needed a dose reduction in the imiquimod group due to AEs. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data. </p> </section> </section> </section> <section id="CD003412-sec-0104"> <h5 class="title">Radiotherapy versus surgical excision (SE) with or without frozen section margin control</h5> <p>One study (<a href="./references#CD003412-bbs2-0006" title="AvrilMF , AuperinA , MargulisA , GerbauletA , DuvillardP , BenhamouE , et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. British Journal of Cancer1997;76(1):100-6. [CENTRAL: CN-00141470] PetitJY , AvrilMF , MargulisA , ChassagneD , GerbauletA , DuvillardP , et al. Evaluation of cosmetic results of a randomised trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plastic and Reconstructive Surgery2000;105(7):2544-51. [CENTRAL: CN-00278207] ">Avril 1997</a>) involving 347 participants (347 lesions) compared SE (at least 2 mm margin with the option of frozen section margin control) against radiotherapy in primary BCCs of the face, involving tumours less than 4 cm in diameter. BCCs included nodular, ulcerated, superficial and pagetoid and morphoeaform. The main outcome measure was histologically‐confirmed persistent tumour or recurrent disease at four years. Three radiation techniques were used: interstitial brachytherapy (n = 95), superficial contact therapy (n = 50) and conventional radiotherapy (n = 20). See <a href="./full#CD003412-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD003412-sec-0105"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0106"> <p><b>Recurrence</b></p> <p>At three years the recurrence rates were 5.2% (9/173) and 0% (0/174) for radiotherapy and SE, respectively. (RR 19.11, 95% CI 1.12 to 325.78; <a href="./references#CD003412-fig-0010" title="">Analysis 3.1</a>). We rated the certainty of evidence as low, rating down two levels for very serious imprecision due to the very wide 95% CI, which although does not include the null effect, indicates that radiotherapy may lead to a slight or markedly increased risk of recurrence when compared to SE. </p> <p>As the study set their primary outcome of recurrence at four years, we have included these data. By four years, radiotherapy may result in a higher risk of recurrence compared to SE with a recurrence rate of 6.4% (11/173) versus 0.6% (1/174), respectively (RR 11.06, 95% CI 1.44 to 84.77; <a href="./references#CD003412-fig-0011" title="">Analysis 3.2</a>). We rated the certainty of evidence as low, rating down for serious indirectness as the outcome was measured outside our three‐year and five‐year time points and for serious imprecision due to the wide 95% CI. </p> </section> <section id="CD003412-sec-0107"> <p><b>Cosmetic outcome (participant‐ and observer‐rated)</b></p> <p>Comparing the rate of participant‐reported good cosmetic outcomes (three‐point scale: bad, fair or good) at four years between the groups, radiotherapy probably worsens the rate of good cosmetic outcome compared to SE frozen (RR 0.76, 95% CI 0.63 to 0.91; <a href="./references#CD003412-fig-0012" title="">Analysis 3.3</a>). At four years, radiotherapy probably worsens the rate of dermatologist‐assessed cosmesis based on the scar (bad, clearly marked or slightly visible) compared to SE (RR 0.48, 95% CI 0.37 to 0.62; <a href="./references#CD003412-fig-0012" title="">Analysis 3.3</a>). We rated the certainty of evidence for both these outcomes as moderate, rating down for serious risk of bias (high risk of blinding bias). We performed an intention‐to‐treat analyses on both these outcomes (as detailed in the methods section) due to fairly large dropout numbers at four years. </p> </section> </section> <section id="CD003412-sec-0108"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0109"> <p><b>Adverse effects</b></p> <p>After radiotherapy, dyspigmentation and telangiectasia (which may affect the cosmetic appearance) developed in more than 65% of the participants by four years. Radiodystrophy affected 41% of the participants at four years and 5% of the patients in the radiotherapy group had necrosis. These AEs were exclusive to the radiotherapy group. The main characteristics of surgical scars were deformations and constrictions and although these decreased with time they still affected 25% and 5% of participants, respectively at four years. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data for this study. </p> </section> </section> </section> </section> <section id="CD003412-sec-0110"> <h4 class="title">2. Radiotherapy</h4> <section id="CD003412-sec-0111"> <h5 class="title">Low‐dose versus high‐dose radiotherapy</h5> <p><a href="./references#CD003412-bbs2-0030" title="LandthalerM , Braun-FalcoO . Use of the TDF factor in soft roentgen radiotherapy [Anwendung des TDF-Faktors in der Röntgenweichstrahlentherapie]. Hautarzt1989;40(12):774-7. [CENTRAL: CN-00194309] [PMID: 2695500]">Landthaler 1989</a> compared low‐dose (48 Gy) against high‐dose radiotherapy (60 Gy) in 319 participants with 290 BCCs (unclear subtype) and 44 SCCs located on the face. </p> <section id="CD003412-sec-0112"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0113"> <p><b>Early treatment failure</b></p> <p>There may be little to no difference in the risk of early treatment failure between low dose radiotherapy (8.1%, 12/148) and high dose radiotherapy (9.6%, 14/142) (RR 0.82, 95% CI 0.39 to 1.72; <a href="./references#CD003412-fig-0016" title="">Analysis 7.1</a>). The certainty of evidence was low due to very serious imprecision where the 95% CI indicates that low dose might lead to an important reduction or an important increase in early treatment failures. </p> </section> </section> </section> </section> <section id="CD003412-sec-0114"> <h4 class="title">3. Cryosurgery</h4> <section id="CD003412-sec-0115"> <h5 class="title">Radiotherapy versus cryosurgery</h5> <p>One study (<a href="./references#CD003412-bbs2-0024" title="HallVL , LeppardBJ , McGillJ , KesselerME , WhiteJE , GoodwinP . Treatment of basal cell carcinoma: comparison of radiotherapy and cryotherapy. Clinical Radiology1986;37(1):33-4. [CENTRAL: CN-00478536] ">Hall 1986</a>) of 93 participants (93 lesions) compared radiotherapy against cryosurgery (unclear subtype, but lesions on nose/ears were excluded). Radiotherapy was applied with 130 kV X‐rays and fractionation depended on lesion size. Cryosurgery was performed with two freeze‐thaw cycles each lasting one minute. </p> <section id="CD003412-sec-0116"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0117"> <p><b>Recurrence</b></p> <p>Radiotherapy may reduce the risk of recurrence (4.1%, 2/49) compared to cryosurgery (38.6%, 17/44) at 2 years follow‐up (RR 0.11, 95% CI 0.03 to 0.43; <a href="./references#CD003412-fig-0017" title="">Analysis 8.1</a>). However, we rated the certainty of evidence as low, rating down for serious indirectness (as the outcome was measured at two years) and serious imprecision (single study with a fairly wide 95% CI). </p> </section> <section id="CD003412-sec-0118"> <p><b>Cosmetic outcome (participant‐ and observer‐rated)</b></p> <p>The study reported that there was no statistically significant difference in cosmetic outcomes between the interventions; however, the raw data were not presented to verify this. </p> </section> </section> <section id="CD003412-sec-0119"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0120"> <p><b>Pain during and after treatment</b></p> <p>The study reported that the degree of pain reported by patients (on questionnaires given during follow‐up) was not statistically significant between the two interventions; however, the data were not presented for further analyses. </p> </section> <section id="CD003412-sec-0121"> <p><b>Adverse effects</b></p> <p>Hypopigmentation was more common than hyperpigmentation with both modes of treatment (81% of those in the radiotherapy group and 88% of those in the cryosurgery group). Seven participants treated with radiotherapy developed some radiation telangiectasia. Hypopigmentation and telangiectasia tend to be lifelong. Five participants treated with cryosurgery developed milia ‐ these all resolved by one year. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from this study. </p> </section> </section> </section> <section id="CD003412-sec-0122"> <h5 class="title">Curettage and cryosurgery versus surgical excision</h5> <p>One study (<a href="./references#CD003412-bbs2-0029" title="KuijpersDI , ThissenMR , BerrettyPJ , IdelerFH , NelemansPJ , NeumannMH . Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatologic Surgery2007;33(5):579-87. [CENTRAL: CN-00588176] ThissenMR , NiemanFH , IdelerAH , BerrettyPJ , NeumannHA . Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatologic Surgery2000;26(8):759-64. [CENTRAL: CN-00298974] ">Kuijpers 2007</a>) compared curettage and cryosurgery against SE in 88 participants with 100 low‐risk BCCs on the head and neck region (96 nBCC, four sBCC) with five years follow‐up. Cryosurgery was performed with two 20‐second freeze‐thaw cycles using a neoprene cone to give a free margin of 5 mm around the tumour. Surgery was performed with 3 mm margins. See <a href="#CD003412-tbl-0008">Table 3</a>. </p> <div class="table" id="CD003412-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Curettage and cryosurgery compared to surgical excision for basal cell carcinoma of the skin</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Curettage &amp; cryosurgery compared to surgical excision for low‐risk BCC</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from a single‐centre in The Netherlands<br/><b>Intervention:</b> curettage &amp; cryosurgery<br/><b>Comparison:</b> surgical excision </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with surgical excision</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Curettage &amp; cryosurgery</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.36<br/>(0.73 to 15.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137 per 1000<br/>(30 to 629) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.78<br/>(0.93 to 8.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>85<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237 per 1000<br/>(79 to 710) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/>(0.78 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participant‐rated at 1 year on a 3‐point scale.<sup>4</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880 per 1000<br/>(780 to 980) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.28</p> <p>(0.16 to 0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>96<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Observer‐rated at 1 year on a 3‐point scale.<sup>4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>833 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>233 per 1000</p> <p>(133 to 392)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early treatment failure</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm. </p> <p><sup>2</sup> Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI and downgraded one level for serious risk of bias as unable to truly blind due to the nature of interventions. </p> <p><sup>3</sup> Downgraded one level for serious imprecision as only a single study with a small sample size. </p> <p><sup>4</sup> 3‐point scale: bad, fair, good. </p> </div> </div> <section id="CD003412-sec-0123"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0124"> <p><b>Recurrence</b></p> <p>At three years, curettage and cryosurgery may slightly increase the risk of recurrence compared to SE (13.7%, 7/51 versus 4.1%, 2/49, respectively) (RR 3.36, 95% CI 0.73 to 15.40; <a href="./references#CD003412-fig-0018" title="">Analysis 9.1</a>). We rated the certainty of evidence as low, downgrading two levels for very serious imprecision (very wide 95% CI that indicates both important benefit and harm).<br/><br/>At five years cryosurgery probably increases the risk of recurrence compared to SE (23.7% versus 8.5%) (RR 2.78, 95% CI 0.93 to 8.34; <a href="./references#CD003412-fig-0019" title="">Analysis 9.2</a>). We rated the certainty of evidence as moderate, downgrading one level for serious imprecision (wide 95% CI that includes important benefit and little to no difference). </p> </section> <section id="CD003412-sec-0125"> <p><b>Cosmetic outcome (participant‐ and observer‐rated)</b></p> <p>Cosmetic outcomes were assessed by observers and patients at one year post treatment on a three‐point scale (bad, fair, good). When participant‐rated, curettage and cryosurgery may slightly decrease the rate of good cosmetic outcomes compared with SE (RR 0.88, 95% CI 0.78 to 0.98; <a href="./references#CD003412-fig-0020" title="">Analysis 9.3</a>).<br/><br/>When dermatologist‐rated, curettage and cryosurgery may decrease the rate of good cosmetic outcome compared to SE (RR 0.28, 95% CI 0.16 to 0.47; <a href="./references#CD003412-fig-0020" title="">Analysis 9.3</a>). We rated the certainty of evidence as low for both of these outcomes rating down for serious risk of blinding bias (unable to truly blind due to nature of interventions) and serious risk of imprecision (single study). </p> </section> </section> <section id="CD003412-sec-0126"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0127"> <p><b>Adverse effects</b></p> <p>Secondary wound infection, treated with systemic antibiotics, was seen in 5.9% (3/51) participants in the curettage and cryosurgery group. In the SE, group systemic antibiotics were needed for secondary wound infection in 8.2% (4/49) of participants in the first and second weeks after treatment. No further AE data from this study were available. </p> </section> </section> </section> </section> <section id="CD003412-sec-0128"> <h4 class="title">4. Currettage and cautery</h4> <section id="CD003412-sec-0129"> <h5 class="title">Curettage and cautery versus curettage versus surgical excision</h5> <p>One small study of 55 participants with 69 BCCs on the face and scalp (majority nBCC) compared: curettage and cautery (C&amp;C) versus SE, curettage versus SE and curettage versus curettage and cautery with just two years follow‐up (<a href="./references#CD003412-bbs2-0039" title="SalmanpoorR , MotevalliD , SakiN , SakiM . Efficacy of excisional surgery, curettage and combined curettage and electrodessication in treatment of basal cell carcinoma. Iranian Journal of Dermatology2012;15(2):66-7. [CENTRAL: CN-00908884] ">Salmanpoor 2012</a>). </p> <section id="CD003412-sec-0130"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0131"> <p><b>Recurrence</b></p> <p>It is uncertain whether the risk of recurrence is improved for curettage versus SE (RR 2.40, 95% CI 0.49 to 11.77; <a href="./references#CD003412-fig-0013" title="">Analysis 4.1</a>), C&amp;C versus SE (RR 0.96, 95% CI 0.15 to 6.28; <a href="./references#CD003412-fig-0014" title="">Analysis 5.1</a>), and curettage versus C&amp;C (RR 0.40, 95% CI 0.08 to 1.97; <a href="./references#CD003412-fig-0015" title="">Analysis 6.1</a>). We rated the certainty of evidence as very low for all these comparisons, rating down for very serious imprecision (very wide 95% CIs) and also for serious indirectness as the study only measured recurrence up to two years. </p> </section> </section> </section> </section> <section id="CD003412-sec-0132"> <h4 class="title">5. Photodynamic therapy (PDT)</h4> <section id="CD003412-sec-0133"> <h5 class="title">PDT versus surgical excision (SE)</h5> <p>Four studies compared PDT with SE, three of which used the photosensitiser methyl aminolevulinate (MAL‐PDT) (<a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a>; <a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a>; <a href="./references#CD003412-bbs2-0002" title="AbbadeL , GigeT , AmaralV , AquinoS , MiotH . Higher recurrence rates of head and neck nodular basal cell carcinoma treated with topical photodynamic therapy (MAL-PDT) compared to surgical excision: a randomized controlled study. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB185. [CENTRAL: CN-01076055] ">Abbade 2015</a>), and one which used the photosensitiser 5‐aminolevulinate (ALA‐PDT) (<a href="./references#CD003412-bbs2-0034" title="MosterdK , ThissenMR , NelemansP , Kelleners‐SmeetsNW , JanssenRL , BroekhofKG , et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. British Journal of Dermatology2008;159(4):864-70. [CENTRAL: CN-00667266] RoozeboomMH , AardoomMA , NelemansPJ , ThissenMR , Kelleners-SmeetsNW , KuijpersDI , et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. Journal of the American Academy of Dermatology August 2013;69(2):280-7. [CENTRAL: CN-00876800] [DOI: 10.1016/j.jid.2016.03.043]">Mosterd 2008</a>).<br/><br/><a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a> compared MAL‐PDT against SE for nBCC of the face in 103 participants (118 lesions) with five years follow‐up. <a href="./references#CD003412-bbs2-0002" title="AbbadeL , GigeT , AmaralV , AquinoS , MiotH . Higher recurrence rates of head and neck nodular basal cell carcinoma treated with topical photodynamic therapy (MAL-PDT) compared to surgical excision: a randomized controlled study. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB185. [CENTRAL: CN-01076055] ">Abbade 2015</a> compared MAL‐PDT against SE in 57 participants (68 lesions) with nBCC in the head and neck area with follow‐up over three years.<br/><br/><a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a> was a non‐inferiority study that compared MAL‐PDT with SE in 196 participants with 246 sBCCs (between 8 mm and 20 mm located anywhere except mid‐face) with one year follow‐up. The inferiority margin was set at a difference of 15% in terms of per cent reduction in lesion count three months after the last treatment.<br/><br/><a href="./references#CD003412-bbs2-0034" title="MosterdK , ThissenMR , NelemansP , Kelleners‐SmeetsNW , JanssenRL , BroekhofKG , et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. British Journal of Dermatology2008;159(4):864-70. [CENTRAL: CN-00667266] RoozeboomMH , AardoomMA , NelemansPJ , ThissenMR , Kelleners-SmeetsNW , KuijpersDI , et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. Journal of the American Academy of Dermatology August 2013;69(2):280-7. [CENTRAL: CN-00876800] [DOI: 10.1016/j.jid.2016.03.043]">Mosterd 2008</a>, compared fractionated ALA‐PDT with SE in 171 primary nBCCs (149 participants) with five years follow‐up.<br/><br/>All the MAL‐PDT studies followed the standard European PDT protocol which defines one cycle as two PDT sessions separated by a one‐week interval. The ALA‐PDT (<a href="./references#CD003412-bbs2-0034" title="MosterdK , ThissenMR , NelemansP , Kelleners‐SmeetsNW , JanssenRL , BroekhofKG , et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. British Journal of Dermatology2008;159(4):864-70. [CENTRAL: CN-00667266] RoozeboomMH , AardoomMA , NelemansPJ , ThissenMR , Kelleners-SmeetsNW , KuijpersDI , et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. Journal of the American Academy of Dermatology August 2013;69(2):280-7. [CENTRAL: CN-00876800] [DOI: 10.1016/j.jid.2016.03.043]">Mosterd 2008</a>) study did two illuminations on the same day separated by 60 minutes and any incomplete responses were re‐treated surgically. <a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a> and <a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a> performed a gentle curettage of lesions to remove scale/crust and allowed a second PDT cycle if there was not a complete response when assessed clinically at three months follow‐up. <a href="./references#CD003412-bbs2-0034" title="MosterdK , ThissenMR , NelemansP , Kelleners‐SmeetsNW , JanssenRL , BroekhofKG , et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. British Journal of Dermatology2008;159(4):864-70. [CENTRAL: CN-00667266] RoozeboomMH , AardoomMA , NelemansPJ , ThissenMR , Kelleners-SmeetsNW , KuijpersDI , et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. Journal of the American Academy of Dermatology August 2013;69(2):280-7. [CENTRAL: CN-00876800] [DOI: 10.1016/j.jid.2016.03.043]">Mosterd 2008</a> and <a href="./references#CD003412-bbs2-0002" title="AbbadeL , GigeT , AmaralV , AquinoS , MiotH . Higher recurrence rates of head and neck nodular basal cell carcinoma treated with topical photodynamic therapy (MAL-PDT) compared to surgical excision: a randomized controlled study. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB185. [CENTRAL: CN-01076055] ">Abbade 2015</a> debulked/shaved tumours under anaesthetic prior to PDT treatments. See <a href="./full#CD003412-tbl-0004">summary of findings Table 4</a> and <a href="#CD003412-tbl-0009">Table 4</a>. </p> <div class="table" id="CD003412-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">ALA‐PDT compared to surgical excision for basal cell carcinoma of the skin</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ALA‐PDT compared to surgical excision for low‐risk BCC</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from a single‐centre in the Netherlands<br/><b>Intervention:</b> ALA‐PDT<br/><b>Comparison:</b> surgical excision </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with surgical excision</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ALA‐PDT</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 10.87<br/>(2.63 to 44.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>173<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247 per 1000<br/>(60 to 1000) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 11.91<br/>(2.90 to 48.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>173<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271 per 1000<br/>(66 to 1000) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cosmetic outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>No study addressed this outcome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Early treatment failure</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.18<br/>(0.66 to 15.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>171<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 per 1000<br/>(15 to 348) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI. </p> <p><sup>2</sup> Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm. </p> </div> </div> <section id="CD003412-sec-0134"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0135"> <p><b>Recurrence</b></p> <p>Although <a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a> followed‐up patients for five years, they presented the per protocol population data and the denominators to be included for our analyses could not be determined for three‐year and five‐year recurrence rates. <a href="./references#CD003412-bbs2-0002" title="AbbadeL , GigeT , AmaralV , AquinoS , MiotH . Higher recurrence rates of head and neck nodular basal cell carcinoma treated with topical photodynamic therapy (MAL-PDT) compared to surgical excision: a randomized controlled study. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB185. [CENTRAL: CN-01076055] ">Abbade 2015</a> showed that at three years, MAL‐PDT may increase the risk of recurrence compared to SE (36.36%, 12/33 versus 0%, 0/35) (RR 26.47, 95% CI 1.63 to 429.92; <a href="./references#CD003412-fig-0021" title="">Analysis 10.1</a>). We rated the certainty of evidence as low, rating down two levels for very serious imprecision (very wide 95% CI which indicated a slight increase or very large increase in recurrence risk).<br/><br/><a href="./references#CD003412-bbs2-0034" title="MosterdK , ThissenMR , NelemansP , Kelleners‐SmeetsNW , JanssenRL , BroekhofKG , et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. British Journal of Dermatology2008;159(4):864-70. [CENTRAL: CN-00667266] RoozeboomMH , AardoomMA , NelemansPJ , ThissenMR , Kelleners-SmeetsNW , KuijpersDI , et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. Journal of the American Academy of Dermatology August 2013;69(2):280-7. [CENTRAL: CN-00876800] [DOI: 10.1016/j.jid.2016.03.043]">Mosterd 2008</a> showed that ALA‐PDT probably increases the risk of recurrence compared to SE at three years (24.7%, 21/85 versus 2.3%, 2/88, respectively) (RR 10.87, 95% CI 2.63 to 44.95; <a href="./references#CD003412-fig-0025" title="">Analysis 11.1</a>). By five years, ALA‐PDT probably increases the risk of recurrence compared to SE (27.1%, 23/85 versus 2.3%, 2/88, respectively) (RR 11.91, 95% CI 2.90 to 48.95; <a href="./references#CD003412-fig-0026" title="">Analysis 11.2</a>). We rated the certainty of evidence for both these outcomes as moderate, rating down for serious imprecision (wide 95% CIs and only one study). </p> </section> <section id="CD003412-sec-0136"> <p><b>Cosmetic outcome (participant‐ and observer‐rated)</b></p> <p>Pooling cosmetic results from <a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a> and <a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a>, we found that when measured at one year, MAL‐PDT probably slightly reduces the rate of participant‐rated good/excellent cosmetic outcomes compared to SE (RR 1.18, 95% CI 1.09 to 1.27, I<sup>2</sup>=0%; <a href="./references#CD003412-fig-0022" title="">Analysis 10.2</a>). When investigator‐rated at one year, MAL‐PDT probably increases the rate of investigator rated good/excellent cosmetic outcomes compared to SE (RR 1.87. 95% CI 1.54 to 2.26, I<sup>2</sup> = 0%; <a href="./references#CD003412-fig-0022" title="">Analysis 10.2</a>). We rated the certainty of evidence as moderate for both these outcomes, rating down for serious risk of bias (unable to truly blind due to nature of interventions). </p> </section> </section> <section id="CD003412-sec-0137"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0138"> <p><b>Pain during and after treatment</b></p> <p><a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a> recorded the frequency of patient reported "pain in skin" and "burning sensation of skin" during treatment and follow‐up as part of their AE data. MAL‐PDT may result in a higher frequency of pain in the skin than SE (13.4%, 7/52 versus 6.1%, 3/49, respectively) (RR 2.20, 95% CI 0.60 to 8.03; <a href="./references#CD003412-fig-0023" title="">Analysis 10.3</a>). We rated the certainty of evidence as low due to the very wide 95% CI. <a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a> reported pain during and after treatment as part of a "photosensitivity reaction" which included all expected reactions to PDT such a "skin discomfort, burning sensation, stinging and erythema". See <a href="#CD003412-tbl-0006">Table 1</a> for further pain data from these studies. </p> </section> <section id="CD003412-sec-0139"> <p><b>Early treatment failure</b></p> <p>At six months follow‐up, it is uncertain whether MAL‐PDT increases early treatment failures compared to SE as the certainty of evidence is very low due to the very wide 95% CI that meant we rated down three levels for very serious imprecision (RR 11.65, 95% CI 0.67 to 202.74; <a href="./references#CD003412-fig-0024" title="">Analysis 10.4</a>). <a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a> and <a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a> did not histologically confirm their early treatment failures and these data were therefore not extracted.<br/><br/><a href="./references#CD003412-bbs2-0034" title="MosterdK , ThissenMR , NelemansP , Kelleners‐SmeetsNW , JanssenRL , BroekhofKG , et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. British Journal of Dermatology2008;159(4):864-70. [CENTRAL: CN-00667266] RoozeboomMH , AardoomMA , NelemansPJ , ThissenMR , Kelleners-SmeetsNW , KuijpersDI , et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. Journal of the American Academy of Dermatology August 2013;69(2):280-7. [CENTRAL: CN-00876800] [DOI: 10.1016/j.jid.2016.03.043]">Mosterd 2008</a> showed that SE may improve the risk of early treatment failures for nBCCs compared to ALA‐PDT (7.2%, 6/83 versus 2.3%, 2/88) (RR 3.18, 95% CI 0.66 to 15.32; <a href="./references#CD003412-fig-0027" title="">Analysis 11.3</a>). We rated the certainty of evidence as low, rating down for very serious imprecision (very wide 95% CI that indicates important improvement or worsening in early treatment failures). </p> </section> <section id="CD003412-sec-0140"> <p><b>Adverse effects</b></p> <p>Based on <a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a>, more participants treated with MAL‐PDT than SE reported AEs 52% versus 29%, (P = 0.03, Fisher exact test). Most of the AEs were transient local reactions commonly associated with PDT, such as burning sensation of the skin, pain in the skin or erythema. <a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a> had similar findings (37% versus 14% reported AEs, respectively). Wound infections were reported in three SE participants in <a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a>, one ALA‐PDT participant from <a href="./references#CD003412-bbs2-0034" title="MosterdK , ThissenMR , NelemansP , Kelleners‐SmeetsNW , JanssenRL , BroekhofKG , et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. British Journal of Dermatology2008;159(4):864-70. [CENTRAL: CN-00667266] RoozeboomMH , AardoomMA , NelemansPJ , ThissenMR , Kelleners-SmeetsNW , KuijpersDI , et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. Journal of the American Academy of Dermatology August 2013;69(2):280-7. [CENTRAL: CN-00876800] [DOI: 10.1016/j.jid.2016.03.043]">Mosterd 2008</a> and one severe wound infection was reported after SE in <a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a>. </p> <p>See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from the respective studies. </p> </section> </section> </section> <section id="CD003412-sec-0141"> <h5 class="title">MAL‐PDT versus ALA‐PDT</h5> <p>One small pilot study (<a href="./references#CD003412-bbs2-0028" title="KuijpersDI , ThissenMR , ThissenCA , NeumannMH . Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. Journal of Drugs in Dermatology2006;5(7):642-5. [CENTRAL: CN-00566805] ">Kuijpers 2006</a>) compared the topical photosensitisers MAL and ALA in 43 participants with a nBCC (&lt; 20 mm diameter) with eight weeks follow‐up. Half of the tumours were debulked prior to PDT and conventional treatment protocols were followed (two PDT sessions one week apart). All treated tumours were excised eight weeks following treatment. A second, non‐inferiority study (<a href="./references#CD003412-bbs2-0033" title="MortonCA , DominicusR , RadnyP , DirschkaT , HauschildA , ReinholdU , et al. A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). British Journal of Dermatology2018;179(2):309-19. [CENTRAL: CN-02000788] [PMID: 29432644]">Morton 2018</a>) compared a newer, stable nanoemulsion ALA formulation (BF‐200 ALA gel) against MAL‐PDT in 231 participants with 275 sBCC and nBCC with one year follow‐up. Conventional treatment protocols were followed for both arms. A third study (<a href="./references#CD003412-bbs2-0040" title="SalmivuoriMK , GrönroosM , TaniT , PölönenI , RäsänenJ , AnnalaL , et al. Hexylaminolevulinate and aminolevulinic acid nanoemulsion have similar tolerability, initial efficacy and cosmetic outcome as methylaminolevulinate in photodynamic therapy of basal cell carcinoma in a prospective randomized double-blinded trial. Journal of Investigative Dermatology2019;139(9):S234. [CENTRAL: CN-01978390] [DOI: 10.1016/j.jid.2019.07.119]">Salmivuori 2019</a>) compared BF‐200 ALA‐PDT, hexylaminolevulinate (HAL)‐PDT and MAL‐PDT in 95 lesions (sBCC and thin nBCCs) with a non‐inferiority trial design. </p> <p>A fourth study (<a href="./references#CD003412-bbs2-0027" title="KesselsJP , KreukelsH , NelemansPJ , RoozeboomMH , vanPeltH , MosterdK , et al. Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5‐aminolaevulinic acid 20% vs. two‐stage topical methyl aminolaevulinate: results of a randomized controlled trial. British Journal of Dermatology2018;178(5):1056-63. [CENTRAL: CN-01991773] ">Kessels 2018</a>) compared two‐fold ALA‐PDT with conventional MAL‐PDT in 162 participants with sBCC over a one‐year follow‐up. The two‐fold group were treated with ALA 20% ointment with both PDT treatments done on the same day, separated by two hours. The MAL‐PDT group had the two PDT treatments separated by one week. </p> <section id="CD003412-sec-0142"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0143"> <p><b>Recurrence</b></p> <p><a href="./references#CD003412-bbs2-0033" title="MortonCA , DominicusR , RadnyP , DirschkaT , HauschildA , ReinholdU , et al. A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). British Journal of Dermatology2018;179(2):309-19. [CENTRAL: CN-02000788] [PMID: 29432644]">Morton 2018</a> and <a href="./references#CD003412-bbs2-0027" title="KesselsJP , KreukelsH , NelemansPJ , RoozeboomMH , vanPeltH , MosterdK , et al. Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5‐aminolaevulinic acid 20% vs. two‐stage topical methyl aminolaevulinate: results of a randomized controlled trial. British Journal of Dermatology2018;178(5):1056-63. [CENTRAL: CN-01991773] ">Kessels 2018</a> had only one‐year follow‐up and <a href="./references#CD003412-bbs2-0040" title="SalmivuoriMK , GrönroosM , TaniT , PölönenI , RäsänenJ , AnnalaL , et al. Hexylaminolevulinate and aminolevulinic acid nanoemulsion have similar tolerability, initial efficacy and cosmetic outcome as methylaminolevulinate in photodynamic therapy of basal cell carcinoma in a prospective randomized double-blinded trial. Journal of Investigative Dermatology2019;139(9):S234. [CENTRAL: CN-01978390] [DOI: 10.1016/j.jid.2019.07.119]">Salmivuori 2019</a> is still ongoing therefore no three‐ or five‐year recurrence rates reported. As one year is closer to our early treatment failure time point we have just reported this. </p> </section> <section id="CD003412-sec-0144"> <p><b>Cosmetic outcome (participant‐ and observer‐rated)</b></p> <p>In <a href="./references#CD003412-bbs2-0033" title="MortonCA , DominicusR , RadnyP , DirschkaT , HauschildA , ReinholdU , et al. A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). British Journal of Dermatology2018;179(2):309-19. [CENTRAL: CN-02000788] [PMID: 29432644]">Morton 2018</a>, a blinded investigator assessed cosmetic outcome at one year using a five‐point scale (impaired, unsatisfactory, satisfactory, good, very good). Only complete responders were included in the analysis. There is probably little to no difference between BF‐200 ALA‐PDT (73.2%, 41/56) and MAL‐PDT (68.4%, 39/57) on the rate of good/very good cosmetic outcomes (RR 1.07, 95% CI 0.84 to 1.36; <a href="./references#CD003412-fig-0028" title="">Analysis 12.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (wide 95% CI that indicates important improvement and worsening of cosmetic outcome).<br/><br/><a href="./references#CD003412-bbs2-0027" title="KesselsJP , KreukelsH , NelemansPJ , RoozeboomMH , vanPeltH , MosterdK , et al. Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5‐aminolaevulinic acid 20% vs. two‐stage topical methyl aminolaevulinate: results of a randomized controlled trial. British Journal of Dermatology2018;178(5):1056-63. [CENTRAL: CN-01991773] ">Kessels 2018</a> used two blinded investigators to assess cosmetic outcome on the standard four‐point scale. Two‐fold ALA‐PDT probably slightly increases the rate of good/excellent cosmetic outcomes compared to MAL‐PDT (RR 1.19, 95% CI 0.98 to 1.46; <a href="./references#CD003412-fig-0028" title="">Analysis 12.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (wide 95% CI). The outcomes from these two studies were not pooled as they used different cosmetic outcome scales. </p> </section> </section> <section id="CD003412-sec-0145"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0146"> <p><b>Pain during and after treatment</b></p> <p>We pooled the pain data from <a href="./references#CD003412-bbs2-0033" title="MortonCA , DominicusR , RadnyP , DirschkaT , HauschildA , ReinholdU , et al. A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). British Journal of Dermatology2018;179(2):309-19. [CENTRAL: CN-02000788] [PMID: 29432644]">Morton 2018</a> and <a href="./references#CD003412-bbs2-0028" title="KuijpersDI , ThissenMR , ThissenCA , NeumannMH . Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. Journal of Drugs in Dermatology2006;5(7):642-5. [CENTRAL: CN-00566805] ">Kuijpers 2006</a> as they had similar PDT protocols and used the same visual analogue scale (VAS). For both studies, VAS scores were slightly higher during cycle two and mean VAS scores ranged over both cycles from 2.4 to 4.8. During cycle one, there is probably little to no difference between ALA‐PDT and MAL‐PDT on the risk of pain, measured using VAS (mean difference (MD) 0.56, 95% CI ‐0.76 to 1.88, I <sup>2</sup> = 57%; <a href="./references#CD003412-fig-0029" title="">Analysis 12.2</a>). We rated the certainty of evidence as low, rating down for serious imprecision due to the fairly wide 95% CI and serious inconsistency as I<sup>2</sup> suggests substantial heterogeneity. During cycle two, there is probably little to no difference between ALA‐PDT and MAL‐PDT on the risk of pain (MD 0.43, 95% CI ‐0.18 to 1.05; I<sup>2</sup> = 0%; <a href="./references#CD003412-fig-0029" title="">Analysis 12.2</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision. </p> <p>Based on <a href="./references#CD003412-bbs2-0027" title="KesselsJP , KreukelsH , NelemansPJ , RoozeboomMH , vanPeltH , MosterdK , et al. Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5‐aminolaevulinic acid 20% vs. two‐stage topical methyl aminolaevulinate: results of a randomized controlled trial. British Journal of Dermatology2018;178(5):1056-63. [CENTRAL: CN-01991773] ">Kessels 2018</a>, there is probably little to no difference in numerical pain scores (0‐10) between two‐fold ALA‐PDT and MAL‐PDT during cycle one (MD ‐0.37, 95% CI ‐1.13 to 0.39; <a href="./references#CD003412-fig-0030" title="">Analysis 12.3</a>). For cycle 2, there is probably a slightly higher numerical pain score with twofold ALA‐PDT over MAL‐PDT (3.36 +/‐ 2.57 versus 2.48 +/‐ 2.57, respectively) (MD 0.88, 95% CI 0.09 to 1.67; <a href="./references#CD003412-fig-0030" title="">Analysis 12.3</a>). We rated the certainty of evidence as moderate for both these outcomes, rating down for serious imprecision. </p> <p>See <a href="#CD003412-tbl-0006">Table 1</a> for further pain data. </p> </section> <section id="CD003412-sec-0147"> <p><b>Early treatment failure</b></p> <p>In <a href="./references#CD003412-bbs2-0028" title="KuijpersDI , ThissenMR , ThissenCA , NeumannMH . Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. Journal of Drugs in Dermatology2006;5(7):642-5. [CENTRAL: CN-00566805] ">Kuijpers 2006</a>, at eight weeks there may be little to no difference between MAL‐PDT and ALA‐PDT on the risk of early treatment failure rates (28.6%, 6/21 versus 27.3%, 6/22, respectively) (RR 0.95, 95% CI 0.37 to 2.49; <a href="./references#CD003412-fig-0031" title="">Analysis 12.4</a>). We rated the certainty of evidence as low due to very serious imprecision (very wide 95% CI that indicates important benefit and harm). Based on <a href="./references#CD003412-bbs2-0040" title="SalmivuoriMK , GrönroosM , TaniT , PölönenI , RäsänenJ , AnnalaL , et al. Hexylaminolevulinate and aminolevulinic acid nanoemulsion have similar tolerability, initial efficacy and cosmetic outcome as methylaminolevulinate in photodynamic therapy of basal cell carcinoma in a prospective randomized double-blinded trial. Journal of Investigative Dermatology2019;139(9):S234. [CENTRAL: CN-01978390] [DOI: 10.1016/j.jid.2019.07.119]">Salmivuori 2019</a>, there may be fewer early treatment failures at 3 months with MAL‐PDT compared to BF‐200 ALA‐PDT (3.2%, 1/31 versus 9.1%, 3/33, respectively) (RR 2.82, 95% CI 0.31 to 25.68; <a href="./references#CD003412-fig-0032" title="">Analysis 13.1</a>). We rated the certainty of evidence as low due to very serious imprecision (very wide 95% CI that indicates important improvement or worsening in early treatment failures). <a href="./references#CD003412-bbs2-0033" title="MortonCA , DominicusR , RadnyP , DirschkaT , HauschildA , ReinholdU , et al. A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). British Journal of Dermatology2018;179(2):309-19. [CENTRAL: CN-02000788] [PMID: 29432644]">Morton 2018</a> did not histologically confirm early treatment failures and we have not extracted these data. </p> <p>Based on <a href="./references#CD003412-bbs2-0027" title="KesselsJP , KreukelsH , NelemansPJ , RoozeboomMH , vanPeltH , MosterdK , et al. Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5‐aminolaevulinic acid 20% vs. two‐stage topical methyl aminolaevulinate: results of a randomized controlled trial. British Journal of Dermatology2018;178(5):1056-63. [CENTRAL: CN-01991773] ">Kessels 2018</a>, there may be slightly more early treatment failures with MAL‐PDT compared with two‐fold ALA‐PDT (5.1%, 4/79 versus 3.8%, 3/79, respectively) (RR 0.75, 95% CI 0.17 to 3.24; <a href="./references#CD003412-fig-0031" title="">Analysis 12.4</a>). We rated the certainty of evidence as low due to very serious imprecision (very wide 95% CI that indicates important improvement or worsening in early treatment failures). </p> </section> <section id="CD003412-sec-0148"> <p><b>Adverse effects</b></p> <p>In <a href="./references#CD003412-bbs2-0033" title="MortonCA , DominicusR , RadnyP , DirschkaT , HauschildA , ReinholdU , et al. A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). British Journal of Dermatology2018;179(2):309-19. [CENTRAL: CN-02000788] [PMID: 29432644]">Morton 2018</a>, the most frequently reported AEs were mild‐to‐moderate pain, erythema, pruritus and oedema and frequencies were comparable between the two groups. Two‐fold ALA‐PDT resulted in more post‐treatment AEs compared with MAL‐PDT. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data. </p> </section> </section> </section> <section id="CD003412-sec-0149"> <h5 class="title">HAL‐PDT versus MAL‐PDT</h5> <section id="CD003412-sec-0150"> <h6 class="title">Early treatment failure</h6> <p>Based on <a href="./references#CD003412-bbs2-0040" title="SalmivuoriMK , GrönroosM , TaniT , PölönenI , RäsänenJ , AnnalaL , et al. Hexylaminolevulinate and aminolevulinic acid nanoemulsion have similar tolerability, initial efficacy and cosmetic outcome as methylaminolevulinate in photodynamic therapy of basal cell carcinoma in a prospective randomized double-blinded trial. Journal of Investigative Dermatology2019;139(9):S234. [CENTRAL: CN-01978390] [DOI: 10.1016/j.jid.2019.07.119]">Salmivuori 2019</a> (detailed above), we are uncertain whether there is any difference in the three‐month early treatment failure rate between HAL‐PDT and MAL‐PDT (6.5%, 2/31 versus 3.2%, 1/31, respectively) because the certainty of evidence was rated as very low due to a very wide 95% CI that meant we rated down three levels for imprecision (RR 2.00, 95% CI 0.19 to 20.93; <a href="./references#CD003412-fig-0033" title="">Analysis 14.1</a>). </p> </section> </section> <section id="CD003412-sec-0151"> <h5 class="title">HAL‐PDT versus BF‐200 ALA‐PDT</h5> <section id="CD003412-sec-0152"> <h6 class="title">Early treatment failure</h6> <p>Based on <a href="./references#CD003412-bbs2-0040" title="SalmivuoriMK , GrönroosM , TaniT , PölönenI , RäsänenJ , AnnalaL , et al. Hexylaminolevulinate and aminolevulinic acid nanoemulsion have similar tolerability, initial efficacy and cosmetic outcome as methylaminolevulinate in photodynamic therapy of basal cell carcinoma in a prospective randomized double-blinded trial. Journal of Investigative Dermatology2019;139(9):S234. [CENTRAL: CN-01978390] [DOI: 10.1016/j.jid.2019.07.119]">Salmivuori 2019</a> (detailed above), there may be fewer early treatment failures at three months with HAL‐PDT compared to BF‐200 ALA‐PDT(6.5%, 2/3 versus 9.1%, 3.33) (RR 0.71, 95% CI 0.13 to 3.97; <a href="./references#CD003412-fig-0034" title="">Analysis 15.1</a>). We rated the certainty of evidence as low (very wide 95% CI that indicates important improvement or worsening in early treatment failures). </p> </section> <section id="CD003412-sec-0153"> <h6 class="title">Adverse effects</h6> <p>Severity of post‐treatment reactions were visually assessed (on a scale: none/minimal/mild/moderate/severe). HAL‐PDT had 12 lesions with a moderate reaction and 13 lesions with a severe reaction. BF‐200 ALA‐PDT had 13 moderate and 11 severe reactions. MAL‐PDT had 13 moderate and nine severe reactions. Overall, there was no significant difference between the three groups P = 0.49). </p> <p>There was one treatment‐related withdrawal from the trial, as one patient from the MAL group experienced remarkable swelling, oedema, erythema and haematoma in the treatment area. </p> </section> </section> <section id="CD003412-sec-0154"> <h5 class="title">PDT versus cryosurgery</h5> <p>Two studies compared PDT against cryosurgery. One study (<a href="./references#CD003412-bbs2-0007" title="Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Methyl aminolaevulinate photodynamic therapy vs. cryotherapy in primary superficial basal cell carcinoma: results of a 36-month follow-up. British Journal of Dermatology2005;153(1):29. Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Topical methyl aminolevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. European Journal of Dermatolology2008;18(5):547-53. [CENTRAL: CN-00668120] ">Basset‐Seguin 2008</a>) compared a single session of MAL‐PDT against cryosurgery in 118 participants with 219 sBCCs over 5 years follow‐up. A second study (<a href="./references#CD003412-bbs2-0052" title="WangI , BendsoeN , KlintebergCA , EnejderAM , Andersson‐EngelsS , SvanbergS , et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. British Journal of Dermatology2000;144(4):832-40. [CENTRAL: CN-00326537] ">Wang 2001</a>) compared a single session of ALA‐PDT (against cryosurgery) in 88 participants with nBCC and sBCC over 1 year follow‐up. The standard European protocol for PDT is two PDT sessions separated by 1 week and therefore the single PDT sessions performed in these studies would no longer be considered the standard of care. See <a href="#CD003412-tbl-0010">Table 5</a>. </p> <div class="table" id="CD003412-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">MAL‐PDT compared to cryosurgery for basal cell carcinoma of the skin</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PDT compared to cryosurgery for low‐risk BCC</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from France, UK, Sweden, Italy, Belgium and Austria<br/><b>Intervention:</b> MAL‐PDT<br/><b>Comparison:</b> cryosurgery </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cryosurgery</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with MAL‐PDT</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/>(0.65 to 1.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>193 (lesions)<sup>4</sup><br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221 per 1000<br/>(126 to 383) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/>(0.62 to 1.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>193 (lesions)<sup>4</sup><br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205 per 1000<br/>(119 to 352) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.23<br/>(1.07 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>99<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participant‐rated at 1 year on a 4‐point scale.<sup>2</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>813 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>999 per 1000<br/>(869 to 1000) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.46 (1.14 to 1.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>99</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Observer‐rated at 1 year on a 4‐point scale.<sup>2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>604 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>882 per 1000</p> <p>(689 to 1000)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Early treatment failure</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.57<br/>(0.14 to 2.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>201 (lesions)<sup>4</sup><br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/>(7 to 119) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12</p> <p>(0.68 to 1.84)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>118</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Frequency reported as AE during the follow‐up period.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>328 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>367 per 1000<br/>(223 to 603) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>AE:</b> adverse event; <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm. </p> <p><sup>2</sup> Downgraded one level for serious risk of bias as unable to truly blind due to the nature of interventions. </p> <p><sup>3</sup> 4‐point scale: poor (extensive occurrence of scarring, atrophy, or induration), fair (slight to moderate occurrence of scarring, atrophy or induration), good (no scarring, atrophy or induration and moderate redness or increase in pigmentation compared with adjacent skin), excellent (no scarring, atrophy, or induration and slight or no redness or change in pigmentation compared with adjacent skin). </p> <p><sup>4</sup> Includes participants with multiple lesions which means differences between groups could be over‐estimated. </p> </div> </div> <section id="CD003412-sec-0155"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0156"> <p><b>Recurrence</b></p> <p>There may be little to no difference between MAL‐PDT and cryosurgery on the risk of recurrence at three years (22%, 22/100 versus 19.4%, 18/93) (RR 1.14, 95% CI 0.65 to 1.98; <a href="./references#CD003412-fig-0035" title="">Analysis 16.1</a>). We rated the certainty of evidence as low, rating down for very serious imprecision (very wide 95% CI that indicates important benefit and harm). </p> <p>At five years there may be little to no difference between MAL‐PDT and cryosurgery on the risk of recurrence (22%, 22/100 versus 20%, 19/93, respectively) (RR 1.08, 95% CI 0.62 to 1.86; <a href="./references#CD003412-fig-0036" title="">Analysis 16.2</a>). We rated the certainty of evidence as low for very serious imprecision (very wide 95% CI that indicates important benefit and harm). </p> </section> <section id="CD003412-sec-0157"> <p><b>Cosmetic outcome (participant‐ and observer‐rated)</b></p> <p>When participant‐rated at one year on a four‐point scale, MAL‐PDT probably increases the rate of good/excellent cosmetic outcomes compared to cryosurgery (100%, 51/51 versus 81.3%, 39/48, respectively) (RR 1.23, 95% CI 1.07 to 1.41; <a href="./references#CD003412-fig-0037" title="">Analysis 16.3</a>). When investigator‐rated on a four‐point scale, MAL‐PDT probably increases the rate of good/excellent cosmetic outcomes compared to the cryosurgery (89%, 45/51 versus 61%, 29/48, respectively) (RR 1.46, 95% CI 1.14 to 1.88; <a href="./references#CD003412-fig-0037" title="">Analysis 16.3</a>). <a href="./references#CD003412-bbs2-0052" title="WangI , BendsoeN , KlintebergCA , EnejderAM , Andersson‐EngelsS , SvanbergS , et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. British Journal of Dermatology2000;144(4):832-40. [CENTRAL: CN-00326537] ">Wang 2001</a> assessed cosmetic outcome based on hypo‐ and hyperpigmentation, scar and tissue defect and then gave an overall investigator rated assessment based on a four‐point scale. The study showed that ALA‐PDT probably increases the rate of good/excellent cosmetic outcomes at one year compared to cryosurgery (92.8%, 39/42 versus 54.1%, 20/37) (RR 1.72, 95% CI 1.26 to 2.34; <a href="./references#CD003412-fig-0040" title="">Analysis 17.1</a>). We rated the certainty of evidence as moderate for all these outcomes, rating down for serious risk of blinding bias due to the nature of the interventions. </p> </section> </section> <section id="CD003412-sec-0158"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0159"> <p><b>Pain during and after treatment</b></p> <p><a href="./references#CD003412-bbs2-0007" title="Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Methyl aminolaevulinate photodynamic therapy vs. cryotherapy in primary superficial basal cell carcinoma: results of a 36-month follow-up. British Journal of Dermatology2005;153(1):29. Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Topical methyl aminolevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. European Journal of Dermatolology2008;18(5):547-53. [CENTRAL: CN-00668120] ">Basset‐Seguin 2008</a> presented pain data within the adverse effects data. There may be little to no difference between MAL‐PDT and cryosurgery on the risk of pain reported as an AE (33%, 19/58 versus 37%, 22/60, respectively) (RR 1.12, 95% CI 0.68 to 1.84; <a href="./references#CD003412-fig-0038" title="">Analysis 16.4</a>). We rated the certainty of evidence as low (very wide 95% CI that indicates important benefit and harm). <a href="./references#CD003412-bbs2-0052" title="WangI , BendsoeN , KlintebergCA , EnejderAM , Andersson‐EngelsS , SvanbergS , et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. British Journal of Dermatology2000;144(4):832-40. [CENTRAL: CN-00326537] ">Wang 2001</a> measured pain during and the first week after treatment by providing participants with a self‐registration VAS form which ranged from 0 mm (no pain) to 115 mm (unbearable pain). Raw data with standard deviations were available for the mean during treatment VAS scores which showed that ALA‐PDT probably results in slightly more pain than cryosurgery (MD 11.00, 95% CI ‐1.12 to 23.12; <a href="./references#CD003412-fig-0041" title="">Analysis 17.2</a>). We rated the certainty of evidence as moderate rating down for serious imprecision (only one study and wide 95% CI). In the first week after treatment, </p> <p>See <a href="#CD003412-tbl-0006">Table 1</a> for further pain data. </p> </section> <section id="CD003412-sec-0160"> <p><b>Early treatment failure</b></p> <p>At three months, there may be slightly fewer early treatment failures with MAL‐PDT compared to cryosurgery (2.9%, 3/103 versus 5.1%, 5/98, respectively) (RR 0.57, 95% CI 0.57 to 2.33; <a href="./references#CD003412-fig-0039" title="">Analysis 16.5</a>). We rated the certainty of evidence as low, rating down for very serious imprecision (very wide 95% CI that indicates important benefit and harm). </p> </section> <section id="CD003412-sec-0161"> <p><b>Adverse effects</b></p> <p>See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data. </p> </section> </section> </section> <section id="CD003412-sec-0162"> <h5 class="title">Imiquimod cream versus MAL‐PDT</h5> <p>One study (<a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a>) assessed whether imiquimod cream and 5‐FU cream were non‐inferior to MAL‐PDT in 601 participants with a single sBCC (anywhere except high‐risk face/scalp) in a three‐arm RCT with five years follow‐up. A pre‐specified non‐inferiority margin of 10% was used. See <a href="./full#CD003412-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD003412-sec-0163"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0164"> <p><b>Recurrence</b></p> <p>Imiquimod cream probably reduces the risk of recurrence at three years compared to MAL‐PDT (22.8%, 34/149 versus 51.6%, 66/128, respectively) (RR 0.44, 95% CI 0.32 to 0.62; <a href="./references#CD003412-fig-0042" title="">Analysis 18.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision as this was a single study. </p> <p>At five years, imiquimod cream probably reduces the risk of recurrence compared to MAL‐PDT (28.6%, 36/126 versus 68.6%, 70/102) (RR 0.42, 95% CI 0.31 to 0.57; <a href="./references#CD003412-fig-0043" title="">Analysis 18.2</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (only one study). </p> </section> <section id="CD003412-sec-0165"> <p><b>Cosmetic outcome (participant‐ and observer‐rated)</b></p> <p>A blinded observer‐rated cosmetic outcome at one year on a four‐point scale. There is probably little to no difference between imiquimod and MAL‐PDT on the rate of good/excellent cosmetic outcomes (RR 0.98, 95% CI 0.84 to 1.16; <a href="./references#CD003412-fig-0044" title="">Analysis 18.3</a>). We rated the certainty of evidence as moderate (only one study). </p> </section> </section> <section id="CD003412-sec-0166"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0167"> <p><b>Pain during and after treatment</b></p> <p>Maximum pain was recorded on VAS for all interventions at the end of each week of treatment. The scores were then interpreted as absent/mild (0‐3), moderate (4‐6) and severe (7‐10). We selected the week or treatment cycle (presented for PDT only) with the highest reported moderate/severe pain to overcome differences in timing of reported pain with the different interventions. Week six had the highest reported pain for imiquimod (18% of patients reported moderate/severe pain) and treatment cycle two for MAL‐PDT (31% of patients reporting moderate/severe pain). Our analysis showed that imiquimod probably reduces the risk of moderate/severe pain compared to MAL‐PDT (RR 0.60, 95% CI 0.41 to 0.87; <a href="./references#CD003412-fig-0045" title="">Analysis 18.4</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (only one study). See <a href="#CD003412-tbl-0006">Table 1</a> for further pain data from this study. </p> </section> <section id="CD003412-sec-0168"> <p><b>Early treatment failure</b></p> <p>At three months, there may be little to no difference between imiquimod and MAL‐PDT on the risk of early treatment failures (10.1%, 19/189 versus 15.8%, 31/196) (RR 0.64, 95% CI 0.37 to 1.09; <a href="./references#CD003412-fig-0046" title="">Analysis 18.5</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (wide 95% CI, including the null effect which indicates there may be an important difference or no difference between the two treatments). </p> </section> <section id="CD003412-sec-0169"> <p><b>Adverse effects</b></p> <p>Participants treated with imiquimod more often reported moderate to severe local swelling, erosion, crust formation and itching of skin compared to the MAL‐PDT group. There were no unexpected serious adverse reactions in the MAL‐PDT group, but 4.8% (nine participants) were reported to have a suspected unexpected serious adverse reaction (SUSAR) in the imiquimod group for influenza‐like symptoms (n = 8) and a local wound infection; however, none of the participants were admitted to hospital. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from this study. </p> </section> </section> </section> <section id="CD003412-sec-0170"> <h5 class="title">5‐fluorouracil cream versus MAL‐PDT</h5> <p>One study (<a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a>) assessed the effects of 5‐FU cream versus MAL‐PDT; this study is described above in section 5. See <a href="#CD003412-tbl-0011">Table 6</a>. </p> <div class="table" id="CD003412-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">5‐FU cream compared to MAL‐PDT for basal cell carcinoma of the skin</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>5‐FU cream compared to MAL‐PDT for low‐risk BCC</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from seven hospitals in the Netherlands<br/><b>Intervention:</b> 5‐FU cream<br/><b>Comparison:</b> MAL‐PDT </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PDT</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 5‐FU cream</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.65<br/>(0.49 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>272<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>524 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340 per 1000<br/>(257 to 450) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.67<br/>(0.53 to 0.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>226<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>686 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>460 per 1000<br/>(364 to 576) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (excellent/good)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/>(0.78 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>379<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blinded observer‐rated at 1 year on 4‐point scale.<sup>3</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>624 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>574 per 1000<br/>(486 to 680) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain (moderate/severe)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.41<br/>(0.26 to 0.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>374<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>During treatment: comparing the week of treatment with highest frequency of reported moderate/severe pain (treatment cycle 2 for PDT, week 4 for 5‐FU cream). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 per 1000<br/>(79 to 192) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Early treatment failure</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.77<br/>(0.47 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>394<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 per 1000<br/>(74 to 199) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for serious imprecision as only a single study with a small sample size. </p> <p><sup>2</sup> Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm. </p> <p><sup>3</sup> 4‐point scale: poor, fair, good, excellent. </p> </div> </div> <section id="CD003412-sec-0171"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0172"> <p><b>Recurrence</b></p> <p>5‐FU cream probably reduces the risk of recurrence compared to MAL‐PDT at three years (34.2%, 50/146 versus 52.4%, 66/126, respectively) (RR 0.65, 95% CI 0.49 to 0.86; <a href="./references#CD003412-fig-0047" title="">Analysis 19.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (only one study).<br/><br/>Similar findings were also seen at five years, where 5‐FU cream probably reduces the risk of recurrence compared to MAL‐PDT (46%, 57/124 versus 68.7%, 70/102, respectively) (RR 0.67, 95% CI 0.53 to 0.84; <a href="./references#CD003412-fig-0048" title="">Analysis 19.2</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (only one study). </p> </section> <section id="CD003412-sec-0173"> <p><b>Cosmetic outcome (participant‐ and observer‐rated)</b></p> <p>There is probably little to no difference between 5‐FU cream and MAL‐PDT on the rate of good/excellent cosmetic outcomes (RR 0.92, 95% CI 0.78 to 1.09; <a href="./references#CD003412-fig-0049" title="">Analysis 19.3</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (only one study). </p> </section> </section> <section id="CD003412-sec-0174"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0175"> <p><b>Pain during and after treatment</b></p> <p>The maximum recorded pain for 5‐FU cream was recorded during week four (final week) of treatment with 12% of patients reporting moderate/severe pain. 5‐FU cream probably reduces the risk of moderate/severe pain compared to MAL‐PDT (RR 0.41, 95% CI 0.26 to 0.63; <a href="./references#CD003412-fig-0050" title="">Analysis 19.4</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (only one study). See <a href="#CD003412-tbl-0006">Table 1</a> for further pain data. </p> </section> <section id="CD003412-sec-0176"> <p><b>Early treatment failure</b></p> <p>There may be little to no difference between 5‐FU cream and MAL‐PDT on the risk of early treatment failure (12.1%, 24/198 versus 15.8%, 31/196) (RR 0.77, 95% CI 0.47 to 1.26; <a href="./references#CD003412-fig-0051" title="">Analysis 19.5</a>). We rated the certainty of evidence as low, rating down two levels for very serious imprecision (very wide 95% CI that indicates important benefit and harm). </p> </section> <section id="CD003412-sec-0177"> <p><b>Adverse effects</b></p> <p>Unexpected serious adverse reactions were reported in 2.1% (four participants) in the 5‐FU cream group: two local wound infections, one case of erysipelas of the leg and one leg ulcer. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data. </p> </section> </section> </section> <section id="CD003412-sec-0178"> <h5 class="title">Laser ALA‐PDT versus broadband halogen light ALA‐PDT</h5> <p>One study (<a href="./references#CD003412-bbs2-0046" title="SolerAM , Angell-PetersenE , WarloeT , TausjoJ , SteenHB , MoanJ , et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: A comparison of two light sources. Photochemistry and Photobiology2000;71(6):724-9. [CENTRAL: CN-00297518] ">Soler 2000</a>) of 83 participants (245 lesions) with sBCC compared two different light sources: laser or broadband lamp light with ALA‐PDT. The study only had six months follow‐up. The laser light was 630 nm from a copper vapour dye laser with doses ranging between 100 J/cm<sup>2</sup> to 150 J/cm<sup>2</sup>. The broadband light used a halogen bulb and a filter to produce red light (570 nm to 740 nm) with a dose ranging between 150 J/cm<sup>2</sup> to 200 J/cm<sup>2</sup> as well as infrared radiation (1180 nm to 2700 nm). </p> <section id="CD003412-sec-0179"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0180"> <p><b>Cosmetic outcome (participant‐ and observer‐rated)</b></p> <p>At six months, cosmetic outcome was rated by two observers (only one blinded) on a four‐point scale (poor, fair, good, excellent). Only tumours that had completely responded were scored leading to an unequal attrition rate between the groups. There may be little to no difference on the rate of good/excellent cosmetic outcomes between the two light sources (RR 0.91, 95% CI 0.82 to 1.01; <a href="./references#CD003412-fig-0052" title="">Analysis 20.1</a>). We rated the certainty of evidence as low, rating down for serious imprecision (only one study) and serious risk of attrition bias. </p> </section> </section> <section id="CD003412-sec-0181"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0182"> <p><b>Pain during and after treatment</b></p> <p>There is probably little to no difference between laser ALA‐PDT and broadband light ALA‐PDT on the frequency of pain (reported as any type of discomfort) during and immediately after treatment (83%, 34/41 versus 76%, 32/42) (RR 1.09, 95% CI 0.87 to 1.35; <a href="./references#CD003412-fig-0053" title="">Analysis 20.2</a>). In the first week after treatment, there is probably little to no difference in the frequency of pain reported between the two light sources (RR 0.93, 95% CI 0.70 to 1.22; <a href="./references#CD003412-fig-0053" title="">Analysis 20.2</a>). We rated the certainty of evidence for both these outcomes as moderate, rating down for serious imprecision (only one study). See <a href="#CD003412-tbl-0006">Table 1</a> for further pain data from this study. </p> </section> <section id="CD003412-sec-0183"> <p><b>Early treatment failure</b></p> <p>The study did not histologically confirm clinical treatment failures; therefore, we have not extracted the data for this outcome. </p> </section> <section id="CD003412-sec-0184"> <p><b>Adverse effects</b></p> <p>Some discomfort during and after illumination was reported by 83% of participants receiving laser ALA‐PDT and 76% of those receiving broadband PDT. No serious AEs were reported during the 6‐month follow‐up. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from this study. </p> </section> </section> </section> <section id="CD003412-sec-0185"> <h5 class="title">Ablative fractional laser (AFXL) MAL‐PDT versus MAL‐PDT</h5> <p>Two small pilot studies compared ablative fractional laser (AFXL) pre‐treatment prior to MAL‐PDT against conventional MAL‐PDT with one year follow‐up. This is based on the rationale that AFXL pre‐treatment increases uptake of MAL deeper into the tumour. One study (<a href="./references#CD003412-bbs2-0023" title="HaakCS , Togsverd-BoK , Thaysen-PetersenD , WulfHC , PaaschU , AndersonRR , et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas - a randomized clinical trial. British Journal of Dermatology2015;172(1):215-22. [CENTRAL: CN-01039978] ">Haak 2015</a>) randomised 32 participants with facial nBCC and the other (<a href="./references#CD003412-bbs2-0011" title="ChoiSH , KimKH , SongKH . Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial. Journal of the European Academy of Dermatology and Venereology2015;30(5):783-8. [CENTRAL: CN-01158122] [DOI: 10.1111/jdv.13453]">Choi 2016</a>) randomised 39 participants (42 lesions) with facial nBCC. The first study used a fractional CO<sub>2</sub> laser and the second an erbium:YAG laser. </p> <section id="CD003412-sec-0186"> <h6 class="title">Primary outcome</h6> <section id="CD003412-sec-0187"> <p><b>Cosmetic outcome (participant‐ and observer‐rated)</b></p> <p>Cosmetic outcomes were assessed by a blinded investigator in both studies at one year using a four‐point scale. The pooled results from both studies showed there may be little to no difference between AFXL‐PDT and MAL‐PDT on the rate of good/excellent cosmetic outcomes (RR 1.12, 95% CI 0.54 to 2.31, I<sup>2</sup> = 66%; <a href="./references#CD003412-fig-0054" title="">Analysis 21.1</a>). We rated the certainty of evidence as low, rating down two levels for very serious imprecision (very wide 95% CI that indicates important benefit and harm). <a href="./references#CD003412-bbs2-0023" title="HaakCS , Togsverd-BoK , Thaysen-PetersenD , WulfHC , PaaschU , AndersonRR , et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas - a randomized clinical trial. British Journal of Dermatology2015;172(1):215-22. [CENTRAL: CN-01039978] ">Haak 2015</a> presented participant reported cosmetic outcomes, showing that there is probably little to no difference between AFXL‐PDT and MAL‐PDT on the rate of good/excellent cosmetic results (RR 0.94, 95% CI 0.75 to 1.17; <a href="./references#CD003412-fig-0054" title="">Analysis 21.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (only one study). </p> </section> </section> <section id="CD003412-sec-0188"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0189"> <p><b>Pain during and after treatment</b></p> <p>Pain was recorded using VAS for both studies but individual data were not presented. Both studies reported in their text that there was “no statistically significant difference” in pain scores between the treatment groups. See <a href="#CD003412-tbl-0006">Table 1</a> for further pain data from these studies. </p> </section> <section id="CD003412-sec-0190"> <p><b>Early treatment failure</b></p> <p>A pooled analysis of both studies showed that AFXL‐PDT probably reduces the risk of early treatment failures compared to MAL‐PDT at three months (RR 0.38, 95% CI 0.17 to 0.84, I<sup>2</sup> = 0%; <a href="./references#CD003412-fig-0055" title="">Analysis 21.2</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (fairly wide 95% CI). </p> </section> <section id="CD003412-sec-0191"> <p><b>Adverse effects</b></p> <p>See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from these studies. </p> </section> </section> </section> <section id="CD003412-sec-0192"> <h5 class="title">MAL‐PDT versus placebo</h5> <p>Two RCTs with the "same design and procedures" (<a href="./references#CD003412-bbs2-0018" title="FoleyP , FreemanM , MenterA , SillerG , El-AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] FoleyP , FreemanM , SillerG , GebauerK , MurrellD , BarnetsonR , et al. A phase III randomized study comparing photodynamic therapy (PDT) using methyl aminolevulinate or placebo cream in nodular basal cell carcinoma (NBCC). Journal of the European Academy of Dermatology and Venereology2003;17(Suppl 3):231. [CENTRAL: CN-00478536] ">Foley 2009a</a> and <a href="./references#CD003412-bbs2-0019" title="FoleyP , FreemanM , MenterA , SillerG , El‐AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] TopeWD , MenterA , El AzharyR , SotoP . A comparison of topical MAL-PDT versus placebo-PDT in nodular basal cell carcinoma: results of a North American study. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology; 2005 Sep 28-Oct 03; Kuala Lumpur, Malaysia. 2005:376. [CENTRAL: CN-00602617] ">Foley 2009b</a>) randomised 131 participants (160 nBCC) to MAL‐PDT versus placebo. We have presented the data analyses as one study under <a href="./references#CD003412-bbs2-0018" title="FoleyP , FreemanM , MenterA , SillerG , El-AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] FoleyP , FreemanM , SillerG , GebauerK , MurrellD , BarnetsonR , et al. A phase III randomized study comparing photodynamic therapy (PDT) using methyl aminolevulinate or placebo cream in nodular basal cell carcinoma (NBCC). Journal of the European Academy of Dermatology and Venereology2003;17(Suppl 3):231. [CENTRAL: CN-00478536] ">Foley 2009a</a> as the data from the separate studies were not available. All tumours were debulked prior to treatment and all treatment sites were excised at three months (clinical non‐responders) or six months (clinical responders) after the last treatment. </p> <section id="CD003412-sec-0193"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0194"> <p><b>Cosmetic outcome (participant‐ and observer‐rated)</b></p> <p>Only the complete clinically/histologically clear lesions were assessed for cosmetic outcome. The authors only presented the investigator‐rated data (four‐point scale). There is probably little to no difference between MAL‐PDT and placebo on the rate of good/excellent cosmetic outcomes (RR 1.05, 95% CI 0.91 to 1.21; <a href="./references#CD003412-fig-0056" title="">Analysis 22.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (fairly wide 95% CI). </p> </section> </section> <section id="CD003412-sec-0195"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0196"> <p><b>Pain during and after treatment</b></p> <p>Frequency of "burning sensation of skin", "pain in skin" and "stinging of skin" were reported as part of treatment‐related local adverse effects. MAL‐PDT probably increases the risk of "pain in skin" compared to placebo (RR 3.94, 95% CI 1.17 to 13.32; <a href="./references#CD003412-fig-0057" title="">Analysis 22.2</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (fairly wide 95% CI). See <a href="#CD003412-tbl-0006">Table 1</a> for further pain data from this study. </p> </section> <section id="CD003412-sec-0197"> <p><b>Early treatment failure</b></p> <p>MAL‐PDT may reduce the risk of early treatment failures compared to placebo (RR 0.36, 95% CI 0.24 to 0.54; <a href="./references#CD003412-fig-0058" title="">Analysis 22.3</a>). We rated the certainty of evidence as low, rating down for serious imprecision (only one study). </p> </section> <section id="CD003412-sec-0198"> <p><b>Adverse effects</b></p> <p>See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from this study. </p> </section> </section> </section> </section> <section id="CD003412-sec-0199"> <h4 class="title">6. Imiquimod cream</h4> <section id="CD003412-sec-0200"> <h5 class="title">Imiquimod cream versus 5‐fluorouracil cream</h5> <p>One study (<a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a>) assessed the effects of imiquimod cream versus 5‐FU cream; this study is described above in section 5. See <a href="#CD003412-tbl-0012">Table 7</a>. </p> <div class="table" id="CD003412-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Imiquimod cream compared to 5‐FU cream for basal cell carcinoma of the skin</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Imiquimod cream compared to 5‐FU cream for low‐risk BCC</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from seven hospitals in the Netherlands<br/><b>Intervention:</b> imiquimod cream<br/><b>Comparison:</b> 5‐FU cream </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 5‐FU cream</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Imiquimod cream</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.68<br/>(0.47 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>291<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>342 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233 per 1000<br/>(161 to 339) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.62<br/>(0.44 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>250<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>460 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285 per 1000<br/>(202 to 400) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (excellent/good)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/>(0.90 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>377<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Observer‐rated at 1 year on 4‐point scale.<sup>4</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>575 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>615 per 1000<br/>(518 to 725) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain (moderate/severe)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.46<br/>(0.89 to 2.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>365<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>During treatment: comparing the week of treatment with highest frequency of reported moderate/severe pain (week 6 for imiquimod, week 4 for 5‐FU cream). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183 per 1000<br/>(111 to 298) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Early treatment failure</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.47 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>387<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/>(57 to 177) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for serious imprecision as only a single study with a small sample size. </p> <p><sup>2</sup> Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI. </p> <p><sup>3</sup> Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm. </p> <p><sup>4</sup> 4‐point scale: poor, fair, good, excellent. </p> </div> </div> <section id="CD003412-sec-0201"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0202"> <p><b>Recurrence</b></p> <p>Imiquimod probably reduces the risk of recurrence compared to 5‐FU cream at three years (23.4%, 34/145 versus 34.2%, 50/146, respectively) (RR 0.68, 95% CI 0.47 to 0.99; <a href="./references#CD003412-fig-0059" title="">Analysis 23.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (only one study).<br/><br/>Imiquimod probably reduces the risk of recurrence compared to 5‐FU cream at five years (28.6%, 36/126 versus 46%, 57/124, respectively) (RR 0.62, 95% CI 0.44 to 0.87; <a href="./references#CD003412-fig-0060" title="">Analysis 23.2</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (only one study). </p> </section> <section id="CD003412-sec-0203"> <p><b>Cosmetic outcome (participant‐ and observer‐rated)</b></p> <p>When blinded observer‐rated at 1 year, there is probably little to no difference between imiquimod and 5‐FU cream on the rate of good/excellent cosmetic outcomes (61.4%, 113/184 versus 57.5%, 111/193, respectively) (RR 1.07, 95% CI 0.90 to 1.26; <a href="./references#CD003412-fig-0061" title="">Analysis 23.3</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (only one study). </p> </section> </section> <section id="CD003412-sec-0204"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0205"> <p><b>Pain during and after treatment</b></p> <p>We compared the week with the highest frequency of reported of moderate/severe pain during treatment for each intervention (week six for imiquimod and week 4 for 5‐FU cream). There is probably a slightly increased risk of moderate/severe pain with imiquimod compared with 5‐FU cream (18.2%, 33/181 versus 12.5%, 23/184) (RR 1.46, 95% CI 0.89 to 2.34; <a href="./references#CD003412-fig-0062" title="">Analysis 23.4</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (wide 95% CI that indicates increased pain or slightly less pain). See <a href="#CD003412-tbl-0006">Table 1</a> for further pain data from this study. </p> </section> <section id="CD003412-sec-0206"> <p><b>Early treatment failure</b></p> <p>There may be little to no difference between imiquimod and 5‐FU cream on the risk of early treatment failures (10%, 19/189 versus 12.1%, 24/198 ) (RR 0.83, 95% CI 0.47 to 1.46; <a href="./references#CD003412-fig-0063" title="">Analysis 23.5</a>). The certainty of evidence is low due to very serious imprecision with a wide 95% CI that indicates there may be an important reduction or an important increase in early treatment failures. </p> </section> <section id="CD003412-sec-0207"> <p><b>Adverse effects</b></p> <p>See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from this study. </p> </section> </section> </section> <section id="CD003412-sec-0208"> <h5 class="title">Imiquimod cream versus radiotherapy</h5> <p>One small study (<a href="./references#CD003412-bbs2-0020" title="Garcia-MartinE , Gil-ArribasLM , IdoipeM , AlfaroJ , PueyoV , PabloLE , et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. British Journal of Ophthalmology2011;95(10):1393-6. [CENTRAL: CN-00801928] ">Garcia‐Martin 2011</a>) randomised 27 participants with nBCC of the eyelid to either imiquimod (five days a week for six weeks) or conventional radiotherapy with two years follow‐up. The study was at high risk of selection bias due to the method of randomisation (based on birthday of participant). </p> <section id="CD003412-sec-0209"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0210"> <p><b>Recurrence</b></p> <p>There were no recurrences in either group during the follow‐up period and therefore we were unable to assess effect size. </p> </section> <section id="CD003412-sec-0211"> <p><b>Cosmetic outcome (participant‐ and observer‐rated)</b></p> <p>Cosmesis was patient‐rated on a three‐point scale (bad, good, excellent), but this was only measured at 6 weeks following treatment. Observer‐rated cosmetic outcomes were also recorded on a three‐point scale, but the data were not presented in the paper. All participants in the imiquimod group rated the cosmetic result as excellent and all those in the radiotherapy group rated the cosmetic result as good. There may be more participant‐rated excellent cosmetic outcomes at 6 weeks with imiquimod compared to radiotherapy (RR 25.19, 95% CI 1.66 to 382.13; <a href="./references#CD003412-fig-0064" title="">Analysis 24.1</a>). We rated the certainty of evidence as low due to the very wide 95% CI. </p> </section> </section> <section id="CD003412-sec-0212"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0213"> <p><b>Pain during and after treatment</b></p> <p>Blink discomfort was reported in 60% (9/15) of participants in the imiquimod group and blink discomfort and dry eye were reported in 50% (6/12) participants in the radiotherapy group. Intense conjunctival irritation occurred in 13.3% (2/15) of participants in the imiquimod group. </p> </section> <section id="CD003412-sec-0214"> <p><b>Early treatment failure</b></p> <p>There were no early treatment failures at six weeks following treatment and therefore no effect size was estimable. </p> </section> <section id="CD003412-sec-0215"> <p><b>Adverse effects</b></p> <p>All participants in the radiotherapy group presented with loss of eyelashes in one or both eyelids, 16.6% (2/12) of participants had inferior eyelid retraction with secondary ectropion, and three of the participants reported dry eye symptoms after radiotherapy. Tolerability during treatment was better in the radiotherapy group. Seven of the 15 participants in the imiquimod group reported 'bad' tolerability, but these symptoms disappeared when the period of cream application ended. Only one patient in the radiotherapy group rated 'bad' tolerability. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data and <a href="#CD003412-tbl-0006">Table 1</a> for pain data from this study. </p> </section> </section> </section> <section id="CD003412-sec-0216"> <h5 class="title">Imiquimod with occlusion versus imiquimod without occlusion</h5> <p>Two similar dose‐response studies <i>(</i><a href="./references#CD003412-bbs2-0048" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. In: 8th World Congress on cancers of the skin, Zurich, Switzerland. 2001:61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] [PMID: 12452875]">Sterry 2002a</a>; <a href="./references#CD003412-bbs2-0049" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. 8th World Congress on cancers of the skin, Zurich, Switzerland2001;-(-):p61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] ">Sterry 2002b</a>) examined imiquimod cream with or without occlusion in sBCC (93 participants; <a href="./references#CD003412-bbs2-0048" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. In: 8th World Congress on cancers of the skin, Zurich, Switzerland. 2001:61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] [PMID: 12452875]">Sterry 2002a</a>) and nBCC (90 participants; <a href="./references#CD003412-bbs2-0049" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. 8th World Congress on cancers of the skin, Zurich, Switzerland2001;-(-):p61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] ">Sterry 2002b</a>). Patients were randomised to one of four groups to apply imiquimod 5% cream two or three days per week either with or without occlusion for six weeks. At the end of the six‐week treatment period, the entire target tumour area was excised and histologically examined for evidence of residual tumour. Size and location of lesions were not given. </p> <section id="CD003412-sec-0217"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0218"> <p><b>Early treatment failure</b></p> <p>Pooling the data from both studies (we also combined the different dosing regimen group as the number of participants was small) found there may be little to no difference between the occlusion and no occlusion groups (38.2%, 34/89 versus 41.5%, 39/94) on the risk of early treatment failures (RR 0.91, 95% CI 0.64 to 1.33; <a href="./references#CD003412-fig-0065" title="">Analysis 25.1</a>, I<sup>2</sup> = 0%). We rated the certainty of evidence as low due to very serious imprecision (wide 95% CI that indicates that includes the possibility of important benefit or harm). </p> </section> <section id="CD003412-sec-0219"> <p><b>Adverse effects</b></p> <p>See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from these studies. </p> </section> </section> </section> <section id="CD003412-sec-0220"> <h5 class="title">Imiquimod versus placebo</h5> <p>One trial (<a href="./references#CD003412-bbs2-0009" title="BeutnerKR , GeisseJK , HelmanD , FoxTL , GinkelA , OwensMA . Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. Journal of the American Academy of Dermatology1999;41(6):1002-7. [CENTRAL: CN-00264417] ">Beutner 1999</a>) randomised 35 participants with sBCC and nBCC to imiquimod cream or vehicle cream in one of five dosing regimens for up to 16 weeks. Another trial of 128 participants (<a href="./references#CD003412-bbs2-0021" title="GeisseJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating superficial BCC. In: The 8th World Congress on Cancer of the Skin; 2001 July 18-21; Zurich, Switzerland. 2001:P58. [CENTRAL: CN-00520431] GeisseJK , RichP , PandyaA , GrossK , AndresK , GinkelA , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a randomized, vehicle-controlled study. Journal of the American Academy of Dermatology2002;47(3):390-8. [CENTRAL: CN-00390933] ">Geisse 2002</a>) compared imiquimod twice daily, once daily, five days per week or three days per week versus vehicle for sBCCs. <a href="./references#CD003412-bbs2-0031" title="MarksR , GebauerK , ShumackS , AmiesM , BrydenJ , FoxTL , et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicentre 6-week dose-response trial. Journal of the American Academy of Dermatology2001;44(5):807-13. [CENTRAL: CN-00326531] ">Marks 2001</a> compared different dosages of imiquimod cream applied for six weeks in 99 Australian participants with primary sBCCs. <a href="./references#CD003412-bbs2-0022" title="GeisseJ , CaroI , LindholmJ , GolitzL , StamponeP , OwensM . Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology2004;50(5):722-33. [CENTRAL: CN-00469536] ">Geisse 2004</a> randomised 724 participants with sBCC to imiquimod cream daily either five times per week or seven times per week for six weeks versus vehicle. One further study (<a href="./references#CD003412-bbs2-0041" title="SchulzeHJ , CribierB , RequenaL , ReifenbergerJ , FerrandizC , DiezG , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. British Journal of Dermatology2005;152(5):939-47. [CENTRAL: CN-00513173] ">Schulze 2005</a>), randomised 166 participants with sBCC to imiquimod cream or vehicle, once a day for six weeks. Another two similar studies (<a href="./references#CD003412-bbs2-0042" title="ShumackS , MarksR , AmiesM , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks treating nodular BCC. 8th World Congress on Cancers of the Skin, Zurich, Switzerland2001;-:p55. [CENTRAL: CN-00849091] ShumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , SchroeterA , et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002a</a>; <a href="./references#CD003412-bbs2-0043" title="RobinsonJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating nodular BCC. 8th World Congress on Cancer of the Skin, Zurich, Switzerland2001;-(-):p57. [CENTRAL: CN-00849091] SchumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , Schroeter, A et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002b</a>) randomised 99 and 92 participants with nBCC, respectively to four different dosing regimens (three or seven days per week or twice daily for three or seven days per week) of imiquimod cream or vehicle over 12 and six weeks, respectively. All these studies were industry sponsored. </p> <section id="CD003412-sec-0221"> <h6 class="title">Early treatment failure</h6> <p>Pooled analysis of the five studies showed that imiquimod reduces the risk of early treatment failures compared to vehicle by 75% (RR 0.25, 95% CI 0.19 to 0.32, I<sup>2</sup> = 57%; <a href="./references#CD003412-fig-0066" title="">Analysis 26.1</a>). We rated the certainty of evidence as high. </p> </section> </section> <section id="CD003412-sec-0222"> <h5 class="title">Dose‐ranging studies</h5> <p>One study (<a href="./references#CD003412-bbs2-0017" title="EzughahFI , DaweRS , IbbotsonSH , FlemingCJ . A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment2008;19(2):111-7. [CENTRAL: CN-00706567] ">Ezughah 2008</a>) compared the tolerability of two regimens of imiquimod for the treatment of sBCC with one year follow‐up: five weeks of once‐daily dosing with a one‐week interval in the middle of the course (R1) versus eight weeks of treatment with once‐daily dosing for alternate weeks (R2). One study (<a href="./references#CD003412-bbs2-0015" title="EigentlerTK , KaminA , WeideBM , BreuningerH , CaroliUM , MöhrleM , et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. Journal of the American Academy of Dermatology2007;57(4):616-21. [CENTRAL: CN-00610509] ">Eigentler 2007</a>) compared imiquimod three times a week over eight weeks versus three times a week over 12 weeks in 102 participants with nBCC up to 1.5 cm, located anywhere on the body (except close to the eyes). </p> <section id="CD003412-sec-0223"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0224"> <p><b>Recurrence</b></p> <p><a href="./references#CD003412-bbs2-0017" title="EzughahFI , DaweRS , IbbotsonSH , FlemingCJ . A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment2008;19(2):111-7. [CENTRAL: CN-00706567] ">Ezughah 2008</a> only followed up patients for one year and as we have not included the early treatment failure data (as not histologically confirmed) we have included these data. R2 imiquimod dosing may result in fewer recurrences than R1 imiquimod dosing (12.5%, 2/16 versus 57.1%, 8/14, respectively) (RR 4.57, 95% CI 1.16 to 18.05; <a href="./references#CD003412-fig-0067" title="">Analysis 27.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision due to the wide 95% CI and the small numbers of participants. </p> </section> </section> <section id="CD003412-sec-0225"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0226"> <p><b>Early treatment failure</b></p> <p>Based on <a href="./references#CD003412-bbs2-0015" title="EigentlerTK , KaminA , WeideBM , BreuningerH , CaroliUM , MöhrleM , et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. Journal of the American Academy of Dermatology2007;57(4):616-21. [CENTRAL: CN-00610509] ">Eigentler 2007</a>, at eight weeks post‐treatment there may be little to no difference in early treatment failure rates between imiquimod three times a week over eight weeks and three times a week over 12 weeks (35.6%, 16/45 versus 37.8%, 17/45) (RR 0.94, 95% CI 0.55 to 1.62; <a href="./references#CD003412-fig-0068" title="">Analysis 28.1</a>). We rated the certainty of evidence as low, rating down two levels for very serious imprecision (very wide 95% CI that indicates important benefit and harm). </p> </section> <section id="CD003412-sec-0227"> <p><b>Pain during and after treatment</b></p> <p>In <a href="./references#CD003412-bbs2-0017" title="EzughahFI , DaweRS , IbbotsonSH , FlemingCJ . A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment2008;19(2):111-7. [CENTRAL: CN-00706567] ">Ezughah 2008</a>, a weekly VAS for tolerability was measured using a 10 cm line scale ranging from 0 cm (not unpleasant) to 10 cm (absolutely intolerable). There may be little to no difference between the eight‐week and five‐week treatment groups on the mean composite VAS scores at eight weeks (median score 0.85 cm versus median score 0.30 cm; 95% CI for difference in medians: 20.40 to 0.9 cm, P = 0.39), as reported in the paper. <a href="./references#CD003412-bbs2-0015" title="EigentlerTK , KaminA , WeideBM , BreuningerH , CaroliUM , MöhrleM , et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. Journal of the American Academy of Dermatology2007;57(4):616-21. [CENTRAL: CN-00610509] ">Eigentler 2007</a> did not present pain data separately for the two treatment arms. See <a href="#CD003412-tbl-0006">Table 1</a> for further pain data from these studies. </p> </section> <section id="CD003412-sec-0228"> <p><b>Adverse effects</b></p> <p>See <a href="#CD003412-tbl-0007">Table 2</a> for AE data from these studies. </p> </section> </section> </section> </section> <section id="CD003412-sec-0229"> <h4 class="title">7. 5‐Fluorouracil</h4> <section id="CD003412-sec-0230"> <h5 class="title">Phosphatidyl choline versus petrolatum vehicle</h5> <p>One small pilot study (<a href="./references#CD003412-bbs2-0038" title="RomagosaR , SaapL , GivensM , SalvarreyA , HeJL , HsiaSL , et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatologic Surgery2000;26(4):338-40. [CENTRAL: CN-00296475] ">Romagosa 2000</a>) compared 5‐FU cream in petrolatum with 5‐FU cream in phosphatidyl choline (a transepidermal carrier to aid penetration) in 13 participants (17 lesions, non sBCC, at least 0.7cm diameter, facial lesions excluded). Participants underwent excision of the treated BCC site at week‐16. </p> <section id="CD003412-sec-0231"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0232"> <p><b>Early treatment failure</b></p> <p>There may be fewer early treatment failures with 5‐FU cream in phosphatidyl choline compared to 5‐FU cream in petrolatum (10%, 1/0 versus 42.9%, 3/7, respectively) (RR 0.23, 95% CI 0.03 to 1.81; <a href="./references#CD003412-fig-0069" title="">Analysis 29.1</a>). We rated the certainty of evidence as low, rating down two levels for very serious imprecision (very wide 95% CI that indicates important benefit and harm). </p> </section> <section id="CD003412-sec-0233"> <p><b>Adverse effects</b></p> <p>In the <a href="./references#CD003412-bbs2-0038" title="RomagosaR , SaapL , GivensM , SalvarreyA , HeJL , HsiaSL , et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatologic Surgery2000;26(4):338-40. [CENTRAL: CN-00296475] ">Romagosa 2000</a> study, local irritation, erythema, ulceration and tenderness were common reactions but were reported to be well‐tolerated by the participants. Minimal itching and discomfort were experienced by some of the participants in both treatment arms. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from this study. </p> </section> </section> </section> <section id="CD003412-sec-0234"> <h5 class="title">Intralesional 5‐fluorouracil/epinephrine gel</h5> <p>One study (<a href="./references#CD003412-bbs2-0032" title="MillerBH , ShavinJS , CognettaA , TaylorRJ , SalascheS , KoreyA , et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. Journal of the American Academy of Dermatology1997;36(1):72-7. [CENTRAL: CN-00135753] ">Miller 1997</a>) compared six treatment regimens of intralesional 5‐FU/epinephrine gel in 122 participants with sBCC and nBCC located on the head, upper and lower extremities: 1 mL versus 0.5 mL both once a week for six weeks; 1 mL versus 0. 5mL both twice a week for three weeks; 0.5 mL twice a week for four weeks versus 0.5 mL three times a week for two weeks. </p> <section id="CD003412-sec-0235"> <h6 class="title">Early treatment failure</h6> <p>There may be fewer early treatment failures with 1 mL intralesional 5‐FU compared with 0. 5mL intralesional 5‐FU when given twice a week for three weeks (5.6%, 1/18 versus 21.1%, 4/19, respectively) (RR 0.26, 95% CI 0.03 to 2.14; <a href="./references#CD003412-fig-0071" title="">Analysis 31.1</a>). We rated the certainty of evidence as low, rating down two levels for very serious imprecision (very wide 95% CI that indicates important benefit and harm). It is uncertain whether there is any difference between the other two intralesional regimens as we rated the certainty of evidence for these comparisons as very low due, rating down three levels for very serious imprecision (<a href="./references#CD003412-fig-0070" title="">Analysis 30.1</a>; <a href="./references#CD003412-fig-0072" title="">Analysis 32.1</a>). </p> </section> <section id="CD003412-sec-0236"> <h6 class="title">Adverse effects</h6> <p>All participants had transient, moderate to severe stinging, burning or pain at the time of injection. Local tissue reactions were confined to the treatment site and included erythema, swelling, desquamation, erosions and eschar in most participants. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from this study. </p> </section> </section> </section> <section id="CD003412-sec-0237"> <h4 class="title">8. Electrochemotherapy</h4> <section id="CD003412-sec-0238"> <h5 class="title">Electrochemotherapy versus surgical excision</h5> <p>One study (<a href="./references#CD003412-bbs2-0012" title="CloverAJ , SalwaS , McKiernanJ , BuckleyC , BourkeM , KellyEJ , et al. Prospective randomised control trial comparing electrochemotherapy and surgery for the primary treatment of basal cell carcinoma. Melanoma Research2016;26:e76. [CENTRAL: CN-01212975] [DOI: 10.1097/CMR.0000000000000285] [EMBASE: 612248066]CloverAJ , SalwaSP , BourkeMG , McKiernanJ , FordePF , O'SullivanST , et al. Electrochemotherapy for the treatment of primary basal cell carcinoma; a randomised control trial comparing electrochemotherapy and surgery with five year follow up. European Journal of Surgical Oncology2020;46(5):847-54. [CENTRAL: CN-02049463] [PMID: 31862134]">Clover 2016</a>) compared bleomycin electrochemotherapy (ECT) to SE in 100 participants with 117 low‐risk and high‐risk BCC (superficial, nodular, infiltrative and morphoeic subtypes). Noduar and nodular/infiltrative BCC were the most common subtype. Location of lesions was not described. Follow‐up was for five years. The author of the abstract was contacted and unpublished data were obtained. </p> <section id="CD003412-sec-0239"> <h6 class="title">Primary outcomes</h6> <section id="CD003412-sec-0240"> <p><b>Recurrence</b></p> <p>ECT may result in more recurrences (10.5%, 4/38 versus 2.8%, 1/36, respectively) than SE at three years (RR 3.79, 95% CI 0.44 to 32.32; <a href="./references#CD003412-fig-0073" title="">Analysis 33.1</a>) and 5 years (13.5%, 5/37 versus 2.8%, 1/36) (RR 4.86, 95% CI 0.60 to 39.63; <a href="./references#CD003412-fig-0074" title="">Analysis 33.2</a>). We rated the certainty of evidence for both these outcomes as low rating down two levels for the very wide 95% CI that includes the possibility of important benefit or harm. </p> </section> <section id="CD003412-sec-0241"> <p><b>Cosmetic outcome (participant‐ and observer‐rated)</b></p> <p>When assessed with the Vancouver scar scale by four blinded plastic surgeons 18 months after treatment, the authors reported there was no significant difference between ECT and SE; however the raw data were not available for further analysis. </p> </section> </section> </section> </section> <section id="CD003412-sec-0242"> <h4 class="title">9. Ingenol mebutate</h4> <section id="CD003412-sec-0243"> <h5 class="title">Day 1 and 2 versus day 1 and 8 regimens</h5> <p>One study (<a href="./references#CD003412-bbs2-0044" title="SillerG , RosenR , FreemanM , WelburnP , KatsamasJ , OgbourneSM . PEP005 (Ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomised phase IIa trial. Australasian Journal of Dermatology2010;51(2):99-105. [CENTRAL: CN-00771587] ">Siller 2010</a>) randomised 60 participants with sBCC to one of two different treatment regimens (days 1 and 2 dosing or days 1 and 8 dosing) and then randomised again within each group to treatment with one of three different concentrations of ingenol mebutate gel (0.0025%, 0.01% and 0.05%), or vehicle. The main outcome measures were the incidence and severity of adverse effects and local skin responses. </p> <section id="CD003412-sec-0244"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0245"> <p><b>Pain during and after treatment</b></p> <p>Intensity of pain data were not presented. Within the adverse effects data, only two patients reported application site pain and these were in the highest dose ingenol group (0.05%) in the days 1 and 8 regimen. See <a href="#CD003412-tbl-0006">Table 1</a> for further pain data from this study. </p> </section> <section id="CD003412-sec-0246"> <p><b>Early treatment failure</b></p> <p>At week‐12, in the day 1 and 2 dosing group, ingenol 0.05% gel probably results in fewer early treatment failures than vehicle gel (37.5%, 3/8 versus 100%, 6/6, respectively) (RR 0.42, 95% CI 0.18 to 0.97; <a href="./references#CD003412-fig-0075" title="">Analysis 34.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision. For the lower ingenol concentration in the day 1 and 2 dosing group, as well as all concentrations in the day 1 and 8 dosing group, there may be little to no difference between ingenol and vehicle (see analysis <a href="./references#CD003412-fig-0076" title="">Analysis 35.1</a> and <a href="./references#CD003412-fig-0077" title="">Analysis 36.1</a> for RRs). We rated the certainty of evidence as low for both these outcomes, rating down for serious imprecision due to the wide 95% CIs and low numbers of participants involved. </p> </section> <section id="CD003412-sec-0247"> <p><b>Adverse effects</b></p> <p>See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from this study. </p> </section> </section> </section> <section id="CD003412-sec-0248"> <h5 class="title">Occlusion versus no occlusion</h5> <p>One study (<a href="./references#CD003412-bbs2-0047" title="RosenR , FreemanM , ZibertJR , KatsamasJ , KnudsenKM , SpelmanL . Ingenol mebutate 0.05% gel under occlusion is efficacious in treating superficial basal cell carcinoma. British Journal of Dermatology2014;171(Suppl 4):50. [CENTRAL: CN-01057057] ">Spelman 2014</a>) compared ingenol mebutate 0.05% gel given on three consecutive days with full occlusion (aluminium disk dressing) versus semi‐occlusion (Opsite™ Disk) and no occlusion in 75 participants with sBCC (4 mm‐15 mm to diameter) on the trunk/extremities in a phase two RCT with four months follow‐up. </p> <section id="CD003412-sec-0249"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0250"> <p><b>Early treatment failure</b></p> <p>At four months, ingenol with full occlusion may reduce the risk of early treatment failures compared to no occlusion (29.6%, 8/27 versus 45.5%, 11/24, respectively) (RR 0.65, 95% CI 0.31 to 1.34; <a href="./references#CD003412-fig-0077" title="">Analysis 36.1</a>), and semi‐occlusion may increase the risk of early treatment failures compared to no occlusion (62.5%, 15/24 versus 45.8%, 11/24, respectively) (RR 1.36, 95% CI 0.80 to 2.33; <a href="./references#CD003412-fig-0077" title="">Analysis 36.1</a>). We rated the certainty of evidence as low for both these outcomes, rating down for serious imprecision due to the wide 95% CI and low numbers of participants involved. </p> </section> <section id="CD003412-sec-0251"> <p><b>Adverse effects</b></p> <p>The percentage of participants with AEs were similar across all three treatment groups. The most common AE was application site pain. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from this study. </p> </section> </section> </section> </section> <section id="CD003412-sec-0252"> <h4 class="title">10. Solasodine glycosides</h4> <p>One study (<a href="./references#CD003412-bbs2-0035" title="PunjabiS , CookLJ , KerseyP , MarksR , CerioR . Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicentre study. International Journal of Dermatology2008;47(1):78-82. [CENTRAL: CN-00629144] PunjabiS , CookLJ , KerseyP , MarksR , FinlayA , SharpG , et al. A double-blind, multicentre parallel group study of BEC-5 cream in basal cell carcinoma. European Academy of Dermatology &amp; Venereology2000;14(Suppl 1):49. [CENTRAL: CN-01616931] ">Punjabi 2008</a>) of 94 participants compared solasodine glycoside (Zycure) cream to matching vehicle in BCCs at least 0.5cm diameter (excluding morphoeic BCC). Lesions were treated twice daily under occlusion with solasodine glycoside cream or vehicle for 8 weeks. </p> <section id="CD003412-sec-0253"> <h5 class="title">Primary outcomes</h5> <section id="CD003412-sec-0254"> <h6 class="title">Cosmetic outcome (participant‐ and observer‐rated)</h6> <p>Cosmetic outcome was evaluated by an assessment of scarring during the follow‐up (categorized as none, mild, moderate, severe). The authors reported there was no statistically significant difference between the treatment groups; however, raw data were not presented for further analysis. </p> </section> </section> <section id="CD003412-sec-0255"> <h5 class="title">Secondary outcomes</h5> <section id="CD003412-sec-0256"> <h6 class="title">Early treatment failure</h6> <p>At the end of 8 weeks of treatment, a 2 mm punch biopsy was performed on all lesions. Solasodine glycoside cream probably reduces the risk of early treatment failures compared to vehicle (33.9%, 21/62 versus 75%, 24/32, respectively) (RR 0.45, 95% CI 0.30 to 0.67; <a href="./references#CD003412-fig-0078" title="">Analysis 37.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (only one study). </p> </section> <section id="CD003412-sec-0257"> <h6 class="title">Adverse effects</h6> <p>No major treatment‐related adverse effects were reported. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from this study. </p> </section> </section> </section> <section id="CD003412-sec-0258"> <h4 class="title">11. Topical valproic acid and tazarotene</h4> <p>One study (<a href="./references#CD003412-bbs2-0001" title="2005-001474-27. A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001474-27/results (first accessed 12 August 2016). ">2005‐001474‐27</a>) randomised 50 participants (subtype not stated, located anywhere except eyelids, nose, lips, anogenital) to topical valproic acid (Baceca® 3% gel) and tazarotene (Zorac® 0.1% gel) against placebo gel and tazarotene. Treatment lasted eight weeks and involved applying valproic acid or placebo gel before bedtime and 15 to 30 minutes later tazarotene was applied. Participants in both groups that did not show a complete clearance after eight weeks, completed a further eight weeks of treatment with valproic acid and tazarotene (cross‐over design). </p> <section id="CD003412-sec-0259"> <h5 class="title">Early treatment failure</h5> <p>At three months follow‐up, there may be slightly fewer early treatment failures in the valproic acid gel and tazarotene group compared with the placebo gel and tazarotene group (31%, 8/25 versus 52%, 13/25, respectively) (RR 0.62, 95% CI 0.31 to 1.22; <a href="./references#CD003412-fig-0079" title="">Analysis 38.1</a>). We rated the certainty of evidence as low, rating down one level for serious imprecision ( wide 95% CI that indicates important benefit and slight harm). </p> </section> <section id="CD003412-sec-0260"> <h5 class="title">Adverse effects</h5> <p>Erythema, itching, ulceration and localised pain were the most frequently reported AEs across both groups. There were no drug‐related severe AEs. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from this study. </p> </section> </section> <section id="CD003412-sec-0261"> <h4 class="title">12. Topical diclofenac gel and calcitriol ointment (vitamin D)</h4> <p>One study (<a href="./references#CD003412-bbs2-0010" title="BrinkhuizenT , FrenckenKJ , NelemansPJ , HoffML , Kelleners-SmeetsNW , Zur HausenA , et al. The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): a phase II, randomized controlled trial. Journal of the American Academy of Dermatology2016;75(1):126-34. [CENTRAL: CN-01342883] [DOI: 10.1016/j.jaad.2016.01.050]">Brinkhuizen 2016</a>) of 128 participants (64 sBCC and 64 nBCC) compared diclofenac 3% gel (Solaraze<sup>TM</sup>), calcitriol 3 μg/g ointment (Silkis®), a combination of both or no topical treatment. The active treatments were applied twice daily under occlusion for eight weeks. We have not included the control arm comparisons in our analyses. </p> <section id="CD003412-sec-0262"> <h5 class="title">Secondary outcomes</h5> <section id="CD003412-sec-0263"> <h6 class="title">Early treatment failure</h6> <p>Early treatment failure was measured at eight weeks of treatment. Diclofenac gel monotherapy may reduce the risk of early treatment failures compared to calcitriol ointment (53.3%, 16/30 versus 97%, 31/32, respectively) (RR of 0.55, 95% CI 0.39 to 0.77; <a href="./references#CD003412-fig-0080" title="">Analysis 39.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (only one study). </p> <p>There may be little to no difference between diclofenac gel monotherapy and combination treatment of diclofenac and calcitriol on the risk of early treatment failures (53.3%, 16/30 versus 61.3%, 19/31, respectively) (RR 0.87, 95% CI 0.56 to 1.35; <a href="./references#CD003412-fig-0081" title="">Analysis 40.1</a>). We rated the certainty of evidence as low, rating down for very serious imprecision due to the 95% CI that indicates important benefit and harm. </p> <p>Calcitriol ointment may increase the risk of early treatment failures compared to combination treatment of diclofenac and calcitriol (97%, 31/32 versus 61.3%, 19/31, respectively) (RR 1.58, 95% CI 1.19 to 2.11; <a href="./references#CD003412-fig-0082" title="">Analysis 41.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (only one study). </p> </section> <section id="CD003412-sec-0264"> <h6 class="title">Adverse effects</h6> <p>In all intervention groups mild to moderate application‐site reactions were reported. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from this study. </p> </section> </section> </section> <section id="CD003412-sec-0265"> <h4 class="title">13. Pulsed dye laser (PDL)</h4> <section id="CD003412-sec-0266"> <h5 class="title">One session versus two sessions</h5> <p>One small pilot study (<a href="./references#CD003412-bbs2-0003" title="Abd El-NabyNM , El-FarNN , Al-Shenawy HA , ElshwadfySE , KouraAA . Pulsed dye laser in the treatment of basal cell carcinoma: a single session versus two sessions–a randomized controlled trial. Indian Journal of Dermatology, Venereology, and Leprology2019;85(5):475. ">Abd El‐Naby 2019</a>) randomised 22 participants with 22 BCCs (17 nBCCs, three sBCC, one pigmented BCC and one cystic BCC located on the face/scalp) to treatment with one or two sessions (two weeks apart) of PDL (595 nm, fluency 7 J/cm<sup>2</sup>, pulse width 20 ms, rate 1 Hz with 4 mm margins) with six months follow‐up. </p> <section id="CD003412-sec-0267"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0268"> <p><b>Early treatment failure</b></p> <p>Four weeks after the last treatment all lesions were excised and early treatment failure rates were very high. Two sessions of PDL may slightly reduce the rate of early treatment failures compared to one session of PDL (81.9%, 9/11 versus 100%, 11/11, respectively) (RR 0.83, 95% CI 0.60 to 1.13; <a href="./references#CD003412-fig-0083" title="">Analysis 42.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision ( small numbers involved in study and wide 95% CI). </p> </section> <section id="CD003412-sec-0269"> <p><b>Adverse effects</b></p> <p>The paper reported the technique was tolerable and safe with minimal side effects but no further data were given. </p> </section> </section> </section> <section id="CD003412-sec-0270"> <h5 class="title">7mm spot size single pulses versus 10 mm spot size stacked pulses</h5> <p>One small pilot study (<a href="./references#CD003412-bbs2-0051" title="TranHT , LeeRA , OganesyanG , JiangSB . Single treatment of non-melanoma skin cancers using a pulsed-dye laser with stacked pulses. Lasers in Surgery and Medicine2012;44(6):459-67. [CENTRAL: CN-00969795] ">Tran 2012</a>) randomised 17 participants with 20 BCCs (13 nBCCs, 6 multifocal BCCs, one superficial BCC located on trunk/limbs) into three treatment groups: a control (no treatment) group; PDL (595 nm, fluency 15 J/cm<sup>2</sup>, pulse width 3 ms) using 7 mm spot size and single pulses and PDL (595 nm, fluency 7.5 J/cm<sup>2</sup>, pulse width 3 ms) using 10 mm spot size and double‐stacked pulses. All lesions were treated with a 4 mm margin of clinically normal skin. The rationale for increasing spot size and stacking pulses is to increase the depth of penetration of the laser. Three SCC‐in‐situ lesions were also treated and we have excluded these from our analyses. We have not analysed the control group data as no placebo/sham treatment was given. </p> <section id="CD003412-sec-0271"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0272"> <p><b>Early treatment failure</b></p> <p>Six weeks after treatment, all treated lesions were excised. PDL with a 10 mm spot‐size and stacked pulses may reduce early treatment failure rates compared to PDL with a 7 mm spot‐size and single pulses (28.6%, 2/7 versus 85.7%, 6/7, respectively) (RR 0.33, 95% CI 0.10 to 1.12; <a href="./references#CD003412-fig-0084" title="">Analysis 43.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (small numbers involved in study and wide 95% CI). </p> </section> <section id="CD003412-sec-0273"> <p><b>Adverse effects</b></p> <p>Mild scarring occurred in both treatment arms and by five months post‐treatment hypopigmentation was noted. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from this study. </p> </section> </section> </section> <section id="CD003412-sec-0274"> <h5 class="title">PDL versus control (sham laser or no treatment)</h5> <p>One study (<a href="./references#CD003412-bbs2-0025" title="KarsaiS , FriedlH , BuhckH , JüngerM , PoddaM . The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: Outcome of a double-blind randomized placebo-controlled trial. British Journal of Dermatology2015;172(3):677-83. [CENTRAL: CN-01068975] ">Karsai 2015</a>) randomised 39 participants (100 sBCC on trunk/extremities) to PDL (wavelength 595 nm; fluence 8 J cm<sup>2</sup>; pulse duration 0.5 ms; spot size 10 mm) or sham treatment with six months follow‐up. A total of four treatment sessions at three‐week intervals were conducted by a dermatologist experienced in laser therapy. Another small pilot study (<a href="./references#CD003412-bbs2-0016" title="EimpunthS , OganesyanG , HammanMS , LeeRA , JiangSI , KimSS . Effectiveness of a 595-nm pulsed dye laser for the treatment of basal cell carcinoma using 1 stacked-pulse session. Journal of the American Academy of Dermatology2014;70(5 (S1)):AB134. [CENTRAL: CN-01057471] ">Eimpunth 2014</a>) randomised 24 participants (24 sBCC or nBCC) to PDL or no treatment. The PDL treatment was one session of double‐stacked pulses of PDL using 10 mm spot size, 3 ms pulse width and a fluence of 7.5 J/cm<sup>2</sup> with a 6 mm margin of normal skin around the clinically apparent tumour also treated. Lesions were all subsequently excised and histologically assessed. </p> <section id="CD003412-sec-0275"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0276"> <p><b>Pain during and after treatment</b></p> <p>Pain was recorded on VAS (0‐10) during treatment. Data presented did not allow for analysis; however, the authors reported that the maximum median score for PDL was 4/10 and for sham was 0/10. See <a href="#CD003412-tbl-0006">Table 1</a> for further pain data from this study. </p> </section> <section id="CD003412-sec-0277"> <p><b>Early treatment failure</b></p> <p>At six months, PDL probably reduces the risk of early treatment failures compared to sham laser (21.4%, 12/56 versus 95%, 42/44, respectively) (RR 0.22, 95% CI 0.14 to 0.37; <a href="./references#CD003412-fig-0085" title="">Analysis 44.1</a>). We rated the certainty of evidence as moderate, rating down for imprecision (only one study). PDL may improve the risk of early treatment failure compared to no treatment RR 0.36, 95% CI 0.15 to 0.86; <a href="./references#CD003412-fig-0086" title="">Analysis 45.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision due to wide CI and small sample size. </p> </section> <section id="CD003412-sec-0278"> <p><b>Adverse effects</b></p> <p>The main AEs in the PDL group were crusts, hyper‐ and hypo‐ pigmentation. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from this study. </p> </section> </section> </section> </section> <section id="CD003412-sec-0279"> <h4 class="title">14. Intralesional interferon therapy</h4> <p>Four trials met our inclusion criteria comparing different dosages of interferon and placebo. There were no active comparator studies. </p> <section id="CD003412-sec-0280"> <h5 class="title">Interferon versus placebo injections</h5> <p>One study (<a href="./references#CD003412-bbs2-0013" title="CornellRC , GreenwayHT , TuckerSB , EdwardsL , AshworthS , VanceJC , et al. Intralesional interferon therapy for basal cell carcinoma. Journal of the American Academy of Dermatology1990;23(4 Pt 1):694-700. [CENTRAL: CN-00071018] ">Cornell 1990</a>) of 165 participants (sBCC and nBCC) compared interferon alpha‐2b (1.5 million units three times weekly for three weeks) against vehicle with one‐year follow‐up. Patients were randomised in a 3:1 ratio, interferon:placebo. Another study (<a href="./references#CD003412-bbs2-0037" title="RogozinskiTT , JablonskaS , BrzoskaIM , WohrC , GausW . Intralesional treatment with recombinant interferon beta is an effective alternative for the treatment of basal cell carcinoma. Double-blind, placebo-controlled study. [Doogniskowe podawanie rekombinantowego interferonu beta. Skuteczna alternatywa w leczeniu basalimoma (wyniki podwojnie slepej proby)]. Przeglad Dermatologiczny1997;84(3):259-63. [CENTRAL: CN-00193051] ">Rogozinski 1997</a>) compared recombinant interferon beta (1 million units three times weekly for three weeks) compared to placebo in 35 participants (subtype, size and location of BCC not reported). </p> <section id="CD003412-sec-0281"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0282"> <p><b>Early treatment failure</b></p> <p>Based on the <a href="./references#CD003412-bbs2-0013" title="CornellRC , GreenwayHT , TuckerSB , EdwardsL , AshworthS , VanceJC , et al. Intralesional interferon therapy for basal cell carcinoma. Journal of the American Academy of Dermatology1990;23(4 Pt 1):694-700. [CENTRAL: CN-00071018] ">Cornell 1990</a> study, when measured at week 20, interferon alpha‐2b probably reduces the risk of early treatment failures compared to intralesional placebo (14.2%, 17/120 versus 71.4%, 30/42, respectively) (RR 0.20, 95% CI 0.12 to 0.32; <a href="./references#CD003412-fig-0087" title="">Analysis 46.1</a>). We rated the certainty of evidence as moderate, rating down for imprecision (only one study). Based on the <a href="./references#CD003412-bbs2-0037" title="RogozinskiTT , JablonskaS , BrzoskaIM , WohrC , GausW . Intralesional treatment with recombinant interferon beta is an effective alternative for the treatment of basal cell carcinoma. Double-blind, placebo-controlled study. [Doogniskowe podawanie rekombinantowego interferonu beta. Skuteczna alternatywa w leczeniu basalimoma (wyniki podwojnie slepej proby)]. Przeglad Dermatologiczny1997;84(3):259-63. [CENTRAL: CN-00193051] ">Rogozinski 1997</a> study, interferon beta probably reduces the risk of early treatment failures compared to intralesional placebo (53%, 8/15 versus 100%, 18/18) (RR 0.55, 95% CI 0.34 to 0.87; <a href="./references#CD003412-fig-0088" title="">Analysis 47.1</a>). We rated the certainty of evidence as moderate, rating down for imprecision (only one study). </p> </section> <section id="CD003412-sec-0283"> <p><b>Adverse effects</b></p> <p>In the <a href="./references#CD003412-bbs2-0013" title="CornellRC , GreenwayHT , TuckerSB , EdwardsL , AshworthS , VanceJC , et al. Intralesional interferon therapy for basal cell carcinoma. Journal of the American Academy of Dermatology1990;23(4 Pt 1):694-700. [CENTRAL: CN-00071018] ">Cornell 1990</a> study, influenza‐like symptoms occurred more commonly in the interferon‐treated group than the vehicle group. In the <a href="./references#CD003412-bbs2-0037" title="RogozinskiTT , JablonskaS , BrzoskaIM , WohrC , GausW . Intralesional treatment with recombinant interferon beta is an effective alternative for the treatment of basal cell carcinoma. Double-blind, placebo-controlled study. [Doogniskowe podawanie rekombinantowego interferonu beta. Skuteczna alternatywa w leczeniu basalimoma (wyniki podwojnie slepej proby)]. Przeglad Dermatologiczny1997;84(3):259-63. [CENTRAL: CN-00193051] ">Rogozinski 1997</a> study, inflammation at the injection site was found in 11 out of 16 participants in the treatment group and four out of 18 receiving placebo. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from these studies. </p> </section> </section> </section> <section id="CD003412-sec-0284"> <h5 class="title">Interferon alpha‐2a and interferon alpha‐2b versus single interferon</h5> <p>One study (<a href="./references#CD003412-bbs2-0004" title="AlpsoyE , YikmazE , BasaranE , YazarS . Comparison of the effects of intralesional interferon alfa-1a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. Journal of Dermatology1996;23(6):394-6. [CENTRAL: CN-00127615] ">Alpsoy 1996</a>) compared interferon alpha‐2a, interferon alpha‐2b or both interferon alpha‐2a and interferon alpha‐2b in 45 participants (sBCC, nBCC and morphoeic BCCs located on the head and trunk) with two years follow‐up. </p> <section id="CD003412-sec-0285"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0286"> <p><b>Early treatment failure</b></p> <p>Interferon alpha‐2a and ‐2b may slightly reduce the risk of early treatment failure compared to interferon alpha‐2a (RR 0.80, 95% CI 0.27 to 2.41; <a href="./references#CD003412-fig-0089" title="">Analysis 48.1</a>). Interferon alpha‐2a and ‐2b may slightly reduce the risk of early treatment failure compared to interferon alpha‐2B (RR 0.80, 95% CI 0.27 to 2.41; <a href="./references#CD003412-fig-0090" title="">Analysis 49.1</a>). There may be no difference in risk of early treatment failures when comparing interferon alpha‐2b with interferon alpha‐2a (RR 1.0, 95% CI 0.36 to 2.75; <a href="./references#CD003412-fig-0091" title="">Analysis 50.1</a>). We rated the certainty of evidence as low for all these comparisons due to very serious imprecision (very wide 95% CI that indicated important benefit or harm). </p> </section> <section id="CD003412-sec-0287"> <p><b>Adverse effects</b></p> <p>Pain was experienced at the injection site and all participants had influenza‐like symptoms (fever, chills, headaches, fatigue, myalgia) especially within the first two weeks after the initiation of therapy. See <a href="#CD003412-tbl-0006">Table 1</a> and <a href="#CD003412-tbl-0007">Table 2</a> and for further pain data and AE data from this study. </p> </section> </section> </section> <section id="CD003412-sec-0288"> <h5 class="title">Sustained release interferon alpha‐2b</h5> <p>One study (<a href="./references#CD003412-bbs2-0014" title="EdwardsL , TuckerSB , PeredniaD , SmilesKA , TaylorEL , TannerDJ , et al. The effects of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinoma. Archives of Dermatology1990;126(8):1029-32. [CENTRAL: CN-00069443] ">Edwards 1990</a>) compared different dosing schedules of sustained release interferon (protamine zinc chelate interferon alpha‐2b) in 65 participants with nBCC and sBCC (location not reported). Participants were randomised to a single dose of 10 million international units (IU) versus the same dose weekly for three weeks. </p> <section id="CD003412-sec-0289"> <h6 class="title">Secondary outcomes</h6> <section id="CD003412-sec-0290"> <p><b>Early treatment failure</b></p> <p>The three times weekly injection treatment group probably reduces the risk of early treatment failures compared with the single dose arm (20%, 6/30 versus 48.5%, 16/33, respectively) (RR 0.41, 95% CI 0.19 to 0.92; <a href="./references#CD003412-fig-0092" title="">Analysis 51.1</a>). We rated the certainty of evidence as moderate rating down for serious imprecision (wide 95% CI and only one study). </p> </section> <section id="CD003412-sec-0291"> <p><b>Adverse effects</b></p> <p>All participants experienced at least one adverse reaction. Side effects were similar for both single and repeated dosage groups, and were those common to interferon. See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from this study. </p> </section> </section> </section> </section> <section id="CD003412-sec-0292"> <h4 class="title">15. Topical Sinecatechins</h4> <p>One study (<a href="./references#CD003412-bbs2-0026" title="KesselsJ , VoetenL , NelemansP , CleutjensJ , HillenLM , MosterdK , et al. Topical sinecatechins, 10%, ointment for superficial basal cell carcinoma: A randomized clinical trial. JAMA Dermatology2017;153(10):1061-3. [CENTRAL: CN-01420948] ">Kessels 2017</a>) compared treatment with 10% sinecatechin ointment (Veregen®) with vehicle in 42 participants with sBCC over eight weeks follow‐up. </p> <section id="CD003412-sec-0293"> <h5 class="title">Secondary outcomes</h5> <section id="CD003412-sec-0294"> <h6 class="title">Early treatment failure</h6> <p>There is probably little to no difference in the risk of early treatment failures between topical sinecatechin ointment (95.2%, 20/21) and placebo (90.5%, 19/21) (RR 1.05, 95% CI 0.89 to 1.25; <a href="./references#CD003412-fig-0093" title="">Analysis 52.1</a>). We rated the certainty of evidence as moderate, rating down for serious imprecision (only one study). </p> </section> <section id="CD003412-sec-0295"> <h6 class="title">Adverse effects</h6> <p>See <a href="#CD003412-tbl-0007">Table 2</a> for further AE data from this study. </p> </section> </section> </section> <section id="CD003412-sec-0296"> <h4 class="title">Summary of pain data</h4> <p>Pain was reported on a variety of different scales, for example visual analogue and three point scales. Occasionally, qualitative data was captured; pain could be reported as burning, stinging, throbbing, irritation, lingering, tingling, tenderness or blinking discomfort. Pain was rarely reported distal to the treatment site for example pharyngolaryngeal pain after ingenol mebutate gel usage (<a href="./references#CD003412-bbs2-0044" title="SillerG , RosenR , FreemanM , WelburnP , KatsamasJ , OgbourneSM . PEP005 (Ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomised phase IIa trial. Australasian Journal of Dermatology2010;51(2):99-105. [CENTRAL: CN-00771587] ">Siller 2010</a>). Depending on the study, patients could be asked to report any pain during or after treatment; this could be as an isolated assessment or could be done at intervals. Burning was the most common type of pain reported with PDT (<a href="./references#CD003412-bbs2-0017" title="EzughahFI , DaweRS , IbbotsonSH , FlemingCJ . A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment2008;19(2):111-7. [CENTRAL: CN-00706567] ">Ezughah 2008</a>; <a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a>; <a href="./references#CD003412-bbs2-0018" title="FoleyP , FreemanM , MenterA , SillerG , El-AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] FoleyP , FreemanM , SillerG , GebauerK , MurrellD , BarnetsonR , et al. A phase III randomized study comparing photodynamic therapy (PDT) using methyl aminolevulinate or placebo cream in nodular basal cell carcinoma (NBCC). Journal of the European Academy of Dermatology and Venereology2003;17(Suppl 3):231. [CENTRAL: CN-00478536] ">Foley 2009a</a> and <a href="./references#CD003412-bbs2-0019" title="FoleyP , FreemanM , MenterA , SillerG , El‐AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] TopeWD , MenterA , El AzharyR , SotoP . A comparison of topical MAL-PDT versus placebo-PDT in nodular basal cell carcinoma: results of a North American study. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology; 2005 Sep 28-Oct 03; Kuala Lumpur, Malaysia. 2005:376. [CENTRAL: CN-00602617] ">Foley 2009b</a>). Some authors reported supplying pre‐treatment analgesia before PDT (Choi 2016, <a href="./references#CD003412-bbs2-0023" title="HaakCS , Togsverd-BoK , Thaysen-PetersenD , WulfHC , PaaschU , AndersonRR , et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas - a randomized clinical trial. British Journal of Dermatology2015;172(1):215-22. [CENTRAL: CN-01039978] ">Haak 2015</a>) or SE (<a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a>). Others reported that physical measures to induce analgesia during PDT were permitted (<a href="./references#CD003412-bbs2-0033" title="MortonCA , DominicusR , RadnyP , DirschkaT , HauschildA , ReinholdU , et al. A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). British Journal of Dermatology2018;179(2):309-19. [CENTRAL: CN-02000788] [PMID: 29432644]">Morton 2018</a>; <a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a>; <a href="./references#CD003412-bbs2-0052" title="WangI , BendsoeN , KlintebergCA , EnejderAM , Andersson‐EngelsS , SvanbergS , et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. British Journal of Dermatology2000;144(4):832-40. [CENTRAL: CN-00326537] ">Wang 2001</a>). Post‐treatment analgesia was occasionally permitted after SE (<a href="./references#CD003412-bbs2-0008" title="Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , MillerPS , et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncology2014;15(1):96-105. [CENTRAL: CN-00959373] WilliamsHC , Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. Journal of Investigative Dermatology2017;137(3):614-9. [CENTRAL: CN-01340067] [EMBASE: 614596349]">Bath‐Hextall 2014</a>), imiquimod, radiotherapy (<a href="./references#CD003412-bbs2-0020" title="Garcia-MartinE , Gil-ArribasLM , IdoipeM , AlfaroJ , PueyoV , PabloLE , et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. British Journal of Ophthalmology2011;95(10):1393-6. [CENTRAL: CN-00801928] ">Garcia‐Martin 2011</a>) and sinecatechin applications (<a href="./references#CD003412-bbs2-0026" title="KesselsJ , VoetenL , NelemansP , CleutjensJ , HillenLM , MosterdK , et al. Topical sinecatechins, 10%, ointment for superficial basal cell carcinoma: A randomized clinical trial. JAMA Dermatology2017;153(10):1061-3. [CENTRAL: CN-01420948] ">Kessels 2017</a>). Pain and tenderness during treatment with imiquimod was expected, and participants were frequently allowed a rest period if needed in order to complete the treatment course (<a href="./references#CD003412-bbs2-0008" title="Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , MillerPS , et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncology2014;15(1):96-105. [CENTRAL: CN-00959373] WilliamsHC , Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. Journal of Investigative Dermatology2017;137(3):614-9. [CENTRAL: CN-01340067] [EMBASE: 614596349]">Bath‐Hextall 2014</a>; <a href="./references#CD003412-bbs2-0017" title="EzughahFI , DaweRS , IbbotsonSH , FlemingCJ . A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment2008;19(2):111-7. [CENTRAL: CN-00706567] ">Ezughah 2008</a>; <a href="./references#CD003412-bbs2-0021" title="GeisseJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating superficial BCC. In: The 8th World Congress on Cancer of the Skin; 2001 July 18-21; Zurich, Switzerland. 2001:P58. [CENTRAL: CN-00520431] GeisseJK , RichP , PandyaA , GrossK , AndresK , GinkelA , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a randomized, vehicle-controlled study. Journal of the American Academy of Dermatology2002;47(3):390-8. [CENTRAL: CN-00390933] ">Geisse 2002</a>; <a href="./references#CD003412-bbs2-0022" title="GeisseJ , CaroI , LindholmJ , GolitzL , StamponeP , OwensM . Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology2004;50(5):722-33. [CENTRAL: CN-00469536] ">Geisse 2004</a>; <a href="./references#CD003412-bbs2-0042" title="ShumackS , MarksR , AmiesM , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks treating nodular BCC. 8th World Congress on Cancers of the Skin, Zurich, Switzerland2001;-:p55. [CENTRAL: CN-00849091] ShumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , SchroeterA , et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002a</a>; <a href="./references#CD003412-bbs2-0043" title="RobinsonJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating nodular BCC. 8th World Congress on Cancer of the Skin, Zurich, Switzerland2001;-(-):p57. [CENTRAL: CN-00849091] SchumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , Schroeter, A et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002b</a>; <a href="./references#CD003412-bbs2-0048" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. In: 8th World Congress on cancers of the skin, Zurich, Switzerland. 2001:61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] [PMID: 12452875]">Sterry 2002a</a> and <a href="./references#CD003412-bbs2-0049" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. 8th World Congress on cancers of the skin, Zurich, Switzerland2001;-(-):p61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] ">Sterry 2002b</a>) with occasional participants unable to complete the treatment due to pain despite this (<a href="./references#CD003412-bbs2-0017" title="EzughahFI , DaweRS , IbbotsonSH , FlemingCJ . A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment2008;19(2):111-7. [CENTRAL: CN-00706567] ">Ezughah 2008</a>; <a href="./references#CD003412-bbs2-0043" title="RobinsonJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating nodular BCC. 8th World Congress on Cancer of the Skin, Zurich, Switzerland2001;-(-):p57. [CENTRAL: CN-00849091] SchumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , Schroeter, A et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002b</a>). In total five patients discontinued treatment due to pain; four after imiquimod application (<a href="./references#CD003412-bbs2-0017" title="EzughahFI , DaweRS , IbbotsonSH , FlemingCJ . A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment2008;19(2):111-7. [CENTRAL: CN-00706567] ">Ezughah 2008</a>; <a href="./references#CD003412-bbs2-0042" title="ShumackS , MarksR , AmiesM , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks treating nodular BCC. 8th World Congress on Cancers of the Skin, Zurich, Switzerland2001;-:p55. [CENTRAL: CN-00849091] ShumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , SchroeterA , et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002a</a>; <a href="./references#CD003412-bbs2-0043" title="RobinsonJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating nodular BCC. 8th World Congress on Cancer of the Skin, Zurich, Switzerland2001;-(-):p57. [CENTRAL: CN-00849091] SchumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , Schroeter, A et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002b</a>) and one after MAL‐PDT (<a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a>). For further details see <a href="#CD003412-tbl-0006">Table 1</a> and <a href="#CD003412-tbl-0007">Table 2</a>. </p> </section> <section id="CD003412-sec-0297"> <h4 class="title">Summary of adverse effects data</h4> <p>Patient‐reported adverse effects did not always align with those reported by the observer (<a href="./references#CD003412-bbs2-0015" title="EigentlerTK , KaminA , WeideBM , BreuningerH , CaroliUM , MöhrleM , et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. Journal of the American Academy of Dermatology2007;57(4):616-21. [CENTRAL: CN-00610509] ">Eigentler 2007</a>). The most commonly reported adverse effects were due to application site reactions seen in the non‐surgical interventions. These manifested as localised inflammation resulting in: itching, weeping, crusting, scabbing, flaking, erythema, blistering, vesicles, eschar, erosions, burning, pain, purpura or swelling. Localised inflammation was reported in 13 of the 14 papers on imiquimod usage (<a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a>; <a href="./references#CD003412-bbs2-0008" title="Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , MillerPS , et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncology2014;15(1):96-105. [CENTRAL: CN-00959373] WilliamsHC , Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. Journal of Investigative Dermatology2017;137(3):614-9. [CENTRAL: CN-01340067] [EMBASE: 614596349]">Bath‐Hextall 2014</a>; <a href="./references#CD003412-bbs2-0015" title="EigentlerTK , KaminA , WeideBM , BreuningerH , CaroliUM , MöhrleM , et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. Journal of the American Academy of Dermatology2007;57(4):616-21. [CENTRAL: CN-00610509] ">Eigentler 2007</a>; <a href="./references#CD003412-bbs2-0017" title="EzughahFI , DaweRS , IbbotsonSH , FlemingCJ . A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment2008;19(2):111-7. [CENTRAL: CN-00706567] ">Ezughah 2008</a>; <a href="./references#CD003412-bbs2-0020" title="Garcia-MartinE , Gil-ArribasLM , IdoipeM , AlfaroJ , PueyoV , PabloLE , et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. British Journal of Ophthalmology2011;95(10):1393-6. [CENTRAL: CN-00801928] ">Garcia‐Martin 2011</a>; <a href="./references#CD003412-bbs2-0021" title="GeisseJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating superficial BCC. In: The 8th World Congress on Cancer of the Skin; 2001 July 18-21; Zurich, Switzerland. 2001:P58. [CENTRAL: CN-00520431] GeisseJK , RichP , PandyaA , GrossK , AndresK , GinkelA , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a randomized, vehicle-controlled study. Journal of the American Academy of Dermatology2002;47(3):390-8. [CENTRAL: CN-00390933] ">Geisse 2002</a>; <a href="./references#CD003412-bbs2-0022" title="GeisseJ , CaroI , LindholmJ , GolitzL , StamponeP , OwensM . Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology2004;50(5):722-33. [CENTRAL: CN-00469536] ">Geisse 2004</a>; <a href="./references#CD003412-bbs2-0031" title="MarksR , GebauerK , ShumackS , AmiesM , BrydenJ , FoxTL , et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicentre 6-week dose-response trial. Journal of the American Academy of Dermatology2001;44(5):807-13. [CENTRAL: CN-00326531] ">Marks 2001</a>; <a href="./references#CD003412-bbs2-0041" title="SchulzeHJ , CribierB , RequenaL , ReifenbergerJ , FerrandizC , DiezG , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. British Journal of Dermatology2005;152(5):939-47. [CENTRAL: CN-00513173] ">Schulze 2005</a>; <a href="./references#CD003412-bbs2-0042" title="ShumackS , MarksR , AmiesM , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks treating nodular BCC. 8th World Congress on Cancers of the Skin, Zurich, Switzerland2001;-:p55. [CENTRAL: CN-00849091] ShumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , SchroeterA , et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002a</a>; <a href="./references#CD003412-bbs2-0043" title="RobinsonJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating nodular BCC. 8th World Congress on Cancer of the Skin, Zurich, Switzerland2001;-(-):p57. [CENTRAL: CN-00849091] SchumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , Schroeter, A et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002b</a>; <a href="./references#CD003412-bbs2-0048" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. In: 8th World Congress on cancers of the skin, Zurich, Switzerland. 2001:61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] [PMID: 12452875]">Sterry 2002a</a>;<a href="./references#CD003412-bbs2-0049" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. 8th World Congress on cancers of the skin, Zurich, Switzerland2001;-(-):p61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] ">Sterry 2002b</a>). </p> <p>Other treatment modalities resulting in localised inflammation include AFXL‐PDT (<a href="./references#CD003412-bbs2-0023" title="HaakCS , Togsverd-BoK , Thaysen-PetersenD , WulfHC , PaaschU , AndersonRR , et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas - a randomized clinical trial. British Journal of Dermatology2015;172(1):215-22. [CENTRAL: CN-01039978] ">Haak 2015</a>), intralesional 5‐FU (<a href="./references#CD003412-bbs2-0038" title="RomagosaR , SaapL , GivensM , SalvarreyA , HeJL , HsiaSL , et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatologic Surgery2000;26(4):338-40. [CENTRAL: CN-00296475] ">Romagosa 2000</a>), PDL (<a href="./references#CD003412-bbs2-0016" title="EimpunthS , OganesyanG , HammanMS , LeeRA , JiangSI , KimSS . Effectiveness of a 595-nm pulsed dye laser for the treatment of basal cell carcinoma using 1 stacked-pulse session. Journal of the American Academy of Dermatology2014;70(5 (S1)):AB134. [CENTRAL: CN-01057471] ">Eimpunth 2014</a>; <a href="./references#CD003412-bbs2-0025" title="KarsaiS , FriedlH , BuhckH , JüngerM , PoddaM . The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: Outcome of a double-blind randomized placebo-controlled trial. British Journal of Dermatology2015;172(3):677-83. [CENTRAL: CN-01068975] ">Karsai 2015</a>; <a href="./references#CD003412-bbs2-0051" title="TranHT , LeeRA , OganesyanG , JiangSB . Single treatment of non-melanoma skin cancers using a pulsed-dye laser with stacked pulses. Lasers in Surgery and Medicine2012;44(6):459-67. [CENTRAL: CN-00969795] ">Tran 2012</a>), radiotherapy (<a href="./references#CD003412-bbs2-0020" title="Garcia-MartinE , Gil-ArribasLM , IdoipeM , AlfaroJ , PueyoV , PabloLE , et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. British Journal of Ophthalmology2011;95(10):1393-6. [CENTRAL: CN-00801928] ">Garcia‐Martin 2011</a>), sinecatechins (<a href="./references#CD003412-bbs2-0026" title="KesselsJ , VoetenL , NelemansP , CleutjensJ , HillenLM , MosterdK , et al. Topical sinecatechins, 10%, ointment for superficial basal cell carcinoma: A randomized clinical trial. JAMA Dermatology2017;153(10):1061-3. [CENTRAL: CN-01420948] ">Kessels 2017</a>), laser/broadband light ALA‐PDT (<a href="./references#CD003412-bbs2-0046" title="SolerAM , Angell-PetersenE , WarloeT , TausjoJ , SteenHB , MoanJ , et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: A comparison of two light sources. Photochemistry and Photobiology2000;71(6):724-9. [CENTRAL: CN-00297518] ">Soler 2000</a>), tazarotene and valproic acid (<a href="./references#CD003412-bbs2-0001" title="2005-001474-27. A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001474-27/results (first accessed 12 August 2016). ">2005‐001474‐27</a>) and placebo/vehicle (<a href="./references#CD003412-bbs2-0018" title="FoleyP , FreemanM , MenterA , SillerG , El-AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] FoleyP , FreemanM , SillerG , GebauerK , MurrellD , BarnetsonR , et al. A phase III randomized study comparing photodynamic therapy (PDT) using methyl aminolevulinate or placebo cream in nodular basal cell carcinoma (NBCC). Journal of the European Academy of Dermatology and Venereology2003;17(Suppl 3):231. [CENTRAL: CN-00478536] ">Foley 2009a</a>; <a href="./references#CD003412-bbs2-0019" title="FoleyP , FreemanM , MenterA , SillerG , El‐AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] TopeWD , MenterA , El AzharyR , SotoP . A comparison of topical MAL-PDT versus placebo-PDT in nodular basal cell carcinoma: results of a North American study. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology; 2005 Sep 28-Oct 03; Kuala Lumpur, Malaysia. 2005:376. [CENTRAL: CN-00602617] ">Foley 2009b</a>; <a href="./references#CD003412-bbs2-0021" title="GeisseJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating superficial BCC. In: The 8th World Congress on Cancer of the Skin; 2001 July 18-21; Zurich, Switzerland. 2001:P58. [CENTRAL: CN-00520431] GeisseJK , RichP , PandyaA , GrossK , AndresK , GinkelA , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a randomized, vehicle-controlled study. Journal of the American Academy of Dermatology2002;47(3):390-8. [CENTRAL: CN-00390933] ">Geisse 2002</a>; <a href="./references#CD003412-bbs2-0026" title="KesselsJ , VoetenL , NelemansP , CleutjensJ , HillenLM , MosterdK , et al. Topical sinecatechins, 10%, ointment for superficial basal cell carcinoma: A randomized clinical trial. JAMA Dermatology2017;153(10):1061-3. [CENTRAL: CN-01420948] ">Kessels 2017</a>; <a href="./references#CD003412-bbs2-0044" title="SillerG , RosenR , FreemanM , WelburnP , KatsamasJ , OgbourneSM . PEP005 (Ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomised phase IIa trial. Australasian Journal of Dermatology2010;51(2):99-105. [CENTRAL: CN-00771587] ">Siller 2010</a>). </p> <p>Local wound infection or suppuration were reported after surgical treatments such as SE (<a href="./references#CD003412-bbs2-0029" title="KuijpersDI , ThissenMR , BerrettyPJ , IdelerFH , NelemansPJ , NeumannMH . Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatologic Surgery2007;33(5):579-87. [CENTRAL: CN-00588176] ThissenMR , NiemanFH , IdelerAH , BerrettyPJ , NeumannHA . Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatologic Surgery2000;26(8):759-64. [CENTRAL: CN-00298974] ">Kuijpers 2007</a>; <a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a>; <a href="./references#CD003412-bbs2-0045" title="EssersBA , DirksenCD , NiemanFH , SmeetsNW , KrekelsGA , PrinsMH , et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Archives of Dermatology2006;142(2):187-94. [CENTRAL: CN-00555278] MosterdK , KrekelsGA , NiemanFH , OstertagJU , EssersBA , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncology2008;9(12):1149-56. [CENTRAL: CN-00665334] SmeetsNW , KrekelsGA , OstertagJU , EssersBA , DirksenCD , NiemanFH , et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet2004;364(9447):1766-72. [CENTRAL: CN-00492695] Van LooE , MosterdK , KrekelsGA , RoozeboomMH , OstertagJU , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European Journal of Cancer2014;50(17):3011-20. [CENTRAL: CN-01043314] ">Smeets 2004</a>; <a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a>), cryosurgery (<a href="./references#CD003412-bbs2-0007" title="Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Methyl aminolaevulinate photodynamic therapy vs. cryotherapy in primary superficial basal cell carcinoma: results of a 36-month follow-up. British Journal of Dermatology2005;153(1):29. Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Topical methyl aminolevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. European Journal of Dermatolology2008;18(5):547-53. [CENTRAL: CN-00668120] ">Basset‐Seguin 2008</a>; <a href="./references#CD003412-bbs2-0029" title="KuijpersDI , ThissenMR , BerrettyPJ , IdelerFH , NelemansPJ , NeumannMH . Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatologic Surgery2007;33(5):579-87. [CENTRAL: CN-00588176] ThissenMR , NiemanFH , IdelerAH , BerrettyPJ , NeumannHA . Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatologic Surgery2000;26(8):759-64. [CENTRAL: CN-00298974] ">Kuijpers 2007</a>; <a href="./references#CD003412-bbs2-0052" title="WangI , BendsoeN , KlintebergCA , EnejderAM , Andersson‐EngelsS , SvanbergS , et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. British Journal of Dermatology2000;144(4):832-40. [CENTRAL: CN-00326537] ">Wang 2001</a>), cryosurgery and curettage (<a href="./references#CD003412-bbs2-0029" title="KuijpersDI , ThissenMR , BerrettyPJ , IdelerFH , NelemansPJ , NeumannMH . Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatologic Surgery2007;33(5):579-87. [CENTRAL: CN-00588176] ThissenMR , NiemanFH , IdelerAH , BerrettyPJ , NeumannHA . Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatologic Surgery2000;26(8):759-64. [CENTRAL: CN-00298974] ">Kuijpers 2007</a>) as well as non‐surgical interventions: imiquimod (<a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a>), 5‐FU (<a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a>), ALA‐PDT (<a href="./references#CD003412-bbs2-0034" title="MosterdK , ThissenMR , NelemansP , Kelleners‐SmeetsNW , JanssenRL , BroekhofKG , et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. British Journal of Dermatology2008;159(4):864-70. [CENTRAL: CN-00667266] RoozeboomMH , AardoomMA , NelemansPJ , ThissenMR , Kelleners-SmeetsNW , KuijpersDI , et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. Journal of the American Academy of Dermatology August 2013;69(2):280-7. [CENTRAL: CN-00876800] [DOI: 10.1016/j.jid.2016.03.043]">Mosterd 2008</a>), but not after MAL‐PDT (<a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a>; <a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a>). </p> <p>Dyspigmentation was seen after treatment with PDL (<a href="./references#CD003412-bbs2-0003" title="Abd El-NabyNM , El-FarNN , Al-Shenawy HA , ElshwadfySE , KouraAA . Pulsed dye laser in the treatment of basal cell carcinoma: a single session versus two sessions–a randomized controlled trial. Indian Journal of Dermatology, Venereology, and Leprology2019;85(5):475. ">Abd El‐Naby 2019</a>; <a href="./references#CD003412-bbs2-0016" title="EimpunthS , OganesyanG , HammanMS , LeeRA , JiangSI , KimSS . Effectiveness of a 595-nm pulsed dye laser for the treatment of basal cell carcinoma using 1 stacked-pulse session. Journal of the American Academy of Dermatology2014;70(5 (S1)):AB134. [CENTRAL: CN-01057471] ">Eimpunth 2014</a>; <a href="./references#CD003412-bbs2-0025" title="KarsaiS , FriedlH , BuhckH , JüngerM , PoddaM . The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: Outcome of a double-blind randomized placebo-controlled trial. British Journal of Dermatology2015;172(3):677-83. [CENTRAL: CN-01068975] ">Karsai 2015</a>, <a href="./references#CD003412-bbs2-0051" title="TranHT , LeeRA , OganesyanG , JiangSB . Single treatment of non-melanoma skin cancers using a pulsed-dye laser with stacked pulses. Lasers in Surgery and Medicine2012;44(6):459-67. [CENTRAL: CN-00969795] ">Tran 2012</a>), imiquimod (<a href="./references#CD003412-bbs2-0015" title="EigentlerTK , KaminA , WeideBM , BreuningerH , CaroliUM , MöhrleM , et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. Journal of the American Academy of Dermatology2007;57(4):616-21. [CENTRAL: CN-00610509] ">Eigentler 2007</a>; <a href="./references#CD003412-bbs2-0041" title="SchulzeHJ , CribierB , RequenaL , ReifenbergerJ , FerrandizC , DiezG , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. British Journal of Dermatology2005;152(5):939-47. [CENTRAL: CN-00513173] ">Schulze 2005</a>), AFXL‐PDT, MAL‐PDT (<a href="./references#CD003412-bbs2-0023" title="HaakCS , Togsverd-BoK , Thaysen-PetersenD , WulfHC , PaaschU , AndersonRR , et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas - a randomized clinical trial. British Journal of Dermatology2015;172(1):215-22. [CENTRAL: CN-01039978] ">Haak 2015</a>) and in 83% of treated with intralesional 5‐FU (<a href="./references#CD003412-bbs2-0032" title="MillerBH , ShavinJS , CognettaA , TaylorRJ , SalascheS , KoreyA , et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. Journal of the American Academy of Dermatology1997;36(1):72-7. [CENTRAL: CN-00135753] ">Miller 1997</a>). </p> <p>Reports of radiodystrophy and necrosis decreased over time after radiotherapy treatment (<a href="./references#CD003412-bbs2-0006" title="AvrilMF , AuperinA , MargulisA , GerbauletA , DuvillardP , BenhamouE , et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. British Journal of Cancer1997;76(1):100-6. [CENTRAL: CN-00141470] PetitJY , AvrilMF , MargulisA , ChassagneD , GerbauletA , DuvillardP , et al. Evaluation of cosmetic results of a randomised trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plastic and Reconstructive Surgery2000;105(7):2544-51. [CENTRAL: CN-00278207] ">Avril 1997</a>). Necrosis (of grafts) was also seen after SE (<a href="./references#CD003412-bbs2-0045" title="EssersBA , DirksenCD , NiemanFH , SmeetsNW , KrekelsGA , PrinsMH , et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Archives of Dermatology2006;142(2):187-94. [CENTRAL: CN-00555278] MosterdK , KrekelsGA , NiemanFH , OstertagJU , EssersBA , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncology2008;9(12):1149-56. [CENTRAL: CN-00665334] SmeetsNW , KrekelsGA , OstertagJU , EssersBA , DirksenCD , NiemanFH , et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet2004;364(9447):1766-72. [CENTRAL: CN-00492695] Van LooE , MosterdK , KrekelsGA , RoozeboomMH , OstertagJU , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European Journal of Cancer2014;50(17):3011-20. [CENTRAL: CN-01043314] ">Smeets 2004</a>). Scarring was seen after the use of PDL (<a href="./references#CD003412-bbs2-0016" title="EimpunthS , OganesyanG , HammanMS , LeeRA , JiangSI , KimSS . Effectiveness of a 595-nm pulsed dye laser for the treatment of basal cell carcinoma using 1 stacked-pulse session. Journal of the American Academy of Dermatology2014;70(5 (S1)):AB134. [CENTRAL: CN-01057471] ">Eimpunth 2014</a>), AFXL‐PDT, MAL‐PDT (<a href="./references#CD003412-bbs2-0023" title="HaakCS , Togsverd-BoK , Thaysen-PetersenD , WulfHC , PaaschU , AndersonRR , et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas - a randomized clinical trial. British Journal of Dermatology2015;172(1):215-22. [CENTRAL: CN-01039978] ">Haak 2015</a>) and ingenol mebutate gel (<a href="./references#CD003412-bbs2-0044" title="SillerG , RosenR , FreemanM , WelburnP , KatsamasJ , OgbourneSM . PEP005 (Ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomised phase IIa trial. Australasian Journal of Dermatology2010;51(2):99-105. [CENTRAL: CN-00771587] ">Siller 2010</a>). "Adverse" scarring was noted after SE (<a href="./references#CD003412-bbs2-0006" title="AvrilMF , AuperinA , MargulisA , GerbauletA , DuvillardP , BenhamouE , et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. British Journal of Cancer1997;76(1):100-6. [CENTRAL: CN-00141470] PetitJY , AvrilMF , MargulisA , ChassagneD , GerbauletA , DuvillardP , et al. Evaluation of cosmetic results of a randomised trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plastic and Reconstructive Surgery2000;105(7):2544-51. [CENTRAL: CN-00278207] ">Avril 1997</a>). </p> <p>Headache was statistically more prevalent after treatment with certain imiquimod regimens (five times per week) than in placebo groups (<a href="./references#CD003412-bbs2-0022" title="GeisseJ , CaroI , LindholmJ , GolitzL , StamponeP , OwensM . Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology2004;50(5):722-33. [CENTRAL: CN-00469536] ">Geisse 2004</a>). Imiquimod also induced influenza‐like symptoms (<a href="./references#CD003412-bbs2-0008" title="Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , MillerPS , et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncology2014;15(1):96-105. [CENTRAL: CN-00959373] WilliamsHC , Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. Journal of Investigative Dermatology2017;137(3):614-9. [CENTRAL: CN-01340067] [EMBASE: 614596349]">Bath‐Hextall 2014</a>; <a href="./references#CD003412-bbs2-0041" title="SchulzeHJ , CribierB , RequenaL , ReifenbergerJ , FerrandizC , DiezG , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. British Journal of Dermatology2005;152(5):939-47. [CENTRAL: CN-00513173] ">Schulze 2005</a>; <a href="./references#CD003412-bbs2-0042" title="ShumackS , MarksR , AmiesM , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks treating nodular BCC. 8th World Congress on Cancers of the Skin, Zurich, Switzerland2001;-:p55. [CENTRAL: CN-00849091] ShumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , SchroeterA , et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002a</a>; <a href="./references#CD003412-bbs2-0043" title="RobinsonJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating nodular BCC. 8th World Congress on Cancer of the Skin, Zurich, Switzerland2001;-(-):p57. [CENTRAL: CN-00849091] SchumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , Schroeter, A et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002b</a>; <a href="./references#CD003412-bbs2-0048" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. In: 8th World Congress on cancers of the skin, Zurich, Switzerland. 2001:61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] [PMID: 12452875]">Sterry 2002a</a>) and deranged haematology results (<a href="./references#CD003412-bbs2-0022" title="GeisseJ , CaroI , LindholmJ , GolitzL , StamponeP , OwensM . Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology2004;50(5):722-33. [CENTRAL: CN-00469536] ">Geisse 2004</a>). Biochemical abnormalities were seen with ingenol mebutate gel usage (<a href="./references#CD003412-bbs2-0044" title="SillerG , RosenR , FreemanM , WelburnP , KatsamasJ , OgbourneSM . PEP005 (Ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomised phase IIa trial. Australasian Journal of Dermatology2010;51(2):99-105. [CENTRAL: CN-00771587] ">Siller 2010</a>). </p> <p>Withdrawal from study, discontinuation of therapy, interrupted therapy regimens or dose reduction due to treatment‐related adverse effects occurred with imiquimod (<a href="./references#CD003412-bbs2-0008" title="Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , MillerPS , et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncology2014;15(1):96-105. [CENTRAL: CN-00959373] WilliamsHC , Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. Journal of Investigative Dermatology2017;137(3):614-9. [CENTRAL: CN-01340067] [EMBASE: 614596349]">Bath‐Hextall 2014</a>; <a href="./references#CD003412-bbs2-0017" title="EzughahFI , DaweRS , IbbotsonSH , FlemingCJ . A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment2008;19(2):111-7. [CENTRAL: CN-00706567] ">Ezughah 2008</a>; <a href="./references#CD003412-bbs2-0021" title="GeisseJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating superficial BCC. In: The 8th World Congress on Cancer of the Skin; 2001 July 18-21; Zurich, Switzerland. 2001:P58. [CENTRAL: CN-00520431] GeisseJK , RichP , PandyaA , GrossK , AndresK , GinkelA , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a randomized, vehicle-controlled study. Journal of the American Academy of Dermatology2002;47(3):390-8. [CENTRAL: CN-00390933] ">Geisse 2002</a>, <a href="./references#CD003412-bbs2-0022" title="GeisseJ , CaroI , LindholmJ , GolitzL , StamponeP , OwensM . Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology2004;50(5):722-33. [CENTRAL: CN-00469536] ">Geisse 2004</a>; <a href="./references#CD003412-bbs2-0031" title="MarksR , GebauerK , ShumackS , AmiesM , BrydenJ , FoxTL , et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicentre 6-week dose-response trial. Journal of the American Academy of Dermatology2001;44(5):807-13. [CENTRAL: CN-00326531] ">Marks 2001</a>; <a href="./references#CD003412-bbs2-0041" title="SchulzeHJ , CribierB , RequenaL , ReifenbergerJ , FerrandizC , DiezG , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. British Journal of Dermatology2005;152(5):939-47. [CENTRAL: CN-00513173] ">Schulze 2005</a>; <a href="./references#CD003412-bbs2-0042" title="ShumackS , MarksR , AmiesM , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks treating nodular BCC. 8th World Congress on Cancers of the Skin, Zurich, Switzerland2001;-:p55. [CENTRAL: CN-00849091] ShumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , SchroeterA , et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002a</a>; <a href="./references#CD003412-bbs2-0043" title="RobinsonJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating nodular BCC. 8th World Congress on Cancer of the Skin, Zurich, Switzerland2001;-(-):p57. [CENTRAL: CN-00849091] SchumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , Schroeter, A et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002b</a>; <a href="./references#CD003412-bbs2-0048" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. In: 8th World Congress on cancers of the skin, Zurich, Switzerland. 2001:61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] [PMID: 12452875]">Sterry 2002a</a>; <a href="./references#CD003412-bbs2-0049" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. 8th World Congress on cancers of the skin, Zurich, Switzerland2001;-(-):p61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] ">Sterry 2002b</a>), diclofenac with or without calcipotriol (<a href="./references#CD003412-bbs2-0010" title="BrinkhuizenT , FrenckenKJ , NelemansPJ , HoffML , Kelleners-SmeetsNW , Zur HausenA , et al. The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): a phase II, randomized controlled trial. Journal of the American Academy of Dermatology2016;75(1):126-34. [CENTRAL: CN-01342883] [DOI: 10.1016/j.jaad.2016.01.050]">Brinkhuizen 2016</a>), MAL‐PDT (<a href="./references#CD003412-bbs2-0018" title="FoleyP , FreemanM , MenterA , SillerG , El-AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] FoleyP , FreemanM , SillerG , GebauerK , MurrellD , BarnetsonR , et al. A phase III randomized study comparing photodynamic therapy (PDT) using methyl aminolevulinate or placebo cream in nodular basal cell carcinoma (NBCC). Journal of the European Academy of Dermatology and Venereology2003;17(Suppl 3):231. [CENTRAL: CN-00478536] ">Foley 2009a</a>; <a href="./references#CD003412-bbs2-0019" title="FoleyP , FreemanM , MenterA , SillerG , El‐AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] TopeWD , MenterA , El AzharyR , SotoP . A comparison of topical MAL-PDT versus placebo-PDT in nodular basal cell carcinoma: results of a North American study. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology; 2005 Sep 28-Oct 03; Kuala Lumpur, Malaysia. 2005:376. [CENTRAL: CN-00602617] ">Foley 2009b</a>; <a href="./references#CD003412-bbs2-0033" title="MortonCA , DominicusR , RadnyP , DirschkaT , HauschildA , ReinholdU , et al. A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). British Journal of Dermatology2018;179(2):309-19. [CENTRAL: CN-02000788] [PMID: 29432644]">Morton 2018</a>; <a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a>), BF 200 ALA‐PDT (<a href="./references#CD003412-bbs2-0033" title="MortonCA , DominicusR , RadnyP , DirschkaT , HauschildA , ReinholdU , et al. A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). British Journal of Dermatology2018;179(2):309-19. [CENTRAL: CN-02000788] [PMID: 29432644]">Morton 2018</a>), solasodine glycosides (<a href="./references#CD003412-bbs2-0035" title="PunjabiS , CookLJ , KerseyP , MarksR , CerioR . Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicentre study. International Journal of Dermatology2008;47(1):78-82. [CENTRAL: CN-00629144] PunjabiS , CookLJ , KerseyP , MarksR , FinlayA , SharpG , et al. A double-blind, multicentre parallel group study of BEC-5 cream in basal cell carcinoma. European Academy of Dermatology &amp; Venereology2000;14(Suppl 1):49. [CENTRAL: CN-01616931] ">Punjabi 2008</a>) and ingenol mebutate gel with or without occlusion (<a href="./references#CD003412-bbs2-0044" title="SillerG , RosenR , FreemanM , WelburnP , KatsamasJ , OgbourneSM . PEP005 (Ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomised phase IIa trial. Australasian Journal of Dermatology2010;51(2):99-105. [CENTRAL: CN-00771587] ">Siller 2010</a>; <a href="./references#CD003412-bbs2-0047" title="RosenR , FreemanM , ZibertJR , KatsamasJ , KnudsenKM , SpelmanL . Ingenol mebutate 0.05% gel under occlusion is efficacious in treating superficial basal cell carcinoma. British Journal of Dermatology2014;171(Suppl 4):50. [CENTRAL: CN-01057057] ">Spelman 2014</a>). </p> <p>Serious adverse effects requiring hospitalisation due to treatment were not specifically reported in any treatment group but the influenza‐like symptoms and wound infections that were seen with small numbers treated with imiquimod and 5‐FU in the <a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a> study were classed as suspected unexpected serious adverse reactions. More details regarding reaction severity, duration of adverse events and changes over treatment course can be found in <a href="#CD003412-tbl-0007">Table 2</a>. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003412-sec-0298" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003412-sec-0298"></div> <section id="CD003412-sec-0299"> <h3 class="title" id="CD003412-sec-0299">Summary of main results</h3> <p>Basal cell carcinoma (BCC) is the most common skin cancer with several different interventions available for high‐ and low‐risk histological subtypes. We aimed to assess the effectiveness of these interventions for primary BCC in immunocompetent individuals and found 52 randomised controlled trials (RCTs) (26 new to this review update) that randomised a total of 6690 participants. We synthesised the data into a total of 52 comparisons. All studies included a majority of BCCs of low‐risk histological subtypes (nodular (nBCC), superficial (sBCC)), with only four studies including a minority of high‐risk histological subtypes. No studies exclusively studied high‐risk histological subtypes and we were unable to retrieve the raw data specific to the high‐risk BCCs for full outcome assessment. Consequently, there was not enough information to draw any conclusions about the effects of interventions on histologically high‐risk BCC. </p> <p>Of the included studies, pooling of the data was feasible for only a very limited number of the reported outcomes, and the largest number of studies we were able to pool was four. Many comparisons were evaluated by only one study, preventing meta‐analysis. We considered surgical excision (SE) versus Mohs micrographic surgery (MMS) as the main comparison in this review. However, only one study (<a href="./references#CD003412-bbs2-0045" title="EssersBA , DirksenCD , NiemanFH , SmeetsNW , KrekelsGA , PrinsMH , et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Archives of Dermatology2006;142(2):187-94. [CENTRAL: CN-00555278] MosterdK , KrekelsGA , NiemanFH , OstertagJU , EssersBA , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncology2008;9(12):1149-56. [CENTRAL: CN-00665334] SmeetsNW , KrekelsGA , OstertagJU , EssersBA , DirksenCD , NiemanFH , et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet2004;364(9447):1766-72. [CENTRAL: CN-00492695] Van LooE , MosterdK , KrekelsGA , RoozeboomMH , OstertagJU , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European Journal of Cancer2014;50(17):3011-20. [CENTRAL: CN-01043314] ">Smeets 2004</a>), which provided only low‐certainty evidence, assessed MMS, even though this is often used as the gold‐standard for high‐risk facial BCC. </p> <p>Broadly, non‐surgical interventions were more commonly assessed than surgical interventions: more than double the number of trials assessed non‐surgical compared to surgical interventions. The most assessed interventions were photodynamic therapy (PDT) (24 studies); topical imiquimod (14 studies); and surgical excision, which is often regarded as the gold‐standard treatment for BCC (10 studies). Eleven studies assessed MAL‐PDT; 6, ALA‐PDT; 2, ablative fractional laser MAL‐PDT, and single studies assessed HAL‐PDT, laser and broadband ALA‐PDT. Between two or four studies assessed radiotherapy, cryosurgery, fluorouracil, intralesional interferon, pulsed dye laser, and ingenol mebutate. No more than one study assessed curettage and cautery, electrochemotherapy, solasodine glycosides, valproic acid and tazarotene gel, sinecatechins, calcitriol and diclofenac. </p> <p>Safety was the most commonly‐evaluated outcome, with 81% of the comparisons assessing adverse effects. Seventy‐five per cent of comparisons assessed early treatment failure, 21% reported 3‐year recurrence, 17% reported 5‐year recurrence, 37% reported on cosmetic outcomes (27% had data for analysis), and 46% reported on pain (19% had data for analysis). </p> <section id="CD003412-sec-0300"> <h4 class="title">Surgical excision (SE)</h4> <p>Surgical interventions have the lowest rates of recurrence at three‐ and five‐ year follow‐up. </p> <p>We found that for high‐risk facial BCC, there may be slightly fewer recurrences with MMS compared to SE at three years and five years (low‐certainty evidence). However, the 95% confidence interval (CI) also includes the possibility of an increased risk of recurrence and no difference between treatments. There may be little to no difference regarding improvement of participant‐ and observer‐rated cosmetic outcomes (low‐certainty evidence) measured at 18 months post‐operatively; however, no raw data were available for this outcome. </p> <p><a href="./references#CD003412-bbs2-0045" title="EssersBA , DirksenCD , NiemanFH , SmeetsNW , KrekelsGA , PrinsMH , et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Archives of Dermatology2006;142(2):187-94. [CENTRAL: CN-00555278] MosterdK , KrekelsGA , NiemanFH , OstertagJU , EssersBA , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncology2008;9(12):1149-56. [CENTRAL: CN-00665334] SmeetsNW , KrekelsGA , OstertagJU , EssersBA , DirksenCD , NiemanFH , et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet2004;364(9447):1766-72. [CENTRAL: CN-00492695] Van LooE , MosterdK , KrekelsGA , RoozeboomMH , OstertagJU , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European Journal of Cancer2014;50(17):3011-20. [CENTRAL: CN-01043314] ">Smeets 2004</a> has been criticised for performing MMS with a standardised 3 mm margin as normally smaller margins are used and this larger margin may have diminished the tissue‐preserving benefit of MMS, potentially worsening the cosmetic outcome (<a href="./references#CD003412-bbs2-0121" title="MullerFM , DaweRS , MoseleyH , FlemingCJ . Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue‐sparing outcome. Dermatologic Surgery2009;35(9):1349-54.">Muller 2009</a>). The study included high‐risk facial BCCs, defined as high‐risk histological subtypes (infiltrative, micronodular, morphoeic, BCC with squamous differentiation) or BCCs located in the 'H‐zone' of the face, or both. </p> <p>The study followed up participants for over 10 years, and although our primary outcome was recurrence at three years and five years, it is important to note that during the five‐ to 10‐year follow‐up period there were an additional 14 recurrences (four in the MMS group and 10 in the SE group), which means that only 44% of BCC recurrences occurred during five years of follow‐up. This is important as clinicians and patients should be aware that recurrences are possible up to 10 years following treatment. </p> <p>For further details see <a href="./full#CD003412-tbl-0001">summary of findings Table 1</a>. </p> </section> <section id="CD003412-sec-0301"> <h4 class="title">Imiquimod</h4> <p>Evidence for low‐risk sBCC and nBCC found that imiquimod probably results in more recurrences than SE at three years (10‐fold increased risk, moderate‐certainty evidence) and at five years (eight‐fold increased risk, moderate‐certainty evidence). This was a non‐inferiority study and imiquimod was found to be inferior to SE as it failed to meet the study's pre‐defined inferiority margin of 0.87. When measured at three years, there may be little to no difference between imiquimod and SE in the number of participant‐rated good/excellent cosmetic outcomes (low‐certainty evidence), but when this outcome is observer‐rated, imiquimod may increase good/excellent cosmetic outcomes (low‐certainty evidence). This discrepancy between participant‐ and observer‐rated cosmetic outcomes may be important and should be highlighted to patients. </p> <p>Although inferior to SE in terms of reducing recurrence rates, imiquimod's performance is still clinically acceptable to patients and clinicians and it is probably the best non‐surgical treatment option for low‐risk BCC. Another important benefit of imiquimod resides in the fact that it can be administered by patients at home, offering the opportunity to manage low‐risk BCCs in the community. With the trend for patients presenting younger and with increasing numbers of BCCs, some now advocate the possibility of general practitioners diagnosing and managing low‐risk BCCs with imiquimod cream and reserving SE for the approximate 1/5 BCCs that relapse, with the majority found to relapse within the first year following treatment (<a href="./references#CD003412-bbs2-0111" title="Kelleners-SmeetsNW , MosterdK , NelemansPJ . Treatment of low-risk basal cell carcinoma. Journal of Investigative Dermatology2017;137(3):539-40.">Kelleners‐Smeets 2017</a>). </p> <p>Side effects of imiquimod cream comprise application site reactions including pain, weeping, itching, redness and swelling and were reported more often in the imiquimod group than in the SE group. The licensed treatment regimen is five days per week dosing for six weeks (sBCC) or 12 weeks (nBCC). <a href="./references#CD003412-bbs2-0008" title="Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , MillerPS , et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncology2014;15(1):96-105. [CENTRAL: CN-00959373] WilliamsHC , Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. Journal of Investigative Dermatology2017;137(3):614-9. [CENTRAL: CN-01340067] [EMBASE: 614596349]">Bath‐Hextall 2014</a> used daily dosing (the discrepancy may have occurred as imiquimod was licensed for BCC after the study had commenced) and therefore more adverse effects may have been recorded during the study than would be expected in clinical practice. Recurrences recorded at five years compared with three years were small, with one additional recurrence for a sBCC treated with imiquimod and one after SE. </p> <p>Out of 14 studies assessing imiquimod, 11 were funded by the science‐based technology company 3M. </p> <p>For further details see <a href="./full#CD003412-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD003412-sec-0302"> <h4 class="title">Radiotherapy</h4> <p>In comparison against SE with the option of frozen section margin control for facial BCCs (including high‐ and low‐risk subtypes), radiotherapy may result in increased recurrences at three years (low‐certainty evidence) and at four years (low‐certainty evidence). When measured at four years, radiotherapy probably results in a lower number of good cosmetic outcomes (irrelevant of whether the outcome was participant‐ or observer‐rated) compared to SE (moderate‐certainty evidence), as dyspigmentation and telangiectasia can occur in people treated with radiotherapy. </p> <p>Different radiation techniques exist (such as conventional X‐ray therapy, interstitial brachytherapy and superficial contact therapy) with the choice of technique dependent on factors such as size and location of the lesion and performance status of the patient. In practice, radiotherapy is usually reserved for cases where lesions are not amenable to surgery. When deciding whether to choose radiotherapy or SE, patients need to consider that radiotherapy will probably involve numerous visits to the radiotherapy department up to five times a week, usually for several weeks. It should be noted that the RCTs for radiotherapy were all conducted decades ago. Since these studies were carried out, radiotherapy technology and protocols have improved and therefore these results may not be representative of modern radiotherapy outcomes. New studies comparing modern radiotherapy against other interventions are needed. </p> <p>For further details see <a href="./full#CD003412-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD003412-sec-0303"> <h4 class="title">Photodynamic therapy (PDT)</h4> <p>PDT was studied in 16 RCTs against various surgical and non‐surgical interventions. Out of 16 PDT studies, seven were industry‐funded (five by PhotoCure/Galderma). </p> <p>Based on participants with low‐risk nBCC on the head and neck region, MAL‐PDT may result in more recurrences than SE at three years (low‐certainty evidence); there were no usable data for assessment at five years. MAL‐PDT probably has slightly more participant‐ and observer‐rated good/excellent cosmetic outcomes at one year compared to SE, based on participants with low‐risk nBCC and sBCC (moderate‐certainty evidence). For further details see <a href="./full#CD003412-tbl-0004">summary of findings Table 4</a>. </p> <p>Based on participants who each had a single low‐risk sBCC, imiquimod probably results in fewer recurrences at three years and five years compared to MAL‐PDT (moderate‐certainty evidence), and there is probably little to no difference in observer‐rated good/excellent cosmetic outcomes measured at one year between MAL‐PDT and imiquimod (moderate‐certainty evidence). This comparison did not measure participant‐rated cosmetic outcomes. For further details see <a href="./full#CD003412-tbl-0005">summary of findings Table 5</a>. </p> <p>There is wide variation in PDT protocols with differences in photosensitising agent, use of prior debulking curettage, timing, source and amount of light irradiation and number of PDT cycles. MAL‐PDT predominates in Europe and Australasia; physicians in the USA mainly use ALA‐PDT. The standard European protocol defines one cycle as two PDT sessions separated by a one‐week interval. MAL‐PDT is significantly more expensive than ALA‐PDT. 5‐ALA, however is disadvantaged by the need to prepare the cream fresh prior to use whereas MAL is available in a standardised preparation which makes it easier to use. The newer, stable nanoemulsion ALA formulation (BF‐200 ALA gel) is now licensed in the EU. HAL has been used for years in bladder cancer detection and its use in BCC treatment has now been investigated. Further studies are required to inform which protocol is most effective. </p> <p><a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a> identified that MAL‐PDT probably leads to fewer recurrences compared to imiquimod for sBCC treatment, in one subgroup of patients only: older patients with sBCC on the lower extremities. </p> </section> <section id="CD003412-sec-0304"> <h4 class="title">Adverse effects</h4> <p>Adverse effects with surgical interventions included wound infections, necrosis of grafts and post‐operative bleeding. Local adverse effects such as itching, weeping, pain and redness occurred frequently with non‐surgical interventions. Treatment‐related adverse effects resulting in study modification or withdrawal occurred with imiquimod and MAL‐PDT. </p> <p>For further details see <a href="#CD003412-tbl-0009">Table 4</a>, <a href="#CD003412-tbl-0010">Table 5</a>, <a href="#CD003412-tbl-0013">Table 8</a>, <a href="#CD003412-tbl-0008">Table 3</a>, <a href="#CD003412-tbl-0012">Table 7</a>, and <a href="#CD003412-tbl-0011">Table 6</a>. </p> <div class="table" id="CD003412-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">ALA‐PDT compared to cryosurgery for basal cell carcinoma of the skin</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PDT compared to cryosurgery for low‐risk BCC</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from a single hospital in Sweden </p> <p><b>Intervention:</b> ALA‐PDT<br/><b>Comparison:</b> cryosurgery </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cryosurgery</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ALA‐PDT</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.72 (1.26 to 2.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Observer‐rated at 1 year on a 4‐point scale.<sup>3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>541 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>930 per 1000 (681 to 1000)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early treatment failure</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>88</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain during treatment assessed by VAS (115mm, where 115mm corresponds to 'unbearable pain' and 0mm corresponds to 'no pain'. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean pain was 32 mm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 11mm higher (1.12 lower to 23.12 higher)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; V<b>AS:</b> visual analogue scale. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for serious risk of bias as unable to truly blind due to the nature of interventions. </p> <p><sup>2</sup> Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI. </p> <p><sup>3</sup> 4‐point scale: blemished, acceptable, good, excellent. </p> </div> </div> </section> </section> <section id="CD003412-sec-0305"> <h3 class="title" id="CD003412-sec-0305">Overall completeness and applicability of evidence</h3> <p>This systematic review has included the full spectrum of interventions for primary BCC by including 52 RCTs (52 comparisons) of varying methodological quality. The evidence we have identified addressed our primary and secondary outcomes to varying degrees. Only 21% of the comparisons we included presented at least three‐year recurrence data, and 17% of comparisons reported 5‐year recurrence data. Given that the majority of recurrences are expected to occur by three years, this means that almost 80% of studies were not able to address our primary recurrence rate outcomes due to inadequate follow‐up time. This threatens the applicability and external validity of the evidence presented. Histologically‐confirmed early treatment failure data were available for all but 13 comparisons. This outcome benefits from not requiring a long follow‐up period and was frequently used as a primary outcome in small, pilot phase 1/2 studies but is generally of limited use when informing decisions in clinical practice. </p> <p>The finding in <a href="./references#CD003412-bbs2-0045" title="EssersBA , DirksenCD , NiemanFH , SmeetsNW , KrekelsGA , PrinsMH , et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Archives of Dermatology2006;142(2):187-94. [CENTRAL: CN-00555278] MosterdK , KrekelsGA , NiemanFH , OstertagJU , EssersBA , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncology2008;9(12):1149-56. [CENTRAL: CN-00665334] SmeetsNW , KrekelsGA , OstertagJU , EssersBA , DirksenCD , NiemanFH , et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet2004;364(9447):1766-72. [CENTRAL: CN-00492695] Van LooE , MosterdK , KrekelsGA , RoozeboomMH , OstertagJU , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European Journal of Cancer2014;50(17):3011-20. [CENTRAL: CN-01043314] ">Smeets 2004</a> that 56% of recurrences of high‐risk facial BCC occur between five and 10 years following surgery suggests that longer follow‐up times are needed for studies on BCC and may represent a flaw in our review methodology. However, a large retrospective review of long‐term BCC recurrence rates identified that only 18% of recurrences occurred between five and 10 years with 67% found to occur within the first three years (<a href="./references#CD003412-bbs2-0130" title="RoweDE , CarrollRJ , Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. Journal of Dermatologic Surgery and Oncology1989;15(3):315-28.">Rowe 1989</a>). This study informed our original review's three‐year time point. Further retrospective studies have reported that 18% to 20% of recurrences occur beyond five years (<a href="./references#CD003412-bbs2-0103" title="GriffithsRW , SuvarnaSK , StoneJ . Do basal cell carcinomas recur after complete conventional surgical excision?British Journal of Plastic Surgery2005;58(6):795-805.">Griffiths 2005</a>; <a href="./references#CD003412-bbs2-0106" title="HruzaGJ . Mohs micrographic surgery local recurrences. Journal of Dermatologic Surgery and Oncology1994;20(9):573-7.">Hruza 1994</a>; <a href="./references#CD003412-bbs2-0126" title="RandleHW . Basal cell carcinoma identification and treatment of the high-risk patient. Dermatologic Surgery1996;22(3):255-61.">Randle 1996</a>). </p> <p>Nineteen comparisons had cosmetic outcome data, of which 14 had data for analysis. There was heterogenous reporting of cosmetic outcomes, using different time points, scales and rater (e.g. participant, observer or both). Observers were generally medically trained (e.g. dermatologist, surgeon), but some studies used non‐medical observers. Histologically‐confirmed early treatment failure was available for all but 13 comparisons. Although 24 studies reported on pain, we were only able to perform analyses on pain data for 10 comparisons; the severity and analgesia required were not routinely reported, and the modes of assessment ranged from patient diaries to rating scales or visual analogue scores. Most studies presented this in their adverse effects data, and due to the heterogeneity, we have collated adverse effects and pain data into additional tables (<a href="#CD003412-tbl-0006">Table 1</a> and <a href="#CD003412-tbl-0007">Table 2</a>). </p> <p>The diversity of the outcome data generated by these trials impacted our ability to make direct comparisons between the studies; therefore, these data are occasionally not reported. The discrepancy in reported outcomes and the inconsistency in reported time points underscores the importance of the work being done to create core outcome sets based on the needs of the stakeholders for clinical trials in BCC (<a href="./references#CD003412-bbs2-0131" title="SchlessingerDI , IyengarS , YanesAF , LazaroffJM , Godinez-PuigV , ChenBR , et al. Development of a core outcome set for clinical trials in basal cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials2017;18(1):490.">Schlessinger 2017</a>). </p> <p>Thirteen comparisons involved a placebo/vehicle/sham/no treatment arm, and imiquimod was over‐represented in this group, with five studies comparing imiquimod against vehicle, involving 1145 participants. This allowed one of the few meta‐analyses included in this review. It should also be noted that all of these imiquimod studies were industry‐funded. BCC is a disease associated with significant local tissue destruction and therefore the harm of non‐treatment is not insignificant. It is for this reason that most placebo‐controlled studies had short follow‐up periods and usually excised the treatment area at the end of the study. Twenty‐six comparisons were head‐to‐head, and such studies are more applicable to clinical practice as they answer more pragmatic and clinically relevant questions. </p> <p>We do not have sufficient evidence to determine the effects of treatment for histologically high‐risk BCC, because only four of our included studies assessed this subtype and no studies exclusively included high‐risk histological subtypes. Only three studies exclusively assessed BCCs located at high‐risk sites (H‐zone of the face), and so there was insufficient evidence to determine the effects of treatment for these BCCs. </p> <p>The vast majority of participants were elderly with a median age of 64.9 years old. Although participants as young as 20 were included, separate data on younger participants were not available and therefore we do not have sufficient evidence to determine if outcomes are different in younger participants. </p> <p>Only one study provided evidence for our main comparison of surgical excision versus MMS. Non‐surgical interventions were most widely evaluated by our included studies, which correlates with the inclusion of low‐risk histological BCC subtypes by all of the studies. </p> <p>Three types of treatment were disproportionately represented compared to the rest of the treatments considered: 48 trials assessed PDT, topical imiquimod, and surgical excision, whereas almost half of that number (26 studies), in total, assessed the following: radiotherapy, cryosurgery, fluorouracil, intralesional interferon, pulsed dye laser, ingenol mebutate, curettage and cautery, electrochemotherapy, solasodine glycosides, valproic acid and tazarotene gel, sinecatechins, and diclofenac. </p> <p>Most of the evidence for the outcomes presented for each of the interventions has come from relatively small, single studies, which meant that meta‐analysis was largely not possible (the exceptions being PDT versus SE, imiquimod versus vehicle and AFXL‐PDT versus PDT). The majority of these single studies were multi‐centre, but many were limited by small sample sizes, and consequently, many of the outcomes reported in this review have wide confidence intervals. This means there is a large amount of imprecision in the results, and therefore, several of our results have low‐certainty evidence which threatens their external validity and reproducibility. </p> <p>Despite these limitations, our study is the most up‐to‐date and extensive systematic review on interventions for BCC. It can be used globally to inform guidelines and to aid clinicians and patients in weighing up the risks and benefits of the various treatment options available for primary BCC. </p> <section id="CD003412-sec-0306"> <h4 class="title">Certainty of the evidence</h4> <p>The GRADE approach was used to rate the certainty of all the evidence in our review (as outlined in the <a href="#CD003412-sec-0024">Methods</a> section). There was a wide variation in the certainty with most outcomes being rated as moderate to low certainty. A few outcomes were rated as very low‐certainty, although these were assessed by comparisons not considered key. The main reasons for rating down the certainty of evidence related to serious risk of bias in the studies (for instance, high risk of selection bias) and serious imprecision with small sample sizes and wide confidence intervals. Where confidence intervals included important benefit and serious harm (i.e. &gt; 1.25 and &lt; 0.75), we rated down two levels for very serious imprecision. A few comparisons had such wide 95% CIs (including 1‐ and more than 100‐fold difference) that we rated them down three levels for imprecision. </p> <p>Only 19 studies were assessed as low risk of bias for blinding of the outcome assessor. For the studies that were unblinded we did not rate down the certainty of evidence for recurrence outcomes as it was unclear if being unblinded would bias the assessments. We did rate down certainty of evidence for high risk of bias when there was unblinded assessment of cosmetic outcomes. </p> <p>Only one study was identified as having a high risk of selection bias, but 22 studies were rated as unclear risk of bias due to the method of random sequence generation not being clearly stated by the study authors. Twenty‐eight studies had unclear risk of bias due to the method of allocation concealment not being stated. All these studies stated that they randomised their participants, and therefore, we have had to assume that they did this correctly and we have not rated down the certainty of evidence for an unclear risk of selection bias assessment. Only six studies were deemed to be at low risk of selective outcome reporting bias, and only 11 studies prospectively registered. This number is very low, and selective outcome reporting may have occurred in studies rated as 'unclear' risk of bias, but we decided not to rate the certainty of evidence down for this. This stresses the importance of having pre‐specified outcomes and prospectively registering studies. </p> <p>The majority of included studies used participants as the unit of analysis; however, 27% of studies reported results based on lesions. Therefore, there is the potential of under‐estimating the variation in the intervention effect from using results which are based on the same people contributing with multiple lesions. However, the majority of these studies included small numbers of people with multiple lesions; therefore, we anticipate that the likely impact on our results is minimal. Additionally, all of the latter studies aimed to treat the lesions individually, rather than using a systemic treatment. </p> </section> </section> <section id="CD003412-sec-0307"> <h3 class="title" id="CD003412-sec-0307">Potential biases in the review process</h3> <p>We attempted to conduct a comprehensive search for studies. Review authors independently assessed eligibility of studies to minimise bias in the study selection process. As we were working from an old protocol, we did decide to make some changes to our methods that have been clearly described in the <a href="#CD003412-sec-0330">Differences between protocol and review</a> section. Changes to our protocol were made at the start of the review process and were approved by Cochrane Skin editorial team. Bias may have been introduced by the time points chosen for some of our outcomes. For instance, when faced with cosmetic outcome data with a range of time points, we had to make a decision on which time point to include for the different comparisons. We attempted to minimise this bias by asking HW to decide on what should be the best time point to include. HW decided we should select a time point at least one year following treatment. The rationale being that scars often take around one year to heal and for the colour to settle. He was not aware of the included studies or any of the results when making this decision, so the risk of bias should be minimal, but ideally this should have been pre‐specified in the protocol. For the SE versus radiotherapy study cosmetic outcome, we reported the time point with the biggest difference between interventions which was four years after treatment which may have introduced selective outcome reporting bias. The reason we reported this time point is because it is well documented that radiotherapy has deteriorating cosmetic outcomes over years and this would not be appreciated if we reported the one‐year time point. Selective outcome reporting bias may also have been introduced by us selecting the maximum pain score recorded during treatment for interventions. We felt this was necessary as pain experienced during treatments is highly variable and depends on the treatment modality. For example, comparing pain on day one for a surgical treatment against a non‐surgical treatment like imiquimod would be meaningless as the surgical intervention will have produced a painful wound whereas imiquimod will likely not have had any effect on day one. </p> </section> <section id="CD003412-sec-0308"> <h3 class="title" id="CD003412-sec-0308">Agreements and disagreements with other studies or reviews</h3> <p>There have been a few systematic reviews assessing interventions for BCC published since our last update. Most recently, <a href="./references#CD003412-bbs2-0097" title="DruckerAM , AdamGP , RofebergV , GazulaA , SmithB , MoustafaF , et al. Treatments of primary basal cell carcinoma of the skin: a systematic review and network meta-analysis. Annals of Internal Medicine2018;169(7):456-66.">Drucker 2018</a> published a comprehensive systematic review and network meta‐analysis (NMA) on treatments for primary BCC. This study only included English‐language publications, and their search yielded fewer randomised controlled trials (RCTs) whilst also including non‐randomised studies. This study also did not specify a time point for recurrence before performing the NMA. Despite these differences, our conclusion that surgical interventions have the lowest recurrence rates for BCC is consistent with theirs. <a href="./references#CD003412-bbs2-0094" title="CollierNJ , HaylettAK , WongTH , MortonCA , IbbotsonSH , McKennaKE , et al. Conventional and combination topical photodynamic therapy for basal cell carcinoma: systematic review and meta‐analysis. British Journal of Dermatology2018;179(6):1277-96.">Collier 2018</a> published a systematic review of PDT for BCC. This study included 15 RCTs and had similar outcome measures as our study, except recurrence at one year and five years were their chosen time points. Our review largely agrees with the results from this review. A systematic review and meta‐analysis on PDT for BCC by <a href="./references#CD003412-bbs2-0146" title="WangH , XuY , ShiJ , GaoX , GengL . Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis. Photodermatology, Photoimmunology &amp; Photomedicine2015;31(1):44-53.">Wang 2015</a> identified eight RCTs, of which seven are included in our review. This review pooled the results of all these studies regardless of PDT method including photosensitising agent (e.g. MAL versus ALA). We decided against pooling all types of PDT as the pharmacology for the photosensitising compounds is different and the evidence for their similar efficacy is of low quality. We disagree with the Wang study where they report that PDT is as effective as pharmacologic treatment (imiquimod and 5‐FU creams). The Wang study combined both imiquimod and 5‐FU in their analyses, and by doing so, they masked imiquimod's probable superior efficacy to PDT in terms of reducing recurrences. </p> <section id="CD003412-sec-0309"> <h4 class="title">Risk of transformation with non‐invasive treatments?</h4> <p>We thought it was important to address the fairly recent literature that has suggested that topical therapies and PDT may cause non‐aggressive sBCCs to "transform" to more aggressive subtypes (e.g. nodular, infiltrative or morphoeaform subtypes). This is an area of contention and others have argued that apparent transformation is more likely the result of sampling error from the diagnostic biopsies. The <a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a> study (MAL‐PDT versus imiquimod versus 5‐FU cream) data were used for a separate observational study to address the question of whether non‐invasive therapies cause sBCCs to transform to higher risk subtypes (<a href="./references#CD003412-bbs2-0142" title="van Delft Lc, NelemansPJ , JansenMH , AritsH , RoozeboomMH , HamidMA , et al. Histologic subtype of treatment failures after noninvasive therapy for superficial basal cell carcinoma: An observational study. Journal of the American Academy of Dermatology 2019, 2019;80(4):1022-8. [DOI: 10.1016/j.jaad.2018.12.028]">van Delft 2019</a>). The study found that of 166 treatment failures (38.6%) were a non‐superficial subtype and the proportion with a more aggressive subtype than the primary tumour were 51.3% (38.74) for early and 28.3% (26/92) for later treatment failures. The authors conclude that more aggressive treatment failure recurrences after noninvasive therapy for sBCC occur most often within the first three months following treatment, probably indicating sampling error and consequent under‐diagnosis of more aggressive components in the primary tumour rather than transformation. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003412-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram." data-id="CD003412-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003412-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003412-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mohs micrographic surgery vs surgical excision, Outcome 1: Recurrence at 3 years (lesions)" data-id="CD003412-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Mohs micrographic surgery vs surgical excision, Outcome 1: Recurrence at 3 years (lesions) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mohs micrographic surgery vs surgical excision, Outcome 2: Recurrence at 5 years (lesions)" data-id="CD003412-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Mohs micrographic surgery vs surgical excision, Outcome 2: Recurrence at 5 years (lesions) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Imiquimod vs surgical excision, Outcome 1: Recurrence at 3 years" data-id="CD003412-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Imiquimod vs surgical excision, Outcome 1: Recurrence at 3 years</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Imiquimod vs surgical excision, Outcome 2: Recurrence at 5 years" data-id="CD003412-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Imiquimod vs surgical excision, Outcome 2: Recurrence at 5 years</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Imiquimod vs surgical excision, Outcome 3: Cosmetic outcome (good/excellent)" data-id="CD003412-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Imiquimod vs surgical excision, Outcome 3: Cosmetic outcome (good/excellent)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Imiquimod vs surgical excision, Outcome 4: Pain (moderate/severe)" data-id="CD003412-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Imiquimod vs surgical excision, Outcome 4: Pain (moderate/severe)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Radiotherapy vs surgical excision (with or without frozen section margin control), Outcome 1: Recurrence at 3 years" data-id="CD003412-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Radiotherapy vs surgical excision (with or without frozen section margin control), Outcome 1: Recurrence at 3 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Radiotherapy vs surgical excision (with or without frozen section margin control), Outcome 2: Recurrence at 4 years" data-id="CD003412-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Radiotherapy vs surgical excision (with or without frozen section margin control), Outcome 2: Recurrence at 4 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Radiotherapy vs surgical excision (with or without frozen section margin control), Outcome 3: Cosmetic outcome (good)" data-id="CD003412-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Radiotherapy vs surgical excision (with or without frozen section margin control), Outcome 3: Cosmetic outcome (good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Curettage vs surgical excision, Outcome 1: Recurrence at 2 years (lesions)" data-id="CD003412-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Curettage vs surgical excision, Outcome 1: Recurrence at 2 years (lesions)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Curettage and cautery vs surgical excision, Outcome 1: Recurrence at 2 years (lesions)" data-id="CD003412-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Curettage and cautery vs surgical excision, Outcome 1: Recurrence at 2 years (lesions) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Curettage and cautery vs curettage, Outcome 1: Recurrence at 2 years (lesions)" data-id="CD003412-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Curettage and cautery vs curettage, Outcome 1: Recurrence at 2 years (lesions) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Low dose radiotherapy vs high dose radiotherapy, Outcome 1: Early treatment failure" data-id="CD003412-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Low dose radiotherapy vs high dose radiotherapy, Outcome 1: Early treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Radiotherapy vs cryosurgery, Outcome 1: Recurrence at 2 years" data-id="CD003412-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Radiotherapy vs cryosurgery, Outcome 1: Recurrence at 2 years</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Curettage and cryosurgery vs surgical excision, Outcome 1: Recurrence at 3 years (lesions)" data-id="CD003412-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Curettage and cryosurgery vs surgical excision, Outcome 1: Recurrence at 3 years (lesions) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Curettage and cryosurgery vs surgical excision, Outcome 2: Recurrence at 5 years (lesions)" data-id="CD003412-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Curettage and cryosurgery vs surgical excision, Outcome 2: Recurrence at 5 years (lesions) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Curettage and cryosurgery vs surgical excision, Outcome 3: Cosmetic outcome (good)" data-id="CD003412-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Curettage and cryosurgery vs surgical excision, Outcome 3: Cosmetic outcome (good) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: MAL‐PDT vs surgical excision, Outcome 1: Recurrence at 3 years (lesions)" data-id="CD003412-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: MAL‐PDT vs surgical excision, Outcome 1: Recurrence at 3 years (lesions)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: MAL‐PDT vs surgical excision, Outcome 2: Cosmetic outcome (good/excellent)" data-id="CD003412-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: MAL‐PDT vs surgical excision, Outcome 2: Cosmetic outcome (good/excellent)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: MAL‐PDT vs surgical excision, Outcome 3: Pain" data-id="CD003412-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: MAL‐PDT vs surgical excision, Outcome 3: Pain</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: MAL‐PDT vs surgical excision, Outcome 4: Early treatment failure (lesions)" data-id="CD003412-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: MAL‐PDT vs surgical excision, Outcome 4: Early treatment failure (lesions)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: ALA‐PDT vs surgical excision, Outcome 1: Recurrence at 3 years (lesions)" data-id="CD003412-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: ALA‐PDT vs surgical excision, Outcome 1: Recurrence at 3 years (lesions)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: ALA‐PDT vs surgical excision, Outcome 2: Recurrence at 5 years (lesions)" data-id="CD003412-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: ALA‐PDT vs surgical excision, Outcome 2: Recurrence at 5 years (lesions)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: ALA‐PDT vs surgical excision, Outcome 3: Early treatment failure" data-id="CD003412-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: ALA‐PDT vs surgical excision, Outcome 3: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: ALA‐PDT vs MAL‐PDT, Outcome 1: Cosmetic outcome (good/very good)" data-id="CD003412-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: ALA‐PDT vs MAL‐PDT, Outcome 1: Cosmetic outcome (good/very good)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: ALA‐PDT vs MAL‐PDT, Outcome 2: Pain (visual analogue score)" data-id="CD003412-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: ALA‐PDT vs MAL‐PDT, Outcome 2: Pain (visual analogue score)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: ALA‐PDT vs MAL‐PDT, Outcome 3: Pain (numerical rating scale)" data-id="CD003412-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: ALA‐PDT vs MAL‐PDT, Outcome 3: Pain (numerical rating scale)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-012.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: ALA‐PDT vs MAL‐PDT, Outcome 4: Early treatment failure" data-id="CD003412-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-012.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-012.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: ALA‐PDT vs MAL‐PDT, Outcome 4: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-012.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: BF‐200 ALA‐PDT vs MAL‐PDT, Outcome 1: Early treatment failure" data-id="CD003412-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: BF‐200 ALA‐PDT vs MAL‐PDT, Outcome 1: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: HAL‐PDT vs MAL‐PDT, Outcome 1: Early treatment failure" data-id="CD003412-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: HAL‐PDT vs MAL‐PDT, Outcome 1: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: HAL‐PDT vs BF‐200 ALA‐PDT, Outcome 1: Early treatment failure" data-id="CD003412-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: HAL‐PDT vs BF‐200 ALA‐PDT, Outcome 1: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-016.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: MAL‐PDT vs cryosurgery, Outcome 1: Recurrence at 3 years (lesions)" data-id="CD003412-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-016.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-016.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: MAL‐PDT vs cryosurgery, Outcome 1: Recurrence at 3 years (lesions)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-016.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-016.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: MAL‐PDT vs cryosurgery, Outcome 2: Recurrence at 5 years (lesions)" data-id="CD003412-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-016.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-016.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16: MAL‐PDT vs cryosurgery, Outcome 2: Recurrence at 5 years (lesions)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-016.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-016.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: MAL‐PDT vs cryosurgery, Outcome 3: Cosmetic outcome (good/excellent)" data-id="CD003412-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-016.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-016.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16: MAL‐PDT vs cryosurgery, Outcome 3: Cosmetic outcome (good/excellent)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-016.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-016.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: MAL‐PDT vs cryosurgery, Outcome 4: Pain" data-id="CD003412-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-016.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-016.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.4</div> <div class="figure-caption"> <p>Comparison 16: MAL‐PDT vs cryosurgery, Outcome 4: Pain</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-016.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-016.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: MAL‐PDT vs cryosurgery, Outcome 5: Early treatment failure (lesions)" data-id="CD003412-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-016.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-016.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.5</div> <div class="figure-caption"> <p>Comparison 16: MAL‐PDT vs cryosurgery, Outcome 5: Early treatment failure (lesions)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-016.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-017.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: ALA‐PDT vs cryosurgery, Outcome 1: Cosmetic outcome (good/excellent)" data-id="CD003412-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-017.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-017.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17: ALA‐PDT vs cryosurgery, Outcome 1: Cosmetic outcome (good/excellent)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-017.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-017.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: ALA‐PDT vs cryosurgery, Outcome 2: Pain" data-id="CD003412-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-017.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-017.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17: ALA‐PDT vs cryosurgery, Outcome 2: Pain</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-017.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-018.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Imiquimod cream vs MAL‐PDT, Outcome 1: Recurrence at 3 years" data-id="CD003412-fig-0042" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-018.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-018.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18: Imiquimod cream vs MAL‐PDT, Outcome 1: Recurrence at 3 years</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-018.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-018.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Imiquimod cream vs MAL‐PDT, Outcome 2: Recurrence at 5 years" data-id="CD003412-fig-0043" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-018.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-018.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18: Imiquimod cream vs MAL‐PDT, Outcome 2: Recurrence at 5 years</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-018.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-018.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Imiquimod cream vs MAL‐PDT, Outcome 3: Cosmetic outcome (good/excellent, observer rated at 1 year)" data-id="CD003412-fig-0044" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-018.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-018.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.3</div> <div class="figure-caption"> <p>Comparison 18: Imiquimod cream vs MAL‐PDT, Outcome 3: Cosmetic outcome (good/excellent, observer rated at 1 year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-018.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-018.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Imiquimod cream vs MAL‐PDT, Outcome 4: Pain (moderate/severe)" data-id="CD003412-fig-0045" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-018.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-018.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.4</div> <div class="figure-caption"> <p>Comparison 18: Imiquimod cream vs MAL‐PDT, Outcome 4: Pain (moderate/severe)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-018.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-018.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Imiquimod cream vs MAL‐PDT, Outcome 5: Early treatment failure" data-id="CD003412-fig-0046" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-018.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-018.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.5</div> <div class="figure-caption"> <p>Comparison 18: Imiquimod cream vs MAL‐PDT, Outcome 5: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-018.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-019.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: 5‐FU cream vs MAL‐PDT, Outcome 1: Recurrence at 3 years" data-id="CD003412-fig-0047" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-019.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-019.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19: 5‐FU cream vs MAL‐PDT, Outcome 1: Recurrence at 3 years</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-019.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-019.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: 5‐FU cream vs MAL‐PDT, Outcome 2: Recurrence at 5 years" data-id="CD003412-fig-0048" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-019.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-019.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19: 5‐FU cream vs MAL‐PDT, Outcome 2: Recurrence at 5 years</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-019.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-019.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: 5‐FU cream vs MAL‐PDT, Outcome 3: Cosmetic outcome (good/excellent, observer rated at 1 year)" data-id="CD003412-fig-0049" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-019.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-019.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.3</div> <div class="figure-caption"> <p>Comparison 19: 5‐FU cream vs MAL‐PDT, Outcome 3: Cosmetic outcome (good/excellent, observer rated at 1 year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-019.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-019.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: 5‐FU cream vs MAL‐PDT, Outcome 4: Pain (moderate/severe)" data-id="CD003412-fig-0050" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-019.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-019.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.4</div> <div class="figure-caption"> <p>Comparison 19: 5‐FU cream vs MAL‐PDT, Outcome 4: Pain (moderate/severe)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-019.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-019.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: 5‐FU cream vs MAL‐PDT, Outcome 5: Early treatment failure" data-id="CD003412-fig-0051" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-019.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-019.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.5</div> <div class="figure-caption"> <p>Comparison 19: 5‐FU cream vs MAL‐PDT, Outcome 5: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-019.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-020.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Laser ALA‐PDT vs broadband light ALA‐PDT, Outcome 1: Cosmetic outcome (good/excellent, observer rated at 6 months)" data-id="CD003412-fig-0052" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-020.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-020.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20: Laser ALA‐PDT vs broadband light ALA‐PDT, Outcome 1: Cosmetic outcome (good/excellent, observer rated at 6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-020.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-020.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Laser ALA‐PDT vs broadband light ALA‐PDT, Outcome 2: Pain" data-id="CD003412-fig-0053" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-020.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-020.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20: Laser ALA‐PDT vs broadband light ALA‐PDT, Outcome 2: Pain</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-020.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-021.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: AFXL MAL‐PDT vs MAL‐PDT, Outcome 1: Cosmetic outcome (good/excellent)" data-id="CD003412-fig-0054" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-021.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-021.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21: AFXL MAL‐PDT vs MAL‐PDT, Outcome 1: Cosmetic outcome (good/excellent)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-021.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-021.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: AFXL MAL‐PDT vs MAL‐PDT, Outcome 2: Early treatment failure" data-id="CD003412-fig-0055" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-021.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-021.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.2</div> <div class="figure-caption"> <p>Comparison 21: AFXL MAL‐PDT vs MAL‐PDT, Outcome 2: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-021.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-022.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: MAL‐PDT vs placebo, Outcome 1: Cosmetic outcome (good/excellent, observer rated at 6 months))" data-id="CD003412-fig-0056" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-022.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-022.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22: MAL‐PDT vs placebo, Outcome 1: Cosmetic outcome (good/excellent, observer rated at 6 months)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-022.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-022.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: MAL‐PDT vs placebo, Outcome 2: Pain (frequency reported as local AE)" data-id="CD003412-fig-0057" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-022.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-022.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22: MAL‐PDT vs placebo, Outcome 2: Pain (frequency reported as local AE)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-022.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-022.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: MAL‐PDT vs placebo, Outcome 3: Early treatment failure (lesions)" data-id="CD003412-fig-0058" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-022.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-022.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.3</div> <div class="figure-caption"> <p>Comparison 22: MAL‐PDT vs placebo, Outcome 3: Early treatment failure (lesions)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-022.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-023.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Imiquimod cream vs 5‐FU cream, Outcome 1: Recurrence at 3 years" data-id="CD003412-fig-0059" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-023.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-023.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23: Imiquimod cream vs 5‐FU cream, Outcome 1: Recurrence at 3 years</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-023.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-023.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Imiquimod cream vs 5‐FU cream, Outcome 2: Recurrence at 5 years" data-id="CD003412-fig-0060" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-023.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-023.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.2</div> <div class="figure-caption"> <p>Comparison 23: Imiquimod cream vs 5‐FU cream, Outcome 2: Recurrence at 5 years</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-023.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-023.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Imiquimod cream vs 5‐FU cream, Outcome 3: Cosmetic outcome (good/excellent, observer rated at 1 year)" data-id="CD003412-fig-0061" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-023.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-023.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.3</div> <div class="figure-caption"> <p>Comparison 23: Imiquimod cream vs 5‐FU cream, Outcome 3: Cosmetic outcome (good/excellent, observer rated at 1 year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-023.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-023.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Imiquimod cream vs 5‐FU cream, Outcome 4: Pain (moderate/severe)" data-id="CD003412-fig-0062" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-023.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-023.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.4</div> <div class="figure-caption"> <p>Comparison 23: Imiquimod cream vs 5‐FU cream, Outcome 4: Pain (moderate/severe)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-023.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-023.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Imiquimod cream vs 5‐FU cream, Outcome 5: Early treatment failure" data-id="CD003412-fig-0063" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-023.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-023.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.5</div> <div class="figure-caption"> <p>Comparison 23: Imiquimod cream vs 5‐FU cream, Outcome 5: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-023.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-024.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 24: Imiquimod vs radiotherapy, Outcome 1: Cosmetic outcome (excellent, participant rated at 6 weeks)" data-id="CD003412-fig-0064" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-024.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-024.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.1</div> <div class="figure-caption"> <p>Comparison 24: Imiquimod vs radiotherapy, Outcome 1: Cosmetic outcome (excellent, participant rated at 6 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-024.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-025.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 25: Imiquimod cream under occlusion vs no occlusion, Outcome 1: Early treatment failure" data-id="CD003412-fig-0065" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-025.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-025.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.1</div> <div class="figure-caption"> <p>Comparison 25: Imiquimod cream under occlusion vs no occlusion, Outcome 1: Early treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-025.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-026.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 26: Imiquimod cream vs vehicle, Outcome 1: Early treatment failure" data-id="CD003412-fig-0066" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-026.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-026.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.1</div> <div class="figure-caption"> <p>Comparison 26: Imiquimod cream vs vehicle, Outcome 1: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-026.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-027.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 27: Imiquimod 5 weeks vs 8 weeks, Outcome 1: Recurrence at 1 year" data-id="CD003412-fig-0067" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-027.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-027.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.1</div> <div class="figure-caption"> <p>Comparison 27: Imiquimod 5 weeks vs 8 weeks, Outcome 1: Recurrence at 1 year</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-027.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-028.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 28: Imiquimod 8 weeks vs 12 weeks, Outcome 1: Early treatment failure" data-id="CD003412-fig-0068" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-028.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-028.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.1</div> <div class="figure-caption"> <p>Comparison 28: Imiquimod 8 weeks vs 12 weeks, Outcome 1: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-028.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-029.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 29: 5‐FU in PC vs 5‐FU in petrolatum, Outcome 1: Early treatment failure (lesions)" data-id="CD003412-fig-0069" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-029.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-029.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.1</div> <div class="figure-caption"> <p>Comparison 29: 5‐FU in PC vs 5‐FU in petrolatum, Outcome 1: Early treatment failure (lesions) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-029.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-030.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 30: 5‐FU/epinephrine gel (1.0 mL once a week for 6 weeks vs 0.5 mL once a week for 6 weeks, Outcome 1: Early treatment failure" data-id="CD003412-fig-0070" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-030.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-030.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.1</div> <div class="figure-caption"> <p>Comparison 30: 5‐FU/epinephrine gel (1.0 mL once a week for 6 weeks vs 0.5 mL once a week for 6 weeks, Outcome 1: Early treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-030.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-031.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 31: 5‐FU/epinephrine gel(1.0 mL twice a week for 3 weeks vs 0.5 mL twice a week for 3 weeks), Outcome 1: Early treatment failure" data-id="CD003412-fig-0071" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-031.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-031.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.1</div> <div class="figure-caption"> <p>Comparison 31: 5‐FU/epinephrine gel(1.0 mL twice a week for 3 weeks vs 0.5 mL twice a week for 3 weeks), Outcome 1: Early treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-031.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-032.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 32: 5‐FU/epinephrine gel(0.5ml twice a week for 4 weeks vs 0.5 mL three times a week for 2 weeks., Outcome 1: Early treatment failure" data-id="CD003412-fig-0072" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-032.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-032.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.1</div> <div class="figure-caption"> <p>Comparison 32: 5‐FU/epinephrine gel(0.5ml twice a week for 4 weeks vs 0.5 mL three times a week for 2 weeks., Outcome 1: Early treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-032.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-033.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 33: Electrochemotherapy vs surgical excision, Outcome 1: Recurrence at 3 years" data-id="CD003412-fig-0073" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-033.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-033.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.1</div> <div class="figure-caption"> <p>Comparison 33: Electrochemotherapy vs surgical excision, Outcome 1: Recurrence at 3 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-033.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-033.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 33: Electrochemotherapy vs surgical excision, Outcome 2: Recurrence at 5 years" data-id="CD003412-fig-0074" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-033.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-033.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.2</div> <div class="figure-caption"> <p>Comparison 33: Electrochemotherapy vs surgical excision, Outcome 2: Recurrence at 5 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-033.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-034.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 34: Ingenol vs vehicle (day 1+2), Outcome 1: Early treatment failure" data-id="CD003412-fig-0075" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-034.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-034.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.1</div> <div class="figure-caption"> <p>Comparison 34: Ingenol vs vehicle (day 1+2), Outcome 1: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-034.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-035.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 35: Ingenol vs vehicle (day 1+8), Outcome 1: Early treatment failure" data-id="CD003412-fig-0076" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-035.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-035.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 35.1</div> <div class="figure-caption"> <p>Comparison 35: Ingenol vs vehicle (day 1+8), Outcome 1: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-035.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-036.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 36: Ingenol under occlusion vs no occlusion, Outcome 1: Early treatment failure" data-id="CD003412-fig-0077" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-036.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-036.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 36.1</div> <div class="figure-caption"> <p>Comparison 36: Ingenol under occlusion vs no occlusion, Outcome 1: Early treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-036.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-037.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 37: Solasodine glycoside cream vs vehicle, Outcome 1: Early treatment failure" data-id="CD003412-fig-0078" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-037.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-037.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.1</div> <div class="figure-caption"> <p>Comparison 37: Solasodine glycoside cream vs vehicle, Outcome 1: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-037.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-038.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 38: Valproic acid gel + Tazarotene gel vs placebo + Tazarotene, Outcome 1: Early treatment failure" data-id="CD003412-fig-0079" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-038.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-038.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 38.1</div> <div class="figure-caption"> <p>Comparison 38: Valproic acid gel + Tazarotene gel vs placebo + Tazarotene, Outcome 1: Early treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-038.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-039.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 39: Diclofenac gel vs calcitriol ointment, Outcome 1: Early treatment failure" data-id="CD003412-fig-0080" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-039.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-039.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 39.1</div> <div class="figure-caption"> <p>Comparison 39: Diclofenac gel vs calcitriol ointment, Outcome 1: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-039.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-040.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 40: Diclofenac gel vs diclofenac+calcitriol, Outcome 1: Early treatment failure" data-id="CD003412-fig-0081" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-040.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-040.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 40.1</div> <div class="figure-caption"> <p>Comparison 40: Diclofenac gel vs diclofenac+calcitriol, Outcome 1: Early treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-040.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-041.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 41: Calcitriol ointment vs calcitriol+diclofenac, Outcome 1: Early treatment failure" data-id="CD003412-fig-0082" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-041.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-041.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 41.1</div> <div class="figure-caption"> <p>Comparison 41: Calcitriol ointment vs calcitriol+diclofenac, Outcome 1: Early treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-041.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-042.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 42: PDL one session vs PDL two sessions, Outcome 1: Early treatment failure" data-id="CD003412-fig-0083" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-042.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-042.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 42.1</div> <div class="figure-caption"> <p>Comparison 42: PDL one session vs PDL two sessions, Outcome 1: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-042.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-043.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 43: PDL 7mm spot‐size single pulses vs PDL 10mm spot‐size stacked pulses, Outcome 1: Early treatment failure (lesions)" data-id="CD003412-fig-0084" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-043.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-043.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 43.1</div> <div class="figure-caption"> <p>Comparison 43: PDL 7mm spot‐size single pulses vs PDL 10mm spot‐size stacked pulses, Outcome 1: Early treatment failure (lesions) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-043.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-044.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 44: PDL vs sham laser, Outcome 1: Early treatment failure (lesions)" data-id="CD003412-fig-0085" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-044.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-044.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 44.1</div> <div class="figure-caption"> <p>Comparison 44: PDL vs sham laser, Outcome 1: Early treatment failure (lesions)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-044.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-045.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 45: PDL vs no treatment, Outcome 1: Early treatment failure" data-id="CD003412-fig-0086" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-045.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-045.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 45.1</div> <div class="figure-caption"> <p>Comparison 45: PDL vs no treatment, Outcome 1: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-045.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-046.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 46: Interferon alpha 2b vs placebo, Outcome 1: Early treatment failure" data-id="CD003412-fig-0087" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-046.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-046.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 46.1</div> <div class="figure-caption"> <p>Comparison 46: Interferon alpha 2b vs placebo, Outcome 1: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-046.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-047.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 47: Interferon beta vs placebo, Outcome 1: Early treatment failure" data-id="CD003412-fig-0088" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-047.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-047.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 47.1</div> <div class="figure-caption"> <p>Comparison 47: Interferon beta vs placebo, Outcome 1: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-047.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-048.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 48: Interferon alpha 2a+2b vs interferon alpha 2a, Outcome 1: Early treatment failure" data-id="CD003412-fig-0089" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-048.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-048.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 48.1</div> <div class="figure-caption"> <p>Comparison 48: Interferon alpha 2a+2b vs interferon alpha 2a, Outcome 1: Early treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-048.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-049.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 49: Interferon alpha 2a+2b vs interferon alpha 2b, Outcome 1: Early treatment failure" data-id="CD003412-fig-0090" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-049.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-049.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 49.1</div> <div class="figure-caption"> <p>Comparison 49: Interferon alpha 2a+2b vs interferon alpha 2b, Outcome 1: Early treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-049.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-050.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 50: Interferon alpha 2b vs interferon alpha 2a, Outcome 1: Early treatment failure" data-id="CD003412-fig-0091" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-050.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-050.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 50.1</div> <div class="figure-caption"> <p>Comparison 50: Interferon alpha 2b vs interferon alpha 2a, Outcome 1: Early treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-050.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-051.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 51: 3x a week vs single dose protamine zinc chelate IFN alpha 2b, Outcome 1: Early treatment failure" data-id="CD003412-fig-0092" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-051.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-051.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 51.1</div> <div class="figure-caption"> <p>Comparison 51: 3x a week vs single dose protamine zinc chelate IFN alpha 2b, Outcome 1: Early treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-051.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003412-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/urn:x-wiley:14651858:media:CD003412:CD003412-CMP-052.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 52: Topical sinecatechin vs placebo, Outcome 1: Early treatment failure" data-id="CD003412-fig-0093" src="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-052.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_t/tCD003412-CMP-052.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 52.1</div> <div class="figure-caption"> <p>Comparison 52: Topical sinecatechin vs placebo, Outcome 1: Early treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/media/CDSR/CD003412/image_n/nCD003412-CMP-052.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003412-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mohs micrographic surgery compared to surgical excision for basal cell carcinoma of the skin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mohs micrographic surgery compared to surgical excision for high‐risk BCC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from hospitals in the Netherlands<br/><b>Intervention:</b> Mohs micrographic surgery<br/><b>Comparison:</b> surgical excision </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Surgical excision</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Mohs micrographic surgery</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.64<br/>(0.16 to 2.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>331<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Study measured outcome at 30 months.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000<br/>(5 to 77) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.61<br/>(0.18 to 2.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>259<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/>(9 to 107) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cosmetic outcome</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Although a reported outcome, raw data were not available. The authors of <a href="./references#CD003412-bbs2-0045" title="EssersBA , DirksenCD , NiemanFH , SmeetsNW , KrekelsGA , PrinsMH , et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Archives of Dermatology2006;142(2):187-94. [CENTRAL: CN-00555278] MosterdK , KrekelsGA , NiemanFH , OstertagJU , EssersBA , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncology2008;9(12):1149-56. [CENTRAL: CN-00665334] SmeetsNW , KrekelsGA , OstertagJU , EssersBA , DirksenCD , NiemanFH , et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet2004;364(9447):1766-72. [CENTRAL: CN-00492695] Van LooE , MosterdK , KrekelsGA , RoozeboomMH , OstertagJU , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European Journal of Cancer2014;50(17):3011-20. [CENTRAL: CN-01043314] ">Smeets 2004</a> state that overall, cosmetic outcomes did not significantly differ between groups. </p> <p>The cosmetic outcomes were judged by participants 18 months post‐operatively, and photographs of a selected group of tumours (first 139 primary) were judged retrospectively by a panel of six individuals. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early treatment failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm. </p> <p><sup>2</sup> Downgraded two levels for very serious indirectness as although the authors did compare the cosmetic outcomes between the two groups, they did not present the data for analysis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mohs micrographic surgery compared to surgical excision for basal cell carcinoma of the skin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003412-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Imiquimod compared to surgical excision for basal cell carcinoma of the skin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Imiquimod compared to surgical excision for low‐risk BCC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from hospitals in the UK<br/><b>Intervention:</b> 5% imiquimod cream<br/><b>Comparison:</b> surgical excision </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with surgical excision</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Imiquimod</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 10.30<br/>(3.22 to 32.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>401<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1000<br/>(51 to 526) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 7.73<br/>(2.81 to 21.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>383<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>175 per 1000<br/>(64 to 481) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.70<br/>(1.35 to 2.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>344<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Observer‐rated at 3 years on a 6‐point scale.<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>356 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>606 per 1000<br/>(481 to 766) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.00<br/>(0.94 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>326<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participant‐rated at 3 years on a 6‐point scale.<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>922 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>922 per 1000<br/>(866 to 977) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain (moderate/severe)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.36<br/>(0.98 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>443<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain measured during treatment.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>219 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>298 per 1000<br/>(215 to 412) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain (moderate/severe)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.47<br/>(0.29 to 0.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>439<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain measured during follow‐up.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>199 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000<br/>(58 to 153) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early treatment failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI. </p> <p><sup>2</sup> Downgraded one level for serious imprecision as only a single study with a small sample size and one level for serious risk of bias as unable to truly blind due to the nature of interventions (i.e. presence or absence of scar will unblind to treatment allocation). </p> <p><sup>3</sup> Downgraded one level for serious imprecision as only a single study with a small sample size and one level for serious risk of attrition bias as fewer pain data were available for the surgical excision group. </p> <p><sup>4</sup> 6‐point scale: unable to see lesion, very poor, poor, fair, good, excellent. </p> <p><sup>5</sup> Measured on a scale from: no pain, mild pain, mild‐to‐moderate pain, moderate pain, moderate‐to‐severe pain and severe pain. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Imiquimod compared to surgical excision for basal cell carcinoma of the skin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003412-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Radiotherapy compared to surgical excision (with or without frozen section margin control) for basal cell carcinoma of the skin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Radiotherapy compared to surgical excision for high‐ and low‐risk BCC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from a single hospital in France<br/><b>Intervention:</b> radiotherapy<br/><b>Comparison:</b> surgical excision (with or without frozen section margin control) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with surgical excision</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with radiotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 19.11<br/>(1.12 to 325.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>347<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000<br/>(6 to 1883) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 4 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 11.06</p> <p>(1.44 to 84.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>347<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 1000<br/>(8 to 487) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.76 (0.63 to 0.91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>347<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participant‐rated at 4 years on a 3‐point scale.<sup>4</sup> ITT analysis performed. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>661 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>502 per 1000<br/>(416 to 601) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.48<br/>(0.37 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>347<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Observer‐rated at 4 years on a 3‐point scale.<sup>4</sup> ITT analysis performed. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>603 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 per 1000<br/>(223 to 374) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early treatment failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>ITT:</b> intention‐to‐treat; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for very serious imprecision due to very wide 95% CI (although excludes 1, there is a greater than 100‐fold difference). </p> <p><sup>2</sup> Downgraded one level for serious indirectness (outcome outside our pre‐specified time‐points) and downgraded one level for serious imprecision as only a single study with a small sample size. </p> <p><sup>3</sup> Downgraded one level for serious risk of bias as unable to truly blind due to the nature of interventions. </p> <p><sup>4</sup> 3‐point scale: bad, fair, good. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Radiotherapy compared to surgical excision (with or without frozen section margin control) for basal cell carcinoma of the skin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003412-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">MAL‐PDT compared to surgical excision for basal cell carcinoma of the skin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>MAL‐PDT compared to surgical excision for low‐risk BCC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from hospitals in Brazil, the UK, Germany, Switzerland and Australia<br/><b>Intervention:</b> MAL‐PDT<br/><b>Comparison:</b> surgical excision </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with surgical excision</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with MAL‐PDT</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 26.47<br/>(1.63 to 429.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>68<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>364 per 1000<br/>(49 to 13027) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (excellent/good)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/>(1.09 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>309<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participant‐rated at 1 year on a 4‐point scale.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>825 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>973 per 1000<br/>(899 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (excellent/good)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.87<br/>(1.54 to 2.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>256<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Observer‐rated at 1 year on a 4‐point scale.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>466 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>871 per 1000<br/>(717 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.20</p> <p>(0.60 to 8.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>101</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Study reported frequency of "pain in skin" and "burning sensation of skin" as part of AEs. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000</p> <p>(37 to 492)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Early treatment failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 6.66<br/>(1.22 to 36.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>173<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000<br/>(14 to 419) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>AEs:</b> adverse effects; <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for very serious imprecision due to very wide 95% CI (although excludes 1, there is a greater than 100‐fold difference). </p> <p><sup>2</sup> Downgraded one level for serious risk of bias as unable to truly blind due to the nature of interventions. </p> <p><sup>3</sup> Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm. </p> <p><sup>4</sup> Downgraded one level for serious imprecision due to small sample size and wide 95% CI. </p> <p><sup>5</sup> 4‐point scale: poor (extensive occurrence of scarring, atrophy, or induration), fair (slight to moderate occurrence of scarring, atrophy or induration), good (no scarring, atrophy or induration and moderate redness or increase in pigmentation compared with adjacent skin), excellent (no scarring, atrophy, or induration and slight or no redness or change in pigmentation compared with adjacent skin). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">MAL‐PDT compared to surgical excision for basal cell carcinoma of the skin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003412-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Imiquimod cream compared to MAL‐PDT for basal cell carcinoma of the skin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Imiquimod cream compared to MAL‐PDT for low‐risk BCC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from seven hospitals in the Netherlands<br/><b>Intervention:</b> 5% imiquimod cream<br/><b>Comparison:</b> MAL‐PDT </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PDT</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Imiquimod cream</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.44<br/>(0.32 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>277<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>516 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>227 per 1000<br/>(165 to 320) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.42<br/>(0.31 to 0.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>228<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>686 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>288 per 1000<br/>(213 to 391) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (excellent/good)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.84 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>370<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blinded observer‐rated at 1 year on 4‐point scale.<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>624 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>611 per 1000<br/>(524 to 723) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain (moderate/severe)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.60<br/>(0.41 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>371<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>During treatment: week of treatment with highest frequency of reported moderate/severe pain (week 6 for imiquimod, treatment cycle 2 for PDT). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>305 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1000<br/>(125 to 266) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Early treatment failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.64<br/>(0.37 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>385<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/>(59 to 172) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for serious imprecision as only a single study with a small sample size. </p> <p><sup>2</sup> Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI. </p> <p><sup>3</sup> 4‐point scale: poor, fair, good, excellent. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Imiquimod cream compared to MAL‐PDT for basal cell carcinoma of the skin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003412-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Pain table</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study (comparator)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Analgesia</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assessment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Severe pain</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Other notable outcomes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0003" title="Abd El-NabyNM , El-FarNN , Al-Shenawy HA , ElshwadfySE , KouraAA . Pulsed dye laser in the treatment of basal cell carcinoma: a single session versus two sessions–a randomized controlled trial. Indian Journal of Dermatology, Venereology, and Leprology2019;85(5):475. ">Abd El‐Naby 2019</a> (one PDL session / two PDL sessions) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 2 patients experienced pain and ulceration in the single‐session group. There was no significant difference between the two groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0004" title="AlpsoyE , YikmazE , BasaranE , YazarS . Comparison of the effects of intralesional interferon alfa-1a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. Journal of Dermatology1996;23(6):394-6. [CENTRAL: CN-00127615] ">Alpsoy 1996</a> (Interferon alpha 2a / 2b / 2a&amp;b) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transient local discomfort at injection site (requiring no treatment) experienced in all patients during injection. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a> (MAL PDT / Imiquimod / 5‐FU) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weekly post‐treatment patient‐reported maximum score for pain and burning sensation on a visual analogue scale (0–10) for six weeks, and maximum score during the first and second photodynamic therapy sessions. Categorised as 0‐3 = mild, 4‐6 moderate, 7‐10 = severe. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Highest overall percentage experienced pain during second PDT treatment (10%). Highest severe pain rating in imiquimod group found at week 6 (7%) and in Fluorouracil group at week 4 (4%). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maximum duration of pain and burning sensation: Imiquimod group = 6 weeks, Fluorouracil group = 4 weeks, PDT group = 2 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0007" title="Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Methyl aminolaevulinate photodynamic therapy vs. cryotherapy in primary superficial basal cell carcinoma: results of a 36-month follow-up. British Journal of Dermatology2005;153(1):29. Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Topical methyl aminolevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. European Journal of Dermatolology2008;18(5):547-53. [CENTRAL: CN-00668120] ">Basset‐Seguin 2008</a> (MAL‐PDT / cryosurgery) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AEs at each follow‐up visit up to three months post‐treatment according to three‐point severity scale (mild/moderate/severe). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1% in cryosurgery group and 5% in MAL‐ PDT group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Local pain in 33% in cryosurgery group compared to 37% in MAL‐PDT group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0008" title="Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , MillerPS , et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncology2014;15(1):96-105. [CENTRAL: CN-00959373] WilliamsHC , Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. Journal of Investigative Dermatology2017;137(3):614-9. [CENTRAL: CN-01340067] [EMBASE: 614596349]">Bath‐Hextall 2014</a> (Imiquimod / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Routine analgesia after surgery. 1 week break and restart at lower frequency of application if unable to tolerate Imiquimod. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During treatment and at 16 weeks using six‐point scale. Number of days of moderate to severe pain. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30% of patients in the imiquimod group and 22% patients in the SE group had moderate or severe pain at some time during treatment. </p> <p>9% of patients treated with imiquimod had moderate or severe pain in the 16 weeks after treatment compared with 20% of patients who underwent SE. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>More patients reported pain during treatment in imiquimod group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0010" title="BrinkhuizenT , FrenckenKJ , NelemansPJ , HoffML , Kelleners-SmeetsNW , Zur HausenA , et al. The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): a phase II, randomized controlled trial. Journal of the American Academy of Dermatology2016;75(1):126-34. [CENTRAL: CN-01342883] [DOI: 10.1016/j.jaad.2016.01.050]">Brinkhuizen 2016</a> (diclofenac / diclofenac and calcitriol / calcitriol and no treatment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weekly patient‐reported pain score on a VAS (0–10).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain at application site most likely to occur in the combination therapy group (40.6%) as compared to the diclofenac group (25.8%) and the calcitriol group (12.5%). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0011" title="ChoiSH , KimKH , SongKH . Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial. Journal of the European Academy of Dermatology and Venereology2015;30(5):783-8. [CENTRAL: CN-01158122] [DOI: 10.1111/jdv.13453]">Choi 2016</a> (Er:YAG AFL‐PDT / MAL‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaesthetic cream prior to procedure.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VAS scores (11‐point scale) during illumination.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All patients experienced mild to moderate pain during PDT illumination. After illumination had ceased, the pain intensity immediately lessened, resolving over the next few hours. VAS scores (11‐point scale) during illumination were similar with Er:YAG AFL‐PDT (4.632 +/‐1.257) and MAL‐PDT (4.222 +/‐ 1.865; P = 0.437). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0017" title="EzughahFI , DaweRS , IbbotsonSH , FlemingCJ . A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment2008;19(2):111-7. [CENTRAL: CN-00706567] ">Ezughah 2008</a> (Imiquimod 8 weeks / 5 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients with intolerable reactions were allowed a rest period.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weekly visual analogue scale scores (10‐point scale).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One patient in 8‐week arm failed to complete course due to severe pain.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Composite weekly median VAS scores for tolerability are low, suggesting little discomfort in both study arms; there was no overall difference between the two groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0018" title="FoleyP , FreemanM , MenterA , SillerG , El-AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] FoleyP , FreemanM , SillerG , GebauerK , MurrellD , BarnetsonR , et al. A phase III randomized study comparing photodynamic therapy (PDT) using methyl aminolevulinate or placebo cream in nodular basal cell carcinoma (NBCC). Journal of the European Academy of Dermatology and Venereology2003;17(Suppl 3):231. [CENTRAL: CN-00478536] ">Foley 2009a</a>/<a href="./references#CD003412-bbs2-0019" title="FoleyP , FreemanM , MenterA , SillerG , El‐AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] TopeWD , MenterA , El AzharyR , SotoP . A comparison of topical MAL-PDT versus placebo-PDT in nodular basal cell carcinoma: results of a North American study. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology; 2005 Sep 28-Oct 03; Kuala Lumpur, Malaysia. 2005:376. [CENTRAL: CN-00602617] ">Foley 2009b</a> (MAL‐PDT / placebo) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects noted at each follow‐up visit and rated as mild/moderate/severe.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Burning more common than stinging or other skin pain. 29% in treatment arm compared to 12% in placebo group. Pain = 18% and 5%, respectively, stinging = 15% and 8%, respectively. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0020" title="Garcia-MartinE , Gil-ArribasLM , IdoipeM , AlfaroJ , PueyoV , PabloLE , et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. British Journal of Ophthalmology2011;95(10):1393-6. [CENTRAL: CN-00801928] ">Garcia‐Martin 2011</a> (Imiquimod / radiotherapy) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tobramycin and dexamethasone drops supplied if pain reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects noted at each follow‐up visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intense conjunctival irritation reported in 2 patents in the Imiquimod group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50% of the patients in the radiotherapy group compared to 60% in the imiquimod group reported symptoms of discomfort with blinking during treatment. One patient complained of slight pain in the lower eyelid during radiotherapy treatment. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0021" title="GeisseJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating superficial BCC. In: The 8th World Congress on Cancer of the Skin; 2001 July 18-21; Zurich, Switzerland. 2001:P58. [CENTRAL: CN-00520431] GeisseJK , RichP , PandyaA , GrossK , AndresK , GinkelA , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a randomized, vehicle-controlled study. Journal of the American Academy of Dermatology2002;47(3):390-8. [CENTRAL: CN-00390933] ">Geisse 2002</a> (Imiquimod BD / OD / 5xpw / 3xpw / vehicle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rest period of up to 14 days allowed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient‐reported adverse effects at each visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain and tenderness at the target site were reported less frequently than itching.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0022" title="GeisseJ , CaroI , LindholmJ , GolitzL , StamponeP , OwensM . Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology2004;50(5):722-33. [CENTRAL: CN-00469536] ">Geisse 2004</a> (Imiquimod 5xpw / 7xpw / vehicle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rest period allowed during which light dressing / emollient could be used.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient‐reported adverse effects at each visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient‐reported adverse effects at each visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0023" title="HaakCS , Togsverd-BoK , Thaysen-PetersenD , WulfHC , PaaschU , AndersonRR , et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas - a randomized clinical trial. British Journal of Dermatology2015;172(1):215-22. [CENTRAL: CN-01039978] ">Haak 2015</a> (AFXL‐PDT / MAL‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mepivacaine 10mg/mL injected prior to procedure.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain scores during LED illumination, scored from 0‐10.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>“AFXL pre‐treatment did not influence median pain scores during LED illumination and pain intensities were similar at first and second illumination: first treatment AFXL‐PDT median 3 (IQR 2–55) vs MAL‐PDT 35 (25–5), second treatment AFXL‐PDT 35 (3–65) vs MAL‐PDT 3 (3–45), (P&gt;0519). The presumed enhanced uptake of MAL did not affect the pain level during illumination. Pain scores were similar during AFXL‐PDT and MAL‐PDT and rated as mild to moderate.” </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0025" title="KarsaiS , FriedlH , BuhckH , JüngerM , PoddaM . The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: Outcome of a double-blind randomized placebo-controlled trial. British Journal of Dermatology2015;172(3):677-83. [CENTRAL: CN-01068975] ">Karsai 2015</a> (PDL / sham) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain intensity using a VAS (0 cm = ‘no pain’ to 10 cm = ‘maximal pain’) at every visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>“The following median values were indicated on the pain intensity scale (ordinal scale 0–10) among patients at the four treatment sessions surveyed (minimum–maximum): Laser treatment: 2 (0–6), 3 (0–6), 3 (0–8) and 4 (0–9); Sham treatment: 0 (0–1), 0 (0–1), 0 (0–1) and 0 (0–2).” </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0026" title="KesselsJ , VoetenL , NelemansP , CleutjensJ , HillenLM , MosterdK , et al. Topical sinecatechins, 10%, ointment for superficial basal cell carcinoma: A randomized clinical trial. JAMA Dermatology2017;153(10):1061-3. [CENTRAL: CN-01420948] ">Kessels 2017</a> (Sinecatechins / placebo) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral paracetamol for local skin reactions (if severe, treatment could be stopped for 1 week) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective symptoms including pain were recorded in personal diary kept by patients once a week during treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A burning sensation was reported in the treatment group in 5% of patients, at week four compared to 1% in the treatment group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0027" title="KesselsJP , KreukelsH , NelemansPJ , RoozeboomMH , vanPeltH , MosterdK , et al. Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5‐aminolaevulinic acid 20% vs. two‐stage topical methyl aminolaevulinate: results of a randomized controlled trial. British Journal of Dermatology2018;178(5):1056-63. [CENTRAL: CN-01991773] ">Kessels 2018</a> (MAL‐PDT / two‐fold fractionated ALA‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain and burning sensation</p> <p>were scored using a numerical rating scale (score 0–10),</p> <p>directly after both illuminations and 1 week later. The maximum</p> <p>pain scores for both illuminations were assessed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>“After the second illumination, mean pain scores were significantly higher in the two‐fold ALA‐PDT group compared with patients treated with MAL‐PDT, with mean pain scores of 3.36 +‐ 2.57 and 2.48 +‐ 2.57 respectively (P=0.039). None of the patients discontinued treatment because of pain. 16.4% in the ALA‐PDT group vs 5.8% in the MAL‐PDT group reported the use of pain medication post‐treatment.” </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0028" title="KuijpersDI , ThissenMR , ThissenCA , NeumannMH . Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. Journal of Drugs in Dermatology2006;5(7):642-5. [CENTRAL: CN-00566805] ">Kuijpers 2006</a> (ALA‐PDT / MAL‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient description of pain and rating on 10‐point visual analogue scale.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Majority of pain was reported as burning or stinging (59 and 41% respectively); also described as throbbing, lingering or tingling. Intensity and character was the same between groups. Generally pain was experienced during illumination and sporadically after, with the second cycle reported as the worst. No radiation reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0031" title="MarksR , GebauerK , ShumackS , AmiesM , BrydenJ , FoxTL , et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicentre 6-week dose-response trial. Journal of the American Academy of Dermatology2001;44(5):807-13. [CENTRAL: CN-00326531] ">Marks 2001</a> (Imiquimod BD / OD / BD for 3 days / OD for 2 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Three‐point rating scale applied by assessor based on descriptive terms used by patient.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain more frequent in the BD group (100%) &gt; OD group (24.2%) &gt; BD for three days (13.3%) &gt; OD for 2 days (3%). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0032" title="MillerBH , ShavinJS , CognettaA , TaylorRJ , SalascheS , KoreyA , et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. Journal of the American Academy of Dermatology1997;36(1):72-7. [CENTRAL: CN-00135753] ">Miller 1997</a> (Intralesional sustained‐release 6‐fluorouracil / epinephrine injectable gel, variable frequencies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reduced dose if</p> <p>tenderness or pain at the injection site or erosion/</p> <p>ulceration. Local anaesthetic not permitted.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At each treatment visit, patients were asked to report injection site</p> <p>pain, including burning or stinging, and tenderness.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All patients experienced transient moderate to severe stinging, burning or pain at the time of injection lasting less than 15 </p> <p>to 20 minutes after drug administration.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0033" title="MortonCA , DominicusR , RadnyP , DirschkaT , HauschildA , ReinholdU , et al. A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). British Journal of Dermatology2018;179(2):309-19. [CENTRAL: CN-02000788] [PMID: 29432644]">Morton 2018</a> (BF 200 ALA‐PDT / MAL‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain management:</p> <p>physical cooling measures, reduction of light intensity</p> <p>at the expense of longer exposure times, or “slight analgesia”.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Local pain experienced during PDT was assessed for each PDT session (on a numerical rating pain scale). </p> <p>Ranking of the subjective sensations</p> <p>pain, burning and itching was done by the patient. Pain during</p> <p>PDT assessed with a numerical rating pain scale ranging</p> <p>from 0 (no pain at all) to 10 (worst possible pain).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain was one of the most frequently reported reactions, experienced by 100% patients undergoing MAL‐PDT and 97.1% patients undergoing BF 200 ALA‐PDT. Local pain experienced during each session showed little variation between both treatments and was most commonly experienced during the first two sessions. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a> (MAL‐PDT / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None in MAL‐PDT group, local anaesthetic in SE group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Local skin reactions during and after treatment at each clinic visit were documented, and rated as mild, moderate or severe. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One patient in MAL‐PDT group discontinued treatment because of severe burning sensation which resolved without medical intervention. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14% in the MAL‐PDT group experienced pain, compared to 6% in the SE group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0042" title="ShumackS , MarksR , AmiesM , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks treating nodular BCC. 8th World Congress on Cancers of the Skin, Zurich, Switzerland2001;-:p55. [CENTRAL: CN-00849091] ShumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , SchroeterA , et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002a</a> (Imiquimod, several regimes for 6 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maximum of two 7‐day periods of rest allowed if local skin reaction occurred.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects documented at every study visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain was one of the three most frequent symptomatic adverse effects and two patients discontinued treatment due to pain. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0043" title="RobinsonJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating nodular BCC. 8th World Congress on Cancer of the Skin, Zurich, Switzerland2001;-(-):p57. [CENTRAL: CN-00849091] SchumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , Schroeter, A et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002b</a> (Imiquimod, several regimes for 12 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maximum of two 7‐day periods of rest allowed if local skin reaction occurred.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects documented at every study visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two patients from the imiquimod twice daily 7‐day dosing group reported severe application site reactions, one with pain at the target site and one with tenderness, stinging and pain at the target site. One patient from the once‐daily, 7 day group reported severe tenderness at the target site. One patient discontinued due to pain, tenderness and drainage at the target site. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0044" title="SillerG , RosenR , FreemanM , WelburnP , KatsamasJ , OgbourneSM . PEP005 (Ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomised phase IIa trial. Australasian Journal of Dermatology2010;51(2):99-105. [CENTRAL: CN-00771587] ">Siller 2010</a> (ingenol mebutate gel 0.0025 % / ingenol mebutate gel 0.01% / ingenol mebutate gel 0.05% / vehicle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment was withheld if there was a severe local reaction occurred after the first dose. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects documented at every study visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain at the application site was most common in ingenol mebutate gel group 0.05% (n=2, treatment arm B), and 1 patient experienced pharyngolaryngeal pain in ingenol mebutate gel group 0.0025% (treatment arm A). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0046" title="SolerAM , Angell-PetersenE , WarloeT , TausjoJ , SteenHB , MoanJ , et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: A comparison of two light sources. Photochemistry and Photobiology2000;71(6):724-9. [CENTRAL: CN-00297518] ">Soler 2000</a> (Laser light / broadband light) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain reported during treatment and in follow‐up period (patient questionnaires).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83% of patients in the laser group and 76% in the broadband group reported some discomfort during and after illumination. Types of pain included stinging and burning sensation. There was no significant difference between the groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0048" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. In: 8th World Congress on cancers of the skin, Zurich, Switzerland. 2001:61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] [PMID: 12452875]">Sterry 2002a</a>/<a href="./references#CD003412-bbs2-0049" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. 8th World Congress on cancers of the skin, Zurich, Switzerland2001;-(-):p61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] ">Sterry 2002b</a> (Imiquimod with / without occlusion) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prescribed rest periods from treatment</p> <p>if local skin reactions or treatment site adverse effects.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects documented at every study visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One patient reported continuous stinging and pain at the application site; one reported irritation and another reported irritation and pruritus. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a> (MAL‐PDT / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cooling of irradiation sites with fan‐cooler during treatment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects documented at every study visit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Post procedural pain was reported in 3 of the surgical participants and none of the MAL‐PDT group. Pain was reported in 2 and 1 of the participants in the MAL‐PDT and surgical groups respectively. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0052" title="WangI , BendsoeN , KlintebergCA , EnejderAM , Andersson‐EngelsS , SvanbergS , et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. British Journal of Dermatology2000;144(4):832-40. [CENTRAL: CN-00326537] ">Wang 2001</a> (ALA‐PDT / cryosurgery) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In the</p> <p>PDT group, low fluence rate to minimise thermal effects and lesions sprayed with water.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain recorded in first week after treatment using 115‐mm visual analogue scale (VAS) for pain indication and analgesia diary. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall VAS scores low for both treatment modalities, and insignificantly higher in PDT group (43 +/‐ 31mm SD in PDT group, 32 +/‐ 27mm SD in cryosurgery group). Most pain reported during treatment. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0001" title="2005-001474-27. A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001474-27/results (first accessed 12 August 2016). ">2005‐001474‐27</a> (placebo gel + tazarotene gel / valproic acid gel + tazarotene gel) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 patients in the placebo group experienced pain in comparison to 6 in the treatment group. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>MAL:</b> methyl aminolevulinate; <b>PDL:</b> pulsed dye laser; <b>PDT:</b> photodynamic therapy; <b>SE:</b> surgical excision; <b>VAS:</b> visual analogue scale; <b>xpw:</b> times per week. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Pain table</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003412-tbl-0007"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse effects table</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study (comparator)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>AEs associated with treatment leading to discontinuation of treatment / participation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Common AEs (number/onset/duration)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Other notable outcomes (number/onset/duration)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0003" title="Abd El-NabyNM , El-FarNN , Al-Shenawy HA , ElshwadfySE , KouraAA . Pulsed dye laser in the treatment of basal cell carcinoma: a single session versus two sessions–a randomized controlled trial. Indian Journal of Dermatology, Venereology, and Leprology2019;85(5):475. ">Abd El‐Naby 2019</a> (one PDL session / two PDL sessions) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the group who received two sessions of treatment, 4 patients experienced dyspigmentation (2 hyper‐ and 2 hypo‐pigmentation). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0005" title="AritsAH , MosterdK , EssersBA , SpoorenbergE , SommerA , De RooijMJ , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology2013;14(7):647-54. [CENTRAL: CN-00872324] JansenMH , KoekelkorenFH , NelemansPJ , AritsAH , RoozeboomMH , Kelleners-SmeetsNW , et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology2018;79(5):961-4. [CENTRAL: CN-01703594] JansenMH , MosterdK , AritsAH , RoozeboomMH , SommerA , EssersBA , et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology2018;138(3):527-33. [CENTRAL: CN-01457400] RoozeboomMH , AritsAH , MosterdK , SommerA , EssersBA , deRooijMJ , et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology2016;136(8):1568-74. [CENTRAL: CN-01197852] [DOI: 10.1016/j.jid.2016.03.043]">Arits 2013</a> (MAL‐PDT / Imiquimod / 5‐FU) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local skin redness reported as moderate or severe in all treatment groups.</p> <p>Patients treated with imiquimod or 5‐FU more often reported moderate to severe local swelling, erosion, crust formation and itching of the skin than patients treated with MAL‐PDT. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unexpected serious adverse effects in 1) Imiquimod group include wound infection (n = 1) and influenza‐like symptoms (n = 8) and 2) in 5‐FU group include two local wound infections, erysipelas of the lower extremity (n = 1), leg ulcer (n = 1). </p> <p>The erysipelas and ulcer were treated with ambulant compression therapy and antibiotics. None of these patients needed hospitalisation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse reactions more common in last treatment weeks.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0006" title="AvrilMF , AuperinA , MargulisA , GerbauletA , DuvillardP , BenhamouE , et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. British Journal of Cancer1997;76(1):100-6. [CENTRAL: CN-00141470] PetitJY , AvrilMF , MargulisA , ChassagneD , GerbauletA , DuvillardP , et al. Evaluation of cosmetic results of a randomised trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plastic and Reconstructive Surgery2000;105(7):2544-51. [CENTRAL: CN-00278207] ">Avril 1997</a> (SE / radiotherapy) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Main adverse characteristics of surgical scars were "deformations" and "constrictions", affecting 25% and 5% of patients respectively by year 4. Radiodystrophy and necrosis affected 41% and 5% of the radiotherapy group at 4 years respectively. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three ophthalmic complications were observed: 1 ectropion, 1 cataract ‐ after surgery. One lacrimal duct stenosis after radiotherapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0007" title="Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Methyl aminolaevulinate photodynamic therapy vs. cryotherapy in primary superficial basal cell carcinoma: results of a 36-month follow-up. British Journal of Dermatology2005;153(1):29. Basset-SeguinN , IbbotsonS , EmtestamL , TarstedtM , MortonC , MarotiM , et al. Topical methyl aminolevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. European Journal of Dermatolology2008;18(5):547-53. [CENTRAL: CN-00668120] ">Basset‐Seguin 2008</a> (MAL‐PDT / cryosurgery) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crusting: MAL PDT = 35%, cryosurgery = 47%.</p> <p>Erythema: MAL PDT = 30%, cryosurgery 21%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blisters: cryosurgery only = 21%.</p> <p>Suppuration: cryosurgery group only.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most were transient, resolving in 5 days.</p> <p>More likely to experience severe AE in MAL‐PDT group and moderate AE in cryosurgery group, although most were mild (73% and 80%, respectively). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0008" title="Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , MillerPS , et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncology2014;15(1):96-105. [CENTRAL: CN-00959373] WilliamsHC , Bath-HextallF , OzolinsM , ArmstrongSJ , ColverGB , PerkinsW , et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. Journal of Investigative Dermatology2017;137(3):614-9. [CENTRAL: CN-01340067] [EMBASE: 614596349]">Bath‐Hextall 2014</a> (Imiquimod / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (5%) participants in the imiquimod group withdrew because of adverse effects (five [42%] of these events were treatment related). </p> <p>Four (2%) of 229 participants withdrew because of adverse effects in the surgery group (all non‐related events). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itching: Imiquimod =211, SE = 129.</p> <p>Weeping: Imiquimod = 160, SE = 81.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher frequency adverse effects more common in imiquimod group include 1) Mild/moderate events: occurrence of new tumours, redness and swelling at tumour site, cold/influenza‐like symptoms, headache, scab at tumour site, spots close to trial tumour, discomfort and bleeding, 2) Severe events: cold/flu, inflammatory reactions. </p> <p>Other high‐frequency adverse effects, more common in SE group include 1) Mild/moderate events: Pain and swelling at tumour site and 2) Severe events: Heat attack / heart failure and pneumonia. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the imiquimod group, 38 (15%) participants needed a dose reduction.</p> <p>No deaths or serious adverse effects were regarded as related to treatment.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0010" title="BrinkhuizenT , FrenckenKJ , NelemansPJ , HoffML , Kelleners-SmeetsNW , Zur HausenA , et al. The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): a phase II, randomized controlled trial. Journal of the American Academy of Dermatology2016;75(1):126-34. [CENTRAL: CN-01342883] [DOI: 10.1016/j.jaad.2016.01.050]">Brinkhuizen 2016</a> (diclofenac / diclofenac and calcitriol / calcitriol and no treatment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 16 cases the severity of the application‐site reactions led to discontinuation of the therapy and prescription (diclofenac = 6, calcitriol = 2, combination = 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema: diclofenac = 21, calcitriol = 20, combined treatment = 22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other commonly reported AEs in all groups include swelling, erosions, pruritus.</p> <p>Other less frequent AEs include crust formation, vesicles, scaling, and paraesthesia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects were mostly mild to moderate.</p> <p>No serious adverse effects were considered to be related to the study medication.</p> <p>Three patients had serious adverse effects requiring hospitalisation.</p> <p>No adverse effects were reported in the control group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0011" title="ChoiSH , KimKH , SongKH . Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial. Journal of the European Academy of Dermatology and Venereology2015;30(5):783-8. [CENTRAL: CN-01158122] [DOI: 10.1111/jdv.13453]">Choi 2016</a> (Er:YAG AFL MAL‐PDT / MAL‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crusting: Er‐YAG AFL‐PDT = 17, MAL‐PDT = 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema, burning sensation at application site, hyperpigmentation and itching more frequent in Er:YAG AFL‐PDT group. </p> <p>Other reactions include scale, bullae, oozing and bleeding.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All patients in both groups experienced some AEs.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0015" title="EigentlerTK , KaminA , WeideBM , BreuningerH , CaroliUM , MöhrleM , et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. Journal of the American Academy of Dermatology2007;57(4):616-21. [CENTRAL: CN-00610509] ">Eigentler 2007</a> (Imiquimod 8 weeks / 12 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema and oedema occurred in 92% of participants. Reporting of vesicles, erosions, ulcerations, desquamation and drainage during treatment was infrequent (12‐53%). Post‐treatment hypopigmentation was reported in 9% of participants. Most AEs were judged by physicians as moderate severity and by patients as moderate (17%) to severe (54%). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Authors reported "no differences between treatment arms in adverse events".</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for AEs were not presented separately for treatment groups.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0016" title="EimpunthS , OganesyanG , HammanMS , LeeRA , JiangSI , KimSS . Effectiveness of a 595-nm pulsed dye laser for the treatment of basal cell carcinoma using 1 stacked-pulse session. Journal of the American Academy of Dermatology2014;70(5 (S1)):AB134. [CENTRAL: CN-01057471] ">Eimpunth 2014</a> (Double‐stacked PDL / control) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Purpura immediately after laser treatment: 100% PDL group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Late AEs in PDL group: blister (21.4%), dyspigmentation (21.4%) and hypertrophic scar (7.14%). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0017" title="EzughahFI , DaweRS , IbbotsonSH , FlemingCJ . A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment2008;19(2):111-7. [CENTRAL: CN-00706567] ">Ezughah 2008</a> (Imiquimod 8 weeks / 5 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient in 5 week group withdrew from the study due to application site reactions.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild erythema (at week 1): 8‐week group = 69%, 5 week group = 69%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other reactions include pain, swelling, weeping, broken skin and scabbing.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema decreased in both groups at week 5.</p> <p>One patient on 8 week course developed severe erythema and soreness and was unable to apply 7<sup>th</sup> treatment. </p> <p>The severity of local site reactions was greatest in the first half of the treatment phase in the 8‐week group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0018" title="FoleyP , FreemanM , MenterA , SillerG , El-AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] FoleyP , FreemanM , SillerG , GebauerK , MurrellD , BarnetsonR , et al. A phase III randomized study comparing photodynamic therapy (PDT) using methyl aminolevulinate or placebo cream in nodular basal cell carcinoma (NBCC). Journal of the European Academy of Dermatology and Venereology2003;17(Suppl 3):231. [CENTRAL: CN-00478536] ">Foley 2009a</a>/<a href="./references#CD003412-bbs2-0019" title="FoleyP , FreemanM , MenterA , SillerG , El‐AzharyRA , GebauerK , et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology2009;48(11):1236-45. [CENTRAL: CN-00734005] TopeWD , MenterA , El AzharyR , SotoP . A comparison of topical MAL-PDT versus placebo-PDT in nodular basal cell carcinoma: results of a North American study. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology; 2005 Sep 28-Oct 03; Kuala Lumpur, Malaysia. 2005:376. [CENTRAL: CN-00602617] ">Foley 2009b</a> (MAL‐PDT / placebo) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 patient in MAL‐PDT group received only one treatment due to local adverse event.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Burning: MAL‐PDT = 19, placebo = 8.</p> <p>Erythema: MAL‐PDT = 14, placebo = 4.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other reactions include stinging of skin, crusting and bleeding (more frequent in treatment group). </p> <p>Severe events: cholangiocarcinoma, cholelithiasis, carotid stenosis, pulmonary oedema and acute MI, melanoma, femoral artery surgery. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One serious AE deemed not treatment‐related.</p> <p>All were mild‐to‐moderate intensity and most lasted &lt;1 day.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0020" title="Garcia-MartinE , Gil-ArribasLM , IdoipeM , AlfaroJ , PueyoV , PabloLE , et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. British Journal of Ophthalmology2011;95(10):1393-6. [CENTRAL: CN-00801928] ">Garcia‐Martin 2011</a> (Imiquimod / radiotherapy) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blink discomfort (during treatment): Imiquimod = 60%, radiotherapy = 50%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intense conjunctival irritation 13.3% imiquimod group, discomfort 8.3% radiotherapy group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After treatment, radiotherapy group reported ectropion, dry eye and loss of eyelashes. imiquimod group reported no post‐treatment AEs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0021" title="GeisseJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating superficial BCC. In: The 8th World Congress on Cancer of the Skin; 2001 July 18-21; Zurich, Switzerland. 2001:P58. [CENTRAL: CN-00520431] GeisseJK , RichP , PandyaA , GrossK , AndresK , GinkelA , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a randomized, vehicle-controlled study. Journal of the American Academy of Dermatology2002;47(3):390-8. [CENTRAL: CN-00390933] ">Geisse 2002</a> (Imiquimod BD / OD / 5xpw / 3xpw / vehicle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thirteen patients discontinued due to local skin reactions, six of which were severe and four of which were due to adverse effects (BD = 1, OD = 2, 5xpw = 1). </p> <p>Four discontinued dosing (3 because of pain, 1 of which was severe, and one because of bleeding). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itching: 5xpw = 62%, OD = 61%, 3xpw = 38%, BD = 30%, vehicle = 13%.</p> <p>Pain: BD = 30%, OD = 16%, 3xpw = 10%, 5xpw = 8%, vehicle = 0.</p> <p>Tenderness: BD = 20%, OD = 16%, 5xpw = 8%, 3xpw = 7%, vehicle = 6%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other reactions include erythema, scabbing, erosion, excoriation/flaking, ulceration, vesicles, induration and oedema. </p> <p>Severe erythema and scabbing occurred more commonly in the twice‐daily treatment groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs occurred in all treatment groups, as did local skin reactions (all of those deemed related to study drug were in the OD group). </p> <p>Six serious AEs, all unrelated to treatment, five of which resulted in hospitalisation.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0022" title="GeisseJ , CaroI , LindholmJ , GolitzL , StamponeP , OwensM . Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology2004;50(5):722-33. [CENTRAL: CN-00469536] ">Geisse 2004</a> (Imiquimod 5xpw / 7xpw / vehicle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4% of the imiquimod 5xpw group and 2% of the 7xpw group discontinued treatment due to AE or local site reaction. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema: most frequently observed and most intense LSR: 5xpw = 87, 7xpw = 92, vehicle = 48. </p> <p>Itching: 5xpw = 16%, 7xpw = 26%.</p> <p>Burning: 5xpw = 6%, 7xpw = 9%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other reactions include oedema, induration, vesicle, erosion, ulceration, scabbing and flaking. </p> <p>The incidence of headache was statistically higher in the Imiquimod 5xpw group compared to the corresponding vehicle group (P = 0.027), although this difference was not seen in the 7xpw group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local site reactions reached maximum intensity at week 3, and most were mild.</p> <p>Local site reactions were experienced in all groups but more likely in imiquimod groups, and these were statistically more likely to be severe (P = 0.001). </p> <p>AEs occurred more frequently during treatment than after and were more likely to occur in the imiquimod 7xpw group than the 5xpw group or the vehicle groups (64% compared to 58% and 36% (combined vehicle groups). </p> <p>Local site reactions were experienced more commonly in 7xpw Imiquimod group compared to the 5xpw group (P = 0.002). </p> <p>AEs considered possibly or probably related to treatment include local site reactions and lymphadenopathy in the 7xpw Imiquimod group. </p> <p>All local site reactions were significantly more likely to be intense than 7xpw group than 5xpw group (P &lt; 0.5). </p> <p>Overall the severe AEs experience by participants were in the 7xpw Imiquimod group.</p> <p>A decrease in WCC and neutrophils was noted in the treatment groups.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0023" title="HaakCS , Togsverd-BoK , Thaysen-PetersenD , WulfHC , PaaschU , AndersonRR , et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas - a randomized clinical trial. British Journal of Dermatology2015;172(1):215-22. [CENTRAL: CN-01039978] ">Haak 2015</a> (AFXL‐PDT / MAL‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immediate skin reactions (white micro‐spots at the surrounding skin surface and minor pinpoint bleeding) seen in all AFXL group. </p> <p>Pigmentary changes and scarring similar in both groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minor bleeding and bruising in debulked areas.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scarring was the most frequently observed reaction at 3 months.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0025" title="KarsaiS , FriedlH , BuhckH , JüngerM , PoddaM . The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: Outcome of a double-blind randomized placebo-controlled trial. British Journal of Dermatology2015;172(3):677-83. [CENTRAL: CN-01068975] ">Karsai 2015</a> (PDL / sham) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crusting (lasted an average of 10 days): intervention group only.</p> <p>Hyperpigmentation: intervention group only (21 of 56 cases, 37%).</p> <p>Hypopigmentation: intervention group only (did not manifest until after the third session; its rate increased with the number of sessions) seen in 52 of 56 cases (93%). </p> <p>Purpura in 100% of the laser group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Purpura was considered a desired concomitant effect and was seen for an average of 6 days. </p> <p>Hyper‐ and hypopigmentation persisted until the end of the final follow‐up at 6 months.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0026" title="KesselsJ , VoetenL , NelemansP , CleutjensJ , HillenLM , MosterdK , et al. Topical sinecatechins, 10%, ointment for superficial basal cell carcinoma: A randomized clinical trial. JAMA Dermatology2017;153(10):1061-3. [CENTRAL: CN-01420948] ">Kessels 2017</a> (Sinecatechins / placebo) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema: sinecatechins 9‐12%, placebo 2‐6%.</p> <p>Oedema: sinecatechins 2‐6%, placebo 0%.</p> <p>Erosions: sinecatechins 4‐7%, placebo 1%.</p> <p>Crusts: sinecatechins 3‐10%, placebo 2%.</p> <p>Itching: sinecatechins 10‐13 %, placebo 1‐3%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other reactions include oedema, erosions, bullae and squamae.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference for all common AEs.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0027" title="KesselsJP , KreukelsH , NelemansPJ , RoozeboomMH , vanPeltH , MosterdK , et al. Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5‐aminolaevulinic acid 20% vs. two‐stage topical methyl aminolaevulinate: results of a randomized controlled trial. British Journal of Dermatology2018;178(5):1056-63. [CENTRAL: CN-01991773] ">Kessels 2018</a> (MAL‐PDT / two‐fold fractionated ALA‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema: MAL‐PDT = 65, ALA‐PDT = 73.</p> <p>Wounds/erosions: MAL‐PDT = 64, ALA‐PDT = 72.</p> <p>Vesicles: MAL‐PDT = 66, ALA‐PDT = 72.</p> <p>All significantly higher after ALA‐PDT compared with MAL‐PDT.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other reactions include swelling, crusts, scaling and pruritus.</p> <p>Four serious AEs unrelated to study treatment (three hospitalizations owing to transient ischaemic attack, chemotherapy for lung carcinoma and dizziness, and one patient died owing to cancer). </p> <p>No serious unexpected adverse reactions were reported in either group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AE incidence higher during treatment period than after treatment.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0029" title="KuijpersDI , ThissenMR , BerrettyPJ , IdelerFH , NelemansPJ , NeumannMH . Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatologic Surgery2007;33(5):579-87. [CENTRAL: CN-00588176] ThissenMR , NiemanFH , IdelerAH , BerrettyPJ , NeumannHA . Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatologic Surgery2000;26(8):759-64. [CENTRAL: CN-00298974] ">Kuijpers 2007</a> (SE / curettage and cryosurgery) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary wound infection requiring systemic antibiotics: curettage and cryosurgery group = 3 patients, SE group = 4 patients. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0031" title="MarksR , GebauerK , ShumackS , AmiesM , BrydenJ , FoxTL , et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicentre 6-week dose-response trial. Journal of the American Academy of Dermatology2001;44(5):807-13. [CENTRAL: CN-00326531] ">Marks 2001</a> (Imiquimod BD / OD / BD for 3 days / OD for 2 days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient discontinued because of a self‐reported application site symptom of pruritus.</p> <p>No patient withdrew from the study because of signs of a local skin reaction assessed by the investigators. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema: BD = 66.7%, OD = 27.3%, BDx3pw, = 13.3 %, OD x3pw = 9.1%.</p> <p>Itching: BD =33.3%, OD = 66.7%, BDx3pw, = 36.7%, OD x3pw = 45.5%.</p> <p>Weeping: decreased as the dosing frequency decreased BD = 66.7% OD = 12.1% BDx3pw, = 3.3%, OD x3pw = 0%. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other reactions include scabbing, flaking, erosion, ulceration, oedema and induration.</p> <p>One patient died as the result of a coincidental cerebrovascular accident.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local skin reactions occurred in all 4 dose regimens; dose‐dependent application site reactions being reported most often. </p> <p>In the twice‐every‐day group, all the local skin reactions were assessed as severe by both the patient and the investigator in two thirds of the patients. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0032" title="MillerBH , ShavinJS , CognettaA , TaylorRJ , SalascheS , KoreyA , et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. Journal of the American Academy of Dermatology1997;36(1):72-7. [CENTRAL: CN-00135753] ">Miller 1997</a> (Intralesional sustained‐release 6‐ fluorouracil / epinephrine injectable gel, variable frequencies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local tissue reactions were confined to the treatment site and included erythema, swelling, desquamation, erosions and eschar in most patients. </p> <p>Hyperpigmentation was observed in 83% of treated patients but typically cleared during the FU period. </p> <p>Ulcerations at the treatment site occurred in 47% of patients; only one patent had a residual scar. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no clinically significant serious or unexpected adverse effects or changes in any lab values or physical examination findings as judged by the investigator to be related to the administration of 5‐FU/epi gel. The number of events per regimen ranged from 17 to 28. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0033" title="MortonCA , DominicusR , RadnyP , DirschkaT , HauschildA , ReinholdU , et al. A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). British Journal of Dermatology2018;179(2):309-19. [CENTRAL: CN-02000788] [PMID: 29432644]">Morton 2018</a> (BF 200 ALA‐PDT / MAL‐PDT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient withdrew due to treatment‐related AEs in the BF 200 ALA group and 2 in the MAL group. </p> <p>Two other patients withdrew due to related treatment emergent adverse effects (one in each group). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most frequently reported reactions included pain, erythema, pruritus and oedema; most frequently at mild to moderate intensity. </p> <p>Frequencies were comparable between the groups and revealed no statistically significant differences. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were ten serious AEs, none of which were related to the study medication.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0034" title="MosterdK , ThissenMR , NelemansP , Kelleners‐SmeetsNW , JanssenRL , BroekhofKG , et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. British Journal of Dermatology2008;159(4):864-70. [CENTRAL: CN-00667266] RoozeboomMH , AardoomMA , NelemansPJ , ThissenMR , Kelleners-SmeetsNW , KuijpersDI , et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. Journal of the American Academy of Dermatology August 2013;69(2):280-7. [CENTRAL: CN-00876800] [DOI: 10.1016/j.jid.2016.03.043]">Mosterd 2008</a> (ALA‐PDT / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary wound infection was observed once after ALA‐PDT treatment. No serious complications such as wound dehiscence or necrosis were observed in either ALA‐PDT or SE group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0035" title="PunjabiS , CookLJ , KerseyP , MarksR , CerioR . Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicentre study. International Journal of Dermatology2008;47(1):78-82. [CENTRAL: CN-00629144] PunjabiS , CookLJ , KerseyP , MarksR , FinlayA , SharpG , et al. A double-blind, multicentre parallel group study of BEC-5 cream in basal cell carcinoma. European Academy of Dermatology &amp; Venereology2000;14(Suppl 1):49. [CENTRAL: CN-01616931] ">Punjabi 2008</a> (Solasodine glycoside cream / vehicle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 patients withdrew due to severity of local irritation in the treatment group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were four serious adverse effects in treatment group (3 unrelated, 1 unlikely to be related to treatment), and 2 in the vehicle group (one unrelated and one unlikely related to treatment). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No SAEs were considered likely or related to the treatment and there was no significant difference between the two groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0036" title="RhodesLE , deRieM , EnströmY , GrovesR , MorkenT , GouldenV , et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology2004;140(1):17-23. [CENTRAL: CN-00460094] RhodesLE , deRieMA , LeifsdottirR , YuRC , BachmannI , GouldenV , et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology2007;143(9):1131-6. [CENTRAL: CN-00612111] ">Rhodes 2004</a> (MAL‐PDT / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One discontinuation due to adverse vent in MAL‐PDT group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema: MAL‐PDT = 7, SE = 1.</p> <p>Skin infection: MAL‐PDT = 0, SE = 3.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three patients had skin infections after SE (none in PDT group).</p> <p>Other local adverse effects included crusting and itching.</p> <p>There were three deaths, all unrelated to treatment, and one patient was diagnosed with breast cancer during treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>More patients with MAL‐PDT than SE experienced adverse effects (52% compared to 29%).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0038" title="RomagosaR , SaapL , GivensM , SalvarreyA , HeJL , HsiaSL , et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatologic Surgery2000;26(4):338-40. [CENTRAL: CN-00296475] ">Romagosa 2000</a> (5‐FU in PC vehicle / 5‐FU in petrolatum base) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local irritation, erythema, ulceration, tenderness were common but well‐tolerated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimal itching in both treatment arms.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0041" title="SchulzeHJ , CribierB , RequenaL , ReifenbergerJ , FerrandizC , DiezG , et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. British Journal of Dermatology2005;152(5):939-47. [CENTRAL: CN-00513173] ">Schulze 2005</a> (Imiquimod / vehicle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two in imiquimod group discontinued due to treatment‐related AEs (one in vehicle group discontinued due to myeloma). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema, oedema, induration, vesicles, erosion, ulceration, scaling/flaking and scabbing/crusting were all significantly more likely to occur in the treatment group (P &lt; 0.001). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Imiquimod‐treated patients also experienced statistically significant changes in skin quality assessment scores for hypo‐ or irregular pigmentation, and skin surface texture. </p> <p>Severe AE more common in treatment group but none due to treatment. No deaths.</p> <p>Central and peripheral nervous system disorders e.g. headache, gastrointestinal disorders and respiratory system disorders were also reported. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local skin reactions were more intense in the imiquimod group (statistically significant).</p> <p>Local skin reactions increased at week 2 and plateaued until week 6.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0042" title="ShumackS , MarksR , AmiesM , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks treating nodular BCC. 8th World Congress on Cancers of the Skin, Zurich, Switzerland2001;-:p55. [CENTRAL: CN-00849091] ShumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , SchroeterA , et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002a</a> (imiquimod, several regimes for 6 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One patient discontinued due to treatment related side effects (OD 7 day dosing group), one discontinued due to cerebral vascular accident. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema and scabbing commonly reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Influenza‐like symptoms, probably related to drug noted in 10 patients.</p> <p>Fatigue in the OD 7 day group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs occurred in all dosing groups (42% possibly / probably due to study treatment).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0043" title="RobinsonJK , MarksR , OwensML , AndresK , GinkelAM . Imiquimod 5% cream for 12 weeks treating nodular BCC. 8th World Congress on Cancer of the Skin, Zurich, Switzerland2001;-(-):p57. [CENTRAL: CN-00849091] SchumackS , RobinsonJ , KossardS , GolitzL , GreenwayH , Schroeter, A et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Archives of Dermatology2002;138(9):1165-71. [CENTRAL: CN-00398024] ">Shumack 2002b</a> (imiquimod, several regimes for 12 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 patients discontinued treatment owing to local skin reaction (2 in OD 5 day group, 4 in OD 7 day group, 2 in BD 7 day group). </p> <p>2 discontinued due to AEs (1 = pain and drainage at target site and 1 = spider bite adjacent to target site). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema and scabbing commonly reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two patients in the BD 7 day group and one in the OD 7 day group reported severe local skin reactions. </p> <p>Influenza‐like symptoms, probably related to drug, were noted in 5 patients.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local skin reactions occurred in all study groups, and were the most commonly reported AE (most mild/moderate intensity). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0044" title="SillerG , RosenR , FreemanM , WelburnP , KatsamasJ , OgbourneSM . PEP005 (Ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomised phase IIa trial. Australasian Journal of Dermatology2010;51(2):99-105. [CENTRAL: CN-00771587] ">Siller 2010</a> (ingenol mebutate gel 0.0025 % / ingenol mebutate gel 0.01% / ingenol mebutate gel 0.05% / vehicle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two discontinued due to AE (one in 0.01% group and one in 0.05% group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The most common reactions were erythema and flaking/scaling/dryness, which occurred in a minimum of 75 and 50% respectively, of all patients in all groups (including vehicle group). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyper‐ and hypopigmentation, erosion/ulceration, oedema, scabbing/crusting, vesicles all more common in ingenol mebutate gel 0.05% group. Most were mild to moderate reactions, although 2 were severe (ingenol mebutate gel 0.01 and 0.05% respectively). </p> <p>Other skin reactions include itch, weeping/exudate, scarring.</p> <p>Other adverse effects include liver function derangement, diarrhoea, erythema, flaking, headache, oedema, pustules at application site, pustular rash, scabbing and telangiectasia. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AE.</p> <p>Severe AE included mild/mod erythema extending beyond treatment site and headache.</p> <p>10 severe local skin reactions seen in Arm A in ingenol mebutate gel 0.01% / ingenol mebutate gel 0.05% groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003412-bbs2-0045" title="EssersBA , DirksenCD , NiemanFH , SmeetsNW , KrekelsGA , PrinsMH , et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Archives of Dermatology2006;142(2):187-94. [CENTRAL: CN-00555278] MosterdK , KrekelsGA , NiemanFH , OstertagJU , EssersBA , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncology2008;9(12):1149-56. [CENTRAL: CN-00665334] SmeetsNW , KrekelsGA , OstertagJU , EssersBA , DirksenCD , NiemanFH , et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet2004;364(9447):1766-72. [CENTRAL: CN-00492695] Van LooE , MosterdK , KrekelsGA , RoozeboomMH , OstertagJU , DirksenCD , et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European Journal of Cancer2014;50(17):3011-20. [CENTRAL: CN-01043314] ">Smeets 2004</a> (MMS / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs in SE group include wound infection, necrosis of grafts or flaps or post‐operative bleeding. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 patients died due to conditions not related to the treatment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12% complications in MMS group and 14% in SE group (P = 0.981).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0046" title="SolerAM , Angell-PetersenE , WarloeT , TausjoJ , SteenHB , MoanJ , et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: A comparison of two light sources. Photochemistry and Photobiology2000;71(6):724-9. [CENTRAL: CN-00297518] ">Soler 2000</a> (laser light / broadband light) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>During the 1st week after treatment, 68% patients in the laser group and 74% of those in the broadband group also reported some degree of discomfort (stinging, itching, pain, suppuration headache, sensation of warmth or blushing). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious AEs reported in the 6‐month follow‐up period.</p> <p>There was no statistically significant difference between the groups.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0047" title="RosenR , FreemanM , ZibertJR , KatsamasJ , KnudsenKM , SpelmanL . Ingenol mebutate 0.05% gel under occlusion is efficacious in treating superficial basal cell carcinoma. British Journal of Dermatology2014;171(Suppl 4):50. [CENTRAL: CN-01057057] ">Spelman 2014</a> (Ingenol mebutate under different occlusion types: full ODr, Semi‐ODr or no‐ODr) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.5% tolerated only one treatment in full‐ODr group, compared to 20.8% in semi‐ODr group and 4.2% in non‐ODr group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local skin reactions in 11.3 full ODr group, 7,5 in semi‐ODr group and 8.9 in no‐ODr group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The majority of AEs were not considered treatment related. The percentage of AEs was similar across all treatment groups, the most common being application site pain. The majority of treatment‐related AEs were in the ALU group, and in this group the majority only tolerated one treatment due to the severity of the local skin reaction. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0048" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. In: 8th World Congress on cancers of the skin, Zurich, Switzerland. 2001:61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] [PMID: 12452875]">Sterry 2002a</a>, sBCC study (Imiquimod with / without occlusion, both 2 or 3 days per week) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two patients discontinued from the study, one due to an adverse event (neurological dysregulation; not treatment‐related) and one due to a local skin reaction. One patient in without‐occlusion group required interrupted dosing and two required rest periods (3xpw with occlusion and 2xpw without occlusion). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itching, burning and hypopigmentation most frequently reported AEs.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two severe application site reactions were considered due to the medication (in 2xpw without occlusion group and in 3xpw with occlusion group). </p> <p>Fever and influenza‐like symptoms were infrequently reported.</p> <p>Four patients experienced serious adverse effects unrelated to the medication.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs occurred in all treatment groups with 59% reporting at least one.</p> <p>32% reported application site reactions, which occurred more often in groups treated three times per week. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0049" title="SterryW , BichelJ , AndresK , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. 8th World Congress on cancers of the skin, Zurich, Switzerland2001;-(-):p61. [CENTRAL: CN-00478768] SterryW , BichelJ , DingL , GinkelAM . Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. SterryW , RuzickaT , HerreraE , TakwaleA , BichelJ , AndresK , et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology2002;147(6):1227-36. [CENTRAL: CN-00411766] ">Sterry 2002b</a>, nBCC study (Imiquimod with / without occlusion, both 2 or 3 days per week) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two discontinued due to local skin reactions (severe erythema, oedema and crust) and three discontinued due to application site reactions. Rest periods were taken by three patients. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding, itching and irritation most frequently reported AEs.</p> <p>Erythema was the most frequently reported local skin reaction and was most common in the 3xpw group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Five experienced severe application site reactions considered probably related to the study drug. In groups receiving 3xpw treatment, severe local skin reactions were most common. </p> <p>Four experienced severe AEs unrelated to study drug.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70% reported adverse effects. 42% reported application site reactions; local skin reactions occurred in all treatment groups, most frequently in the 3xpw occlusion group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0050" title="SzeimiesRM , IbbotsonS , MurrellDF , RubelD , FrambachY , De BerkerD , et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology2008;22(11):1302-11. [CENTRAL: CN-00668334] ">Szeimies 2008</a> (MAL‐PDT / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 patients in MAL‐PDT group and one in SE group (none treatment related).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Photosensitivity reactions: MAL‐PDT = 37%, SE = 0%.</p> <p>Wound infection: MAL‐PDT = 0%, SE = 5.2%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other reported AEs included erythema, post‐procedural pain, milia and wound dehiscence.</p> <p>21 serious AEs were reported; none were considered related and any permanent discontinuations were unrelated to treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment‐related AEs were higher in MAL‐PDT group than in SE group (37% versus 14.6%).</p> <p>All AEs were mild to moderate severity except one severe wound infection in SE group.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0051" title="TranHT , LeeRA , OganesyanG , JiangSB . Single treatment of non-melanoma skin cancers using a pulsed-dye laser with stacked pulses. Lasers in Surgery and Medicine2012;44(6):459-67. [CENTRAL: CN-00969795] ">Tran 2012</a> (PDL 7mm spot single pulses / PDL 10mm stacked pulses) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both treatment group participants developed eschars at 2 weeks, followed by mild erythema at 1 month and hypopigmentation at 5 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0029" title="KuijpersDI , ThissenMR , BerrettyPJ , IdelerFH , NelemansPJ , NeumannMH . Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatologic Surgery2007;33(5):579-87. [CENTRAL: CN-00588176] ThissenMR , NiemanFH , IdelerAH , BerrettyPJ , NeumannHA . Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatologic Surgery2000;26(8):759-64. [CENTRAL: CN-00298974] ">Kuijpers 2007</a> (cryosurgery / SE) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infections: SE = 2, cryosurgery = 3.</p> <p>In the cryosurgery group, 90% complained about moderate to severe swelling of the treatment area, followed by leaking from the defect. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One death (unrelated to study tumour).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0052" title="WangI , BendsoeN , KlintebergCA , EnejderAM , Andersson‐EngelsS , SvanbergS , et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. British Journal of Dermatology2000;144(4):832-40. [CENTRAL: CN-00326537] ">Wang 2001</a> (ALA‐PDT / cryosurgery) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were two patient deaths, and both were unrelated to the BCC or the treatment.</p> <p>One patient reported pain radiating from treatment site (PDT group) and one developed bacterial infection cryosurgery group). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003412-bbs2-0001" title="2005-001474-27. A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001474-27/results (first accessed 12 August 2016). ">2005‐001474‐27</a> (placebo gel + Tazarotene gel / Baceca® + Tazarotene gel) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema (17/25 and 20/25 in the two treatment groups).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itch (18 versus 15 patients), ulceration (11 versus 16 patients) and local pain (8 versus 6 patients). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant differences between the two groups. Extension phase outcomes not reported.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>MAL:</b> methyl aminolevulinate; <b>PDL:</b> pulsed dye laser; <b>PDT:</b> photodynamic therapy; <b>SE:</b> surgical excision; <b>xpw:</b> times per week. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse effects table</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003412-tbl-0008"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Curettage and cryosurgery compared to surgical excision for basal cell carcinoma of the skin</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Curettage &amp; cryosurgery compared to surgical excision for low‐risk BCC</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from a single‐centre in The Netherlands<br/><b>Intervention:</b> curettage &amp; cryosurgery<br/><b>Comparison:</b> surgical excision </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with surgical excision</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Curettage &amp; cryosurgery</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.36<br/>(0.73 to 15.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137 per 1000<br/>(30 to 629) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.78<br/>(0.93 to 8.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>85<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237 per 1000<br/>(79 to 710) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/>(0.78 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participant‐rated at 1 year on a 3‐point scale.<sup>4</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880 per 1000<br/>(780 to 980) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.28</p> <p>(0.16 to 0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>96<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Observer‐rated at 1 year on a 3‐point scale.<sup>4</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>833 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>233 per 1000</p> <p>(133 to 392)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early treatment failure</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm. </p> <p><sup>2</sup> Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI and downgraded one level for serious risk of bias as unable to truly blind due to the nature of interventions. </p> <p><sup>3</sup> Downgraded one level for serious imprecision as only a single study with a small sample size. </p> <p><sup>4</sup> 3‐point scale: bad, fair, good. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Curettage and cryosurgery compared to surgical excision for basal cell carcinoma of the skin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003412-tbl-0009"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">ALA‐PDT compared to surgical excision for basal cell carcinoma of the skin</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ALA‐PDT compared to surgical excision for low‐risk BCC</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from a single‐centre in the Netherlands<br/><b>Intervention:</b> ALA‐PDT<br/><b>Comparison:</b> surgical excision </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with surgical excision</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ALA‐PDT</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 10.87<br/>(2.63 to 44.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>173<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247 per 1000<br/>(60 to 1000) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 11.91<br/>(2.90 to 48.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>173<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271 per 1000<br/>(66 to 1000) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cosmetic outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>No study addressed this outcome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Early treatment failure</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.18<br/>(0.66 to 15.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>171<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 per 1000<br/>(15 to 348) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI. </p> <p><sup>2</sup> Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">ALA‐PDT compared to surgical excision for basal cell carcinoma of the skin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003412-tbl-0010"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">MAL‐PDT compared to cryosurgery for basal cell carcinoma of the skin</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PDT compared to cryosurgery for low‐risk BCC</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from France, UK, Sweden, Italy, Belgium and Austria<br/><b>Intervention:</b> MAL‐PDT<br/><b>Comparison:</b> cryosurgery </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cryosurgery</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with MAL‐PDT</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/>(0.65 to 1.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>193 (lesions)<sup>4</sup><br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221 per 1000<br/>(126 to 383) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/>(0.62 to 1.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>193 (lesions)<sup>4</sup><br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205 per 1000<br/>(119 to 352) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.23<br/>(1.07 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>99<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participant‐rated at 1 year on a 4‐point scale.<sup>2</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>813 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>999 per 1000<br/>(869 to 1000) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.46 (1.14 to 1.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>99</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Observer‐rated at 1 year on a 4‐point scale.<sup>2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>604 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>882 per 1000</p> <p>(689 to 1000)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Early treatment failure</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.57<br/>(0.14 to 2.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>201 (lesions)<sup>4</sup><br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/>(7 to 119) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12</p> <p>(0.68 to 1.84)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>118</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Frequency reported as AE during the follow‐up period.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>328 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>367 per 1000<br/>(223 to 603) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>AE:</b> adverse event; <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm. </p> <p><sup>2</sup> Downgraded one level for serious risk of bias as unable to truly blind due to the nature of interventions. </p> <p><sup>3</sup> 4‐point scale: poor (extensive occurrence of scarring, atrophy, or induration), fair (slight to moderate occurrence of scarring, atrophy or induration), good (no scarring, atrophy or induration and moderate redness or increase in pigmentation compared with adjacent skin), excellent (no scarring, atrophy, or induration and slight or no redness or change in pigmentation compared with adjacent skin). </p> <p><sup>4</sup> Includes participants with multiple lesions which means differences between groups could be over‐estimated. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">MAL‐PDT compared to cryosurgery for basal cell carcinoma of the skin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003412-tbl-0011"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">5‐FU cream compared to MAL‐PDT for basal cell carcinoma of the skin</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>5‐FU cream compared to MAL‐PDT for low‐risk BCC</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from seven hospitals in the Netherlands<br/><b>Intervention:</b> 5‐FU cream<br/><b>Comparison:</b> MAL‐PDT </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PDT</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 5‐FU cream</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.65<br/>(0.49 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>272<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>524 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340 per 1000<br/>(257 to 450) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.67<br/>(0.53 to 0.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>226<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>686 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>460 per 1000<br/>(364 to 576) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (excellent/good)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/>(0.78 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>379<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blinded observer‐rated at 1 year on 4‐point scale.<sup>3</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>624 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>574 per 1000<br/>(486 to 680) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain (moderate/severe)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.41<br/>(0.26 to 0.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>374<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>During treatment: comparing the week of treatment with highest frequency of reported moderate/severe pain (treatment cycle 2 for PDT, week 4 for 5‐FU cream). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 per 1000<br/>(79 to 192) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Early treatment failure</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.77<br/>(0.47 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>394<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 per 1000<br/>(74 to 199) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for serious imprecision as only a single study with a small sample size. </p> <p><sup>2</sup> Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm. </p> <p><sup>3</sup> 4‐point scale: poor, fair, good, excellent. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">5‐FU cream compared to MAL‐PDT for basal cell carcinoma of the skin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003412-tbl-0012"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Imiquimod cream compared to 5‐FU cream for basal cell carcinoma of the skin</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Imiquimod cream compared to 5‐FU cream for low‐risk BCC</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from seven hospitals in the Netherlands<br/><b>Intervention:</b> imiquimod cream<br/><b>Comparison:</b> 5‐FU cream </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with 5‐FU cream</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Imiquimod cream</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.68<br/>(0.47 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>291<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>342 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233 per 1000<br/>(161 to 339) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.62<br/>(0.44 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>250<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>460 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285 per 1000<br/>(202 to 400) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (excellent/good)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/>(0.90 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>377<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Observer‐rated at 1 year on 4‐point scale.<sup>4</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>575 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>615 per 1000<br/>(518 to 725) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain (moderate/severe)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.46<br/>(0.89 to 2.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>365<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>During treatment: comparing the week of treatment with highest frequency of reported moderate/severe pain (week 6 for imiquimod, week 4 for 5‐FU cream). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183 per 1000<br/>(111 to 298) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Early treatment failure</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.47 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>387<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/>(57 to 177) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for serious imprecision as only a single study with a small sample size. </p> <p><sup>2</sup> Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI. </p> <p><sup>3</sup> Downgraded two levels for very serious imprecision as very wide 95% CI indicating the possibility of important benefit or harm. </p> <p><sup>4</sup> 4‐point scale: poor, fair, good, excellent. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Imiquimod cream compared to 5‐FU cream for basal cell carcinoma of the skin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003412-tbl-0013"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">ALA‐PDT compared to cryosurgery for basal cell carcinoma of the skin</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PDT compared to cryosurgery for low‐risk BCC</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with basal cell carcinoma of the skin<br/><b>Setting:</b> secondary care with outpatients from a single hospital in Sweden </p> <p><b>Intervention:</b> ALA‐PDT<br/><b>Comparison:</b> cryosurgery </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cryosurgery</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ALA‐PDT</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence at 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrence at 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cosmetic outcome (good/excellent)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.72 (1.26 to 2.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>79</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Observer‐rated at 1 year on a 4‐point scale.<sup>3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>541 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>930 per 1000 (681 to 1000)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early treatment failure</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No study addressed this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>88</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pain during treatment assessed by VAS (115mm, where 115mm corresponds to 'unbearable pain' and 0mm corresponds to 'no pain'. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean pain was 32 mm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 11mm higher (1.12 lower to 23.12 higher)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; V<b>AS:</b> visual analogue scale. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for serious risk of bias as unable to truly blind due to the nature of interventions. </p> <p><sup>2</sup> Downgraded one level for serious imprecision as only a single study with a small sample size and a wide 95% CI. </p> <p><sup>3</sup> 4‐point scale: blemished, acceptable, good, excellent. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">ALA‐PDT compared to cryosurgery for basal cell carcinoma of the skin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/full#CD003412-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mohs micrographic surgery vs surgical excision</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Recurrence at 3 years (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Recurrence at 5 years (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mohs micrographic surgery vs surgical excision</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Imiquimod vs surgical excision</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Recurrence at 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Recurrence at 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Cosmetic outcome (good/excellent) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Observer rated at 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Participant rated at 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Pain (moderate/severe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 During treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 During follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Imiquimod vs surgical excision</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Radiotherapy vs surgical excision (with or without frozen section margin control)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Recurrence at 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Recurrence at 4 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Cosmetic outcome (good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Participant rated at 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Observer rated at 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Radiotherapy vs surgical excision (with or without frozen section margin control)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Curettage vs surgical excision</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Recurrence at 2 years (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Curettage vs surgical excision</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Curettage and cautery vs surgical excision</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Recurrence at 2 years (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Curettage and cautery vs surgical excision</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Curettage and cautery vs curettage</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Recurrence at 2 years (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Curettage and cautery vs curettage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Low dose radiotherapy vs high dose radiotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Low dose radiotherapy vs high dose radiotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Radiotherapy vs cryosurgery</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Recurrence at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Radiotherapy vs cryosurgery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Curettage and cryosurgery vs surgical excision</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Recurrence at 3 years (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Recurrence at 5 years (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Cosmetic outcome (good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.1 Participant rated at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.2 Obsever rated at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Curettage and cryosurgery vs surgical excision</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">MAL‐PDT vs surgical excision</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Recurrence at 3 years (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Cosmetic outcome (good/excellent) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 Participant rated at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.09, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 Observer rated 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.54, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Early treatment failure (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">MAL‐PDT vs surgical excision</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">ALA‐PDT vs surgical excision</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Recurrence at 3 years (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Recurrence at 5 years (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">ALA‐PDT vs surgical excision</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">ALA‐PDT vs MAL‐PDT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Cosmetic outcome (good/very good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Pain (visual analogue score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.1 Cycle 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [‐0.76, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.2 Cycle 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [‐0.18, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Pain (numerical rating scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.1 Cycle 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.2 Cycle 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">ALA‐PDT vs MAL‐PDT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">BF‐200 ALA‐PDT vs MAL‐PDT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">BF‐200 ALA‐PDT vs MAL‐PDT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">HAL‐PDT vs MAL‐PDT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">HAL‐PDT vs MAL‐PDT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">HAL‐PDT vs BF‐200 ALA‐PDT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">HAL‐PDT vs BF‐200 ALA‐PDT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">MAL‐PDT vs cryosurgery</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 Recurrence at 3 years (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.2 Recurrence at 5 years (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.3 Cosmetic outcome (good/excellent) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.1 Participant rated at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.2 Observer rated at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.4 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.5 Early treatment failure (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">MAL‐PDT vs cryosurgery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">ALA‐PDT vs cryosurgery</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.1 Cosmetic outcome (good/excellent) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.2 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">ALA‐PDT vs cryosurgery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Imiquimod cream vs MAL‐PDT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.1 Recurrence at 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.2 Recurrence at 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.3 Cosmetic outcome (good/excellent, observer rated at 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.4 Pain (moderate/severe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.5 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Imiquimod cream vs MAL‐PDT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">5‐FU cream vs MAL‐PDT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.1 Recurrence at 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.2 Recurrence at 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.3 Cosmetic outcome (good/excellent, observer rated at 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.4 Pain (moderate/severe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.5 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">5‐FU cream vs MAL‐PDT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Laser ALA‐PDT vs broadband light ALA‐PDT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.1 Cosmetic outcome (good/excellent, observer rated at 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.2 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2.1 Discomfort during/after illumination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2.2 Discomfort during 1st week after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Laser ALA‐PDT vs broadband light ALA‐PDT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">AFXL MAL‐PDT vs MAL‐PDT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.1 Cosmetic outcome (good/excellent) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.1 Observer rated at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.54, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.2 Participant rated at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.75, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.2 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.17, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">AFXL MAL‐PDT vs MAL‐PDT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">MAL‐PDT vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.1 Cosmetic outcome (good/excellent, observer rated at 6 months)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.2 Pain (frequency reported as local AE) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.3 Early treatment failure (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">MAL‐PDT vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Imiquimod cream vs 5‐FU cream</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.1 Recurrence at 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.2 Recurrence at 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.3 Cosmetic outcome (good/excellent, observer rated at 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.4 Pain (moderate/severe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.5 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Imiquimod cream vs 5‐FU cream</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0036">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0037"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Imiquimod vs radiotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24.1 Cosmetic outcome (excellent, participant rated at 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Imiquimod vs radiotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0037">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0038"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Imiquimod cream under occlusion vs no occlusion</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.1 sBCC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.2 nBCC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Imiquimod cream under occlusion vs no occlusion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0038">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0039"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Imiquimod cream vs vehicle</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.19, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Imiquimod cream vs vehicle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0039">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0040"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Imiquimod 5 weeks vs 8 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27.1 Recurrence at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Imiquimod 5 weeks vs 8 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0040">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0041"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">Imiquimod 8 weeks vs 12 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">Imiquimod 8 weeks vs 12 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0041">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0042"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">5‐FU in PC vs 5‐FU in petrolatum</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29.1 Early treatment failure (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">5‐FU in PC vs 5‐FU in petrolatum</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0042">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0043"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">5‐FU/epinephrine gel (1.0 mL once a week for 6 weeks vs 0.5 mL once a week for 6 weeks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">5‐FU/epinephrine gel (1.0 mL once a week for 6 weeks vs 0.5 mL once a week for 6 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0043">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0044"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">5‐FU/epinephrine gel(1.0 mL twice a week for 3 weeks vs 0.5 mL twice a week for 3 weeks)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">5‐FU/epinephrine gel(1.0 mL twice a week for 3 weeks vs 0.5 mL twice a week for 3 weeks)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0044">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0045"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">5‐FU/epinephrine gel(0.5ml twice a week for 4 weeks vs 0.5 mL three times a week for 2 weeks.</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">5‐FU/epinephrine gel(0.5ml twice a week for 4 weeks vs 0.5 mL three times a week for 2 weeks.</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0045">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0046"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">Electrochemotherapy vs surgical excision</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33.1 Recurrence at 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33.2 Recurrence at 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">Electrochemotherapy vs surgical excision</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0046">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0047"> <div class="table-heading"><span class="table-label">Comparison 34.</span> <span class="table-title">Ingenol vs vehicle (day 1+2)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1.1 Ingenol 0.05% vs vehicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1.2 Ingenol 0.01% vs vehicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1.3 Ingenol 0.0025% vs vehicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 34.</span> <span class="table-title">Ingenol vs vehicle (day 1+2)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0047">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0048"> <div class="table-heading"><span class="table-label">Comparison 35.</span> <span class="table-title">Ingenol vs vehicle (day 1+8)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1.1 Ingenol 0.05% vs vehicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1.2 Ingenol 0.01% vs vehicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1.3 Ingenol 0.0025% vs vehicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 35.</span> <span class="table-title">Ingenol vs vehicle (day 1+8)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0048">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0049"> <div class="table-heading"><span class="table-label">Comparison 36.</span> <span class="table-title">Ingenol under occlusion vs no occlusion</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1.1 Full occlusion vs no occlusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1.2 Semi‐occlusion vs no occlusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 36.</span> <span class="table-title">Ingenol under occlusion vs no occlusion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0049">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0050"> <div class="table-heading"><span class="table-label">Comparison 37.</span> <span class="table-title">Solasodine glycoside cream vs vehicle</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 37.</span> <span class="table-title">Solasodine glycoside cream vs vehicle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0050">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0051"> <div class="table-heading"><span class="table-label">Comparison 38.</span> <span class="table-title">Valproic acid gel + Tazarotene gel vs placebo + Tazarotene</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 38.</span> <span class="table-title">Valproic acid gel + Tazarotene gel vs placebo + Tazarotene</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0051">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0052"> <div class="table-heading"><span class="table-label">Comparison 39.</span> <span class="table-title">Diclofenac gel vs calcitriol ointment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 39.</span> <span class="table-title">Diclofenac gel vs calcitriol ointment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0052">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0053"> <div class="table-heading"><span class="table-label">Comparison 40.</span> <span class="table-title">Diclofenac gel vs diclofenac+calcitriol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 40.</span> <span class="table-title">Diclofenac gel vs diclofenac+calcitriol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0053">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0054"> <div class="table-heading"><span class="table-label">Comparison 41.</span> <span class="table-title">Calcitriol ointment vs calcitriol+diclofenac</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 41.</span> <span class="table-title">Calcitriol ointment vs calcitriol+diclofenac</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0054">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0055"> <div class="table-heading"><span class="table-label">Comparison 42.</span> <span class="table-title">PDL one session vs PDL two sessions</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 42.</span> <span class="table-title">PDL one session vs PDL two sessions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0055">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0056"> <div class="table-heading"><span class="table-label">Comparison 43.</span> <span class="table-title">PDL 7mm spot‐size single pulses vs PDL 10mm spot‐size stacked pulses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43.1 Early treatment failure (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 43.</span> <span class="table-title">PDL 7mm spot‐size single pulses vs PDL 10mm spot‐size stacked pulses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0056">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0057"> <div class="table-heading"><span class="table-label">Comparison 44.</span> <span class="table-title">PDL vs sham laser</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44.1 Early treatment failure (lesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 44.</span> <span class="table-title">PDL vs sham laser</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0057">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0058"> <div class="table-heading"><span class="table-label">Comparison 45.</span> <span class="table-title">PDL vs no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 45.</span> <span class="table-title">PDL vs no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0058">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0059"> <div class="table-heading"><span class="table-label">Comparison 46.</span> <span class="table-title">Interferon alpha 2b vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 46.</span> <span class="table-title">Interferon alpha 2b vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0059">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0060"> <div class="table-heading"><span class="table-label">Comparison 47.</span> <span class="table-title">Interferon beta vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 47.</span> <span class="table-title">Interferon beta vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0060">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0061"> <div class="table-heading"><span class="table-label">Comparison 48.</span> <span class="table-title">Interferon alpha 2a+2b vs interferon alpha 2a</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 48.</span> <span class="table-title">Interferon alpha 2a+2b vs interferon alpha 2a</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0061">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0062"> <div class="table-heading"><span class="table-label">Comparison 49.</span> <span class="table-title">Interferon alpha 2a+2b vs interferon alpha 2b</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 49.</span> <span class="table-title">Interferon alpha 2a+2b vs interferon alpha 2b</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0062">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0063"> <div class="table-heading"><span class="table-label">Comparison 50.</span> <span class="table-title">Interferon alpha 2b vs interferon alpha 2a</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 50.</span> <span class="table-title">Interferon alpha 2b vs interferon alpha 2a</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0063">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0064"> <div class="table-heading"><span class="table-label">Comparison 51.</span> <span class="table-title">3x a week vs single dose protamine zinc chelate IFN alpha 2b</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 51.</span> <span class="table-title">3x a week vs single dose protamine zinc chelate IFN alpha 2b</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0064">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003412-tbl-0065"> <div class="table-heading"><span class="table-label">Comparison 52.</span> <span class="table-title">Topical sinecatechin vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52.1 Early treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 52.</span> <span class="table-title">Topical sinecatechin vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003412.pub3/references#CD003412-tbl-0065">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003412.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003412-note-0018">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003412-note-0025">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003412-note-0023">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003412-note-0024">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD003412-note-0022">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD003412-note-0021">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD003412-note-0020">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003412-note-0019">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003412\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003412\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003412\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003412\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003412\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003412\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003412\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003412\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003412\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003412\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003412\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003412\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003412\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003412\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003412\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003412\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003412\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003412\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=dLyXbLct&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003412.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003412.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003412.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003412.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003412.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718629604"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003412.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718629608"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003412.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd4ffba67f47a',t:'MTc0MDcxODYzMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 